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Linkage Analysis of Mendelian forms of Complex Disorders in a South
American Population
Abstract
Genetic analysis in Mendelian forms of complex disorders may help increase our 
understanding of the biology of these disorders. Genes identified in Mendelian forms 
could also be relevant for disease susceptibility of the more common forms of the 
disease. I have studied a collection of patient samples from Antioquia, Colombia, 
including Mendelian and sporadic forms of four well characterized diseases: 
Parkinson’s [PD], Generalized epilepsy with Febrile Seizures Plus [GEFS+], Batten’s 
disease and Type 1 Diabetes [T1D]. In addition, I studied two extended families with 
unusual disorders. Affected individuals in one family presented with episodic crisis of 
abdominal pain, possibly corresponding to Abdominal Epilepsy [AE]. Patients from 
the other family presented with a multiform movement disorder [MMD], at times 
diagnosed as Parkinson’s or Huntington’s disease. Brain pathology from an affected 
individual showed the presence of iron deposits as a key finding. I subsequently 
performed linkage analysis of these families. Initial analysis focused on testing 
linkage to known candidate genes or regions. If these proved negative or if no 
candidate gene/region was available, a genome scan was then conducted.
I have excluded all previously known genes/loci in two out of six families with 
GEFS+. The remaining four families were found linked to either SCN1A or 
GABRG2 genes. In a family with Parkinson disease, a novel mutation was identified 
in exon 3 of the PARK2 gene. It was not possible to establish whether a common 
chromosome was involved in the same mutation reported separately by both a 
Spanish group and we since those mutant chromosomes are presenting a very 
different haplotype in both populations. In Batten disease, the first mutation in CLN5 
gene outside Europe was found, which leads to a variant of the juvenile form rather 
than to a late infantile presentation of Neuronal Ceroid Lipofuscinosis. For TID, a 
haplotype on chromosome 2 was found to be segregating with the disease in a large 
family with autoimmune T1D.
Regarding the two genome wide scans, in MMD, suggestion of linkage to two 
functionally candidate genes was found. These are the Neurogolobin (NGB) and the 
Ferritin heavy polypeptide (FTH1) genes. In Abdominal epilepsy, a locus was 
identified on chromosome 8 and fine mapping led to the identification of a critical 
region extending 1.3 Mb at 8ql3.
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CHAPTER ONE
INTRODUCTION
This thesis describes studies aimed at identification of the genes involved in a variety 
of Mendelian forms of disorders which are more commonly of complex aetiology. 
Series of large families from Antioquia-Colombia with Parkinson’s disease, 
Generalized Epilepsy with Febrile Seizures Plus [GEFS+], Batten’s disease, Type 1 
Diabetes [T1D], Multiform Movement Disorder [MMD] and Abdominal epilepsy have 
been studied.
In the first five disorders, both linkage and association analysis, as a direct analysis of 
candidate genes/loci was carried out. After having excluded several candidate loci in 
MMD and having no clear candidate genes for Abdominal epilepsy, a genome wide 
scan was conducted in both disorders which involved typing, on average, one STR 
every six cM.
Genes identified in Mendelian forms of Complex disorders can help increase our 
understanding of the biology of these disorders and could also be relevant in common 
forms of the disease. For several inherited diseases, virtually everything that is known 
about the biological processes underlying the disease process derives from knowledge 
of the protein affected by the mutations that lead to the disease.
In this first section the background for the success to candidate gene and positional 
cloning approaches in Mendelian traits (and Mendelian-like) is described. Also, 
description of which could be the most appropriate approaches for the case of complex 
traits is provided.
2
1. Gene mapping of complex traits
Complex traits involve several loci contributing towards a phenotype, in addition to 
interaction between them. Also, environmental factors are expected to play a role. 
These factors in addition to irregular expressivity, incomplete penetrance and the 
existence of phenocopies complicate the situation \
As different loci participate in the phenotype, each probably with very low effect, 
linkage analysis studies have not been very successful in identifying these 
susceptibility loci. Therefore, association or Linkage disequilibrium (LD) studies have 
received more attention in the expectation that these may be more effective in 
identifying these small effects 2’3.
Despite the fact that no consensus has been adopted about what strategy is the best to 
identify complex disease genes, many searches have been launched to identify new 
markers to use. Thus, projects are underway looking for SNPs (Single Nucleotide 
Polymorphisms), in order to provide with a high density map of markers that then can 
be used in association or LD studies 4.
Two main methodologies are used for looking for genes involved in Complex traits: 
Map-based and gene (and sequence) based approaches. The map-based approach 
would require an estimate of 500,000 to 1,000,000 SNPs to be typed in individuals 
from European descent, and perhaps two-fold more for individuals from African 
populations (due to shorter haplotype-block and higher diversity)5’6.
t
The alternative to the map-based approach is based on typing SNPs in coding or 
promoter regions. SNPs in coding sequence are easier to identify as disease- 
predisposing variants since it is possible to assess the predicted severity of the amino 
acid change. Some amino acid substitutions might have weak physiological effects that
3
added to other weak effects in other genes may result in the phenotype. The gene- 
based approach if applied to the whole genome will require 50,000 to 100,000 SPNs 
(Ten-fold less than in map-based) to be typed, in order to evaluate the estimated total 
number of genes.
Variants in regulatory regions have been less frequently identified (see Table 1.1) but 
it is expected that a more frequent involvement in disease aetiology to be identified, at 
least in complex traits.
Most SNPs show low allele frequencies. Thus, there are more SNPs with minor 
frequencies of 1% than SNPs with minor frequencies of 20% 7’ 8. This difference in 
frequency might be reflected in the relative risk associated to the SNP in relation to a 
disease phenotype. For example, for SNPs with a strong effect on function, early 
onset, severe diseases may be involved and be at a lower frequency range than a SNP 
involved in later onset and/or milder diseases 9. This observation is in agreement with 
the degree of selection that may have acted on the disease-associated SNPs. A 
comprehensive analysis of genetic susceptibility needs to focus on the lower frequency 
range of potential disease-causing alleles (e.g. less than 1%) 9. Importantly, these 
studies might be more efficient in certain populations that because of their particular 
history may have more homogeneous genetic components.
2. Linkage analysis in Mendelian traits
i
2.1 The beginning of a positional cloning study
The process of finding mutations that cause diseases where a biochemical defect is
unknown is called positional cloning. The main steps for positional cloning involve
4
identifying families, collecting biological samples, genotyping markers, initial location 
by linkage, fine and physical mapping, and mutation identification l.
Positionally cloning begins with linkage analysis. This method is applied in families 
presenting with a particular disease (or trait). It consists of testing for linkage between 
polymorphic markers and the disease. Clear definition of the phenotype is critical since 
it may happen that the signals of lod scores be obscured by misclassification of 
phenotypes, or even, in some cases, could result in failure of detection of linkage.
When multiple families are analyzed, genetic heterogeneity, complex modes of 
inheritance and misdiagnosis regularly lead to poor lod scores. An appropriate 
approach to linkage when the initial results are not straightforward is to use a first data 
set to try to make an appropriate hypothesis and then to replicate the study on a new 
cohort using the predetermined additional phenotypic ideas derived from the first 
analysis 9.
2.2 The first successes of positional cloning
The early successes of positional cloning by linkage analysis included identification of 
the genes underlying chronic granulomatous disease, the X-linked muscular 
dystrophies, cystic fibrosis, Fanconi anemia, Ataxia talangietasia and 
Neurofibromatosis I (Reviewed in 9). Of these, Cystic fibrosis was the one where 
linkage mapping alone led to the identification of the CFTR gene 10, n . These studies 
were conducted analysing RFLPs (Restriction Fragment Length Polymorphisms), 
which detected SNPs.
5
2.3 Simple inheritance
Most of the genes that have been identified by positional cloning were originally 
mapped in families presenting with inheritance patterns that clearly were consistent 
with an autosomal dominant, co-dominant, autosomal recessive, or X-linked mode. 
Since the disorders presenting with such a clear inheritance pattern are rare, the 
number of meioses that can be evaluated in such studies is limited, therefore, the 
resolution level is 1-10 cM. The standard procedure, after detecting initial linkage 
using a set of markers is to re-examine the same samples with markers spaced more 
closely in the region of interest. However, the limitation in the resolution remains in 
the number of meioses. And then, when the actual mutant gene is found, there is often 
evidence of more than one mutation leading to the same phenotype, incomplete 
penetrance, and different degrees of severity which complicates the situation.
2.4 Homozygosity mapping
Homozygosity mapping is used to map recessive traits and consists of evaluating 
affected relatives of known degree for chromosomal regions inherited in common from 
a common ancestor . This method has the advantage that only a few individuals are 
required and that genetic heterogeneity is less likely to affect the analyses because each 
set of closely related individuals is very likely to carry the same mutation 
(autozygosity)9. This method is particularly suitable in populations with high rates of 
inbreeding. For example, from the five genes identified as causing Fanconi anemia, at 
• least three were mapped by homozygosity mapping, taking advantage of the low 
probability of heterogeneity 13‘15.
6
3. Genetic Markers.
Eukaryotic genomes show considerable DNA sequence variations (polymorphisms) 
within individuals and between populations. Two types of DNA polymorphisms are 
particularly well characterised: STRs and SNPs.
Short Tandem Repeats (STRs) or microsatellite repeats consist of 1-6 unit repeats 16. 
One of their advantages is that they can be typed using the polymerase chain reaction 
(PCR). They have high mutation rate and many alleles, which can be easily detected 
in the population by means of denaturing sequencing gels. Polymorphism in STRs 
arise from mutational events such as unequal crossover, replication slippage or double­
strand break repair 17'19. Their heterozygosity reaches values greater than 0.7 and they 
are also very abundant in the genome; they are often found in non-coding regions of 
genes and often they are non-functional. However, there are associations of STRs in 
UTRs (UnTranslated Regions) and introns which suggest they play a role in gene
90expression and disease . In addition, polymorphisms of tandem repeats within protein 
coding sequences are known to modulate disease risk and can result in coding changes 
leading to diseases such as myotonic dystrophy 21, Huntington’s disease 22. The most
♦ • • 9  Tcommon repeat is the dinucleotide CA . STRs are commonly found through both 
prokaryotic and eukaryotic genomes24.
Single or Simple Nucleotide Polymorphisms (SNPs) consist of the substitution of one 
nucleotide by another or the addition or deletion of one or a few nucleotides. SNPs are 
more abundant than STRs showing a SNP every 1000 bases 25. As usually only two
7
alleles are found in populations, the information content per SNP marker is lower than 
multiallelic STR markers and heterozygosities only up to 0.5 are possible.
For two SNP markers (composite marker) to provide similar information to one STR, 
several assumptions must be met. Amongst these, no association between the two 
linked SNPs, phase unequivocally determined, the number of haplotypes at the 
composite marker should correspond to the number of alleles at the STR and the
0 f \haplotype frequencies should correspond to the allele frequencies of the STR
4. Databases for genes identified
4.1 Disease associated genes
Databases such as Online Mendelian Inheritance in Man (OMIM, 
http://www.ncbi.nlm.mh.gov/entrez/querv.fcgi?db=omim/). Human Gene Mutation 
Database (HGMD, http://www.hgmd.cr.ac.uk/) and Locus Link 
(http://.www.ncbi.nlm.nih.gov/locuslink/) provide up to date information of the 
number of genes as wells as the phenotypes associated to them. Thus, HGMD in
thAugust 08 , 2005 reported 1863 disease associated genes. From these, the great 
majority correspond to the so called Mendelian traits, suggesting that only the “easy” 
ones (simple inheritance) have been found so far.
4.2 Type and frequency of mutations
HGMD has classified the mutations reported by type and frequency. By August 2005 
over 47339 mutations in 1863 genes associated with human diseases had been
8
reported. Table 1.1 summarizes frequencies of mutations in human disease 
phenotypes. Mutations including in-frame amino acid substitutions or stop codons are 
the most frequent ones (-57%), followed by deletions (-17%) and splice site mutations 
(-9.5%).
CHANGE NUMBER PERCENTAGE (% )
Micro-lesions
Missense/Nonsense 27099 57.24
Splicing 4480 9.46
Regulatory 560 1.18
Small deletions 7888 16.66
Small insertions 3145 6.64
Small indels 447 0.94
Gross lesions
Repeat variations 117 0.25
Gross insertions & duplications 422 0.89
Complex rearrangements (including
inversions) 557 1.17
Gross deletions 2624 5.57
Total 47339 100
Table 1.1. Relative frequency o f types o f mutations underlying disease phenotypes reported in HGMD 
website updated on 08/08, 2005.
5. Isolate populations
Isolate populations have been documented as very powerful for gene mapping of 
complex traits. Most cases of allelic association will result from linkage 
disequilibrium (LD). An important source of LD is recent admixture of two 
populations, and the length of the region of LD can be large when few generations arei
available to allow its decay 1. However, there is debate about the advantage of isolate 
populations in identifying genes affecting complex traits 27, since LD in isolate and 
outbred populations has been shown to be similar in some studies.
9
Nevertheless, differences in LD between isolated and outbred populations have been 
documented, particularly for SNPs, in addition to their reduced genetic heterogeneity, 
which can significantly increase genotypic relative risk 28. Thus, Finnish, Sardinians 
and Ashkenazi populations present a higher LD level for SNPs to a distance greater 
than 200 kb.
Complex traits are expected to be more homogeneous in isolate populations because of 
the small number of founders and genetic drift, increasing the power of linkage 
analysis. This is because fewer genes will be contributing towards a disease trait, and 
therefore the effect of each susceptibility gene will be easier to detect29.
6. Antioquia (Colombia)
Colombia is located in the Northwest of South America. The country is politically 
divided in 32 departments (provinces) and a capital district, Bogota. The great majority 
of Colombians are catholic and their language is Spanish.
One important department in Colombia, by its economical and political status, is 
Antioquia (Figure 1.1). This is located in Northwest Colombia between the central 
and western branches of the Andean mountains. It is estimated that Antioquia 
currently has 4,500,000 inhabitants. The metropolitan area of its capital, Medellin, has 
approximately 3,000,000 people. People originated in Antioquia are called “paisas”.
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It has been reported that Europeans founded the first non-Amerind settlement in what 
is present-day Colombia in the early 16th century allowing the establishment of a 
“criollo” population.
Several lines of genetic evidence suggest that Antioquia is an isolate population. First, 
using classic markers (blood-groups), the ancestral ethnic component was estimated as
'i i
85% Caucasian and 15% Amerindian . The genetic contribution by negroids was 
essentially zero. Second, strong admixture distortions in the gender vectors of the 
original founders of the paisa community was found by using DNA markers (STRs 
and SNPs). This study concluded that -94% of the Y chromosome are European, 5% 
African and 1% are Amerind 32. Similarly, they found that -90%  of the mtDNA 
(mitochondrial DNA) in Antioquia is of Amerindian origin. These results indicate a 
highly asymmetric pattern of mating in early Antioquia, involving mainly European 
men and local native women . Further analysis of DNA markers in Antioquia, 
provided evidence of LD patterns suggested by the sex bias founding, which can be 
exploited for the identification and fine mapping of disease variants in complex 
disorders33.
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Figure 1.1. Map o f  Colombia showing Antioquia in green colour. 
Map modified from http://www.crwflags.com/fotw/rn isc/co(.gif
In addition to the sources o f LD in Antioquia, another special feature o f this population 
is the large number o f children per family. This was characteristic until the last 
generation that in conjunction with the homogeneity o f the population makes it
i
interesting for gene mapping purposes. By using large families, two founder effects 
have been described in Antioquia for two Mendelian forms o f  the complex disorders 
Early-onset Alzheimer’s 34,35 and Juvenile Parkinson’s 36 diseases. Both Mendelian
12
and complex traits could be assessed in this population by combining linkage analysis 
and LD methods.
7. Aims
My thesis aimed to make progress in the genetic characterization of several Mendelian 
forms of Complex disorders, including Parkinson’s disease, Generalized Epilepsy with 
Febrile Seizures Plus [GEFS+], Batten’s disease, Type 1 Diabetes [T1D], Multiform 
Movement Disorder [MMD] and Abdominal Epilepsy. All the samples analyzed here 
were collected from individuals from Antioquia-Colombia.
Specific aims
• To evaluate candidate genes/loci by linkage analysis
• To examine the best candidate loci by SSCP and/or sequence analysis
• In some cases to conduct a genome wide scan, to identify the chromosomal region 
where the mutant gene lies
• To undertake fine mapping of regions where novel loci are identified
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CHAPTER TWO
METHODS
Several different methods have been used in developing this thesis work. The great 
majority of methods employed here are related to linkage mapping. Thus, two-point 
linkage analysis (including power simulations), multipoint analysis and haplotyping 
were the basis of my thesis. Here I present some basic concepts of the methods used 
for analysis of the families studied and the data collected in them. Common protocols 
among chapters are described in the final part of this chapter.
1. Methods of analysis, Basic Principles and implementation
1.1 Linkage Analysis
Gene linkage is a measure of the coinheritance of two or more loci in a family which 
occurs when the loci are in close proximity and there is little recombination between 
them. To better understand this concept, let us assume that a father transmits his 
paternal chromosome 1 to his child and that the mother transmits her paternal 
chromosome 1 to their child too. On this chromosome we are looking at two marker 
loci, Ml and M2. In Figure 2.1 it is easy to notice that the father has inherited from his 
mother alleles 2 and 3 at marker loci Ml and M2; this determines his phase as 12/23 as 
shown in Figure 2.1 A, indicated by a vertical bar. Also, a similar analysis allows us to 
identify the mother’s phase as 31/23.
• If a recombinational event occurs, as result of crossing over during the meiosis, the 
child will receive a combination of chromosome 1 portions from his grandparents 
through his parents.
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Figure 2.1 A. Phase known in a three generations 
pedigree. Hypothetical data for two marker loci.
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Figure 2.1 B. Phase known pedigree, 
showing a recombinant child for M2. 
Filled symbols indicate individuals 
presenting with a certain dominant trait 
(disease).
In Figure 2.IB the child has received alleles 13 from his father, which represents a 
combination of both his paternal grandparents’ chromosomes 1. Thus, the 
recombination happened in his father and the child is said to be a recombinant for 
marker locus 2 (M 2)37.
The rate of recombination (0) is a function of the genetic distance. If k times a 
recombination event is observed between these two loci among n observations 
(meioses), it would provide that the estimated theta is
A k
e —
n
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For example, if we had observed that in Figure 2. IB there were four children instead 
of one and that only the one shown was actually a recombinant, it would produce an 
estimated theta
e - y 4 - 0 .2 5
As this value is lower than 0.5 (free recombination), it indicates linkage between Ml 
and M2. Also, if we consider the same situation for Ml and the trait as for Ml and
A
M2, it would indicate 6 = 0 , i.e. no recombination between Ml and the trait locus. As 
the father is fully informative i.e. doubly heterozygous (heterozygous for Ml and the 
trait locus) and as we have already identified his phase, he provides the maximum 
information for linkage.
The lod score method
While in animal systems the statistical approach to evaluate linkage usually involves 
chi-square, in humans more complicated calculations are required. This extra difficulty 
arises because of the variability of family structure, limitations in family size, and the 
limitation to determination of phase in doubly heterozygous parents.
The lod score method was developed by Morton (1955) 38 by integrating the 
probability test of Haldane and Smith 39 with the sequential sampling developed by 
Wald40.
Two steps are required to calculate the logarithm of odds (lod). First, the likelihood of 
the pedigree is calculated considering the number of recombinants and
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nonrecombinants. Then, the common logarithm is calculated for the likelihood ratio. 
Application of the common logarithm allows adding up the resulting scores across 
families 41.
Assuming that we have three non-recombinants and one recombinant (in our example), 
the probabilities for each one is calculated separately. The probability 1- 0 for these 
three non-recombinants to happen independently is (1- 0)3 . The probability for the 
recombinant is 01.
In a general form, it is:
R= Recombinant; NR= nonrecombinant
If this likelihood is divided by its value under 0 =0.5, free recombination, the 
likelihood ratio is obtained, which is also called the odds ratio.
L(Q) = dR( l -  G)nr
£*(0 ) = L(0)/l ( 0.5)
In our example, it would be:
Then, the common logarithm of the odds is the lod score (Z).
Z(6>)-logloL(0)/L(O.5)
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If a lod score > 3 is found, it represents statistical evidence in favour of linkage. If a 
Z<-2 is found, it represents exclusion of that locus for either a Mendelian or complex 
trait42.
Phase unknown
When it is not possible to establish phase (i.e. two-generations pedigree or both parents 
are doubly heterozygous for same alleles), it is not possible to count recombinants and 
nonrecombinants, since both situations have equal a priori probabilities. Then, 
estimation of the recombination fraction is done by the maximum likelihood method, 
which in linkage analysis is found numerically by varying the values of the parameter 
(0) until an approximate maximum is found37.
If phase was unknown, the actual likelihood ratio needs to be multiplied by 0.5.
Z{6) = log10>j —■ eR( l - 0 ) NR ' 1
(0.5)* (0.5)"*
\
2 (0.5)™(0.5)fi
Multipoint analysis
An extension of the two-point analysis is the multipoint lod score analysis. This
consists of analyzing a fixed map of markers and a trait locus. Thus, the order of the
markers does matter now and the analysis consists of testing for linkage of the trait
locus along the set of markers from one end through to the other. Multipoint analysis
has certain advantages over two-point analysis. First, a locus that was originally
uninformative can become informative through haplotype information. Second, in fine
mapping, multipoint analysis is very useful to pinpoint a disease locus l. The greatest
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utility of multilocus analysis is locating the linked disease, providing that the mode of 
inheritance is well known 43. The multipoint lod score is defined as:
Z(*) = log10[L(*)/L(oo)]
where L(x) is the likelihood that a disease locus is located at a distance X on a fixed 
map consisting of several markers. L(a) is the likelihood that the disease locus is not 
on the map (0= 0.5).
The above likelihood ratio often is expressed as a location score, which is a simple 
multiple of the lod score. Thus, S(x)=Ln[L(x)/L(a)] 44.
The maximum multipoint lod score possible is equal to the maximum possible two- 
point lod score when all meioses are informative 43.
Models in a linkage analysis
At its most elementary level, a model postulates the number of loci necessary to 
explain the phenotypes. Any Mendelian model deals with three different probabilities: 
Priors, penetrances and transmission probabilities 45. Models contain variables called 
parameters, whose values are estimated based on observations. When the families 
under study show a clear mode of inheritance, the so called parametric methods can 
reliably be used in analyzing the data obtained. The most critical parameters are mode 
of inheritance, penetrance, allele frequencies and phenocopy rate. Among these, the 
most drastic one is the inheritance pattern. For example, if a particular trait segregates
I
• in an autosomal recessive fashion and mistakenly is assumed to be autosomal 
dominant, dramatical differences in the actual lod score would be observed. If the 
family shown in Figure 2.2, which presents a child affected by a recessive disorder, 
were analyzed assuming dominance, very negative lod scores would be obtained even
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at low penetrance (50%) (Z= -1.44). Using recessive conditions (penetrance 100%) 
and same allele frequencies in this family the lod score was 1.703 at 0= 0 (Table 2.1). 
Therefore, if mode of inheritance is not clear, a non-parametric analysis method is 
instead recommended. An alternative is to analyze the data collected using different 
models, where the inheritance pattern, penetrance and phenocopy rate can be varied. 
Allele frequencies are relatively easier to estimate than the other parameters. 
Estimating gene frequencies will prevent large fluctuations in lod scores. Population 
frequency of each marker and disease allele is required for the computation of the 
likelihood 43.
If every founder in the pedigree has unambiguosly determined genotypes, then 
estimating the allele frequencies will have no effect on the calculation of the lod 
scores. Allele frequencies are normally estimated from a sample of a normal 
population; they also can be estimated from the founders of a large pedigree or set of 
pedigrees, taking them as an independent sample. Alternatively, the ILINK program of 
the LINKAGE package can also be used to estimate allele frequencies when some of 
the founders have not been typed 46.
Table 2.1 shows that the allele 1 frequency (at the marker locus) has more effect on the 
analysis than the frequency of the disease allele, especially when the disease allele 
frequency is smaller.
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Figure 2.2. Family segregating a recessive trait. Genotypes are available for III and IV generations. 
All four founders are missing their genotypes.
Frequency of disease allele
Frequency of 
allele 1 0.5 0.1 0.01 0.0001
0.9 0.531 0.585 0.624 0.632
0.5 0.558 0.789 0.835 0.858
0.1 0.677 1.06 1.322 1.38
0.01 0.8 1.333 1.611 1.654
0.0001 0.828 1.38 1.66 1.703
Table 2.1. Maximum Lod scores obtained for family shown in Figure 2.2, at 0= 0.
This happens because the penetrances at the disease locus tells us more about about the 
disease locus genotypes of the untyped individuals than we know about their marker 
locus genotypes. The fact that we have less information for the genotypes at the 
marker locus of the untyped individuals makes the gene frequency particularly relevant
43
4 Software used to calculate Lod scores and haplotvpes
The LINKAGE package 44 was mainly used to calculate two-point lod scores. This 
package is based in the pioneering algorithm of Elston and Stewart45.
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To calculate two-point lod scores MLINK from the package LINKAGE was used44. It 
was assumed that the allele frequencies were 1/n, where n= number of alleles.
To calculate multipoint lod scores in the Multiform Movement Disorder family, 
GENEHUNTER v 2.1 47 was used. This software uses the Lander-Green algorithm 
improved by Kong and Cox 48. The largest a pedigree that can be run in 
GENEHUNTER is 2N-F<16, where N= number of non-founders and F= number of 
founders 47
Simwalk2 49 was used to obtain both multipoint lod scores in the rest of families 
analyzed here as well as to find the most likely haplotypes for the entire set of families. 
Simwalk2 uses the Markov Chain Monte Carlo algorithm 49. To prepare Simwalk2 
input files, MEGA2v3.0_r4 was used50.
Finally, haplotype of pedigrees were drawn using HaploPainter51.
Checking for Mendelian inconsistencies
After collecting genotypes in family members, checking for Mendelian inconsistencies 
is always recommended. This should be done before analyzing the data. To evaluate 
whether alleles transmitted to children in every nuclear family in a pedigree are 
consistent with Mendel’s laws four particular situations are tested: The alleles of a
I
.child and a parent should be compatible, the child should be compatible with each 
parent separately when both parents are considered simultaneously, there should be no 
more than four alleles in a sibship, and no more than two alleles in a sibship when two 
of them are homozygotes for two different alleles 52. Pedcheck implements four
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different algorithms to evaluate four different error levels 52, which can detect 
inconsistencies that other software for checking Mendelian inconsistencies do not 
detect, such as UNKNOWN 53 of the LINKAGE package 44. UNKNOWN may fail 
detecting inconsistencies in very complex pedigrees54.
1.2 Power simulations
When beginning a gene mapping study, one may wish to know beforehand which 
individuals in the pedigree (s) are those that eventually will provide the most 
information at the time of analzing the genotypes; also one may wish to know the 
power of the set of families to reach a statistically significant lod socre. These are 
questions that can be answered by means of a power simulation. A simulation is based 
only on the structure of the pedigree, the number of affected individuals and the 
informativeness of the markers. No biological samples have yet been collected.
Successive risk calculations are the principle of the simulations. They calculate the 
conditional probability distribution, P(g/x), of the genotypes given the phenotypes in a 
pedigree with N people.
So, if x= (xi, X2 , ...xn) represent the vector of phenotypes of the N inviduals and if 
g=(gl, g2, ...gN) represent the vector of multilocus including phase information, then 
P(glx) = P(gx/x)P(g2 lg{,x)P(g3 lgvg2,x ) ...37> 55.
Various factors influence the possibility of establishing linkage, such as penetrance,l
heterogeneity, and informativeness of markers.
Marker heterozygosity determines the frequency with which a parent is potentially
informative (double heterozygote) 37. Heterozygosity is the probability that an
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individual is heterozygous for two alleles at a marker locus with given allele 
frequencies. It is defined as H, where H  = 1 -  ^  pf,and p t is the population frequency
of the fth allele. For a gene with a alleles, H is largest with equally frequent alleles, /?, 
=z P j =  1 la. Then, heterozygosity takes the simple form, H  -1  -  IIa 37.
For example, a locus with four equally frequent alleles has a maximum heterozygosity 
of H= 0.75. From here, it is worth mentioning that the number of alleles does influence 
heterozygosity. For example, a SNP will only provide a maximum H= 0.5 when both 
its alleles are equally frequent. In contrast, since STRs normally show more than four 
alleles, it is common to find that their heterozygosity is greater than 0.75.
Simulations are run at a given theta (9<0.5), “true recombination fraction”. Every 
pedigree in the simulation is replicated by a given number of times (one hundred to 
one thousand). In every replicate, the marker alleles are different but will segregate in 
a Mendelian manner. The so called ELOD is the expected lod score at that 
predetermined 0, and is calculated by dividing the sum of the lod scores by the number 
of replicates. This value determines the average expected lod score for that particular 
family if the model used in the simulation nearly corresponds to what will be obtained 
in the genotypes. The maximum lod score is the highest lod score obtained at any 
value of recombination fraction in the entire set of replicates. This corresponds to the 
highest potential lod score when all meioses are fully informative under the assumed 
model and allele frequencies.
The power refers to the percentage of replicates Where a given lod score (e.g. Z>3) was 
obtained at the true recombination fraction, per pedigree.
Power Simulation Software
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There are at least three software packages that can be used in estimating the power of a 
set of pedigrees. They are SIMLINK 56, SIMULATE 57 and SLINK 55. They all have 
common features and differences. For example, all three programs allow the 
simulation of a marker locus unlinked to a disease locus. SLINK and SIMLINK, 
however, allow the simulation of genetic marker data for a locus linked to a disease 
locus.
SLINK was used to estimate the power of the families studied here. All simulations 
were carried out in 100 replicas of the pedigrees. In each case, a marker locus with 
four alleles equally frequent was simulated.
2. Laboratory methods
2.1 Genome wide scans
Markers across all the genome were typed for both Multiform Movement Disorder and 
Abdominal Epilepsy.
Samples were prepared to 100 ng/pL in 130 pL making a total of 13000 ng of DNA 
and then were shipped to the Icelandic company deCODE for markers to be typed. 
Five hundred and fifty two markers were typed at an average density of six cM. 
Marker repeats consisted of 490 dinucleotides, 57 tetranucleotides and 5 
trinucleotides. Their average heterozosity was 70.36. Appendix 1 shows a list of the 
markers typed by deCODE including their genetic position, cytogenetic band and
^  I
‘ heterozygosity.
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2.2 Microsatellite marker typing
Different fluorescent labels were used to allow pooling and load them together onto a 
gel in an ABI-377 sequencer (Applied Biosystems).
STRs were amplified in an MJ Research (DYAD™) thermocycler, in a final volume of 
10 pL using 30-100 ng of genomic DNA, 0.33pM of each primer and IX of Qiagen 
HotStarTaq Master Mix Kit. Their PCR conditions were as follows: 94°15’ followed 
by 10 cycles of 94°30” 55°30” and 72°30”; then 20 cycles of 89o15,,55°15,,72°30” and 
a final extension at 72° for 10 min. Once the fragments were run on an ABI-377 
sequencer (Perkin-Elmer), the allelic sizes were determined using Genescan 2.1 and 
Genotyper 3.5 software (Applied Biosystems).
2.3 Single Strand Conformational Polymorphism analysis. SSCP
SSCPs were run in 10% non-denaturing polyacrylamide gels. This procedure involved 
five steps:
1) Preparation of the gel (10%). The acrylamide solution was prepared from a 
stock at 50% acrylamide-bisacrylamide (37.5:1) (BioRad), adding 5 mL of this 
solution to 1.25 mL 10X TBE (Tris-Boric Acid EDTA) buffer. Plus 18.75 mL 
of water and, to accelerate the polymerization reaction, 100 pL of ammonium 
persulphate (APS) and 40 pL of (TEMED ) NNN’N ’-Tetramethilehtilenedia 
mine (BDH) were added. The gel was prepared in a vertical electrophoresis 
device with spacers of 0.75 mm.
t
2) Each sample contained 3 pL of water, 4 pL Formamide, 1 pL of PCR product. 
Samples were denatured at 94°C for 5 minutes and then were chilled on ice.
3) Run electrophoresis was carried out using 0.5X TBE in the gel tank, and 300 V 
for 4 hours at room temperature.
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4) Staining. Silver staining was performed using a standard protocol that is used 
in the lab: Fixation involved using 200 mL of 10% ethanol, 0.5 % acetic acid 
for 3 minutes. The solution was then poured off and this process repeated once 
again.
For staining: 200 mL of 0.1% AgNC>3 for 3 minutes (twice) was used.
The staining was developed using 200 mL of 1.5% NaOH, 20 mg Na(BH4) and
0.8 mL 37% formaldehyde. Bands appeared in 5-20 minutes.
Drying gels was done after rinsing the gels three times in distilled water and 
transferred them onto a piece of 3MM paper. Drying of the gels was carried out 
in a Gel Dryer Model 583 (Bio-Rad) for 2 hours.
2.4 Sequencing
Following a PCR purification step for removing primer excess, dNTPs, Taq and buffer 
using the QIAquick PCR purification kit (QIAGEN), sequence of bases was performed 
using the Big Dye Terminator v3.1 Cycle sequencing kit (Applied Biosystems). 
Sequence reactions were performed in an MJ Research (DYAD™) thermocycler in a 
final volume of 20 pL according to manufacturer specifications. After purification in 
columns from the QIAquick PCR purification kit (QIAGEN), samples were dissolved 
in 3 pL of loading buffer containing 2.5 pL formamide plus 0.5 pL of bromophenol 
blue and run in a polyacrylamide gen 6% on an ABI-377 (Perkin-Elmer).
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CHAPTER THREE
PARK2 AND EARLY ONSET 
PARKINSON DISEASE
I
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1. INTRODUCTION
1.1 Generalities
Parkinsonism is a feature of several distinguishable entities such as Parkinson’s 
disease, Lewy bodies disease (Dementia Lewy bodies) and Tauthopathies.
r  o
James Parkinson made the first description of Parkinson’s disease (PD) in 1817 .
The disease is manifested as a movement alteration characterized by bradykinesia, 
tremor, and postural instability 58. In general the response to the therapy (L-dopa) is 
good but “on-off’ phenomena and induced treatment dyskinesia rapidly appear 59. 
Classical (or late) onset PD presents at > 50 years. Parkinsonism in the first decades of 
life was in the past considered to be distinct from PD; these cases are now considered 
as two groups: Early onset PD (EOPD) or Juvenile PD (JPD). EOPD presents age at 
onset <45 years, while JPD presents age at onset < 25 years. PD affects over 1% of the 
general population older than 55 years 60.
Symptoms associated with PD appear due to the degeneration of the dopaminergic 
neurons in various regions of the central nervous system including the substantia nigra, 
the locus coeruleus and basal nuclei 61. Microscopic Lewy bodies within these nuclei 
are the pathological hallmark of PD. Neuronal death is accompanied by the appearance 
of cytoplasmic Lewy body inclusions, which ^re composed of a range of proteins 
including a-synuclein, ubiquitin, neurofilaments and oxidized/nitrated proteins
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Genes recently identified play an important role in the mechanisms of Parkinson 
pathology. It is currently known that Parkin (encoded by PARK2 gene) has a ligase 
function of proteins ubiquitinated and that mutations in it lead to loss of function 
reducing its ability to regulate degradation of substrate removal 63. It has also been 
observed that an O-glycosylated form of a-synuclein is ubiquitinated by Parkin, 
suggesting that loss of Parkin function will result in a-synuclein accumulation 64. One 
patient with parkin mutations has been reported as Lewy body positive 65. In addition, 
overexpression of mutant a-synuclein produces an inhibition of proteosome-associated 
proteolytic activities 66.
It was believed until recently that environmental factors such as viral infections 67 and
so
neurotoxins were the main cause of Parkinsonism. However, the identification in 
recent years of mutations in six different genes (SNCA 69 PARK2 70, UCHL1 71, PARK7 
72 PINK1 73 and MAPT 74) and of at least six different loci linked to the disorder 
(PARK3 75, PARK4 76, PARK8 77, PARK9 78, PARK10 79 and PARK1180) project the 
importance of genetic factors (Table 3.1).
Considering their aetiology as well as their pattern of segregation, several forms of
Parkinsonism can be identified. There are both a sporadic type (or idiopathic) and
familial forms. Genetic risk factors probably are also involved in the idiopathic forms 
81. Sporadic cases have been reported as carriers of mutations in genes identified in 
some familial forms 82> 83 (Table 3.1), but no mutations have yet been associated with 
the classical form of the disease, which is described as a complex trait. More recently, 
two separate studies in families have found linkage to lp32 (PARK10) 79,84. Because 
of the late age at onset of the patients involved in these two studies, it seems likely that
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this locus is more frequently involved in the classical form of the disease than any of 
the other genes/loci previously identified.
Type Chromosome Protein Gene/Locus References
I. Sporadic
4q21.1 a-Synuclein SNCA/PARK1
85
6q25.2 parkin PARK2 70 , 86, 87
lp32 ? PARK10 79 , 84
II. Familial
Dominant
4q21.1 a-Synuclein SNCA/PARK1
85
4p UCH-L1 UCHL1/PARK5 71
2pl3 ? PARK3 75
4pl4-16.3 ? PARK4 76
12pll.2-ql3.1 ? PARK8 77
17q21.1 tau MAPT 74 , 88
lp32 ? PARK 10 79, 84
2q36-37 ? PARK11 80
Recessive
6q25.2 parkin PARK2 70, 86, 87
lp35-36 Pinkl PINK1/PARK6 89
lp35 djl DJ1/PARK7
72, 90
lp36 ? PARK9 78
Table 3.1. Genetics o f Parkinsonism
1.2 Autosomal Dominant Parkinson’s Disease (AD-PD).
PARK1
In 1996, reports of AD-PD began to appear by Polymeropoulus and colleagues.
I
; Through a genome wide scan approach in a large Italian kindred and using 140 genetic 
markers, with an average density of 20 cM, they found that markers localizing in the 
region 4q21-23 were the only ones showing linkage to the disease with a maximum lod
Of
score (Zmax)= 6.0 at a recombination fraction (0)= 0 for marker D4S2380 . Through
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saturation of markers in this region and having observed some recombinants between 
the genetic markers and the disease it could be established that the locus PD1 (known 
today as PARK1) was located between markers D4S2371 and D4S2986 constituting a 
six cM interval. It was known at that time that there were four genes within this region 
which should be sequenced to search for disease causing mutations; these genes 
encoded for: Alcohol dehydrogenase, formaldehyde dehydrogenase, a-synuclein and 
UDP-N-acetyl glucosamine phosphotransferase91}. The four exons of SNCA were 
examined revealing a transition in its fourth exon, consisting of G to A in position 209 
of its cDNA (c.209 G>A), which causes an aminoacid substitution of Ala for Thr in 
position 53 of the protein. This substitution could be tested simply by means of a 
screening test using the restriction enzyme Tsp45 I, which targets the mutant sequence. 
In addition to the Italian family, three Greek PD families carried this mutation. None 
of 314 control chromosomes, of Italian origin, carried the mutation 69.
The substitution Ala53Thr lies in a region of the protein where the secondary structure 
predicts an a-helix formation bounded by beta sheets. This mutation interrupts the a- 
helix and extends the beta sheet structure, which is involved in self-aggregation and 
could lead to the formation of amyloid plaques or Lewy bodies 92, 93. A second 
mutation was found a year later in a German family, which consists of a nucleotide 
substitution of G for C in position 88 resulting in an Ala30Pro mutation 94. More 
recently, another family was found to carry a triplication of a large region that 
contained the gene 95. Last year a fourth mutation was reported in SNCA 96. These 
findings further support the implication of a-synuclein in the pathogenesis of the 
disease. Interestingly, the Ala53Thr is not a conserved aminoacid among different 
species. In the alignment of human a-synuclein with its homolog from rat (Rattus 
nervecus), zebra finch (Serinus canaria), cow (Bos Taurus) and Torpedo californica it
was found that, in this particular position, only Bos Taurus had an Alanine in this 
residue. The others had either Threonine (Thr=T) or Asparagine (Asn=N).
PARK5
Another gene identified as responsible for AD-PD is the one encoding Ubiquitin 
carboxy-terminal hydrolase LI (PARK5), in which a missense mutation (Ile93Met) has 
been reported in exon 4, leading to a partial loss (-50%) of the catalytic activity of this 
thiol-protease 71. This change can be tested using BsmFI since the mutation (c. 277 
O G ) creates a new site for the enzyme. None of 500 control chromosomes carried the 
mutation.
UCH-L1 comprises over 2% of the total brain protein 97, and belongs to a family of 
deubiquitinating enzymes. It is believed that it cuts the ubiquitin polymers breaking 
them down to monomers and hydrolyses bonds between ubiquitin molecules and small 
adducts such as glutathione and cellular amines 98. Also, its presence has been 
reported in Lewy bodies " .
These three features (abundance in brain, presence in Lewy bodies and being involved 
in the ubiquitin-dependent proteolytic pathway) show that UCH-L1 fits in the picture 
of PD pathogenesis. UCHL1 mutation contributes to the genetic aetiology of just a 
small number of patients with familial PD. Mutations in both SNCA and UCHL1 
present incomplete penetrance (-85%) 69,100}.
MAPT
A mutation in yet another gene was found in a family with frontotemporal dementia 
and Parkinsonism (FTDP-17). A splice-site mutation in MAPT causes the disorder by 
destabilizing a putative stem-loop structure involved in regulating the alternative
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splicing of exon 10 74. In addition, Hutton and colleagues found missense MAPT 
mutations in families with FTDP-17 88. Even though this phenotype is very variable, 
these families show a phenotype that is very similar to idiopathic PD 101.
There are several AD-PD loci where no genes have yet been isolated. This is the case 
for PARKS, PARK4, PARK8, PARK10 and PARK11 75'77; Hicks, 2002; Pankratz, 2003; 
Li, 2002}.
1.3 Autosomal Recessive Parkinson Disease (AR-JP).
PARK2
In order to delineate the molecular mechanisms of EOPD, there was great interest in
O/T
the SOD2 gene, which encodes the manganese superoxide dismutase (MnSOD) , 
which is an intramitochondrial enzyme that acts on the superoxide anion originated in 
the mitochondrial respiratory chain 98. The following three considerations suggested 
the presence of oxidative stress in the mitochondria of the brain of PD patients and a 
possible role of MnSOD modulating this process.
1) Studies on the brain indicated the alteration of function of the mitochondrial 
respiratory chain in PD 102'104.
2) That there could be a causal relation between the inhibition of the functions in the 
respiratory mitochondrial chain and the release of superoxide anions in the 
mitochondria98.
I
.3) That the MnSOD is inducible by superoxide anions 105 and that its increased 
activity in the substantia nigra of PD brain had been demonstrated 106.
These hints led Matsumine and colleagues to sequence the five exons of the SOD2 
gene in 13 Japanese families as part of a functional candidate gene approach. Only one
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family was found to present perfect segregation of the disease with a genetic variant. 
This variation was located in exon 2 and consisted of a transition of C to T leading to 
the aminoacid substitution Ala9Val. In light of this observation they decided to 
evaluate ten polymorphic markers (STR’s) around SOD2, covering 17 cM in the 
chromosomal region 6q25.27 and tested for genetic linkage in those 13 families 
finding a Zmax= 7.26 and 7.71 for D6S305 (0=0.03) and D6S253 (0=0.02) loci, 
respectively 86. These two markers were rather far from SOD2.
Simultaneously, Jones and colleagues were evaluating families from four different 
ethnic groups using the genome wide approach with an average density of 22 cM 87. 
They found linkage to the same chromosomal region as Matsumine and colleagues, 
and further evaluation of additional markers in the region let them exclude the SOD2 
gene by observing two recombinant individuals, narrowing down the candidate region 
to 6.9 cM between markers D6S305 and D6S1599 87.
At the same time another group was evaluating BAC’s (Bacterial Artificial 
Chromosome) corresponding to the same region and by using exon trapping 
methodology and sequencing cDNA, they identified the PARK2 gene, which has 12 
exons and spans 1.5 Mb. Its product (Parkin) has 465 aminoacids with a moderate 
similarity to Ubiquitin at the amino terminus, and at the C-terminus end to a RING- 
finger motif 70. Four families with deletions of exons were reported in this study. In 
one family there was a deletion of five exons (3-7) and another three unrelated families 
had deletions of exon 4. PARK2 is expressed in various tissues but it is abundant in the 
brain including the substantia nigra 70. Since tfien more families and sporadic cases 
have been reported as due to PARK2 mutations. To date, 41 exon rearrangements 
including 27 different deletions, 13 duplications and 1 triplication have been reported 
83, ioo, 107-115 5 9  point mutations have also been reported36’83,107,108,110,113,116‘126. It
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is now clear that rather than deletions, point mutations are the commonest cause of 
Parkinson disease due to PARK2 mutations. It has also been observed that the most 
frequent deletion involves exons 3-4 and that the most frequently reported point 
mutation is c.924 C>T in exon 7 (reviewed in 127).
Genetic heterogeneity
Locus and allelic heterogeneity have been observed for both AD-PD and AR-PD.
For AR-JP the first evidence of locus heterogeneity arose when analyzing haplotypes 
in two branches of a Greek family with JPD. It was evident that patients in one of the 
branches carried PARK2 mutations (Ex5-7 del) and patients from the other branch did 
not, nor did they share a haplotype or show linkage to this gene 10°. In addition, it has 
been reported that approximately 50% of the AR-JP families are due to mutations in 
PARK2 implying that the remaining families must have a different causal gene and 
consistently two other loci have already been identified on chromosome lp (Table 
3.1). These two loci are PARK6 89 and PARK7 90. In the latter, another gene involved 
in the ubiquitin-proteasome pathway has recently been identified 72 (Table 3.1).
Most of AD-PD patients do not carry mutations in either PARK1 or PARK5 and it has 
more recently been shown that new loci are involved in this form of Parkinsonism 74‘77.
1.4 Preliminary results
 ^ (
. Even though different genes are involved in EOPD, the most frequently implicated is
PARK2 and, furthermore, there are several reports suggesting that even being a carrier
• 65 83 110of PARK2 mutations is a risk factor for being affected by Parkinson disease ’ ’ 
ii3, ii8,128,129 all these reports evaluated the entire PARK2 gene nor used methods
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to test for dosage effects, such as deletions or duplications. They have mainly used 
SSCP and sequence, which might allow for some deletions or multiplications to go 
undetected. Also, all these studies lack familial structures that could allow haplotype 
reconstruction to identify sights of compound heterozygous in families with multiplex 
affected individuals.
Prior to the start of this thesis, two founder effects in Antioquia-Colombia for two 
PARK2 mutations were reported in three multiplex families and one sporadic case with 
EOPD 36. Patients from families PJF1 and PJF3 were homozygous for a G to A 
transition in exon 6 at position 736 (c.736 G>A). This mutation leads to the 
substitution of Cys for Tyr at position 212 of parkin. In addition, in family PJF2 a 
homozygous GT insertion between nucleotides 321 and 322 (321-322insGT) in exon 3 
was detected in all affected individuals. The sporadic case was also found to be 
homozygous for this mutation 36. In addition, three Colombian sporadic-like patients 
were shown to be carriers (heterozygous) of the c.736 G>A mutation (A.R.L 
unpublished data) and they were bom in the same town (Peque-Antioquia) as family 3 
(PJF3). Therefore, it was interesting to know whether those affected individuals 
originating in same small town (Peque) and carrying the same PARK2 mutation are 
actually members of a same extended pedigree.
On the other hand, in 2002 a Spanish group reported, in their patients, the mutation 
c.736 G>A, previously reported in Antioquia 117 raising the question whether the 
observation of same mutation in Antioquia was due to recurrent mutation or to a 
common ancestor.
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1.5 Aims
The focus of this chapter was to evaluate whether the three sporadic-like patients from 
Antioquia-Colombia are compound heterozygous involving a third mutation in the 
population or were just carriers. Also, given that the mutation c.736 G>A was 
separately reported in Spain 117 and Antioquia to evaluate whether this observation was 
due to a common ancestor or alternatively was due to a recurrent mutation. In 
addition, in order to examine the extent of the founder effect for PARK2 in Antioquia, 
I performed the molecular characterization of 23 additional sporadic EOPD patients 
from the province.
2. Materials and Methods
2.1 Patients
Patients were recruited from the Servicio de Neurologia of the Universidad de 
Antioquia (NEUROCIENCIAS). 23 sporadic patients with early-onset PD from the 
provincial capital (Medellin) were included in this study. These patients have no 
known relationship to each other and originate in various parts of the province. To be 
able to contrast with the sporadic cases, 17 control trios from Antioquia were also 
included.
In addition three different sporadic-like cases ajid other four patients (from 6 nuclear 
families) were born in Peque. Also, two Colombian families (PJF1 and PJF3) 36 and 
one Spanish family 117 carrying the mutation c. 736 G>A were studied. In addition
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two families where segregation of the 321-322insGT mutation was reported 36 were 
also studied.
2.2 Screening for the C212Y mutation
The missense mutation G736A, resulting in the Cys212Tyr substitution in PARK2 was 
tested in all familial and sporadic cases using the forward primer sequence (C212Y) 
5 ’ TCTTTCAGGAATTTTTCTTTACAT3 ’, which includes a mismatch identified by 
the underlined base. This mismatch in an individual with the mutation will complete 
the core for the restriction enzyme Ndel. The reverse primer was Exon 6R (Table 3.2) 
(Kitada et al. 1998). PCRs were performed in an MJ Research (DYAD™) 
thermocycler in a final volume of 25 microliters with 30-100 ng/pL of genomic DNA,
0.33 pM of each primer, IX of BioTaq buffer, 1.5 mM of Magnesium, 0.2 mM of each 
dNTP. PCR conditions included 94o 5’ of initial denaturing followed by 10 cycles of 
94° 15”, 48° 15” and 72°30”; then 20 cycles of 89°15”, 48°15” and 72°30”, followed by 
a final elongation step of 72° 10’. Digestion with the restriction enzyme Ndel was done 
overnight using 5-10 units per sample according to manufacturer specifications (New 
England Biolabs). Digested PCR fragments were examined in a 3.5% agarose gel 
stained with ethidium bromide.
2.3 Screening for the 321-322 insGT in Exon3
To type this mutation a fluorescence based approach was used. The forward primer for 
exon 3^was labelled with the dye 6-FAM in the 5’ end and runs were performed on an 
ABI-377 (Applied Biosystems).
In order to appropriately compare carriers, homozygous and non-carrier controls were 
included. The expected normal size is 311 bp.
40
2.4 Microsatellite marker typing
Microsatellite markers typed are shown in Table 3.3. All eleven markers were 
evaluated in four Colombian families (PJF1, PJF2, PJF3, PJF4) and the Spanish 
family. In addition, 17 control trios and 23 sporadic cases were tested for 4 of these 
eleven markers (D6S1550, D6S253, D6S305, D6S980).
2.5 Haplotvpe analysis
It was performed for the four Colombian families and the Spanish family studied here. 
In addition, the control trios were analyzed to infer haplotypes in their children. Please 
refer to the methods chapter.
2.6 SSCP
SSCP was performed either to confirm the genotype for c.736>G or in the rest of 
exons. Please refer to methods chapter.
2.7 Sequencing
Sequencing was conducted on exons that showed a variant conformation on SSCP. 
Please refer to methods chapter.
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2.8 Population allele-specific markers (PAS')
In order to examine the major component of the Peque population (i.e. Amerindian or 
European), six PAS were evaluated in 46 unaffected individuals from Peque (Table 
3.4). These markers were MID93, MID472, MID1326, MID1327, MID1338 and 
MID 1705. PCR conditions used the following touch down: 94° for 15 min, followed 
by ten cycles of 94° for 15sec, 63°(-0.5o each cycle) for 30 sec, 72° for 30sec; finally, 
twenty cycles of 89° for 15sec, 52-58° for 15sec, 72° for 30sec. A final extension step 
at 72° for 10 min, was added.
The PCRs were performed in a volume of 10 pL as described above in the 
microsatellite marker typing section. Admixture estimation was performed with admix
130
2.9 Association analysis
Hardy-Weinberg equilibrium was tested using Genepop on the web 
(http://wbiomed.curtin.edu.au/genepop/). Association analysis for the four intragenic 
STRs was performed in a three-step procedure. First, allele frequencies were estimated 
in both cases and parents from the control group, using Genepop on the web 
(http://wbiomed.curtin.edu.au/genepop/). Then, a chi-square test was applied to 
determine whether a statistical difference of allele frequencies was observed between 
groups^ Finally, evaluation of the haplotype frequencies was examined in Arlequin
1 q i #
2000 }. To do this analysis, haplotype definition was performed in the children
from the control trios; then, most likely haplotypes in the cases were compared with 
those present in the children from the control trios.
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Exon Oligo F (5'-3') Oligo R (5-31)
1 GCGCGGCTGGCGCCGCTGCGCGCA GCGGCGCAGAGAGGCT GTAC
2 AT GTT GCT AT C ACC ATTT AAGGG AGATTGGCAGCGCAGGCGGCATG
3 ACATGTCACTTTTGCTTCCCT AGGCC AT GCT CC AT GC AG ACT GC
4 AC AAGCTTTT AAAG AGTTT CTTGT AGGCAATGTGTTAGTACACA
5 AC AT GT CTT AAGG AGT AC ATTT TCTCTAATTT CCTGGCAAAC AGT G
6 AG AG ATT GTTT ACTGTG G AAAC A GAGTGATGCTATTTTTAGATCCT
7 T GCCTTTCCAC ACT G AC AGGT ACT T CT GTTCTT C ATT AGC ATT AG AG A
8 TGATAGTCATAACTGTGTGTAAG ACTGTCTCATTAGCGTCTATCTT
9 GGGT G AAATTT GC AGT C AGT AAT AT AAT CCCAGCCC AT GT GCA
10 ATTGCCAAATGCAACCTMTGTC TTGGAGGAATGAGTAGGGGATT
11 ACAGGGAACATAAACTCTGATCC CAACACACCAGGCACCTTCAGA
12 GTTTG GG AATGC GTGTTTT AGAATTAGAAAATGAAGGTAGACA
4 1   m p
Table 3.2. Primer sequences used to amplify the PARK2 exons
MARKER LABEL ASR LANE
D6S253 HEX 271-291 1
D6S255 FAM 163-175 1
D6S386 HEX 168-198 1
D6S1277 FAM 292-318 1
D6S1550 HEX 122-136 1
D6S1599 TET 131-155 1
D6S1581 FAM 215-229 1
D6S1579 HEX 147-163 2
D6S437 FAM 129-163 2
D6S980 FAM 292-324 2
D6S305 FAM 200-230 2
Table 3.3. Markers used to evaluate the PARK2 locus.
ASR= Average Size Range. LA^E= Lane to be loaded onto the ABI-377.
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3. Results
3.1 Haplotype analysis in the pedigrees
A schematic view of the markers evaluated in PARK2 locus is shown in Figure 3.1. 
Haplotypes for the pedigrees tested are shown in Figures 3.2-3.7.
Haplotype analysis revealed that affected individuals in PJF1 (Figure 3.2) were 
homozygous for the same mutant chromosomes. The homozygosity region in this 
family extends about 16 cM in a physical length of 6.9 Mb, from D6S1550 up to the 
most telomeric marker evaluated, which was D6S386 (Figures 3.1& 3.2).
In contrast to PJF1, affected individuals in PJF3 (Figure 3.3) showed two mutant 
chromosomes. One of these shared most of the haplotype found in PJF1. They shared 
alleles from markers D6S1581 up to D6S1277. The second mutant chromosome was 
identical to the first, from marker D6S1550 up to D6S1599, with the only exception 
being marker D6S980 where there is an allele 11 instead of an allele 10. This interval 
matches the region of homozygosity in this family, which contains the PARK2 gene 
(Figure 3.1). Extension of PJF3 revealed that the three sporadic-like cases from Peque 
belong to other branches of the pedigree. In all, 14 more affected individuals were 
identified in this extended pedigree (extended PJF3) distributed in six additional
i
nuclear families (Figure 3.4). One of these nuclear families showed a dominant-like 
mode of inheritance (V:9, VI: 1 and VI:2). Interestingly, it was found that the three 
sporadic-like cases that were joined onto the extended pedigree (V:l, V:12, VI:2) were 
carriers of the G736A mutation and, in addition, they all shared a common second
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haplotype (Table 3.5). SSCPs revealed an altered conformation in exon 2 for at least 
one of these samples (Figure 3.8). Sequencing uncovered a substitution of G to A in
thposition 212 of the PARK2 cDNA. This change involves the 37 codon, where a 
Proline (Pro=P) is conserved since the codon CCG changes to a synonymous one, 
CCA encoding Pro again. The A allele was found in 21.15% of the controls from 
Peque, suggesting that it is not a causal disease variation.
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Figure 3.1. PARK2 locus diagram. A, the structure o f the protein Parkin. Above are shown its three parts (Ubl -Ubiquitin like-, LR -Linking region- and 
RING box). IBR -In between RINGs-, *= approximate location ofCys212Tyr. Underneath the amino acid numbering is shown. B, The map o f the eleven 
microsatellites evaluated and their position respective to PARK2 exons. The mutation c.736G>A, which results in the amino acid substitution Cys212Tyr, 
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Further analysis by SSCP did not reveal new sequence variations. However, an exon 3 
duplication 109 was found in individuals V:1 and VI:2 (Suzanne Lesage, personal 
communication), which was assumed to be present in individual V: 12 as well.
Extension of the pedigree of the sporadic case reported in Pineda-Trujillo and 
colleagues (2001) established that there were no more affected individuals in this 
family. Haplotype and mutation carrier states were in agreement with the observed 
phenotypes. This family was named PJF4 (Figure 3.6). PJF2 (Figure 3.5) and PJF4 
have the same PARK2 mutation in exon 3, which is an insertion of two base pairs 
(321-322 insGT) . Haplotype analysis revealed that the maximum homozygosity 
region extends from D6S255 to D6S1277, with the exception of locus D6S980 where 
individual 11:3 (from PJF2) appears as heterozygous 4/5. Segregation of the mutation 
with the phenotype was perfect in these four families, with the only exception of 
individual 11:3 in PJF3, who is a non-penetrant individual for mutation c.736 G>A.
3.2 Suggestion of a recurrent mutation involving c.736G>A mutation
117Evaluation of haplotypes in the Spanish family carrying the c. 736 G>A mutation 
showed that the two populations are carrying completely different chromosomes 
(Figure 3.7).
i
3.3 Sporadic cases
Allele frequencies for the four tested markers are shown in Figures 3.9-3.12 and 
haplotype frequencies are shown in Tables 3.6-3.7. Association analysis revealed that
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markers D6S1550 and D6S980 are associated with the disease (Table 3.8). The 
associated alleles for D6S1550 were 126 and 134, which in Figure 3.9 correspond to 
alleles 3 and 7, respectively. Allele 294 of marker D6S980 is overrepresented in cases, 
in contrast to controls. In Figure 3.12, this allele corresponds to allele 9. Haplotype 
analysis showed that these alleles are present in the four most frequent haplotypes 
present in the cases (Table 3.7). Haplotypes in the 17 controls were unique (Table 
3.6).
For three out of four markers there was no significant deviation from the frequencies 
expected under Hardy-Weinberg equilibrium. D6S1550 showed a significant 
deviation from Hardy-Weinberg equilibrium (Table 3.9), which might indicate that at 
least one of the assumptions is violated, e.g. random mating. None of the four markers 
showed significant intermarker LD either in the parents or in cases (Table 3.10), 
although the pair D6S1550-D6S980 shows a marginal P-value.
Allele frequency for the shorter allele
Marker name Dye Chromosome Peque European Amerindian
MID93 TET 22 0.706 0.209 0.965
MID472 HEX 6 0.542 0.815 0.425
MIDI 326 FAM X 0.333 0.701 0.015
MIDI 327 FAM X 0.389 0.544 0.037
MID1338 HEX X 0.083 0.704 0.398
MIDI 705 HEX X 0.083 0.814 0.146
Table 3.4. MID markers used to evaluate the Amerindian versus European component in Peque
population and frequencies for their shorter allele.
Frequencies in Europeans and Amerindians were taken from 
htt://research.marshfieldclinic.org. 1
’Peque= 0.72 Amerindian.
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region shared among affected individuals.
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alfected individual.
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Table 3.5. Haplotypes for extended JPF3. ID’s correspond to figure 4. 
*= affected individuals; ? phenotype unknown.
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CONTROLS
Haplotype Freq. D6S1550 D6S253 D6S305 D6S980
1 1 128 271 230 312
2 1 128 271 218 316
3 1 128 271 222 294
4 1 128 283 218 290
5 1 128 271 224 298
6 1 120 271 218 290
7 1 128 271 230 296
8 1 136 271 218 292
9 1 136 271 218 296
10 1 128 271 228 296
11 1 128 287 228 296
12 1 136 271 204 284
13 1 136 281 218 296
14 1 128 271 222 298
15 1 128 287 204 296
16 1 130 271 234 292
17 1 128 271 204 296
18 1 128 271 218 288
19 1 126 271 226 288
20 1 130 287 230 296
21 1 126 271 224 286
22 1 130 271 228 290
23 1 126 287 204 276
24 1 130 271 230 290
25 1 126 287 224 284
26 1 130 271 218 288
27 1 126 287 222 296
28 1 134 271 204 296
29 1 128 271 204 292
30 1 128 271 234 288
31 1 134 271 218 290
32 1 126 285 218 298
33 1 134 281 224 290
34 1 126 271 222 302
Table 3.6. Haplotypes in 17 controls for D6S1550-D6S253-D6S305-D6S980
CASES
Haplotype Freq. D6S1550 D6S253 D6S305 D6S980
1 1 120 271 204 9
2 1 120 271 238 286
3 1 120 283 222 290
4 1 124 271 228 280
5 1 126 271 204 288
6 1 126 271 218 280
7* 126 271 218 290
8 1 126 271 222 290
9 1 126 271 224 282
10* 126 271 224 294
11 1 126 271 226 294
12 1 126 271 230 286
13 1 126 273 218 ?
14* 126 279 218 312
15 1 126 283 222 292
16 1 126 283 230 312
17 1 126 285 204 294
18 1 126 287 204 288
19 1 126 287 204 298
20 1 126 287 228 294
21 1 126 289 224 298
22 1 128 271 204 276
23 1 128 271 204 298
24 1 128 271 234 290
25 1 130 271 218 294
26 1 130 271 220 294
27 1 130 279 234 286
28 1 130 281 222 294
29 1 130 283 228 294
30 1 130 ? 204 298
31 1 132 271 230 304
32 1 134 271 220 280
33 1 134 271 234 298
34 1 134 279 , 218 280
35* 134 281 204 316
36 1 134 285 204 290
37 1 134 ? 228 312
Table 3.7. Haplotypes in 22 cases for D6S1550-D6S253-D6S305-D6S980 Individual 23rd was taken out 
of the analysis because o f missing genotypes at three loci. The * indicates four haplotypes that 
represent 23.4% of the disease chromosome.
Haplotype association between cases and controls resulted in a P-value=0.0075
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Figure 3.8. SSCP for c.212 G>A polymorphism in exon 2.
Lane 1= V:2, Lane 2= VI:2, Lane 3= Control-1, Lane 4= VI:4, Lane 5= Control-2. VI:2 and 
VI:4 are carriers.
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Figure 3.9. Allele frequencies for marker D6S1550 in 23 sporadic cases and controls (parents from the 
control trios).
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Figure 3.10. Allele frequencies for marker D6S253 in 23 sporadic cases and controls (parents from the 
control trios).
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Figure 3.11. Allele frequencies for marker D6S305 in 23 sporadic cases and controls (parents from the 
control trios).
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Figure 3.12. Allele frequencies for marker D6S980 in 23 sporadic cases and controls (parents from the 
control trios).
Locus P-value
D6S1550 0.0153
D6S253 0.0638
D6S305 0.7841
D6S980 0.0003
Table 3.8. P values for chi-square obtained in global association analysis between 23 PD cases and 
controls (parents from control trios).
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LOCUS P-value
D6S1550 0.0118
D6S253 1
D6S305 0.6089
D6S980 0.113
Table 3.9. P values for the goodness o f fit for Hardy-Weinberg Equilibrium for markers D6S1550, 
D6S253, D6S305 and D6S980 in parents from control trios.
Controls (parents) Cases
Locus pair P-Value P-Value
D6S1550&D6S253 0.28 0.473
D6S1550&D6S305 0.932 0.18
D6S253&D6S305 0.229 0.815
D6S1550&D6S980 0.238 0.061
D6S253&D6S980 0.953 0.688
D6S305&D6S980 0.828 0.918
Table 3.10. P values for Linkage Disequilibrium in both cases and controls 
(Parents).
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4. Discussion
The purpose of this chapter was to examine whether those affected individuals, who 
were carriers of the c.736G>A mutation in PARK2 were compound heterozygous 01  
were phenotypically affected while being heterozygous for this mutation alone. In 
addition, polymorphic markers were typed in the vicinity of PARK2 to evaluate 
whether the Colombian families carrying the c.736G>A mutation were carrying the 
same chromosome (haplotype background) as a Spanish family where the same 
mutation was reported. Moreover, a set of 23 sporadic patients were evaluated for four 
of these markers as part of a search for association of PARK2 with the disease in this 
group of patients.
Haplotype analysis in the families studied revealed a large shared haplotype in family 
PJF1, which suggests that both parents might share a close common ancestor.
The observation in PJF2 of heterozygosity in marker D6S980 in individual 11:3 and 
given that she is affected and homozygous for the mutation 321-322insGT, suggests 
that this heterozygosity might be due to a mutation in the marker rather than to a 
recombination event, since a recombination would have taken away the mutation, 
leaving the individual as heterozygous. The observation in family PJF3 of one of the 
mutant chromosomes showing a difference only in marker D6S980 supports the idea 
of a high mutation rate at this locus.
Admixture analysis of Peque population revealed that 72% of its genetic component is
i
Amerindian (Table 3.4). The Spanish family presents a chromosome carrying the 
mutation c.736G>A, which is completely different from those in the two Colombian 
families. This observation, in addition to the admixture results, points towards that a 
recurrent mutation has occurred independently in the two populations. However, this
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interpretation needs to be taken with caution since there it is not known how old the 
Spanish chromosome is and because recombination may have happened in the vicinity 
of the mutation taking away those alleles that are in linkage disequilibrium in the 
Colombian mutant chromosomes. Therefore, more closely linked markers (i.e. SNPs) 
should be typed in c.736G>A vicinity and if haplotype sharing is still not observed, 
then the hypothesis of a recurrent mutation would be supported.
The finding of a second mutation in the extended PJF3 is remarkable. This is the third 
PARK2 mutation in Antioquia. Nonetheless, its frequency among the sporadic cases 
does not seem to be significant as judged by the haplotypic data.
The association analysis points to other PARK2 mutations that went undetected, since 
strong association was obtained for two of the four STRs tested. Moreover, when the 
haplotypes where considered in the association analysis a highly significant P-value 
was obtained (Tables 3.6 & 3.7).
Two of the three mutations described are in one of the functional domains of parkin. 
These are 321-322 insGT and the exon 3-duplication, which are associated with an 
earlier age at onset compared with the age at onset for individuals homozygous for c. 
736 G>A, which lies in the linking region of the protein, suggesting that these two are 
more severe than c. 736 G>A. The first two mutations affect the ubiquitin-like domain 
in parkin, which acts as a ligase E3 in the ubiquitination pathway before proteosomal 
degradation 63.
I
In conclusion, a third PARK2 mutation has been found in Antioquia, which is a 
duplication of exon 3. This mutation seems to account for none of the sporadic cases 
as judged by the haplotype analysis. In contrast, in the soporadic cases four out of 37
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haplotypes account for 23.4% of the patient chromosomes (Table 3.7), which will 
eventually be associated to PARK2 mutations. If this were the case, it would constitute 
another founder effect in this isolate population, where evidence of linkage 
disequilibrium (LD) due to admixture and founder effects have already been
- I ' }  i f
documented ’ ’ . Antioquia appears optimal for gene mapping by LD methods
In addition, the finding of exon 3-duplication in apparently heterozygous affected 
individuals adds evidence to refute previous reports claiming that carrier condition 
would be enough for developing symptoms 65,83,110’113,118,128,129.
Finally, in order to establish whether a recurrent mutation has been observed in the 
Colombian and Spanish chromosomes carrying the c.736 G>A mutation, more 
analyses need to be done in its vicinity, e.g. typing SNPs more tightly linked than 
markers D6S253 and D6S305.
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CHAPTER FOUR
CHARACTERIZATION OF A 
FAMILY WITH A MULTIFORM 
MOVEMENT DISORDER
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1. Introduction
Distinct forms of Parkinsonism have been reported as caused by mutations in genes 
and loci described in the previous chapter. In addition, other genes responsible for 
different well characterized disorders have also been associated with Parkinsonism as 
part of their phenotype spectrum. In this introduction I will focus on three of those 
genes that can lead to a similar phenotype to the one presented by a family presenting 
with Multiform Movement Disorder (MMD), where Parkinsonism is the clinical 
landmark. These are Huntington’s disease, Pantothenate Kinase 2 and Ferritin Light 
chain genes. Also, preliminary clinical, pathological and genetic analyses are 
discussed.
1.1 Pantothenate Kinase 2 (PANK2) gene.
Hallervorden-Spatz syndrome (HSS) is a spectrum of disorders characterized by 
neurodegeneration and iron accumulation in the brain with an autosomal recessive 
inheritance mode 132. The classical form of the disease originally described, starts in 
childhood with dystonia, dysartria, rigidity and has a relentlessly progressive course, 
ending in early death. Pathological characteristics include pigmentary degeneration of 
the retina and iron deposition in the basal ganglia is evident in MRI and postmortem 
examination; this is described as the “eye of the tiger” sign 132. The atypical form of 
the disease has late onset (adolescence) and its progression is slower than in the 
classical form.
The term HSS has now been changed to Neurodegeneration with Brain Iron 
Accumulation (NBIA) 133. To emphasize the fact that mutations in the PANK2 gene
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are the major cause of NBIA, more recently it has been proposed that individuals with 
mutations in this gene be classified as Panthothenate Kinase-associated 
neurodegeneration (PKAN) 134 instead of presenting HSS or NBIA that might not be 
due to PANK2 mutations.
The process to find PANK2 mutations began with a homozygosity map strategy that 
made it possible localize the putative gene to chromosomal region 20pl3 135. Then, 
more polymorphic microsatellite markers were added in the candidate region. Since no 
common haplotypes were identified among families and not knowing what the 
candidate gene could be, all 21 known or predicted genes were to be analyzed. After 
studying 15 of those genes, a 7-bp deletion in the coding region sequence of a gene 
homologous to the murine pantothenate kinase 1, was identified in the index family. 
Hence, this gene was named pantothenase kinase 2, PANK2 134. Other missense or null 
mutations were found in 32 of 38 patients with classical HSS. In addition, individuals 
with atypical HSS also presented missense mutations.
1In another study nonsense mutations were found in atypical HSS patients , but in 
contrast to the first report of mutations associated with the disorder, this second study 
found PANK2 mutations in all classical HSS patients. A common (-25%) mutation 
has been identified in both classical and atypical HSS patients 133,134.
PANK2 spans 35 kb and is a member of a family of eukaryotic genes consisting of a 
group of six exons that encode homologous core proteins, preceded by a series of 
alternative initiating exons, some of which encode unique amino-terminal peptides 134. 
Human PANK1, PANK2 and PANK3 are strikingly similar to their murine ortologs and 
the difference between paralogs is not over 20%. These genes are located on human 
chromosomes 10q23, 20pl3 and 5q35, respectively. Human PANK4 is located on 
lp36 134.
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Pantothenate kinase is an essential regulatory enzyme in the Coenzyme A (CoA) 
biosynthesis, catalyzing the cytosolic phosphorylation of pantothenate (vitamin B5), N- 
pantothenoy 1-cysteine and pantotheine 136. The disease could result from product 
deficit (Phosphopantothenate) and a secondary excess of metabolites downstream of 
the block (Cysteine, N-pantothenoyl-cysteine and pantetheine). Pank2 mutations are 
predicted to result in CoA depletion and defective membrane biosynthesis in those 
tissues in which this is the major pantothenate kinase or in those tissues with the 
greatest CoA demand 134.
Intrafamilial variability has been reported including psychiatric symptoms that have 
resulted in misclassification 137. Senile chorea has also been associated with NBIA, 
since the eye of tiger sign has been evident in these patients 138 and cortical dementia 
has also been added to the spectrum 139. Although age of onset in most of NBIA 
patients is in the second or third decade of life 134,140, there are also some reports of 
elder patients (68 years old) 14!.
1.2 Huntington disease (HD) gene.
Huntington disease is characterized by movement disorders, psychiatric symptoms 
(mainly depression) and dementia with autosomal dominant inheritance. Death will 
occur approximately 15-20 years after the first symptoms appear. The pathological 
target in this disorder is the medium spiny neurons of the striatum.
The localization of the HD (or IT 15) gene was performed in 1983 142 but it was only
0 0ten years later that the actual gene was identified . This gene has 67 exons and spans 
169,41 Kb. A mutation in exon 1 was identified, consisting of an expansion of a triplet 
CAG, that encodes glutamine 22. Normal alleles range from 6-35 copies of this
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trinucleotide. It has been observed that alleles with < 26 copies do not present meiotic 
instability (trend to expansion) 143,144. In contrast, > 27 CAGs are commonly reported 
as instable in sperm; the range of alleles 25-35 is called intermediate because of being 
very prone to expansion over 36 CAGs 145,146. The bigger the CAG repeat, the higher 
the instability for the CAG repeat 145, 147,148. Anticipation has been observed, with 
onset tending to become earlier in successive generations 149
Affected individuals have been observed with >36 CAG repeats and penetrance is 
higher when more repeats are carried by the patient. It has been reported that >42 
repeats will always be penetrant (100% penetrant) 149 but <41 might or might not lead 
to symptoms since there have been reports of individuals older than 90, with 41 repeats 
who have died disease-free 150,151.
The expansion of the polyglutamine tract in the huntingtin (htt) protein confers 
cytotoxic properties to htt and compromises some of its endogenous functions 152,153. 
It is likely that post-translational modifications such as phosphorylation, 
ubiquitination, sumoylation, palmitoylation and proteolysis, play an important role in 
the pathogenesis of HD 154' 157.
1.3 Ferritin Light Peptide (FTL) gene.
Ferritin plays an important role in iron storage and in the control of intracellular iron 
distribution. It is composed of 24 heavy (H) and light (L) subunits. H and L are 
regulated by a common cytoplasmic protein, the iron regulatory protein (IRP), which 
binds to the iron responsive-element (IRE), located on the 5’ end of both H and L 
chains gnes (reviewed in 158).
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Curtis and colleagues (2001) reported an unknown, dominantly inherited disorder that 
variably presented with symptoms of Huntington’s disease (HD) or Parkinsonism and 
late onset in a large kindred from Cumbrian-England. Brain histopathology showed 
widespread reddish discoloration of the basal ganglia. The globus pallidus contained 
abundant iron-positive, most of which were also positive for ferritin. The imaging and 
histology data are similar to those of NBIA 159. Their approach in the genetic study 
consisted of first ruling out known neurological disorders by routine diagnostic tests 
and then, performing a linkage analysis study. They found linkage to 19ql3.3, where 
a maximum lod score (Z) of 6.38 at theta (0) zero was obtained. Refining the region 
was possible by adding available family members and polymorphic microsatellite 
markers in the initial candidate region. Haplotype analysis showed a 3.5 cM region of 
maximum disequilibrium between markers D19S596 and D19S866 corresponding to a 
2 Mb physical distance. From this interval they chose FTL as a candidate on the basis 
of the suspected involvement of iron in neurodegenerative disorders 160.
FTL has 4 exons and spans 1.56 Kb. They identified a variant in exon 4 by using 
SSCP. Sequence analysis revealed an insertion of an Adenine after position 460, in all 
affected individuals in a large pedigree. This was not found in 300 Cumbrian controls. 
Five additional patients carrying this mutation presented the disease at 36-58 years. All 
these individuals had dominant family histories of various neurological disorders. This 
mutation is predicted to alter 22 C-terminal residues of the protein and extend the 
chain for four additional residues. Of the five domains of the protein, this mutation 
affects the two last (D -E)159.
Another mutation identified in this gene was a 2-bp insertion in exon 4, which was 
identified in a family with tremor, cerebellar ataxia, parkinsonism and pyramidal signs. 
The pathology revealed accumulation of both light and heavy ferritin
Polypeptide 161. The third reported FTL mutation associated with ferritinopathy is an 
insertion of C at nt 646-647 in exon 4 162. Mutations in FTL have also been associated 
with hyperferritinemia-cataract syndrome 163'168.
A mutation in the IRE of the heavy-ferritin chain has been reported in a Japanese 
family affected with a dominant inherited iron overload in the liver and spleen. The 
mutation c.49A>T significantly increases the binding affinity of IRP 158. The heavy 
ferritin chain gene lies on chromosome 1 lq l3.
1.4 Preliminary work.
In this chapter the characterization of a family presenting with various clinically 
related movement disorders is presented. This family originates in Antioquia- 
Colombia and was ascertained in NEUROCIENCIAS, Universidad de Antioquia. This 
family presents with a neurodegenerative disorder that at times seems typical of 
Parkinson disease, at times more like Huntington and at times more like Hallervorden- 
Spatz syndrome. Affected individuals have been defined as having any of these 
diseases. Clinical details for five out of six affected individuals are summarized in 
Table 4.1.
It is remarkable that there is not clear diagnosis and that there is a lack of a unique and 
dear clinical entity segregating in the family shown in Figure 4.1. Therefore, we have 
named this disorder as Multiform Movement Disorder (MMD).
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ID First symptom Age at onset Evolution
Response
to
medication
Diagnostic
impression
11:4
Psychotic episode, Involuntary 
movements of upper limbs, 
mouth and tongue. Onset at 77 
years old
Resting distal tremor, 
marked tremor of both 
hands. Parkinsonism.
No Late Parkinsonism, Lewy Body disease
111:1
Progressive recent memory 
loss.
Onset at 53 years old
Parkinsonism, Seizures YES
Huntington, Lewy 
Body disease, 
Hallervorden-spatz 
syndrome, 
Parkinsonism
111:6 Recent memory loss and pain in one foot. Onset at 43 years old
Behavioural changes, 
disphagia, facial tics, 
involuntary movements 
of mouth, eyelids.
?
Huntington, Dentato- 
rubro-palydolysial, 
Parkinsonism, 
Hallervorden-spatz
111:7 Diskynesia, recent memory loss. Onset at 53 years old
Irritability, insomnia. 
Family described he had 
tremor when drawing or 
writing
?
Huntington, 
Halllervorden-spatz 
syndrome, Lewy 
Body disease
111:8
Tremor in right hand three days 
after occipital trauma. Onset at 
52 years old
Migraine, generalised 
stiffnes, marked resting 
tremor of upper right 
limb
YES
Parkinson disease of 
focal origin, 
secondary 
diskinesias
Table 4.1. Summary o f clinical features o f affected individuals in family with Multiform Movement 
Disorder (MMD). Individuals are identified as in Figure 4.1.
Interestingly, brain pathology in one of the diceased patients (111:6) showed massive 
iron accumulation in various part of her brain, adding ferritinopathy as a likely 
diagnosis.
As part of a candidate genes approach, I have tested for linkage to several genes 
related with the likely diagnoses shown in Table 4.1 in addition to ferritnopathy. Thus, 
markers tightly linked to PARK1, PARK2, PARK8, PANK2, HD and FTL genes/loci 
were tested in this family (Figure 4.1). This analysis was performed typing 
polymorphic genetic markers in the parents and, initially, in the affected children. 
When necessary unaffected children were also typed.
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Analyses were performed taking into consideration the reported inheritance pattern for 
each gene. Thus, PARK1, PARK8, HD and FTL were analyzed with a dominant 
inheritance mode and high penetrance (0.985). The two remaining genes (PARK2 and 
PANK2) were analyzed using an autosomal recessive inheritance mode and the same 
penetrance as above.
Marker tested in PARK1 (D4S1572) was not informative for linkage since the affected 
father 11:4 was homozygous (Figure 4.1). The remaining markers provided information 
for exclusion. In marker D6S305, affected individuals presented different genotypes, 
suggesting that linkage to PARK2 locus was not present. For example individuals 111:1 
and 111:7 did not share any allele at this marker locus.
PARK8
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Figure 4.1. Candidate genes/loci tested in MMD family.
All markers were picked from Linkage mapping set v.2 (Perkin-Elmer), with exception o f D6S305.
We missed samples o f 1:1,1:2, and 11:3 individuals. Very in the end o f my thesis a sample o f individual 
111:3 became available.
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PARK8 was evaluated using markers D12S85 and D12S345. In D12S85 all affected 
children received an allele 1 from 11:4, but unaffected individual 111:5 also received 
allele 1. The second marker in PARK8 showed that all affected children, with 
exception of 111:1, received allele 3 from 11:4. Alternatively, 111:1 received allele 1 in 
D12S345, reinforcing the suggested exclusion in D12S85.
For PANK2 marker D20S889 was evaluated. Available data suggested exclusion since 
affected individuals received different alleles from their affected father (11:4). Finally, 
for the Huntington disease gene, marker D4S412 was tested. Alleles at this marker 
locus were randomly transmitted from 11:4 to affected individuals. Thus, individual 
111:1 received allele lffom 11:4, whereas 111:8 received allele 3.
For FTL marker D19S902 presented random segregation of alleles, since individual 
11:4 transmitted allele 3 to 111:1 and allele 2 to the rest of his children (affected and 
unaffected). Marker D19S571 presented a particular situation since both the parents 
were heterozygous for the same alleles (i.e. 1/2), leading to inability to identify the 
origin of the parental alleles in a heterozygous child. Thus, unaffected individuals 111:2 
and 111:5 are heterozygous 1/2 same as their parents. Even more, affected individual 
111:1 received allele 1 from 11:4, and affected individual 111:8 received allele 2. These 
results indicate that neither linkage nor segregating haplotype was observed (Figure
4.1).
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1.5 Aims.
A family presenting with an unclear phenotype, at times resembling Parkinson, at 
times Huntington and at times NBIA is studied here. Based on this information, 
candidate genes/loci evaluated, were PARK1, PARK2, PARK8, PANK2 and HD. 
Having obtained brain pathology results indicating massive iron deposits consistent 
with ferritinopathy, the FTL gene was evaluated by means of two polymorphic 
markers. No evidence of linkage was obtained.
The focus of this chapter was to perform a genome wide analysis in this family as a 
strategy for looking for the actual mutated gene causing the disorder.
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2. Materials and Methods
2.1 Power simulation
Power simulations were performed assuming automosomal dominant inheritance and 
high penetrance (0.985). A marker locus with four equally frequent alleles was 
simulated in 100 replicas, using SLINK 55. The disease frequency was assumed to be 
rare (0.0001). The actual simulated pedigree is shown in Figure 4.1. Individuals 
simulated as available were those with a sample code.
2.2 Genome wide scan
deCODE markers were typed across the genome in all available individuals at an 
average density of 6 cM . See laboratory methods in chapter two.
2.3 Microsatellite marker typing
Based on the multipoint lod scores identified, more markers were typed in two of the 
regions identified (Table 4.2). For chromosome 12, markers D12S1601, D12S1703, 
D12S2195, D12S2206 and D122S337 were added into the candidate region. Marker 
D12S1294 was typed again since it had presented a high rate of failure in the data 
provided by deCODE.
For chromosome 14, markers D14S1433, D14S53, D14S983, D14S1020, D14S100S 
and DL4S1000 were added into the candidate region. In this region, an additional 
unaffected individual (111:3) was available for analysis.
Marker typing was performed as indicated in the section on micro satellite marker 
typing in chapter two.
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PCR conditions included a denaturing step of 15 min, followed by 94° 30 sec, 55° 15 
sec, 72° 30 sec for 30 cycles. A final extension step of 10 min was added.
CHROMOSOME MARKER LABEL SEQUENCE (5’ to 3 ’) ASR
12 D12S1601 FAM AGCTACTTCAG AA A ACT ATTTG AC A 193-203
GCAGGAACTTAACTCTTGCTT
D12S1703 TET CTAGCCTGGGAAACATAGTAAGACC 205-243
CTTTCAGTGAGCGGAGACG
D12S2195 HEX GGGTTGGGAACCCTCAAAC 201
CCTTTTTATTAAATGAATGAGTTCC
D12S2206 HEX TAAAGGGGTCAATTCAGCAG 107-127
TCTGGGTACTCCAGTGTTGG
D12S337 FAM CTGCAAAAACCCAGTGCT 133-139
TTATGGAGGCTCTCCGAGT
D12S1294 TET CCAGTTTAGACACCCAGGAT 197-198
ATATTTCAGAACCGCAGCAG
14 D14S1433 HEX ACAGTTCCCAAGACTAAACAGC 162-176
TGGAATTCAGTTATTTGTTAATGC
D14S53 TET CAACAAGAGCGAAACTCGC 135-155
GAAGACTCAAGATATAGCAG
D14S983 TET TGGACTGGTTAGCCTCAGTG 222-270
GCATCAACTGGCTTCCAATC
D14S1020 FAM GCCTTTACAGAGGGACTCATC 228-268
TCTACTGGGAGCTAGGGCAC
D14S1008 FAM TGGCAAGGATGTAGAACACT 112-126
CTTAGCCTGGGTGACAGAG
D14S1000 HEX TGGATTGTATTGCCAACTG 107-133
TGTGTACCCAAGCATAAGTAGG
Table 4.2. STR markers used to fine mapping regions on chromosomes 12 and 14 in MMD family. 
Oligo F was labelled as indicated. Oligo R had no label. ASR= average size range. 
Sequences and ASRs were obtained from UCSC genome browser 
(http: // genome, ucsc. edu f ).
2.4 Two-point, multipoint and haplotype analysis.
I ^
Two-point lod scores were calculated using MLINK from the package LINKAGE 
and assuming autosomal dominant inheritance. Allele frequencies were those 
provided by deCODE. They, in turn, estimated them from a pool of samples of
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individuals with different ethnic backgrounds. Penetrance was set to 0.985 (same as in 
the power simulation).
Multipoint lod scores and haplotypes were obtained with simwalk2 49 using same 
conditions as for two-point analysis.
3. Results.
3.1 Power simulation
Table 4.3 shows power simulation results. This simulation indicated that although no 
Z>3 is likely to be reached in this family, a maximum lod score of 2.37, was expected 
at zero recombination fraction.
As the power of the pedigree structure was not high enough as to reach a lod score of 
3, the pathological findings were greatly valued to make the decision of running a 
genome wide scan.
Expected Lod Score (Z) Probability o f reaching Z> to:
0 Average Z max 1 2 3
0 1.34 2.37 66 34 0
0.05 1 2.14 52 21 0
Table 4.3. Power simulation o f family with MMD.
Power simulation also indicated an approximately 50% chance of reaching a Z>1 at 0= 
0.05 was provided by the pedigree structure.
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3.2 Genotvping results
Table 4.4 shows statistical summary of deCODE marker typing. Although there was 
no data at all for marker locus D1S219, and a high failure rate for marker D12S1294, 
deCODE marker typing efficiency was as high as 97%. The individual with the least 
average genotypes was 111:2 (87%). In contrast the individuals with the most genotypes 
were 11:1, 11:2, 111:5 and 111:6 (99%). Per chromosome, the least genotypes were 
obtained for chromosome 9 (92%). The highest typing efficiency was obtained for 
chromosome 22 (100%, Table 4.4).
Marker typing efficiency for markers on candidate regions on chromosomes 12 and 14 
was 100%.
3.3 Two-point analysis
Tables 4.6-4.27 show two-point lod scores (Z) for chromosomes 1-22 (see appendix 
2), respectively and a summary of lod scores above 0.9 is shown in Table 4.5. 
Two-point lod scores above 0.9, at any recombination fraction, were found on 
chromosomes 1 (Z=1.7), 5 (Z=1.03), 7 (Z=0.97), 11(Z=0.97), 14 (Z=1.18) and 16 
(Z=1.23) (See summary in Table 4.5).
On chromosome 1, the highest lod score (Z=1.7 at 0= 0) was obtained for marker locus 
D1S452 (Table 4.5), where allele 4 was segregating with the disorder. Individual 11:2,
i
who is" unaffected, received allele 4 and the remaining unaffected individuals 
alternatively received allele 7 (Figure 4.2).
On chromosome 11 there were three markers where the same score was obtained (Z= 
0.97; Table 4.5). Marker locus D11S937 segregated allele 10 to the affected
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INDIVI CHROMOSOME
DUAL 1 2 . 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Av
11:1 0.98 1.00 0.97 1.00 0.96 1.00 0.93 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.93 0.93 1.00 1.00 1.00 1.00 c
11:2 1.00 1.00 1.00 0.97 1.00 0.96 0.97 1.00 0.96 1.00 1.00 0.96 0.94 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 c
11:4 0.98 1.00 0.97 0.97 1.00 0.96 0.97 1.00 0.84 1.00 0.95 0.96 0.94 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.96 C
11:5 0.98 0.94 1.00 1.00 1.00 0.96 0.97 0.91 0.92 1.00 0.95 1.00 1.00 1.00 0.95 0.94 0.95 0.93 0.93 1.00 1.00 1.00 1.00 c
111:1 0.96 0.97 0.94 1.00 1.00 0.96 0.97 1.00 0.96 0.89 1.00 0.93 1.00 1.00 0.95 1.00 1.00 1.00 0.93 0.93 1.00 1.00 1.00 c
111:2 0.80 0.83 0.91 0.93 0.96 0.75 0.87 0.87 0.68 0.89 0.85 0.86 0.82 0.96 0.90 0.89 0.86 0.93 0.93 0.80 0.93 1.00 0.88 C
111:4 0.98 1.00 0.97 1.00 0.96 1.00 0.93 0.91 0.96 1.00 1.00 1.00 1.00 1.00 0.95 0.94 1.00 1.00 0.93 0.93 0.93 1.00 1.00 C
111:5 1.00 1.00 0.97 1.00 1.00 1.00 1.00 1.00 0.96 1.00 1.00 0.96 1.00 1.00 1.00 1.00 1.00 1.00 0.93 1.00 1.00 1.00 1.00 C
111:6 1.00 0.97 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.96 0.95 0.96 0.94 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 c
111:7 0.98 0.94 0.97 0.97 1.00 1.00 1.00 1.00 0.88 1.00 0.95 0.89 0.82 0.96 0.95 1.00 0.91 1.00 0.93 0.93 1.00 1.00 1.00 c
111:8 1.00 0.97 0.97 1.00 1.00 1.00 0.97 0.96 0.96 1.00 0.90 0.89 0.94 1.00 0.90 1.00 1.00 0.93 1.00 0.93 1.00 1.00 0.96 C
Average 0.97 0.97 0.97 0.98 0.99 0.96 0.96 0.97 0.92 0.98 0.96 0.95 0.95 0.99 0.96 0.98 0.98 0.98 0.96 0.96 0.99 1.00 0.98 C
Table 4.4. deCODE marker typing efficiency.
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individuals with the only exception of individual 111:7, who is affected and received 
allele 12. Unaffected individuals alternatively received allele 12 (Figure 4.3). For 
marker D11 S I886 allele 3 was transmitted to affected individuals, with exception of
Recom bination fraction
Locus/
Chromosome
Genetic
map 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
Chromosome 1
D1S2628 168.68 -0.35 -0.19 -0.1 -0.04 -0.01 0.5 0
D1S452 176.39 1.69 1.34 0.96 0.55 0.18 0 1.7
D1S2818 187.03 -3.1 -0.73 -0.22 -0.04 0 0.5 0
Chromosome 5
D5S1725 106.88 0.29 0.21 0.13 0.06 0.02 0 0.29
D5S409 114.89 0.26 0.78 0.67 0.42 0.14 0.1 0.78
D5S2027 120.95 0.55 1.02 0.84 0.52 0.17 0.088 1.03
D5S2065 122.49 0.55 1.02 0.84 0.52 0.17 0.088 1.03
D5S490 134.52 -0.33 -0.18 -0.09 -0.04 -0.01 0.5 0
Chromosome 7
D7S2459 120.05 -4.46 0.71 0.62 0.37 0.11 0.113 0.72
D7S2418 122.15 -5.27 0.97 0.82 0.51 0.17 0.101 0.97
D7S530 133.2 -6.08 0.39 0.44 0.32 0.12 0.173 0.45
Chromosome 11
D11S4087 73.81 -4.12 0.06 0.23 0.16 0.05 0.204 0.23
D11S937 85.42 -5.27 0.97 0.82 0.51 0.17 0.101 0.97
D11S1780 94.12 -5.56 -0.3 -0.1 -0.03 -0.01 0.5 0
D11S1886 107.71 -7.01 0.97 0.82 0.51 0.17 0.101 0.97
D11S4206 110.81 0.34 0.25 0.15 0.08 0.02 0 0.34
D11S908 118.66 -0.13 -0.08 -0.04 -0.02 0 0.5 0
D11S4089 126.83 -6 0.43 0.47 0.33 0.12 0.164 0.48
D llS 4 151 135.73 -4.33 0.97 0.82 0.51 0.17 0.101 0.97
D11S2367 148.23 -4.17 0.43 0.47 0.33 0.12 0.163 0.48
Chromosome 14
D14S81 99.25 -7.09 0.07 0.24 0.17 0.05 0.203 0.24
D14S1054 102.52 1.18 0.91 0.62 0.33 0.1 0.001 1.18
D14S987 106.22 -7.49 -0.78 -0.23 -0.03 0.01 0.5 0.24
Chromosome 16
D16S505 108.07 0.55 1.07 0.93 0.64 0.26 0.098 1.07
D16S763 120.63 1.23 1.07 0.84 0.54 0.2 0 1.23
D16S2621 131.46 -6.16 0.11 0.33 0.28 0.11 0.222 0.34
Table 4.5; Summary o f Two-point LOD scores above 0.9. ' 
For a complete information see appendix 2.
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Figure 4.2. Markers tested on chromosome 1. Marker D1S452 showed the highest two-point lod score.
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individual 111:7 who received allele 1. Alternatively all unaffected children received 
allele 1 (Figure 4.3). On marker D11S4151, allele 8 was transmitted to affected 
individuals with the only exception of individual 111:7 who received allele 7 from the 
affected father. Allele 7 was transmitted to all three unaffected children (Figure 4.3).
On chromosome 14, the highest lod score (Z= 1.18) was obtained for marker locus 
D14S1054 (0=0). However, its flanking markers showed Z<-2, therefore not 
supporting a linked region (Table 4.5). In contrast, marker locus D14S616 showed a Z 
max= 0.97 (0=0.1) and its flanking markers showed either positive lod scores or 
greater than -2, allowing support of the region as linked to the disorder (Table 4.5).
On chromosome 16 the highest lod score was obtained for contiguous markers 
D16S505 (Z=1.23) and D16S763 (Z= 1.07; Table 4.5).
In marker D16S505, all affected individuals received allele 5 from 11:4; alternatively, 
all unaffected children received allele 6 from 11:4. In marker D16S763, allele 4 was 
transmitted from 11:4 to all his affected children. Alternatively, unaffected children 
received allele 6 (Figure 4.5).
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Figure 4.3. Markers tested 
on chromosome 11. 
Markers D11S937, 
D11S1886 and D 114151 
showed the highest two- 
point lod scores.
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Figure 4.4. Fine mapping on chromosome 14.
Extra markers were D14S53, D14S983, D14S1020, D12S1008 and D14S1000. Underlined appear markers from the original genome search. The mutant chromosome 
(green) is carried by affected individuals and one unaffected, individual (111:3). Incomplete penetrance may explain this observation. Boxed appears the haplotype 
segregating with the disease
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3.4 Multpoint analyses
Figures 4.6, 4.7, 4.8, 4.9 and 4.10 show positive multipoint lod scores among all 23 
chromosomes. Positive multipoint lod scores were obtained on chromosomes 1,11, 
12, 14 and 16. The highest multipoint lod scores were: 1.04 for chromosome 1 at map 
position 176.39 in the interval D1S2628-D1S2818 (Figure 4.6); 1.27 for chromosome 
11 at map position 140.73 in the interval D11S4151-D11S2367 (Figure 4.7); 1.70 for 
chromosomel2 at map position 89.31 in the interval D12S283-D12S351 (Figure 4.8);
2.1 for chromosome 14 at map position 74.94 in the interval D14S258-D14S616 
(Figure 4.9); and Z=0.55 for chromosome 16 at map position 118.12 in the interval 
D16S516-D16S2621 (Figure 4.10). Despite having presented relatively low two-point 
lod scores (Table 4.17), chromosome 12 presented the second highest multipoint lod 
score after chromosome 14.
3.5 Haplotvpe analysis
Additional markers were added in the candidate regions identified by multipoint 
analysis on chromosomes 12 and 14.
On chromosome 12, addition of five markers in the candidate region led to the 
identification of a disease-associated haplotype, which included alleles 9-2-4-1-1-1-1-1 
at markers D12S83-D12S1601 -D12S1294-D12S1703-D12S2195-D12S2206-
D12S337-D12S326 (Figure 4.11). However, this haplotype was present in one 
unaffected individual (111:2) and individual 111:5 also presented this haplotype, with the 
only exception of allele 1 at marker D12S326, where this individual carries allele 4 
(Figure 4.13); the presence of this haplotype in four affected siblings in addition to two 
unaffected individuals indicates no linkage of the disease to chromosome 12.
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Figure 4.9. Plotting multipoint lod scores o f chromosome 14
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Figure 4.10. Plotting multipoint lod scores o f chromosome 16
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Figure 4.11. Fine mapping on chromosome 12.
Extra markers were D12S1601, D12S1703, D12S2195, D12S2206 and D12S337. Underlined appear markers from the original genome 
search. The mutant chromosome (green) is carried by affected individuals and two unaffected individuals, suggesting exclusion o f this locus.
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On chromosome 14, five additional markers were typed, including individual 111:3, 
leading to the identification of a disease-associated haplotype characterized by alleles 
5-2-2-2-2-3-2 at markers D14S258-D14S1433-D14S53-D14S983-D14S1020 
D14S1008-D14S1000. However, the recently available individual (111:3) carries this 
haplotype (Figure 4.4). Other than this unaffected individual, all other carriers of this 
haplotype are affected individuals. This observation suggests incomplete penetrance.
On chromosome 16, a disease-associated haplotype characterized by alleles 5-4 and 
involving markers D16S505-D16S763 was identified (Figure 4.5). This haplotype is 
only present in affected children from 11:4. However, individual 11:2 (unaffected) 
carries this haplotype.
4. Discussion
The family studied in this chapter presents a clinical heterogeneous movement disorder 
accompanied with recent memory loss. Clinical information is consistent with 
Hallervorden-spatz, Huntington and Parkinson’s disease. Exclusion of the candidate 
genes/regions for these disorders and the pathological findings revealing iron deposits 
in the brain of an affected person from this family, allowed us to engage in a genome 
wide scan, expecting to find linkage to a region where a plausible iron metabolism 
• related gene is located.
Considering the low power observed in the power simulations (Z= 1.34 at 0= 0) and 
the fact that not many regions were identified in the two-point analysis, a cut off lower
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than the expected average lod score of 1 at 0=0.05 was used to define candidate 
regions. Thus, considering a two-point lod score > 0.9, chromosomes 1, 5, 7, 11, 14 
and 16 were initially identified as candidates. After multipoint analysis for all 
chromosomes, positive lod scores were obtained only for chromosomes 1, 11, 14 and 
16. In addition, Chromosome 12 presented a lod score of 1.70 in the interval 
D12S1294-D12S326. All lod scores obtained in these analyses were lower than 3 
(Z<3), suggesting that they all could be false positive results 42.
Fine mapping was carried out for regions on chromosomes 12 and 14. For 
chromosome 12, it was found that two unaffected individuals were carrying the 
disease-associated haplotype (Figure 4.11), which suggests exclusion of this region as 
harbouring a mutant gene causing the disorder in this family. Fine mapping of the 
region on chromosome 14 included a new recently available individual (111:3). 
Haplotype segregation was perfect with the disorder, with exception of the new 
individual, who carries the disease-associated haplotype (Figure 4.4). Incomplete 
penetrance may explain why an unaffected person carries the mutant chromosome.
The Neuroglobin gene (NGB), which is an important candidate gene related to the iron 
metabolism, lies in this interval. NGB is a brain oxygen transporter 169. Levels of this 
transporter have been differentially found in the brain of people with disorders such as 
Alzheimer’s disease, where a reduced capability of oxygen transport has been 
associated with neuronal death, triggering the disease 170. It is suspected that other 
related disorders, such as Parkinson, also have links with the level or efficiency of 
oxygen transport by this molecule 171, leaving open the possibility that this gene is 
implicated in the disorder presented here.
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If chromosome 14 was definitely excluded, candidate regions on chromosomes 1, 11 
and 16 should undergo fine mapping. Based on the multipoint lod scores, the order of 
further evaluation could be as follows: Chromosome 11, then chromosome 1 and 
finally chromosome 16. Interestingly, on chromosome 11 there were three hints of 
linkage involving markers D11S937, D ll SI 886 and D11S4151. The two first were 
shown in the two-point analysis but not in the multipoint analysis. Markers D11S4087 
and D11S4206 flank this region, which extends approximately 37 cM. The heavy- 
ferritin chain gene (FTHl) lies in this region. Even though the haplotype and 
multipoint analysis do not support this locus, a double recombinant in individual 111:7, 
in this interval, would fit with FTHl as responsible for the disease in this family. IRE 
mutations of FTHl have been reported in a large Japanese family presenting with iron
1 CO
deposits in liver and spleen . FTHl mutations could clearly explain the pathology 
findings and the disease itself in our family. This is assumed based on reports by 
Curtis and colleagues (2001) of a disorder clinically similar to the one presented here, 
where brain pathology is also similar to the one presented by our patients. In their 
study, they found mutations in the ferritin light chain {FTL) and iron deposits159 in a 
similar manner to our family. We excluded FTL and therefore FTHl is a very 
reasonable candidate gene.
However, if no mutation was identified in FTH l, despite no evident candidate gene in 
the second region on chromosome 11, this should be evaluated in more detail by 
typingjextra markers in the region of D 11S4151.
Candidate genes in the chromosomal region on chromosome 1 around marker D1S452 
are not evident. However, initial testing of extra markers would help us focus in 
particular chromosomal regions where plausible candidate genes locate.
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Candidate genes in the interval D16S505-D16S763 (on chromosome 16) are not clear. 
However, EFCBP2 presents relatively high expression in brain and is known to bind 
calcium in neurons.
In addition, chromosomes 5 and 7 are to be taken into consideration for further 
examination in case of excluding all candidate regions where positive multipoint lod 
scores were obtained.
In conclusion, no perfect haplotype segregation with the disorder has yet been found. 
However, up to date data suggests that NGB and FTHl genes are both positional and 
functional candidate genes in the family studied here.
Furthermore, if chromosomes 14 and 11 turn out to be excluded, other regions on four 
different chromosomes (1, 5, 7 and 16) can still be further analyzed in searching for 
the mutant gene responsible for the disorder in this family.
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CHAPTER FIVE
LINKAGE ANALYSIS OF FAMILIES
WITH
GENERALIZED EPILEPSY WITH 
FEBRILE SEIZURES PLUS, GEFS+
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1. Introduction
1.1 General aspects on epilepsies.
Epilepsy is a group of neurological disorders characterized by a marked increment of 
the neuronal excitability inducing recurrent auto limited convulsions in the absence of 
acute triggering factors 172, 173. Attacks may remain confined to an elemental or 
complex alteration of the behaviour or can progress to focal or generalized 
convulsions. Convulsions can be partial or generalized, depending on whether the 
epileptic discharges involve, in the beginning, one hemisphere or both, respectively 174. 
The term epilepsy should not be used to describe single epileptic seizures, seizures that 
occur during the process of an acute illness or occasional provoked seizures (i.e. 
febrile seizures) (reviewed in 175).
Reported prevalence rates in epilepsy vary between 0.2 and 4.2 % 176. In Colombia, 
particularly in Medellin-Antioquia, it has been estimated that the prevalence is 2.14 %
177
There are over 40 clinical forms of epilepsy, which are classified according to their 
aetiology and/or their clinical presentation 174. Epilepsies are classified as partial and 
generalized, which also can be further classified as symptomatic or idiopathic. In the 
first a discernible cause (e.g. brain or metabolism abnormalities) can be established.
The term idiopathic epilepsy is reserved for those cases affected by convulsions where 
neither brain structure or metabolism abnormalities are detected, and are presumed to 
have genetic basis. Idiopathic epilepsy is age related, usually has good response to
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1 78treatment and may present either Mendelian or complex inheritance . According to 
the type of convulsion, idiopathic epilepsy is subdivided into Idiopathic generalized 
epilepsy (IGE) and Idiopathic partial epilepsy (IPE). Recent findings suggest that 
some symptomatic epilepsies have an important genetic component179.
Twin studies have found a high concordance rate for the type of epilepsy. Thus, 94%
of monozygotic twins presented the same subtype of epilepsy, whereas 71% of
180dizygotic twins shared their epilepsy subtype , which indicates a strong genetic 
component. Despite the fact that several studies have confirmed the importance of 
genetic factors in the expression of idiopathic epilepsy, its genetic basis is complex 
and very likely involves locus and allelic heterogeneity, in addition to environmental 
factors 181.
There are four main types of IGE. These are Juvenile myoclonic epilepsy (JME), 
Childhood and Juvenile absenses epilepsy (CAE and JAE) and epilepsy with grand 
mal seizures on awakening (EGMA). The commonest of these is JME.
In recent years, several genes related to epilepsy have been mapped by linkage and 
association studies; so far, over 15 autosomal genes and one mitochondrial one have 
been identified (Table 5.1).
Moreover, several genetic linkage studies have provided evidence, sometimes 
inconsistent, of the influence of other loci conferring susceptibility to develop 
epilepsy. Sometimes the same locus has been linked to different forms of epilepsy and, 
also, sometimes a single form of epilepsy has shown linkage to different loci (Table
5.1).
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Clinical form Chromosomallocation Gene/Locus References
Partial
Nocturnal Autosomal dominant Epilepsy of 
frontal lobe
Autosomal dominant Partial Epilepsy with 
auditive characteristics 
Rolandic Epilepsy
20q 13.2
i q
10q
15ql4
CHUN A 4 
CHRNB2 
LGI1
CHRNA 7?
1 8 2
18 3
1 8 4 ,  1 8 5  
1 8 6
Generalized
Progressive Myoclonic Epilepsy type 1
Progressive Myoclonic Epilepsy with red 
ragged fibbers, MERRF
Batten disease
Progressive Myoclonic Epilepsy of 
Lafora’s type
Progressive epilepsy with mental 
retardation
21q22.3 
mtDNA 
16pl2.1-l 1.2 
6q23-25 
8p
CSTB
tRNA(lys)
CLN3
EPM2A
CLN8
1 8 7 - 1 8 9
1 9 0
1 9 1 - 1 9 3  
1 9 4 ,  1 9 5  
1 9 6 ,  1 9 7
Idiopathic generalized
Juvenile Myoclonic Epilepsy
Juvenile Myoclonic Epilepsy with absences 
IGE (JME, CAE, JAE, EGMA)
Myoclonic Epilepsy autosomal recessive of 
the infancy
Generalized idiopathic epilepsy 
Benign Neonatal Convulsions
6p21.2
15ql4
5q34
IP
3q26
16pl3
8q24
3p
20ql 3.2 
8q24
?(HLA) (EMJ1)
? (EMJ2) 
GABRA1 (EMJ4)
? (EMJ3)
CLCN2
?
?
?
KCNQ2 (EBN1) 
KCNQ3 (EBN2)
1 9 8 - 2 0 1
2 0 2 ,  2 0 3
2 0 4
2 0 5
2 0 6
2 0 7
2 0 8  
2 0 9
2 1 0 - 2 1 2
2 1 3 , 2 1 4
Special Syndromes
Febrile Convulsions, FS 8q13-21 ? (FEB1) 2 1 5
19pl 3.3 ? (FEB2) 2 1 6
5ql 4-15 MASS1(FEB4) 2 1 7 , 2 1 8
Febrile Convulsions Plus, GEFS+ 19ql 3 SCNJB (GEFSP1) 2 1 9
2q24 SCN1A (GEFSP2) 2 2 0 - 2 2 2
SCN2A 2 2 3
5q32-35 GABRG2 (GEFSP3) 2 2 4
* Table 5.1. Molecular genetics o f epilepsies. (Modified from 225).
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Even though, IGE is classified as a genetic disorder, the majority of cases lack 
evidence of a clear genetic basis. Part of the difficulty of identifying susceptibility 
genes originates from incomplete penetrance, variable expressivity and genetic 
heterogeneity, in addition to environmental factors.
It is expected that identification of genes responsible for Mendelian forms of common 
types of IGE will help identify susceptibility genes for the common forms. In addition, 
large-scale genome screening methods applied to large populations of patients with 
common types of epilepsy will help to identify variations in other genes that are 
associated with the disease.
1.2 Genes in GEFS+
In contrast to most cases of IGE, Generalized epilepsy with febrile seizures plus 
(GEFS+) presents monogenic inheritance. Generalized seizures during fever episodes 
(febrile seizures, FS) occur in 2-5% of children under six 226. Of these, about 5% 
develop non-febrile seizures or epilepsy later in life (FS+). GEFS+ is characterized by 
FS and FS+, or because they present non-febrile tonic-clonic seizures111.
Historically, FS and epilepsies have been considered different conditions; however, 
GEFS+ connects these two entities showing that there is a genetic link between them. 
GEFS+ has been described in families presenting with febrile convulsions and 
following an autosomal dominant inheritance mode with incomplete penetrance 228.
Four genes causing GEFS+ and one causing FS have been identified so far.
SCN1B (GEFSPll
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First, the voltage gated B1 sodium neuronal channel encoded by the gene SCN1B 
presented mutations in an Australian family, in which 26 of its members had GEFS+. 
The approach used to identify this gene involved linkage analysis, using a penetrance 
of 64% and a phenocopy rate of 3% 85,215. They found that a region on chromosome 
19q 13.1 was co-segregating with the disorder. SCN1B lies in this region, which has 
five coding exons and extends 9.73 Kb. Single strand conformational analysis 
followed by sequencing revealed a transversion of C to G in nucleotide 387 (exon 3), 
leading to the substitution of Cysl21Trp219.
This mutation changes a conserved cysteine residue, altering a disulfide bridge that 
normally maintains an extracellular fold. A second GEFSP1 family was reported, 
where a C l21W mutation in SCN1B was found . This mutation was not present in 
96 control individuals.
SCN1A fGEFSP21
The second GEFS+ locus was also identified by linkage analysis. Baulac and 
colleagues (1999) studied a large family where SCN1B was excluded and identified 
linkage to a 20 cM region on chromosome 2q24-q3 3 230. Moulard and colleagues 
subsequently studied five additional families with GEFS+ (and one with FS), being 
able to refine the linked region on chromosome 2 23 \  The following year, Escayg and 
colleagues (2000) 220 found that the family described by Baulac and colleagues (1999) 
carried a mutation in the SCN1A gene, which leads to the substitution Argl648His. 
They also found that one of the families described by Moulard and colleagues (1999) 
carried a mutation in codon 875, causing the substitution Thr to Met. These nucleotide 
changes were not found in more than 100 controls.
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SCN1A has 26 exons and extends 84.48 Kb. It encodes the sodium channel a-subunit, 
which is comprised of four domains (D1-D4), each of which is composed of six 
transmembrane segments (S1-S6).
A wide range of point mutations have now been reported in SCN1A, which have been 
associated with GEFS+ 220'222>232’235 and with other types of epilepsy including Severe 
myoclonic epilepsy of infancy (SMEI) 236‘239. Most of SMEI mutations have been 
reported in the pore forming loop of the protein and the majority of them are nonsense 
mutations 236, in contrast to those associated with GEFS+, which are all missense 
mutations.
Functional studies of some of the reported SCN1A mutations have shown disruption of 
channel inactivation, resulting in increased Na+ influx and leading to hyperexcitability 
and suggesting a gain of function 240. In contrast, SCN1B mutations in GEFSP1 have 
been identified as loss-of-function mutations, which also indirectly decrease the rate of 
inactivation of the sodium channel 219.
SCN2A
SCN2A lies in the same chromosomal region as SCN1A, 2q24-q33. Together with 
SCN3A and SCN9A, they constitute a neuronal sodium channel (SCN) cluster on this 
chromosomal region 221 (Figure 5.1). Sugawara and colleagues (2001) evaluated 
nineteen Japanese families with GEFS+. They looked for mutations in SCN1B, SCN1A 
and SCN2A genes in the index cases from these families. They included SCN2A 
because it is also expressed in high levels in the central nervous system with a tissue 
specific profile. They found two additional mutations in SCN1A and, for the first time, 
a mutation in SCN2A, which consisted of a c.1571 G>A transition, leading to the
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substitution R187W. This mutation was not found in 112 controls and is highly 
conserved among the voltage gated sodium channel alpha subunit family members and 
through evolution 223.
GABRG2 tGEFSP3^
More recently, a fourth gene associated with GEFS+ was identified in 5q34 (GEFSP3). 
It was known beforehand that a cluster of gamma amino-butyric acid (GABAa) 
receptor subunit genes is located in this region, including a l  (GABRA1), a6 
(GABRA6), p2 (GABRB2) and y2 (GABRG2) subunits 241,242. These genes have nine 
{GABRG2 and GABRA6) and eleven exons (GABRA1 and GABRB2). After having 
found linkage to this region in a French family with GEFS+, sequencing of GABRG2, 
which extends 85.71 Kb, revealed an A to T transversion in exon 8, leading to the 
substitution K289M 243. In this family, 13 affected, 2 obligated carriers and one 
unaffected individuals were heterozygous for this mutation. This mutation lies in a 
highly conserved segment localized in the extracellular loop between transmembrane 
segments M2 and M3, and was not found in 800 control chromosomes. Subsequently, 
more GABRG2 mutations have been reported in GEFS+ 244'246.
GABAa receptors are heteropentameric proteins, with an integral chloride channel 
mediating rapid synaptic inhibition, and possess specific binding sites for GABA, 
benzodiazepines, barbiturics and steroids 247. The GABAa receptor gene family 
includes six major classes of subunits, which are a , |3, 6, y, e and ji. The a-subunit has 
six subtypes; ^-subunit, four subtypes; y-subunit, three subtypes; and the remaining 
three types y, e and n only have one form 247. The subunit combination most frequently 
found in the brain is a1 p2y2 248.
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In addition to the four GEFS+ genes described, mutations in one gene have been found
in FS. This study was started in a large Japanese FS family and then 39 additional FS
families confirmed linkage to the chromosomal region 5ql4-15 217 (FEB4). Based on
the report of a naturally occurring murine mutation in the gene massl (Monogenic
audiogenic seizure-susceptible), which causes audiogenic seizures in the Frings mouse
strain 249, and knowing that the human orthologue maps to 5ql4, Nakayama and
colleagues looked for mutations in MASS1 and found the disease causing S2652X
mutation, as well as other variations. S2652X was not found in any of 200 control
chromosomes and is predicted to disrupt the C-terminal end of the protein. A small
repetitive motif of MAS SI shares homology with several sodium-calcium exchangers 
218
Furthermore, three other FS chromosomal regions awaiting for genetic identification 
have also been associated with FS, but not with afebrile seizures. These are FEB1 at 
8ql3-q21215, FEB2 at 19pl3.3216 and FEB2 at 2q23-24 25°.
Mutations in these genes account for less than 10% of families with GEFS+, indicating 
that other genes might more frequently play role in GEFS+ aetiology. This is 
supported by a number of families reported where the current known GEFS+ and FS 
genes have been excluded 223)251
Despite findings of disease causing mutations in the five described genes, that 
segregate with the disorder through families supporting the idea of a mendelian-like 
inheritance mode in GEFS+ and FS, other studies have supported a polygenic 
inheritance model 252, suggesting that the genes identified so far in GEFS+ might
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correspond to Mendelian forms of the complex disorder, similar to what happens in 
IGE. Interestingly, those suggested genes in the polygenic inheritance model have not 
yet been identified
1.3 Aims
This study aimed to characterize a set of six families with GEFS+ from Antioquia- 
Colombia. First, by testing for linkage to the previously reported FEB loci and GEFS+ 
genes. Families showing exclusion will be studied by whole genome scan.
The characterization of these families is important because it will, eventually, lead to 
the identification of causing disease mutations that can then be used for diagnostic 
purposes, predictive tests in as yet unaffected children and will help to evaluate the 
degree of genetic heterogeneity in GEFS+ in this population. In addition, it might 
identify families, from this set, where exclusion for the GEFS+ genes and FEB loci 
would suggest the participation of unidentified genes.
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2. Patients and Methods
2.1 Families
Six families are included in this study (Figures 5.3-5.8). All of them were ascertained 
in the Paediatric Neurology Service of Hospital Universitario San Vicente de Paul and 
Medicine Faculty of Universidad de Antioquia (Medellin-Colombia). Pedigrees were 
extended focusing on a history of seizures (febrile or non-febrile) in relatives of each 
index case. All available individuals with a positive history underwent a full 
neurological examination and the characteristics of the seizures evaluated by 
interviewing relatives and reviewing available clinical records. Seizures were 
classified according to international criteria 174. Blood samples were collected from 
available individuals who signed a written informed consent, designed for this 
particular study. DNA was isolated using the QIAGEN DNA extraction kit following 
the manufacturer’s instructions.
2.2 Power simulation
Power simulations were performed assuming locus homogeneity. It was assumed 
penetrance of 0.96 and a mutated gene frequency of 1/10000. A microsatellite marker 
locus with four equally frequent alleles was simulated in one hundred replicas with the 
software SLINK55.
*2.3 Genotvping and linkage analysis
Polymorphic microsatellite markers tightly linked to GEFS+ genes and FEB loci were 
evaluated (Table 5.2). Each marker had a fluorescent label to allow for pooling and to 
run them in one single lane onto an ABI-377 (Applied Biosystems).
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MARKER DYE LOCUS/GENE CHROMOSOME ASR REFERENCE
D8S530 6-FAM
D19S177 HEX
D2S382 6-FAM
D5S644 6-FAM
D19S425 HEX
D5S1403 TET
FEB1 8q 13 213-231 215
FEB2 19p 159-177 216
FEB3/SCN1 A/ 
SCN2A 2q24 160-180
230,231
FEB4 5ql4-15 90-116 217
SCN1B 19q 13 260-290 219
GABRG2 5q34 210-240 224
Table 5.2. Polymorphic microsatellite markers evaluated in Colombian GEFS+ families. 
Average size range.
ASR=
In some families additional markers were examined, in FEB3: D2S2330 and D2S2157 
(Figure 5.1 and Figure 5.3).
In FEB2: D19S894, D19S216 and D19S1034 (Figure 5.4 and Figure 5.5).
In GABR: D5S436, D5S410, D5S1403, D5S1955, D5S2118, SHGC-132760 and 
D5S422 (Figure 5.2 and Figure 5.6).
Marker typing was performed as indicated in the section on Microsatellite marker 
typing.
Linkage analysis was performed using same conditions as for the simulations and 
assuming equal allele frequencies for alleles at every marker locus.
Additionally, analyses were performed with varying penetrances values and 
phenocopy rates. Thus Family 1 was also analyzed using pentrance= 0.96 and 
phenocopy rate of 3%. All families were also analyzed assuming penetrance= 0.65 and 
phenocopy rate of 2%.
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CEN SCN3A SCN1A
165769546 SCN2AI 166673262 SCN9AI
1659760981 1668803151
D2S2157I D2S382I D2S2330I
165652687 165793277 166522920
2q24
Figure 5.1. SCNA cluster at chromosomal region 2q24. Above are indicated the SCNA genes o f this cluster. Underneath are indicated the 
microsatellite markers evaluated in this study. Physical positions are shown fcr both markers and genes. CEN= centromere. This diagram is not to 
scale.
CEN
/ /
GABRB2I
1606534491
GABRA6I
1610455481
GABRA1
161208147| GABRG2I
1614273641
D5S436I
14518411l|
/ / D5S410I
152755168|
D5S1403I
157298280| D5S1955
160671382
D5S2118I
1606868801 SHGC-132760
161346716
D5S422I
162086437|
5q32
Figure 5.2. GABR cluster at chromosomal region 5q32. Above are indicated the GABR genes o f  this cluster. Underneath are indicated the 
microsatellite markers evaluated in this study. Physical positions are shown for both markers and genes. CEN= centromere. This diagram is not to 
scale.
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2.4 Mutation screening
SCN1A exons 4, 15,18, 21 and 26 were amplified using primers and PCR conditions 
reported by Malacame and colleagues 253. Mutation screening was carried out by 
digesting the third fragment of exon 26 with Tsp45I (New England Biolabs), at 37° C 
overnight Digestion products were then examined on 3% agarose gels stained with 
ethidium bromide.
2.5 Aminoacid sequence alignment
Aminoacid alignment was done using CLUSTAL W in http://www.ebi.ac.uk/culstalw
254
3. Results
3.1 Pedigrees
Clinical details in all these families were consistent with GEFS+. Families 1 and 7 
included twelve affected individuals each (Figures 5.3 and 5.5, espectively). Family
5.3 included seven affected individuals (Figure 5.7); Families 4 and 6 each had six 
affected individuals (Figures 5.4 and 5.8). Family 5 included eight affected individuals 
(Figure 5.6). All cases in these families had a history of febrile seizures with the first 
episode occurring between 3 months and 3 years. Several of the patients who are over 
six years of age have also had afebrile seizures. All families are consistent with an 
• autosomal dominant inheritance mode with incomplete penetrance. The highest rate of 
non-penetrance was present in Family 5.
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3.2 Power analysis
Table 5.3 shows the simulation results. Assuming locus homogeneity, the set of 
families would provide a power of approximately 100% to identify significant linkage. 
Individually, only families 1 and 5 were powerful enough to reach a Z>3.
Assuming that no phenocopies are included in the families, all pedigrees, with 
exception of Family 3, provide an expected maximum lod score over 2.
Pedigree
Expected Lod Score (Z) Probability of LOD score > to:
reaching a
Average 0=0 Max 1 2 3
Familyl 2.95 5 93 74 44
Family3 1.48 2.38 70 41 0
Family4 1.1 1.9 55 0 0
Family5 2.1 3.13 94 58 7
Family6 1.79 2.66 79 59 0
Family7 1.74 2.53 83 41 0
Total 11 15.78 100 100 100
Table 5.3. Power simulation for Colombian GEFS+ families.
3.3 Linkage and haplotvpe analysis
Table 5.4 shows two-point lod scores for markers at the FEB loci and GEFS+ genes in 
our set of families. Even though markers were at zero cM from the respective 
genes/loci tested, only Family 3 showed its highest lod score at 0= 0 (Marker 
D19S177).
FEB3/SCN1A/SCN2A locus
Linkage to the FEB3 locus was suggested for families 1, 6 and 7 at theta= 0.1 (Table 
5.4, marker D2S382). When the analysis assumed a phenocopy rate of 3%, lod scores 
increased dramatically for family 1 (Table 5.5). In this family, significantly negative 
’lod scores (<-2) were observed at theta 0 for all markers tested with exception of 
D2S382 at FEB3/SCN1A/SCN2A, which showed a maximum lod score of 2.24. 
Genotypes at two additional markers in the FEB3 region resulted in maximum lod
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scores (at 0 recombination fraction) of 2.83 and 1.19 for D2S2330 (closer to the gene, 
Figure 5.1) and D2S2157, respectively (Figure 5.3).
An increase in lod scores when analyzing at low penetrance (0.65) and phenocopy rate 
= 0.02 was also observed in Families 6 and 7 (Table 5.6) for locus FEB3. Family 6 
now showed its highest lod score for marker D2S382 at 0=0 (Zmax= 1.21), in contrast 
to Z max= 0.78 at 0= 0.1 assuming penetrance of 0.96 and phenocopy rate of zero 
(Table 5.4). Family 7 now presented Z= 0.62 at 0= 0 for marker D2S382 in contrast to 
Z= -3.12 at 0= 0 in the first analysis (Table 5.4). Similarly, Z at 0= 0.1 increased from 
0.7 (Table 5.4) to 0.84 (Table 5.6) in this Family. Markers D2S2157 and D2S2330 at 
FEB3 also showed suggestion of linkage in these families. Interestingly, Family 7 
only presented its maximum lod score at 0= 0 for marker D2S2157 and not for 
markers D2S382 and D2S2330. This may be explained by one of two possibilities. 
One possibility is that actually a recombination has happened in the interval D2S2157- 
D2S382 taking away the disease-associated alleles in individual 111:7 for markers 
D2S382 and D2S2330. This explanation implies that neither SCN2A or SCN1A is the 
carrier of the mutation in this family, and alternatively would probably implicate 
SCN3A (see Figure 5.5). The second possible explanation is that individual 111:7 did 
not receive her allele 6 at marker D2S2157 from her mother and thus she has got a 
completely different haplotype from the rest of affected individuals in the pedigree and 
therefore she must correspond to a phenocopy.
Families 1, 6 and 7 together provided Z> 3 for all three marker loci at theta= 0, 
evidencing linkage to FEB3 (Table 5.6).
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MARKER D19S177 (FEB2)
________________ Recombination fraction, 8_______________
0 0.1 0.2 0.3 0.4 0.5
MARKER D2S382 (FEB3/SCN1A/SCN1B)
Recombination fraction, 0 
0 0.1______ 0.2 0.3 0.4 0.5
Total -26.49 -5.85 -2.73 -1.25 -0.45 0 Total -27.75 -2.49 -0.33 0.16 0.11 0
Fam7 -9.5 -1.33 -0.58 -0.23 -0.05 0 Fam7 -3.12 0.70 0.60 0.36 0.11 0
Fam6 / 0.15 0.09 0.05 0.02 0 0 Fam6 0.65 0.78 0.6 0.34 0.13 0
Fam5 -9.01 -2.42 -1.1 -0.48 -0.15 0 Fam5 -11.32 -2.33 -0.9 -0.26 0 0
Fam4 0.06 0.09 0.07 0.03 0 0 Fam4 -3.53 -1.38 -0.8 -0.45 -0.19 0
Fam3 0.32 0.27 0.21 0.14 0.07 0 Fam3 -6.56 -0.94 -0.4 -0.16 -0.04 0
Faml -8.51 -2.56 -1.4 -0.77 -0.35 0 Faml -3.87 0.68 0.57 0.33 0.1 0
MARKER D5S1403 (GABRG2) MARKER D8S530 (FEB1)
Recombination fraction, 0 Recombination fraction, 0
0 0.1 0.2 0.3 0.4 0.5 0 0.1 0.2 0.3 0.4 0.5
Total -38.98 -4.51 -1.14 0.12 0.36 0 Total -50.65 -9.8 -4.59 -2.16 -0.86 0
Fam7 -9.51 -1.57 -0.78 -0.37 -0.13 0 Fam7 -8.1 0.03 0.22 0.14 0.01 0
Fam6 -5.65 0.22 0.45 0.44 0.28 0 Fam6 -10.02 -1.07 -0.5 -0.22 -0.06 0
Fam5 -1.61 1.1 1.07 0.78 0.38 0 Fam5 -12.01 -1.62 -0.66 -0.25 -0.06 0
Fam4 -7.02 -0.54 -0.17 -0.01 0.04 0 Fam4 -2.78 -0.09 0.01 0 0 0
Fam3 -4.66 -0.01 0.18 0.2 0.13 0 Fam3 -5.3 -3.67 -1.68 -0.8 -0.3 0
Faml -10.53 -3.7 -1.89 -0.92 -0.34 0 Faml -12.44 -3.39 -1.68 -0.8 -0.3 0
MARKER D5S644 (FEB4) MARKER D19S425 (SCN1B)
Recombination fraction, 0 Recombination fraction, 0
0 0.1 0.2 0.3 0.4 0.5 0 0.1 0.2 0.3 0.4 0.5
Total -45.62 -5.63 -1.76 -0.23 0.21 0 Total -34.07 -7.07 -3.07 -1.22 -0.32 0
Fam7 -9.46 -2.38 -1.14 -0.52 -0.17 0 Fam7 -6.19 -1 -0.37 -0.12 -0.02 0
Fam6 -13.61 -0.78 0.03 0.24 0.18 0 Fam6 -5.91 -1 -0.36 -0.08 0.02 0
Fam5 -13.61 -0.78 0.03 0.24 0.18 0 Fam5 -6.52 -0.94 -0.35 -0.12 -0.02 0
Fam4 -5.11 -0.66 -0.34 -0.19 -0.1 0 Fam4 -4.22 -2.83 -1.52 -0.79 -0.32 0
Fam3 0.08 0.16 0.16 0.12 0.07 0 Fam3 -4.43 -2.83 -1.52 -0.79 -0.32 0
Faml -9.85 -1.71 -0.59 -0.09 0.07 0 Faml -6.81 -1.15 -0.44 -0.11 0.01 0
Table 5.4. Two-point lod scores at FS (FEB) and GEFS+ genes in families 1-7. Penetrance= 0.96, phenocopy rate= 0
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Figure 5.3. Pedigree offamily 1. Filled symbols indicate affected individuals with GEFS+, symbols with dots indicate individuals with FS. Clear
symbols represent unaffected individuals. Question mark (?) indicates phenotype unknown. Haplotypes were inferred for 1:1, 1:2, HI,5 and ni:9 since no
sample was available from them. Haplotypes at FEB3 locus are shown.
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Recombination fraction, 0
MARKER LOCUS 0 0.1 0.2 0.3 0.4 Z Max ™eta
Max
D8S530 FEB 1 -4.09 -1.53 -0.64 -0.25 -0.08 0.01 0.57
D19S177 FEB 2 -2.01 -0.68 -0.34 -0.20 -0.11 0.58 0.9
D2S382 FEB 3/SCN1A/SCN2A 2.24 1.83 1.39 0.92 0.44 2.24 0.0
D5S644 FEB 4 -2.19 0.04 0.42 0.47 0.32 0.48 0.27
D19S425 SCN1B -3.62 -1.51 -0.76 -0.34 -0.11 0.01 0.55
D5S1403 GABR G2 -6.70 -2.59 -1.27 -0.57 -0.18 0.01 0.54
Table 5.5. Two-point lod scores for markers at FS loci (FEB) and GEFS+ genes in Family 1. 
Penetrance 0.96 and phenocopies rate= 0.03.
Haplotype analysis revealed a disease-associated haplotype for each Family 1, 6, and 
7, supporting linkage to FEB3 and suggesting allelic heterogeneity across families 
(Figures 5.3, 5.4 and 5.5). Thus, in family 1, all affected individuals, except IV:3 carry 
a haplotype characterized by alleles 4, 3 and 6 at markers D2S2157, D2S382 and 
D2S2330, respectively. A recombination event was observed between markers 
D2S2157 and D2S382 in individual 111:15, who is unaffected but carries the disease- 
associated allele 4 (Figure 5.3).
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Figure 5.4. Pedigree offemily 6. Filled symbols indicate affected individuals with GEFS+. Clear symbols represent unaffected individuals. Haplotypes
were inferred for individual 1:1 since no sample was available from him.
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were inferred for individuals 1:1, 1:2, 11:2, 111:4, ni:9 and IV:2 since no sample was available from them. Individual V:1 corresponds to a phenotocpy.
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Figure 5.7. Pedigree of family 3. Filled symbols indicate affected individuals with GEFS+. Clear symbols represent unaffected individuals. Haplotypes
were inferred in 1:1, 11:3, 11:5 and 11:7 since no sample was available from them.
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Figure 5.8. Pedigree 
of family 4. Filled 
symbols indicate 
affected individuals 
with GEFS+. Clear 
symbols represent 
unaffected 
individuals. 
Haplotypes were 
inferred for 1:1, 1:2, 
m i, n:2, n:3, n:4, 
ni:3 and HI:4 since 
no sample was 
available from them
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ua
_______________ Recombination fraction, 8______________
MARKER Families 0 0.1 0.2 0.3 0.4 0.5
Total 3.24 2.58 1.87 1.15 0.49 0
D2S2157 Family 1 1.54 1.31 1.03 0.7 0.34 0
Family 6 0.16 0.09 0.04 0.01 0 0
Family 7 1.55 1.18 0.8 0.44 0.15 0
Total 3.63 3.2 2.33 1.38 0.54 0
D2S382
Family 1 1.81 1.44 1.05 0.65 0.27 0
Family 6 1.21 0.92 0.61 0.32 0.12 0
Family 7 0.62 0.84 0.67 0.41 0.15 0
Total 3.32 3.03 2.25 1.39 0.59 0
D2S2330
Family 1 2.26 1.83 1.36 0.87 0.38 0
Family 6 0.97 0.74 0.5 0.28 0.11 0
Family 7 0.08 0.46 0.39 0.24 0.1 0
Table 5.6. Two-point lod scores for markers tested at FEB3 locus in families 1, 6 and 7. 
Penetrance=0.65 and phenocopies rate= 0.02
In family 6, all affected individuals and carriers have a haplotype characterized by 
alleles 4, 3 and 4 at markers D2S2157, D2S382 and D2S2330, respectively. Individual 
111:6, who is unaffected, is a carrier of the disease-associated haplotype (Figure 5.4). 
In family 7, all affected individuals except 111:7 carry a haplotype characterized by 
alleles 6, 5 and 1 at markers D2S2157, D2S382 and D2S2330, respectively (Figure 
5.5).
GABR cluster
Linkage to GABRG2 was suggested for Family 5 (Table 5.4, marker D5S1403). 
Significantly negative lod scores (<-2) were observed at 0= 0 for all markers tested, 
. with exception of marker D5S1403. This locus showed a maximum Z = l.l at 0= 0.1 
(Z= -1.61 at 0= 0). When analyses were performed using penetrance 0.65 and 
phenocopies rate= 0.02, the lod score raised to 2.31 at marker D5S1403 at 0= 0 (Table
5.7). Evaluation of additional markers D5S436, D5S410 and D5S422 allowed the
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identification of a disease-associated haplotype and also showed a recombinant 
involving the most telomeric marker, D5S422 (Figure 5.6). Thus there was in 
individual 111:3 a recombination event between markers D5S1403 and D5S422 in the 
disease-associated chromosome causing the Z max to be obtained at a 0 > 0 (Table
5.7) The differences among the lod scores at 0= 0 for the other three markers shown in 
Table 5.7 may be explained as follows. For marker D5S436 individual 11:2 was 
inferred to be homozygous (3/3) (Figure 5.6) since all her children inherited the same 
allele and thus was non-informative. For marker D5S410, it is easy to see that allele 4 
segregated with the disease. However, individual V:l, who is affected did not have 
allele 4, which in this type of analysis is interpreted as recombinant and therefore Z 
max was not at 0 = 0. The most likely interpretation is that individual V:1 is a 
phenocopy (see below). For marker D5S1403 all meioses were informative and no 
evidence of recombination was observed since every affected individual received at 
least one allele 2 (including individual V :l) (Figure 5.6).
MARKER
Recombination fraction, 0
Z max0 0.1 0.2 0.3 0.4 0.5 0 max
D5S436 1.07 0.84 0.62 0.42 0.21 0 0.001 1.07
D5S410 0.47 0.82 0.69 0.45 0.18 0 0.092 0.82
D5S1403 2.31 1.86 1.36 0.85 0.34 0 0.001 2.31
D5S422 0.44 0.8 0.68 0.46 0.2 0 0.096 0.8
Table 5.7. Two-point lod scores for markers tested at GABR locus in family 5. 
Penetrance=0.65 and phenocopy rate= 0.02
After testing three additional markers in the region (D5S1955, D5S2118 and SHGC- 
; 132760), a new recombinant was identified (Figure 5.6). Individual 11:3 showed a 
recombination event involving marker SHGC-132760. Marker D5S2118 was 
monomorphic. All affected individuals carry a disease-associated haplotype 
characterized by alleles 3, 4, 2, 2 and 1 at markers D5S436, D5S410, D5S1403,
D5S1955 and D5S2118, respectively. However, the affected individual V:1 does not 
carry this haplotype, suggesting that she is a phenocopy. Zmax for markers D5S1955, 
D5S2118 and SHGC-132760 were 0.4 at 0= 0; 0.12 at 0= 0 and 1.29 at 0= 0.077, 
respectively.
FEB2 locus
Linkage to locus FEB2 was suggested for families 3 and 4 (Table 5.4, marker 
D19S177). Evaluation of three additional markers (D19S894, D19S216 and 
D19S1034) in this region could not either confirm or reject linkage to FEB2 in 
Families 3 and 4. Lod scores were in the interval -2 < Z < 1 (Table 5.8). However, in 
Family 4 there was not a common haplotype segregating with the disease, suggesting 
exclusion of this locus. For example, individual 111:1 transmitted his haplotype 9-1-2-3 
to his two affected children IV: 1 and IV:4 and transmitted his alternative allele to IV:2 
who has two affected children. These two affected individuals (V:l and V:2) have 
another haplotype characterized by alleles 6-1-2-1. Moreover, individual IV:6 has a 
different haplotype from the previous two (Figure 5.8).
Even so, in Family 3 all affected individuals carry a haplotype characterized by alleles 
1, 5, 4 and 3 at markers D19S894, D19S216, D19S177 and D19S1034. Affected 
individuals 11:2 and 11:6 were homozygous for these haplotypes, so that, their meioses 
were not informative for linkage resulting in weak lod scores (Table 5.8 and Figure
5.7). The fact that 1:1 and 1:2 share a haplotype suggests that they both have a recent 
common ancestor. This also assumes that 1:2 is a carrier who is non-penetrant and that 
this is also the case for 11:4 and 11:8 but is in agreement with linkage to FEB2 on a 
haplotype basis. Therefore, more markers need to be tested in this region to clearly 
determine whether this locus is linked to the disease in Family 3 or not.
121
MARKER
___________Recombination fraction, 8______________
0 0.1 0.2 0.3 0.4 0.5
Total -0.14 -0.26 -0.31 -0.26 -0.13 0
D19S894 Family 3 0.24 0.17 0.1 0.05 0.02 0
Family 4 -0.37 -0.42 -0.42 -0.31 -0.15 0
Total -1.53 -0.6 -0.28 -0.09 0.01 0
D19S216 Family 3 -0.49 -0.45 -0.35 -0.21 -0.09 0
Family 4 -1.04 -0.14 0.06 0.12 0.09 0
Total 0.63 0.47 0.32 0.19 0.08 0
D19S177 Family 3 0.37 0.28 0.2 0.12 0.05 0
Family 4 0.26 0.18 0.12 0.07 0.03 0
Total 0.86 0.66 0.46 0.27 0.11 0
D19S1034 Family 3 0.38 0.27 0.18 0.09 0.03 0
Family 4 0.48 0.39 0.28 0.17 0.08 0
Table 5.8. Two-point lod scores for markers tested at FEB2 locus in families 3 and 4. Penetrance=0.65 
and phenocopies rate= 0.02.
3.4 Sequencing 
Families 1. 6 and 7
Sequencing of SCN1A exons 4, 15, 18, 19, 21 and 26 was performed in two carriers of 
the disease-associated haplotype in Family 1 (11:6 and 111:10). A heterozygous A to G 
substitution was identified in exon 26 at position 5213 of the SCN1A mRNA (c.5213 
A>G, Figure 5.9). This base change destroys a recognition site for enzyme Tsp45I. 
Restriction enzyme digestion of the third fragment of exon 26 PCR products showed 
that the c.5213A>G base change is present in the individuals that were considered 
affected, except for IV 3, who presumably represents a FS phenocopy. This DNA 
mutation was not observed in 60 unaffected controls from Antioquia. The c.5213A>G 
results in an aspartate for glycine substitution at position 1742 of the protein 
(D1742G). This substitution lies in the evolutionarily conserved segments S5 and S6 
. of domain IV in the SCN1A channel (Figure 5.10).
This mutation is not present in either family 6 or 7. SSCP analysis for the same 
SCN1A exons as evaluated by sequencing in Family 1, did not reveal any 
conformational polymorphism in either Family 6 or 7.
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Figure 5.9. Mutation 
screening o f  exon 26 o f  
SCN1A. (A) Partial 
nucleotide sequence o f  the 
exon showing the 
heterozygous A>G 
substitution indicated with 
letter R. (B) Restriction 
digestion o f  exon 26 with 
Tsp45I. The mutation 
c.5213A>G destroys the 
restriction site. Labels o f the 
lanes to the individuals 
examined as in figure 3.
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Figure 5.10. Amino acid sequence alignment ofthe loop between segments S5 and S6 in domain D-IV ofhuman neuronal sodium channels. The aspartate 
residue (D) that is substituted by glycine (G) is boxed.
(B)
111:8 11:5 111:10 111:16 IV:17 111:6 IV:5 111:12
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Family 5
Sequencing of all nine GABRG2 exons in Family 5 revealed two nucleotide changes. 
One of these DNA changes was found on exonl and consists of an adenine deletion in 
position +286 of the GABRG2 mRNA, three bases before the start codon. This 
variation lies in a tract of twelve adenines and was present in both affected and 
unaffected individuals. The second variation was found on exon 5 and consisted of a 
substitution of C to T in position 540 of the cDNA and had previously been reported as 
a frequent polymorphism 243. This observation suggested that a mutation in either an 
intron or the promoter region went undetected. There was also a chance that the 
mutant gene was other than GABRG2 (e.g. GABRA1, GABRA6 or GABRB2). 
Evaluation of markers D5S1955, D5S2118 and SHGC-132760, which lie in between 
markers D5S1403 and D5S422 (see Figure 2), revealed an additional recombinant. 
Affected individual 11:3 presented disruption of the disease-associated haplotype since 
a recombination event between markers D5S2118 and SHGC-132760 was observed 
(Figure 5.6). SHGC-132760 lies in between contiguous genes GABRG2 and GABRA1 
(Figure 5.2)
4. Discussion
The purpose of this chapter was to characterize six Colombian families with GEFS+ 
initially by evaluating linkage to four FEB loci (FEBl-3 and MASS1 gene) and four 
. GEFS+ genes (SCN1A, SCN2A, SCN1B and GABRG2) previously reported. Most of 
GEFS+ mutations reported frequently are in the SCN1A gene. So far, twelve SCN1A 
mutations leading to GEFSP2 have been reported 220‘222’ 232> 233’ 235. Recently, 
mutations in SCN1A have also been associated with SMEI 236,237. Most of which are
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located in the functionally critical pore forming of SCN1A (S4-S6) and could therefore 
have a major impact in the kinetic properties of this sodium channel 237. Functional 
studies SCN1A mutations have shown disruption of channel inactivation, resulting in 
increased Na+ influx and leading to hyperexitability and suggesting a gain of function
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Suggestive linkage was found for at least four of the families studied here. Three of 
these (Families 1, 6 and 7) were linked to markers on 2q23-q24, the region where 
FEB3, SCN1A and SCN2A map. The fourth family was linked to GABRG2 (Family 5). 
Families linked to 2q23-q24 each presented a disease-associated haplotype. 
Sequencing of SCN1A exons in Family 1 revealed a c. 5213 A>G mutation, which lead 
to the D1742G aminoacid substitution. This substitution lies in the pore forming region 
of domain IV. The high penetrance of this mutation (100%) and the severity of the 
clinical manifestations might be explained by the functional importance of its location 
within the protein. The high penetrance contrasts with the characteristic medium
Of 1^ ff
penetrance (65%) reported for GEFS+ ’ , where normally a rate of non-penetrants
is observed.
Since this mutation was not present in the other 2q23-q24 linked families, allelic 
heterogeneity of this disorder in Antioquia is indicated.
Mutations in GABRG2 have also been reported for both GEFS+ and SMEI 243'246. 
Three GEFS+ mutations have been reported in GABRG2 and only one for SMEI. This 
supports a clinical relationship between GEFS+ and SMEI, in agreement with the 
suggestion that SMEI constitutes the most severe form of the GEFS+ clinical spectrum 
246. Sequencing of all GABRG2 in two affected individuals from Family 5 did not 
reveal a mutation. Identification of a recombinant for markers SHGC-132760
125
confirmed exclusion of GABRG2 (Figure 5.2 and Figure 5.6) and therefore it is 
expected that either GABRA1, GABRA6 or GABRB2 is the mutant gene in this family.
Families 3 and 4 seem not to show linkage to the genes/loci tested. Initially, linkage to 
the region FEB2 could not be excluded but once three additional linked markers were 
tested, linkage was excluded in Family 4. In contrast, all affected individuals in 
Family 3 carried the same haplotype. However, as individuals 1:1 and 1:2 are carriers 
of the same haplotype it is possible that affected individuals carry the same haplotype 
but from different origin (i.e. paternal or maternal) (Figure 5.6). The fact that two of 
the affected individuals were homozygous for these haplotypes, meant that these 
meioses were uninformative and therefore the lod score analysis did not support any 
decision in favour of or against linkage. If after testing more markers in this region and 
if exclusion was obtained, Families 3 & 4 and would be candidates for a genome wide 
scan, aimed at identifying new GEFS+ genes.
In conclusion, four of six families studied here are linked to FEB3 locus and GABR 
cluster. Family 1 carries D1742G mutation located in the pore forming region of 
domain IV of SCN1A. Families 6 and 7 are currently been further evaluated in 
SCN1A. Family 5 is linked to the GABR cluster and we have found evidence of 
exclusion of GABRG2 gene, only gene in the cluster previously associated with 
GEFS+ 224. Sequencing of the other GABR genes in this region will reveal which of 
these is bearing the mutation in this family and will constitute the first genetic 
evidence of that gene as implicated in GEFS+. Family 4 is not linked to any of the 
genes/loci evaluated. Family 3 still might be linked to FEB2, where at the moment 
there is not an evident candidate gene to look at.
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The heterogeneity evidenced here allows me to conclude that GEFS+ is a highly 
clinically and genetically heterogeneous trait, even in families from isolate 
populations, such as Antioquia.
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CHAPTER SIX
LINKAGE ANALYSIS AND 
MUTATION SCREENING IN A 
FAMILY WITH ATYPICAL BATTEN
DISEASE
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1. Introduction
1.1 Generalities
The Neuronal Ceroid Lipofuscinoses (NCLs) are a group of inherited 
neurodegenerative disorders, characterized by the accumulation of autofluorescent 
lypopigments (Ceroid and Lipofuscin) in neurons and other cell types within the 
lysosomes 255,256 that belong to the group of progressive myoclonus epilepsies (PMEs)
9 <7. NCLs as a group are the commonest neurodegenerative disorder in childhood. Its 
incidence has been estimated as over 1 in 25000 live births 258, with an increased 
prevalence in the populations of north Europe. Common clinical features to all NCLs 
are progressive cognitive, motor and visual decline, and seizures. Seizures can be 
generalised, tonic-clonic, myoclonic, astatic or atonic 257.
At least ten NCL subtypes have been identified. Diagnostic criteria are based on age of 
onset, clinicopathological findings and genetics. Storage material is composed of 
neutral lipids and phospholipids, and to a lesser extent glycolipids with a major 
fraction of autofluorescent insoluble proteins.
The major storage components in infantile NCL are two types of Sphingolipid 
Activator Proteins (SAPs) or saposins (Table 6.1) 259. SAPs are small, heat stable, 
lysosomal proteins, originating from a single precursor molecule that, by cleavage, 
releases four mature SAPs (A-D) 260. SAPs activate lysosomal hydrolases involved in 
* glycosphingolipid degradation and the glycosphingolipid substrate. SAPs A and D 
accumulate in infantile NCL 261. The major storage component in late-infantile, 
juvenile, and some adult NCLs is subunit c of the mitochondrial ATP synthase
A X '!
complex (Table 6.1) ’ . Subunit c is an essential membrane component of the
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proton channel of the large oligomeric complex ATP synthase, which generates ATP 
by the process of oxidative phosphorylation. It is known that indigestible material 
remains within lysosomes, and as exocytosis in neurons is poor 264the formation of 
electron-dense residual bodies is favoured.
The onset of NCLs is usually in childhood. Childhood forms are autosomal recessive, 
while the rare adult forms can be either autosomal recessive or dominant 265’266 (Table
6.1). All NCL types were known as Batten disease until 1990s when different genetic 
loci were identified, but this is still the best-known name for the juvenile type.
1.2 Molecular genetics of NCLs
There are three major clinical forms of NCL: Infantile (INCL), Late infantile (LINCL) 
and Juvenile or Batten (JNCL). Six genes have been identified that underly these 
forms: INCL (CLN1) 267}, LINCL (CLN2) “ *} and JNCL (CLN3) m . Genes 
underlying two variant late infantile and one juvenile forms caused by mutations in 
CLN5, CLN6 and CLN8, respectively, have recently been identified 197, 269-271 (Table
6 . 1).
Some of the CLN genes have been associated with different clinical forms. Thus, 
CLN1 mutations have been associated with INCL, LINCL and JNCL 272’273. Similarly, 
CLN2 mutations have been associated with both LINCL and JNCL 268,274,275.
CLN1
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CLN1 is located on chromosome lp32, has 9 exons and extends 24.55Kb 261. CLN1 
encodes the enzyme palmitoyl protein thiosesterase 1 (PPT1), which removes 
palmitate residues from proteins. In non-neuronal cells it is transported to the lysosome
7 7  f \  7 7 7via the mannose-6-receptor-mediated pathway, and is also secreted ’ . Even
though, PPT1 does not seem to localize to lysosome in mature neurons, it is
77JIpreferentially targeted to axons . Despite having no elevated expression in any 
particular human tissue type 279, its association with the disease is based on its 
increased expression during the development of neurons from cortical neurogenesis 
through cortical development 280.
Forty-three mutations have been reported so far, which are distributed through out the 
gene. CLN1 mutations include 20 missense, 9 nonsense, 10 small deletions or
insertions and four mutation affecting splice sites (reviewed in 28!).
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NCL type Ultrastructure gene Chromosomalregion
Major storage 
material
Age o f  
onset References
Childhood
Infantile GROD CLN1 lp32 SAPs 6-24months
267
Late Infantile
Classical CVB CLN2 1 Ipl 5 Subunit c 2-4 years 274, 275
Finnish FPP/RL CLN5 13p22 269, 282
Variant FPP/RL CLN6 15q21-q23 270, 271
Variant FPP/RL CLN7 ND
Variant GROD+/-RL CLN1 lp32 272, 273
Juvenile
Classical
Progressive
Variant
FPP
RL
GROD
CLN3
CLN8
CLN1
16pl2
8p23
lp32
Subunit c 4-10years
191
197
283
Variant CL CLN2 11 p 15 284, 285
Adulthood 
Kufs disease/ 
Parry disease
FPP/RL or 
GROD CLN4
CLN1
ND
lp32
Subunit c avg. 30 years
266
265
Table 6.1. Molecular Genetics o f the NCLs.
GROD: Granular osmiophilic deposits; CVB: curvilinear profiles; FPP: fingerprint 
profiles; ND: Not yet determined. (Modified from 286)
CLN2
CLN2 is located on chromosomal region 1 lpl5, has 13 exons and extends 6.66 Kb 275. 
CLN2 encodes the lysosomal enzyme tripeptidyl peptidase (TPP1), which removes 
tripeptides from the N terminus of small proteins such as subunit c of mitochondrial 
ATP synthase that accumulates in most of forms of NCL ’ . TPP1 is produced as
a glycosylated precursor polypeptide that is processed to the mature enzyme in the 
lysosome 289. Enzyme activity occurs in the brain by the age of two years in the
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cerebral cortex 290. Enzyme assay of TPP1 enables accurate diagnosis of NCL caused 
by CLN2 mutations 291.
Fifty-two mutations have been reported in CLN2, which include 7 small deletions, 2
small insertions, 29 missense mutations, 5 nonsense mutations and 9 mutations
• • 181 affecting splice sites or intronic sequences (reviewed in ).
CLN3
CLN3 is located on chromosomal region 16pl2, has 15 exons and extends 15 kb 191. 
CLN3 encodes a 438 aminoacid glycosilated membrane protein that is believed to 
localize in the lysosome and also in other additional locations in neurones 292*294. 
Although its cellular function is still unknown, it has been implicated in vacuolar 
homeostasis in yeast ’ . Interestingly, mice models show a preferential loss of
GABAergic neurons ’ . Consistently inhibition of GAD by anti-GAD antibody has
been shown in cln3-knockout mice serum that associates with brain tissue but is not 
present in sera or brain of normal mice 298.
Thirty-eight mutations have been reported in CLN3, which include 5 small deletions, 5 
small insertions, 4 large deletions, 9 missense mutations, 8 nonsense mutations, 5
i
mutations affecting splice sites and 1 intronic mutation (reviewed in ). A 1.02 kb 
deletion that is present in about 85% of the disease chromosomes is the most common 
mutation in CLN3 191’299.
Clinical Features of Classical Juvenile (Batten Disease')
For the classical juvenile type (Batten), there are very well characterized clinical and 
pathological features. Clinical symptoms begin with vision failure between five and 
ten years of age. It continues with convulsions and progressive deterioration of the 
cognitive functions until death, in the second or third decade of life. Diagnostic
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criteria include the presence of inclusions in many cell types that resemble fingerprints 
in the electronic microscope 30°, macular degeneration, presence of vacuolated 
lymphocytes in peripheral blood
CLN5
7A 0CLN5 is located on chromosomal region 13p22, has 4 exons and extends 13 Kb
CLN5 encodes a 407 aminoacid glycosylated protein, with an expression increase
during cortical neurogenesis 280. This protein is synthesized as a four precursor forms,
1
which are thought to be lysosomal soluble . Interaction of CLN5 with CLN2 and 
CLN3 proteins has been reported. All CLN5 mutants have lost their ability to interact 
with CLN2 while keeping their ability to interact with CLN3, according to
• • • 302coimmunoprecipitation assays
Four mutations have been reported for CLN5. Three of these mutations result in a 
truncated protein and the fourth is a missense mutation. To date, CLN5 mutations
7AQ WXhave been identified in Finnish and Swedish families and in one Dutch patient 
All these patients presented a late infantile CLN type.
CLN6
CLN6 is located on chromosomal region 15q21-q23. It has 7 exons and spans 22.69
970 771Kb ’ . I t  is predicted that CLN6 encodes a 311 aminoacid protein with seven 
hypothetical transmembrane domains which, similar to CLN3 and CLN5, has no
7 7 0  7 7 1homology with known proteins or recognized functional domains
Eighteen mutations have been reported, including missense, frameshift, splice site and
nonsense mutations (reviewed in 281.
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CLN8
CLN8 locates at chromosomal region 8p23, has three exons and extends 20.5 Kb 197. 
CLN8 is a 286 aminoacids protein that locates in the endoplasmic reticulum (ER) and 
also shuttles between the ER and the ER-golgi intermediate complex 304. Five 
mutations have been reported so far. Four of which lead to aminoacid substitutions, 
and the fifth mutation (frameshift) is predicted to result in a truncated CLN8 protein 
(Reviewed in 281).
Different loci explain different clinical forms of the disease. Also different clinical 
forms may have their cause in a same gene with its different mutations (Table 6.1). 
Furthermore, some patients for whom mutation screening of known NCL genes have 
proved negative results, in addition to animal models have shown that there may be 
other genes implicated in this disorder. Studying new collections of patients of 
homogeneous origin or analyzing pedigrees with enough power will result in 
identification of other until now uncovered genes related with the disease. It is then 
clear that clinical as well as genetic heterogeneity is common feature in this group of 
disorders.
1.3 Preliminary work and aims
Little is known about the genetic aspects underlying the group of NCLs in Colombia.
A nuclear family including two siblings (VI:2 and VI:3; Figure 6.1) with a clinical 
. diagnosis of Batten was identified in northwest Colombia. Genealogic inquiries 
revealed consanguinity between the unaffected parents. Genealogy extension revealed 
a third affected child in another consanguineous branch of the family who died at age 
14 years (Figure 6.1).
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Figure 6.1. Pedigree o f the Colombian family with Batten disease studied here.
Two affected siblings in one nuclear family (VI:2 and VI:3) and one affected individual (V:3) in another 
nuclear family from the same pedigree are shown. Individual VI:2 died during the course o f this study. 
Age at onset (age at death) in affected individuals is shown. Available individuals were all those alive 
with exception of individuals IV:3, IV:4 and V:6. This was taken into consideration for the power 
simulation.
Based on the consanguineous nature of the pedigree, a homozygosity search was 
proposed aiming to identify homozygosity only in the available patients and not in the 
unaffected relatives.
The population of northwest Colombia is of mixed Spanish, Native American, and
'X')African ancestry , and no northern European ancestry was documented in this 
pedigree.
4 Symptoms started at 9 years of age with visual failure, loss of strength, and tremor of 
lower limbs. The patients deteriorated rapidly, with blindness and inability to walk 
occurring within 1 year of the initiation of symptoms. A few months after onset, the
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patients also had behavioural changes, a gradual loss of language, myoclonus, and 
seizures.
Evaluation of markers linked to CLN3 showed that the affected individuals were 
heterozygous for the same alleles (4/5 and 2/3) at markers D16S298 D16S299, 
respectively (Figure 6.3), providing lod scores of Of -1.3 at 0= 0 for both markers 
(Table 3). However, the affected individuals had the same genotypes for both markers 
while none of their siblings (Figure 6.3) had these genotypes, making more difficult to 
exclude CLN3.
Given the large number of Alu sequences within CLN3 305, recombination within the 
gene was a possible explanation for the heterozygosity observed in the patients. Also, 
although compound heterozygotes were not expected in this pedigree because of 
consanguinity, it seemed that two different CLN3 mutations could be segregating in 
the family. Consequently, SSCP for all 15 CLN3 exons and sequencing of exons 11 
and 13 was carried out. No genetic variants were found, supporting the idea that any 
other locus, possibly previously unreported, was involved in this pedigree.
This chapter describes further studies on this family.
The aim of this chapter was to characterize an extended Colombian pedigree 
presenting with clinically Batten disease (Juvenile type).
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2. Methods
2.1 Power simulation
Power simulation was performed assuming autosomal recessive inheritance mode and 
full penetrance. A mutant allele frequency of 0.0001 was assumed. Also, a marker 
locus with four equally frequent alleles was simulated in 100 replicas 55. The actual 
simulated pedigree corresponds to that shown in Figure 6.1.
2.2 Candidate genes.
Linkage to known NCL genes was evaluated using tightly linked microsatellite 
markers as shown in Table 6.2. Marker typing was performed as indicated in the 
section on microsatellite marker typing in chapter one. PCR amplification with 
reported primers was carried out with 30 cycles of 94° for 30 seconds, 53° to 62° C as 
annealing temperature, and 72° C for 30 seconds (Table 6.2).
Gene Marker AnnealingTemperature
CLN1 D1S193 55
CLN2 D11S1338 55
CLN3 D16S298 62
D16S299 53
D13S156 55
CLN5 D13S162 50
D13S1306 55
CLN6 D15S1000 55
D15S983 56
CLN8
AFM265wb5 55
44CA 60
Table 6.2. Markers tested for evaluating known NCL genes.
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2.3 Linkage and Haplotvpe analysis
Linkage analysis was performed assuming an autosomal recessive inheritance mode 
and full penetrance as in power simulation. Allele frequencies were assumed equal to 
1/n, n= number of alleles. Haplotypes were reconstructed using simwalk2. Refer to the 
methods chapter.
2.4 Sequencing
Full sequencing was conducted for the exons of CLN5 and CLN8 genes. Refer to the 
methods chapter.
2.5 Screening for mutation R112H
A sequence change identified in exon 2 of CLN5 destroys a restriction site for PshAI. 
Screening of this mutation was carried out by digestion of PCR products with 20 units 
of PshAI (New England Biolabs, Beverly, MA) at 37° C for 18 hours. Restriction 
fragments were resolved in a 3% agarose gel stained with ethidium bromide (0.5 
mg/mL) (Figure 6.4B).
3. Results
3.1 Pathology
Electron microscopy of skin biopsy from patient VI :2 revealed inclusions consisting of 
fingerprint profiles, often condensed, and occasionally associated with lipid droplets, 
suggestive of a variant NCL (Figure 6.2). No curvilinear or rectilinear profiles 
indicative of a mixed histopathology were seen (Dr Anderson, Personal 
communication; Histopathology Department, UCL).
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Figure 6.2. Electron microscopy o f  skin biopsy from patient IV:3. (A) White asterisk indicates storage 
inclusions in sweat gland epithelial cells. (B) Higher magnification o f  one inclusion showing a 
fingerprint pattern, often condensed and occasionally associated with a lipid droplet.
3.2 Power simulation
Table 6.3 shows the power simulation results. These indicate that on average a linked 
locus will provide a lod score over 2 in this pedigree. The pedigree structure is much 
more powerful but unavailability o f samples from some individuals limited the power.
Expected Lod score (Z) at 
0=0 Probability Z>
Average Max 1 2  3
2.22 2.93 96 71 0
Table 6.3. Power simulation for Colombian family with clinical NCL as shown in Figure 2.
' 3.3 Linkage analysis
Table 6.4 shows the lod scores for markers linked to CLN1, CLN2, CLN3, CLN6 and 
CLN8. Analysis was performed with the data from the pedigree shown in Figure 6.3.
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Marker D1S193 (CLN1) was found heterozygous in the two affected individuals 
(alleles 2/3, Figure 6.3). This was a similar situation to that found for markers linked to 
CLN3, where patients were heterozygous for same alleles and none of their siblings 
had the same genotype as they did. Linkage analysis resulted in a negative lod score 
for this marker (Table 6.4).
Marker D11S1338 (CLN2) was found heterozygous in the two affected individuals and 
as clear evidence of exclusion, they both had different genotypes (1/2 for VI:2 and 2/3 
for VI:3, Figure 3). Z= - infinity at theta= 0 was obtained (Table 6.4).
Two markers linked to CLN6 were evaluated. D15S1000 was heterozygous for the 
same alleles (2/3) in both affected individuals. And marker D15S983 was homozygous 
(1/1) in one unaffected individual apart from the two affected children (Figure 6.3). 
Lod score was negative for D15S1000 and Z= 0.5 for D15S983 was obtained at theta= 
0 (Table 6.4).
CLN3
CLN1 D1S193 
CLN2 D11S1338
CLN8
CLN6
D16S298
D16S299
D15S1000
D15S983
AFM265wb5
44CA
0 0
1 3
2 5
3 3 
0 0 0 0 
1 2 0 0
Vl:1 via
9(14)
Vl:3
9
2 3 
2 3 
4 5 
2 3 
2 3 
1 1 
2 2 
2 3
Vl:4
CLNl D1S193
CLN2 D11S1338
1 2 
1 2 
1 5 
1 3 
1 3 
1 1 
1 2 
1 3
2 3 
1 2 
4 5 
2 3 
2 3 
1 1 
2 2 
2 3
1 2 
1 1 
1 2 
1 3 
1 3 
1 2 
1 2 
1 3
CLN6
CLN3
CLN8
D16S298
D16S299
D15S1000
D15S983
AFM265wb5
44 C A
Figure 6.3. Nuclear family showing genotypes for markers linked to five NCL genes.
* Identification of individuals is as in Figure 1. Individual VI:2 died during the course o f this study. Age 
at diagnosis (age at dead) is shown.
Two markers linked to CLN8 were evaluated. AFM265wb5 was homozygous only in 
the affected individuals (2/2) (Figure 6.3). This was consistent with linkage to the 
disease and the lod score now raised to 1.17 at theta= 0 (Table 6.4). Evaluation of a 
second linked marker, 44CA, revealed heterozygosity in the affected children for the 
same alleles (2/3). Lod score was again negative (-1.6 at 0= 0).
Recombination fraction, 0
NCL gene MARKER 0 0.1 0.2 0.3 0.4
CLN1 D1S193 -1.6 0.2 0.2 0.1 0
CLN2 D11S1338 -00 -0.53 -0.17 -0.05 -0.01
CLN3
D16S298 -1.3 0.4 0.3 0.2 0.1
DS16S299 -1.3 0.4 0.3 0.2 0.1
CLN6
D15S1000 -1.6 0.2 0.2 0.1 0
D15S983 0.5 0.3 0.19 0.08 0.02
CLN8
AFM265wb5 1.17 0.78 0.46 0.22 0.06
44CA -1.6 0.2 0.2 0.1 0
Table 6.4. Two-point lod scores for markers at CLN1, CLN2, CLN3, CLN6 and CLN8 genes.
Three CLN5 flanking markers were tested (D13S156, D13S162 and D13S1306), 
which were found to be homozygous in only the two affected individuals and not in 
unaffected family members (Figure 6.4A). Both affected individuals were 
homozygous 1/1 for the three markers and typing these markers in the other branch of 
the family, where the third affected child was identified, revealed that all unaffected 
individuals where at the most heterozygous for allele 1, with exception of individuals 
» IV:2 and V: 1 (Figure 4A). These two individuals were homozygous for allele 1 at 
marker locus D13S156. The haplotype characterized by alleles 1-1-1 at markers 
D13S156-D13S162-D13S1306 was only homozygous in both available affected
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individuals. Two-point linkage analysis resulted in lod scores higher than 2 for 
markers D13S162 and D13S1306 (Table 6.5).
Thus it seemed that CLN5 was linked to the disease in our family. For the marker 
DBS 156, the affected individuals were homozygous 1/1 as was their brother VI:4. 
Since all the children of V:6 received an allele 1 from him, it was inferred that he was 
homozygous 1/1 (No sample was available). In addition, individual IV:2 and his 
daughter V:1 were also found to be homozygous 1/1 for this marker.
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Figure 6.4. (A) Colombian pedigree with clinical 
NCL. Affected individuals are indicated their age at 
onset (age at death). Haplotypes for markers at CLN5 
locus are shown. In CLN5 a number 2 indicates 
mutation c. 1627G>A.Haplotypes were inferred for 
individuals IV:3, IV:4 and V:6. (B) Restriction 
enzyme digestion with PshAI o f  a PC R fragment from 
CLN5 exon 2 in the nuclear family ofthe two living 
affected siblings. Patients present only one undigested 
band o f 375 bp. Unaffected individuals appear as 
either heterozygous or homozygous for the wild allele 
(bands 262 and 113 bp).
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The meioses of IV:2 and V:6 were therefore not informative for linkage purposes. 
Moreover, the homozygosity observed in two other unaffected individuals in the 
pedigree (VI:2 and V :l) dropped the lod score for this marker locus to 0.72 at 0= 0 
(Table 6.5). However, the linked marker D13S162 was only homozygous in the two 
available affected individuals. Other individuals were either heterozygous for allele 1 
or did not carry this allele at all. Z= 2.76 at 0= 0 was obtained for this marker (Table 
6.5). Similarly, D13S1306 was only homozygous in the affected individuals and no 
unaffected individuals were found to be homozygous for allele 1 in the pedigree 
(Figure 6.4A). Z= 2.42 was obtained at theta= 0 (Table 6.5). Although, both D13S162 
and D13S1306 show perfect segregation with the disease, different lod scores were 
obtained for them. This difference in lod scores is due to the difference in frequencies 
of the alleles at each marker and the fact that the genotypes of individual V:6 had to be 
inferred.
MARKER
Recombination fraction, 0
0 0.1 0.2 0.3 0.4
D13S156 0.72 0.49 0.27 0.12 0.03
D13S162 2.76 2.05 1.35 0.74 0.3
D13S1306 2.42 1.77 1.15 0.64 0.27
Table 6.5. Two-point lod scores for markers at CLN5 locus.
3.4 Sequencing of CLN8 and CLN5
' Sequencing of the three exons of CLN8 revealed a homozygous c.908 A>G transition 
in exon 3, which leads to the substitution Asn for Ser in position 225 of the protein 
(N225S). This change was observed in two unaffected individuals of the family (V:l 
and VI: 1).
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Sequencing of CLN5 exons identified a G to A transition in exon 2 (c.1627 G>A) that 
co-segregates with the disease-associated haplotype (Figure 6.5A). This nucleotide 
change leads to an Argl 12His substitution in the protein (R112H). This mutation was 
not present in any o f 29 control individuals from the same population. Alignment of 
available CLN5 sequences shows that arginine 112 is conserved across vertebrates, 
including rodent, amphibian, and bird species (Figure 6.5B).
A
B
Human R F D F R P K P D P Y C Q A K Y T F C P T G S P I P V M E G D D D I E V F R L Q A P V W E F K Y G D L L G H L
Mouse . . S . . . T . . . . K D N . V . . . L . . . . .  I . . . . F
Rat . . S . . . T . . . . K D N . V . . . L . . . . .  I . . . . F
Pig . . S . . E . . . . . K D . . V ................
Chicken . . S . R . . . . . . . .  A . . . . K E E . I . . . Y .
X.tropicalis . . S . . . T . . . . K D N . V . . . L . . . . F
X.laevis . . E . . . N . . . . G S . . . . K N E • I ■ Q • L • . . . F
Silurana . . E . . . T . . M . N S . . . . K N E . I . Q . Y . . . . F
Rainbow trout . . . C . A A . S . . E . M F P . . . . . D R . . Y . N N W . V . S . . . ............... S . . . K M
Zebrafish . V . K . D V . F L . P . . . . . D . . . . . K E S . L . S I . . . QT . . . M . K F
Fugu . . . H . D V . . F . E . I . P . . . . . D R V . D V R N S . V . S . Y . . QT  . . . ............... S . . . K M
Tetraodon . . R . D V . S F . E . I . P . . . . . D R . . D L R D S . V . S . Y . . QT  . . . ............... N . . . K M
Figure 6.5. (A) Partial sequence ofCLN5 exon 2 tom  individuals VI:3 (homozygous) upper panel, and V:7 
(heterozygous) in lower panel. Arrow indicates the mutant nucleotide position. (B) Alignment o f  the CLN5 
aminoacid sequence encoded by exon 2 in 12 vertebrate species. Arginine 112 is boxed.
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4. Discussion
The purpose of this chapter was to characterize an extended Colombian family with 
juvenile NCL (Batten disease). Patients started their symptoms at age 9 and continued 
to have a progressive and severe disease that ended in death for two of them at age 14 
(V:3 and VI:2). The subsequent onset of seizures was consistent with a diagnosis of 
Batten disease (Juvenile NCL). However, no vacuolated lymphocytes were found in 
samples from the patients that were available. Furthermore, pathological examination 
suggested a variant rather than a classic juvenile form (Dr Anderson, Personal 
communication; Histopathology Department, UCL), since the classical fingerprints
i a z  ' i n ' 7
encompassed with curvilinear profiles or lamellar inclusions ’ were not observed 
in our patients, but instead condensed fingerprint profiles occasionally associated with 
lipid droplets were found. These two observations suggested that this variant might be 
due to a mutation in a novel NCL locus.
Candidate NCL genes were then analyzed first. Genetic analysis confirmed that the 
disease in this family is not caused by mutations in CLN3, nor in CLN1, CLN2, CLN6 
or CLN8. However, markers linked to CLN5 locus were consistent with the 
transmission of the disease. Thus, available affected individuals were homozygous for 
alleles 1-1-1 at markers D13S156-D13S162-D13S1306. Consistently, parents of the 
third affected individual (V:3) were carriers of such a haplotype, leaving the possibility 
that she was homozygous for the haplotype and therefore for the mutation associated 
with it.
Sequencing of CLN5 exons led to the identification of a novel mutation that consisted 
of a c.1627 G>A transition. This mutation leads to the substitution of the conserved 
Arg 112 (Figure 3B) and was not found in the control individuals.
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To date, CLN5 mutations have been reported only in Finnish and Swedish families and 
in one Dutch individual ’ . All these patients presented an identical late infantile
onset NCL. There are clear clinical differences between northern European patients 
described with CLN5 mutations and the patients that we are reporting here. First, the 
age of onset was on average 3.25 years old . In contrast, for our three patients the 
age of onset was 9 years old. The first symptoms observed in the European patients 
were clumsiness and disturbance of concentration, whereas our patients presented first 
with symptoms of visual failure. However, the age of onset of seizures was 
approximately the same in the European and the Colombian patients. It was on average
9.3 years old for the Europeans and 9.5 years old for the Colombian patients.
This is the first CLN5 mutation outside northern Europe. These findings also show that 
mutations in CLN5 can result in a juvenile as well as the late infantile NCL. CLN5 
should thus be considered as a candidate for late infantile and juvenile NCLs, even 
outside northern Europe.
Recently, it was reported that the CLN5 protein is targeted to the lysosome 301, where
1AA
it interacts with CLN2 and CLN3 proteins Pathogenic mutations may affect 
interaction with other CLN proteins or trafficking of CLN5, as well as possibly 
causing loss of function. Evaluation of the molecular effect of disease-causing 
mutations should facilitate an understanding of disease mechanism, including the 
formation of lysosomal deposits
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CHAPTER SEVEN
GENETIC CHARACTERIZATION OF 
AN EXTENDED PEDIGREE WITH 
FAMILIAL ABDOMINAL PAIN
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1. Introduction
1.1 An extended family with many member suffering from Abdominal pain.
A four generation family in which many members presented with unexplained 
abdominal pain was recruited from the Servicio de Neurologia (NEUROCIENCIAS) 
from Universidad de Antioquia-Colombia. Eight affected females and seven affected 
males were identified. Both sexes transmitted the disease (Figure 7.1).
K:i *2 14 H* M *10 * 1 2
M :S ■1:7 I N *
Figure 7.1. Colombian family with abdominal pain. It includes twenty-seven individuals. No samples 
were available from individuals 1:1,11:1,11:3 and 11:4.
Age of onset of this condition was 1 day-10 months. Most frequently the first crisis 
was between 3-4 months. The crises were in general more frequent in infancy than in 
other periods of life. This may be the case because adults have learnt how to inhibit 
development of a crisis. Young children have had up to two crises per day.
Once the crisis has begun it can sometimes be stopped by having food, usually sweet, 
or by applying heat or resting. Crises can be stopped in the first 5-15 minutes; but after 
this time having any food will cause nausea and vomiting.
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Usually, the pain begins in the shoulders, chest and back area, then it descends and 
generalizes to all the body, with exception of the head, face and visceral structures. 
Pain is described as a burning sensation and is associated with loss of strength, 
difficulty of breathing, abundant sweating, coldness and generalized paleness. In 
addition, perioral cyanosis, hand spasms and generalized muscular contracture can also 
be present. It resembles colic in that is spasmodic and the pain ascends and descends 
during the crisis. However, in contrast to the pain in colic, in this disorder there is pain 
of the abdominal wall rather than visceral pain. This disease mainly affects the striated 
muscular system (shoulders, arms and abdomen).
During a crisis, the intensity of the pain increases gradually. When pain reaches its 
maximum, the patient falls into a deep sleep for one to two hours (Postictal sleep). 
When he/she wakes up the pain is gone but there is a feeling of weariness. Postictal 
sleep can be inhibited by stress (This was the case of one patient in the army). During 
a crisis there is no loss of consciousness but it leads to a post-ictal period characterized 
by somnolence and muscular tiredness. In all, crisis may last half an hour to an hour.
Some of the family members observed that crises are more frequent during other 
illnesses. In addition, hangover, excessive exercise or fasting are clear triggering 
factors. The grandmother of the family observed that the crises seemed to be identical 
in all affected individuals in the family, “It looks like a carbon-copy in the all”.
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Further, clinical characterization of these patients is underway but it is likely that the 
most appropriate diagnosis is Abdominal Epilepsy (AE), which is a form of autonomic 
epilepsy.
1.2 Literature review on Abdominal Epilepsy (AE).
Partial and generalized epilepsies alter autonomic function during ictal (during crisis), 
post-ictal and inter-ictal states. All aspects of autonomic function can be affected, 
including the parasympathetic, sympathetic and adrenal medullar systems 308. 
Autonomic symptoms can be divided into cardiovascular changes, respiratory 
manifestations, gastrointestinal symptoms, cutaneous manifestations, pupillary 
symptoms, genital and sexual manifestations as well as urinary symptoms 309. 
Gastrointestinal symptoms can be subdivided into epigastric auras, abdominal 
epilepsy, ictal spitting and ictal vomiting and ictal retching. Whereas epigastric auras 
frequently precede or are associated with complex partial seizures, abdominal 
sensations as the sole manifestation of epileptic seizures are rare 310,3U. However, 
gastrointestinal signs and symptoms may be the primary or only manifestation of 
seizures, and are therefore referred to as abdominal epilepsy (AE) 312.
The main criteria to establish a differential diagnosis of AE are the occurrence of 
paroxysmal gastrointestinal complaints that are unexplained after complete clinical 
evaluation, symptoms of a central nervous system disturbance and abnormal 
electroencephalogram (EEG) with findings specific for a seizure disorder, and a
T 1 ^sustained abolition of symptoms on anticonvulsant medication . EEG has rarely 
been evaluated during an AE crisis and is not necessary for the diagnosis 314, 315. 
Moreover, not all of the patients have presented an abnormal EEG
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However, some authors stress the importance of both disturbances of consciousness 
and specific EEG abnormalities as the types of evidence that could truly separate AE 
from other causes of recurrent abdominal pain 31°.
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Most reported cases are children and adolescents ’ . In a recent review of the 36
patients reported in the last 34 years in the English literature, Zinkin and Peppercorn 
319 showed that age of onset of AE ranged between 1 to 66 years old. They also found 
that males and females are affected about equally (53% females). Gastrointestinal 
manifestations of seizures included abdominal pain (86%), nausea and/or vomiting 
(28%), diarrhoea (5%) and bloating (3%) 319.
The abdominal pain was commonly sharp or colicky, in the periumbilical area and 
upper abdominal, including epigastric and right upper quadrant.
Neurological manifestations included lethargy, fatigue and/or post-ictal sleep (36%); 
some loss of consciousness was reported in 64% of the 36 patients, including complete 
loss of consciousness or generalized tonic-clonic seizures (36%). Less frequently, 
dizziness (8%), headaches (14%), pallor/sweats (11%), fever (6%) and blindness (6%) 
were found. Treatment was with anticonvulsants, most commonly phenytoin, 
Phenobarbital or carbamazepine, improving, most with complete or near complete 
resolution of symptoms. The duration of episodes was typically no more than a few
3 1Qminutes, but 5 (14%) had symptoms lasting for half an hour or more
Most cases of AE are of temporal lobe origin 3l3. However, several cases have been 
traced to parietal lobe lesions 320.
Rather than considering AE to be a separate entity, it may be more appropriate to 
simply recognize that some patients will have significant gastrointestinal symptoms as
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a manifestation of their seizures. When abdominal pain is followed by a generalized 
seizure, it might be referred to as an “abdominal aura” 319.
1.3 Aims
Even though AE was documented several years ago, no indication of a genetic link 
was reported previously. It is even the case that the occurrence of two affected 
individuals in the same family has never been documented.
However, this large Colombian family has 15 individuals affected with a condition 
classifiable as AE. Although we have clear assignment affected and unaffected 
individuals, this genetic study was undertaken ahead of the full clinical 
characterization since, for example, no EEG has yet been taken for any individual in 
the family. The disorder in this family presents as a clear autosomal dominant 
condition.
Given that there were no clear candidate genes to test for, the aim of this chapter was 
to evaluate genetic markers across the genome as part of a genome wide approach. In 
this way it might be possible to find linkage to a chromosomal region that could indeed 
be a novel locus associated with epilepsy (i.e. AE) . If this were achieved a further 
fine mapping step would be performed with the aim of identifying the mutant gene.
2. Methods
2.1 Power simulation
Power simulations were performed assuming autosomal dominant inheritance and high 
penetrance (0.985). A marker locus with four equally frequent alleles was simulated in
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one hundred replicas using SLINK 55. The disease frequency was assumed to be rare 
(0.0001). The actual simulated pedigree is shown in Figure 7.1.
2.2 Genome wide scan
A genome wide scan of microsatellites markers were typed by deCODE in all 
available individuals at an average density of 6 cM, as described in Chapter 2.
2.3 Microsatellite marker typing
In addition to the deCODE scan, eight additional markers were typed in the interval 
D8S512-D8S279. These were D8S533, D8S1775, D8S1767, D8S1792, D8S1117, 
D8S543, D8S1795 and D8S1807. Primer sequences and fluorescent labels were as 
shown in Table 7.1.
Marker typing was performed as indicated in Chapter 2.
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MARKER LABEL SEQUENCE 5' to 3' ASR
D8S1795 HEX TGAGCCCAATATGACAATGC
219-227
CC A A A A ATN C AC AA ACCT G
D8S1807
TET CCAAAACATTGCTCCC
CGCCTGTCCCTAGTTC
226-240
D8S543
FAM TGGTGTCATTGCTTTCTAGTCT
TGCACAGGTGAGTAAATTTGTAA
116-140
D8S1792
FAM AACTCCAAAACCTATAGANCAT
TCCGTTCCATGCTCTTC
238-290
D8S1767
HEX GCATGAGGTTTACAGTTAATGATGT
CAGTCAAATAAATTACATGTCCATC
137-159
D8S533
TET CTTTGCCAGGGTGTTCAGAG
AGAGCCTTGTTTCATGGGAC
159-169
D8S1775
FAM TGGCAAATACACACTCTGCT 
CCA A AT AGGCTG ATG AG A A ACT
136-162
D8S1117
HEX TTATTTTCCTGCAGACTCCG
CAGGAGAAAAGCATGCAGAT
183-204
Table 7.1. STR markers used to fine mapping the AE locus. Oligo F was labelled as indicated. Oligo R 
had no label. ASR= average size range. Sequences and ASRs were obtained from UCSC genome 
browser (http://genome.ucsc.eduA.
2.4 Two-point, multipoint and haplotype analysis.
Two-point lod scores were calculated using ML INK from the package LINKAGE 44 
and assuming autosomal dominant inheritance. Allele frequencies were those 
provided by deCODE, who had estimated them from a pool of samples of individuals 
with different ethnic backgrounds. Penetrance was set to 0.985 (same as in the power 
simulation).
Multipoint lod scores and haplotypes were obtained with simwalk2 49 using same 
conditions as for two-point analysis.
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3. Results
3.1 Power analysis
Table 7.2 shows power simulation results. This simulation indicated that this family on 
its own is powerful enough as to obtain evidence of linkage at 0=0. If phenocopies are 
not present in the pedigree, there is 30% chance of obtaining evidence of linkage (i.e. 
Z> 3) to a locus 5 cM away from the actual tested marker locus (0= 0.05) is still 
feasible in this pedigree.
Expected Lod Score (Z) Probability o f reaching Z> to:
Average Z max 1 2 3
0= 0  
0= 0.05
3.32 5.38 
2.37 4.96
94 87 46 
81 64 30
Table 7.2. Power simulation o f  family with Abdominal epilepsy.
3.2 Genotvping results
Table 7.3 shows a statistical summary of the deCODE marker typing. Although there 
were no data at all for marker locus D1S219, on average the deCODE marker typing 
efficiency was as high as 96%. The individual with the fewest genotypes was 11:9 
(91%). In contrast, the individual with the most genotypes was 11:7 (99%). Per 
chromosome, the least genotypes were obtained for the X chromosome (91%). The 
highest typing efficiency was obtained for chromosome 22 (100%; Table 7.3).
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INDIVID , 
UAL
CHROMOSOME
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X
1:2 1.00 1.00 0.94 1.00 1.00 1.00 1.00 1.00 1.00 0.96 0.95 0.96 1.00 0.96 0.95 1.00 1.00 1.00 0.87 1.00 1.00 1.00 1.00
11:2 1.00 1.00 0.97 1.00 1.00 0.96 1.00 0.96 0.96 1.00 1.00 0.93 0.94 0.96 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00
11:5 0.98 1.00 0.94 0.97 0.96 0.96 1.00 1.00 0.92 1.00 1.00 0.96 0.94 0.96 1.00 1.00 0.95 1.00 0.93 1.00 1.00 1.00 0.96
11:6 0.98 0.94 0.94 0.97 0.93 0.86 0.83 0.91 0.92 0.89 0.95 0.93 0.76 0.91 0.90 0.89 0.95 0.93 0.87 0.93 0.93 1.00 1.00
11:7 1.00 1.00 0.94 1.00 1.00 0.93 1.00 0.96 0.96 1.00 1.00 0.96 1.00 1.00 0.95 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
11:8 1.00 1.00 0.94 0.97 1.00 0.96 0.97 0.96 0.92 1.00 0.95 1.00 1.00 0.96 1.00 1.00 1.00 1.00 0.93 0.93 0.93 1.00 0.88
11:9 0.98 0.92 0.97 1.00 0.96 0.96 1.00 0.96 0.92 1.00 0.90 0.96 0.94 1.00 0.90 0.83 1.00 0.93 0.93 0.93 1.00 1.00 0.00
11:10 0.98 0.97 0.94 0.97 0.96 0.93 1.00 0.91 0.92 1.00 0.85 0.89 0.94 0.91 0.90 0.94 1.00 0.93 1.00 0.87 0.93 1.00 1.00
11:11 0.98 1.00 0.97 0.97 0.93 0.96 1.00 0.96 1.00 1.00 1.00 0.93 0.94 1.00 0.95 1.00 1.00 1.00 0.93 0.93 0.93 1.00 0.00
11:12 0.96 1.00 0.94 1.00 1.00 0.93 1.00 1.00 0.96 0.96 1.00 0.96 1.00 0.96 1.00 0.94 1.00 1.00 1.00 1.00 1.00 1.00 1.00
11:13 1.00 1.00 1.00 1.00 0.96 1.00 0.97 1.00 1.00 1.00 0.95 1.00 1.00 1.00 0.95 0.94 1.00 1.00 0.93 0.93 1.00 1.00 0.96
11:14 1.00 0.94 0.97 0.97 0.93 0.93 0.97 1.00 0.96 0.93 1.00 0.96 1.00 0.96 0.85 0.89 0.95 1.00 0.93 0.87 1.00 1.00 0.96
111:1 0.98 1.00 0.91 0.90 0.96 0.96 0.97 0.87 0.88 1.00 0.95 0.89 0.94 0.96 1.00 0.94 0.95 1.00 0.87 1.00 1.00 1.00 0.96
111:2 1.00 0.97 1.00 0.97 0.93 0.89 0.97 1.00 0.88 0.89 0.95 0.93 0.94 0.96 1.00 0.94 1.00 0.93 0.93 0.87 1.00 1.00 1.00
111:3 0.96 0.94 1.00 0.97 0.96 0.96 0.97 0.96 0.88 0.96 0.90 0.89 0.94 1.00 0.95 0.94 0.91 0.93 0.87 0.93 1.00 1.00 0.96
111:4 0.96 0.97 1.00 1.00 0.96 1.00 0.97 0.96 0.92 1.00 0.90 0.89 0.82 1.00 0.90 0.83 1.00 0.93 0.93 1.00 1.00 1.00 1.00
111:5 1.00 0.94 0.89 0.97 0.93 0.93 1.00 0.96 0.92 1.00 1.00 0.96 1.00 0.96 0.90 0.89 1.00 1.00 1.00 1.00 1.00 1.00 1.00
111:6 0.98 1.00 0.97 0.86 0.93 0.96 1.00 0.96 0.92 1.00 0.90 1.00 1.00 0.96 0.85 0.89 1.00 0.93 0.87 0.93 1.00 1.00 1.00
111:7 1.00 1.00 0.97 1.00 0.96 0.96 1.00 0.96 0.96 1.00 1.00 0.96 1.00 0.96 1.00 0.94 1.00 1.00 0.93 1.00 1.00 1.00 1.00
111:8 0.98 0.97 0.94 0.93 0.96 0.93 1.00 1.00 0.92 0.96 1.00 0.93 0.94 1.00 0.95 1.00 1.00 1.00 1.00 0.93 1.00 1.00 0.00
111:9 0.98 1.00 0.94 0.90 1.00 0.96 0.93 1.00 1.00 0.96 1.00 1.00 0.94 1.00 1.00 0.94 1.00 1.00 1.00 1.00 1.00 1.00 1.00
111:10 0.96 0.97 0.94 1.00 1.00 0.96 0.93 1.00 1.00 0.89 0.95 1.00 0.94 1.00 1.00 1.00 0.95 1.00 0.93 0.93 0.93 1.00 1.00
IV:1 0.98 0.97 0.94 1.00 1.00 0.93 1.00 1.00 0.96 1.00 1.00 0.89 0.94 0.96 1.00 0.94 0.95 1.00 1.00 0.93 1.00 1.00 0.96
Average 0.98 0.98 0.96 0.96 0.96 0.95 0.97 0.97 0.94 0.97 0.96 0.95 0.95 0.98 0.95 0.93 0.98 0.98 0.94 0.95 0.99 1.00 0.91
Table 7.3. deCODE marker typing efficiency.
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184 genotypes were required for fine mapping (eight markers in 23 individuals). From 
these only one failure was obtained in individual 11:11 at marker D8S543. Marker 
typing efficiency in fine mapping corresponded to 99.46%.
3.3 Two-point analysis
Tables 7.5-7.26 show two-point lod scores (Z) for chromosomes 1-22, (see appendix
3), respectively and a summary of lod scores above 2 is shown in Table 7.4.
Recombination fraction
Locus/
Chromosome
Genetic
map 0 0.1 0.2 0.3 0.4
Theta
Max Z max
Chromosome 2
D2S337 86.05 -12.22 0.7 1.15 0.99 0.54 0.212 1.15
D2S2152 94.62 -12.19 2.24 2.04 1.5 0.75 0.115 2.24
D2S2110 99.58 -8.8 -0.09 0.15 0.14 0.04 0.5 0.12
Chromosome 3
D3S3551 99.23 -13.34 -0.05 0.54 0.56 0.31 0.251 0.6
D3S3653 106.92 2.73 2.28 1.77 1.18 0.52 0 2.73
D3S1271 115.24 -8.26 1.53 1.32 0.93 0.41 0.091 1.53
Chromosome 8
D8S1763 73.88 -2.23 2.05 1.74 1.22 0.56 0.078 2.06
D8S512 78.06 4.18 3.48 2.7 1.83 0.86 0 4.18
D8S279 86.52 -5.91 1.57 1.69 1.35 0.77 0.164 1.72
D8S1707 97.46 2.11 1.79 1.43 1.02 0.55 0 2.11
D8S1778 106.89 2.7 2.28 1.83 1.31 0.71 0 2.7
D8S1762 108.03 2.76 2.92 2.39 1.68 0.82 0.045 3.04
D8S1470 118.7 -3.01 1.36 1.23 0.93 0.52 0.104 1.36
Chromosome 9
D9S2149 55.3 -13.55 0.09 0.62 0.6 0.29 0.238 0.66
D9S1777 67.34 2.14 1.78 1.37 0.9 0.37 0 2.14
D9S1876 70.42 -12.83 0.9 1.14 0.92 0.45 0.189 1.14
Chromosome 13
D13S1315 119 -13.51 -3.05 -1.36 -0.55 -0.14 0.5 0
D13S293 131.92 2.4 2.04 1.63 1.16 0.63 0 2.4
Table 7.4. Summary o f Two-point LOD scores above 2. 
For a complete information see appendix 3.
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Two-point lod scores over 2 were found on chromosomes 2, 3, 8, 9 and 13. For four of 
these, the maximum lod score was obtained at theta= 0 and for one it was obtained at 
theta= 0.1. Thus, on chromosome 2 a Zmax= 2.24 at 0= 0.1 was obtained (Table 7.4); 
for chromosomes 3, 9 and 13, Zmax= 2.73, 2.14 and 2.4 were obtained, respectively 
(Tables 7.4).
The only statistically significant two-point lod score was obtained for chromosome 8. 
A Zmax= 4.18 at 0= 0 for marker D8S512 was obtained (Table 7.4). Flanking markers 
at both sides of D8S512 were negative (<-2) at 0= 0. They presented their Zmax (1.72 
and 2.06) at 0= 0.164 and 0.078, respectively (Table 7.4). Figure 7.2 shows two-point 
lod scores at 0= 0 for markers on chromosome 8 and illustrates the very negative lod 
scores for the flanking markers to D8S512, i.e. D8S1763 and D8S279. Nevertheless, 
telomeric markers to D8S279 (D8S1707, D8S1778 and D8S1762) also presented Z>2 
(Table 7.4 and Figure 7.2).
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Figure 7.2. Two-point Lod scores for markers on chromosome 8, at 0=0
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The second highest lod score was obtained for marker D3S3653 (map position 
106.92), on chromosome 3 with a Zmax= 2.73 at 0= 0 (Figure 7.3). Its flanking 
markers presented Z <-2 at 0=0 and their Zmax were 0.6 and 1.53 for markers 
D3S3551 and D3S1271, respectively (Table 7.4).
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Figure 7.3. Two-point Lod scores for markers on chromosome 3, at 0=0 
3.4 Multipoint analysis
Multipoint analysis was performed for both chromosomes 3 and 8. Multipoint scores 
for chromosome 3 resulted all in exclusion (Z<-2), with exception of Z= -1.44 at map 
postion 94.06 and Z= -1.05 at map position 122.78 (Figure 7.4). These two locations 
are distant from D3S3653, which maps at 106.92 cM.
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Figure 7.4. Multipoint LOD scores for chromosome 3.
Multipoint analysis for chromosome 8 showed a maximum lod score of 4.42 in the 
interval D8S512-D8S279, at map position 79.75 cM (Figure 7.5). Statistically 
significative lod scores (Z>3) were also obtained for the telomeric region to marker 
D8S279 (Figure 7.5), where Z> 2 was obtained in the two-point analysis (D8S1707, 
D8S1778 and D8S1762; Figure 7.2 and Table 7.4).
3
o
80 160
3
■6
9
M ap p o s itio n
Figure 7.5. Multipoint LOD scores for chromosome 8. The highest peak corresponds to Z= 4.42 at map 
position 79.75 cM.
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Eight additional markers in this interval (D8S512-D8S279) were therefore tested and 
this resulted in a maximum multipoint lod score of 4.57 at map position 80.5 between 
markers D8S1767 and D8S1792. Analyzing the data with full penetrance instead of
0.985 (as was used in the simulation) a raise in the maximum multipoint lod score was 
observed to 4.63, at the same genetic position (Figure 7.6).
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Figure 7.6. Fine mapping o f AE locus. Multipoint lod scores for eight additional markers in the interval 
D8S512-D8S279.
3.5 Haplotvpe analysis
Figure 7.7 shows haplotype reconstruction for chromosome 8. Evaluation of the eight 
additional markers at a density of 1 marker every cM in the interval D8S512-D8S279 
resulted in the identification of a disease-associated haplotype (Figure 7.8). All 
affected individuals carry a disease-associated haplotype characterized by alleles 2-3- 
* 2-2-2 at marker loci D8S1792-D8S1117-D8S543-D8S1795-D8S1807. A 
recombination event was evident in the interval D8S1767-D8S1792 in the affected 
individual 111:8. Similarly, three recombinant chromosomes were observed in 
unaffected individuals 11:5, 11:7 and 11:14 in the interval D8S1117-D8S543. Since
these three individuals carry alleles 2-2-2 at marker loci D8S543-D8S1795-D8S1807, 
the disease-associated haplotype can then be narrowed down to alleles 2-3 at marker 
loci D8S1792 and D8S1117, respectively.
Looking in more detail at marker locus D8S512, it can be noticed that all affected 
individuals have inherited an allele 3. However, in individual 111:8 there is uncertainty 
as to which allele 3 he has inherited. This is due to the fact that his parents (11:11 and 
11:12) are both heterozygous for same alleles as 111:8 (Figures 7.7 and 7.8). 
Nonetheless, considering the haplotypic information, it can be observed that in 
individual 111:8 allele 3 was not received from his affected mother. This is inferred by 
considering the next marker locus down in the haplotype (i.e. D8S533), where an 
allele 4 could only be inherited from his mother. This allele 4 is in coupling (same 
chromosome) with allele 1, which are only present in his mother. This clarifies why 
the highest multipoint lod score was not obtained at 0=0 in D8S512 but in the interval 
D8S512-D8S279 (Figure 7.6). The normal maternal chromosome was transmitted to 
111:8 up to the interval D8S1767-D8S1792, where a recombination was evident.
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Figure 7.7. Haplotype reconstruction for deCODE markers typed on chromosome 8. Genotypes were 
inferred for individuals 1:1. 11:1, 11:3 and 11:4. The maximum two-point lod score was obtained for 
marker D8S512 and the maximum multipoint lod score was found in the interval D8S512-D8S279.
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Figure 7.8. Fine mapping o f AE locus. No samples were available for individuals 1:1, 11:1, 11:3 and 11:4, therefore their genotypes were inferred. 
Boxed appears the disease-associated haplotype
4. Discussion
The inherited condition in the family examined here clearly shows an autosomal 
dominant inheritance with high penetrance (probably 100%). Evaluation of markers 
across the genome, with a density of 6 cM, resulted in the identification of a locus on 
chromosome 8. Initial two-point linkage analysis showed a significant lod score 
(Z=4.18 at 0=0) for marker D8S512. Then, multipoint analysis showed that the highest 
lod score was obtained in the interval D8S512-D8S279, which comprises an 8 cM 
region. Fine mapping of this region resulted in identification of a disease-associated 
haplotype and multipoint analysis including these eight new markers showed a 
maximum lod score of 4.63 at map position 80.5 cM, which corresponds to the interval 
D8S1767-D8S1192. All affected individuals carry the haplotype characterized by 
alleles 2 and 3 at marker loci D8S1792 and D8S1117. The centromeric flanking 
marker was defined in individual 111:8, who presentes a recombination event in the 
interval D8S1767-D8S1792. The telomeric boundary was identified in individuals 11:5, 
11:7 and 11:14 as being in the interval D8S1117-D8S543. The interval D8S1767- 
D8S1792-D8S1117-D8S543 covers a region of 1.3 Mb, which corresponds to 1.85 
cM.
Interestingly, in this chromosome arm there are at least four other epilepsy-related loci. 
These are Benign Adult Familial Myoclonic Epilepsy (BAFME) at 8q23.2-q24.11 321, 
Familial febrile convulsions (FEB1) at 8ql3-q21 215, Childhood absence epilepsy 
{ECA I) at 8q24 322 and Benign Familial Neonatal Epilepsy (.EBN2) at 8q24 (KCNQ3) 
214. Strikingly, our candidate region is within FEB1 locus. FEB1 is flanked by markers 
D8S533 and D8S279 215. The candidate genes they suggested are outside our
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candidate region. However, it could be the case that both disorders are due to 
mutations in the same gene, located in our candidate region. There are many examples 
of clinical heterogeneity of syndromes that are relative to mutations in a single gene. 
For example, mutations in SCN1A have been described in both Generalized epilepsy 
with febrile seizures plus (GEFS+) and severe myoclonic epilepsy of the infancy 
(SMEI) 236,237; also, GABRG2 mutations have been associated with GEFS+, SMEI and 
childhood absence epilepsy (CAE) phenotypes 243-246. Likewise, CLN1 mutations have 
been associated with different clinical forms of Neuronal Ceroid Lipofuscinoses
^01
(NCLSs) . So, although the clinical entity reported by Wallace and colleagues 
(1996) is very different from the one I am reporting here, both are types of epilepsy. 
Another difference between FEB1 and AE  expressivity is the associated penetrance. 
The mutant allele in FEB1 is suggested to be 60-65% penetrant, while I am proposing 
that AE is highly penetrant (probably 100%).
Future work
In this candidate region there are only three identified genes, DEPDC2 and VEST1 in 
addition to a hypothetical protein, DKFZp547E186. DEPDC2 has 45 exons and 
extends 279.58 kb. There is no evidence of its function but it has been suggested that it 
might play a role in an intracellular signalling cascade, and have Guanyl-nucleotide 
exchange factor activity and protein binding 323,324. VEST1 has 20 exons, extends 
488.30 Kb and, to date, its function is completely unknown 324. A possible approach to 
uncover the mutant gene, responsible for the disease in this family, could involve the 
evaluation of functional domains of other implicated proteins in epilepsy, to see 
whether they have some degree of homology with DEPDC2, VEST1 or 
DKFZp547E186 proteins. Once identified a level of homology, sequence of that 
particular gene would reveal the actual genetic change underlying the functional
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alteration. If no homology was identified, sequencing of all the three genes would be 
the next step.
In conclusion, a highly significant lod score was identified for chromosome 8, which 
after fine mapping showed an increase of the lod score. Moreover, a small haplotype at 
8ql3.2 that clearly segregates with the disease was identified. The candidate region is 
flanked by markers D8S1767 and D8S543. This is the first locus reported for 
abdominal epilepsy so far.
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CHAPTER EIGHT
LINKAGE ANALYSIS OF TYPE 1 
DIABETES MELLITUS IN AN 
EXTENDED PEDIGREE
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1. Introduction
1.1 Generalities
Diabetes mellitus (DM) is a group of metabolic illnesses characterised by 
hyperglycaemia resulting from defects in the secretion and/or action of insulin. 
Symptoms of a clear hyperglycaemia include polyurea, polydipsia, loss of weight, 
sometimes polyphagia, and blurred vision 325.
Most cases of diabetes are located in two large etiopathogenetic groups: in one of 
them, the Type 1 Diabetes Mellitus (T1D), the cause is the absolute deficiency of 
secretion of the insulin and it can be subdivided in autoimmune (T1 AD) and idiopathic 
(T1BD). The second category, the Type 2 Diabetes Mellitus (T2D), is caused by a 
combination of both resistance and an inadequate secretion of insulin 325. A third 
category is named other types of DM. This category includes MODYs (Maturity onset 
of Diabetes in the Young), which is characterized by age of onset < 25 years old, 
autosomal inheritance with high penetrance, and no antibodies have been associated 
with this disorder 326. These features together with non dependence on insulin, at 
diagnosis, led them to be classified in the past as a form of T2D. And the fourth type 
of Diabetes is referred to as Gestational Diabetes.
DM is one of the most common illnesses around the world, with a frequency around 
3% 327. T1D is a disease mostly of white populations and its prevalence varies among 
different countries. The highest prevalence is in northern Europe ranging from 3.7 to 
20 per 100.000 328. At United States a prevalence of 0.4% has been reported 329. A
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concordance rate of 50% or less in T1D monozygotic (MZ) twins contrasts with the 
familial aggregation and a concordance of almost 100% in monozygotic twins in T2D 
. Incomplete concordance observed in MZ twins indicates that environmental 
factors also contribute to the aetiology. Some studies have provided insights that 
viruses, cow’s milk proteins amongst other suggestions, contain the antigens which 
provoke the antibodies involved in the autoimmune response; for example, congenital 
rubella infection has been shown to be associated with increased risk of T1D 331. 
Nevertheless, T1D shows increased relative risk in siblings and children of affected 
parents, suggesting an important genetic component. The risk to siblings has been 
reported as 15-fold higher than is the population prevalence ; similarly, children 
from affected parents have been reported at an increased risk and particular increase 
has been noticed when the affected parent is the father
1.2 Genetics of T1D.
To date more than twenty different putative loci have been described (Table 8.1) and it 
has been estimated that approximately another 50 loci remain to be identified. Two 
different approaches have been used extensively to identify susceptibility genes in 
T1D: Candidate genes and positional cloning approaches. The first studies were based 
on the candidate gene approach. Thus, because of the function of the HLA genes 
(Human Leucocyte Antigens) in the immune response and the fact that autoimmunity 
was strongly implicated in the pathogenesis of this disease, these genes were likely 
candidates in T1D.
Indeed human susceptibility to T1AD is associated to the HLA locus at 6p21.3, named 
IDDM1. Two particular loci in HLA have been shown to account for approximately 
50% of the heritable component of susceptibility in T1D.
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Locus Localisation Markers
IDDM1 6p21.3
HLA-DRB1,
DQB1
IDDM2 11 p 15 INS-VNTR
IDDM3 15q26 D15S507
IDDM4 11 q 13
FGF3,
D11S1337
1DDM5 6q25 ESR
IDDM6 18q21 JK, D18S487
IDDM7 2q31
HOXD8, 
D2S152
IDDM8 6q27
D6S264,
D6S446
IDDM9 3q21-q25 D3S1576
IDDM10 lO pll-q25 D10S193
IDDM1J 14q24.3-q31 D14S67
1DDM12 2q33 CTLA4
IDDM13 2q35 D2S164
ID DM  14 — —
IDDM15 6q21 D6S283
IDDM16 14q32.3 D14S542, IGH
IDDM17 10q25 D10S554
IDDM18 5q33-q34 IL12B
Unnamed lq42 D1S1617
Unnamed 16q22-q24 D16S3098
Unnamed 19p 13 D19S247
Unnamed 19q 13 D19S225
Unnamed X pl3-pl 1 DXS1068
Unnamed 7pl3 GCK
Unnamed 12q14-q 15 IFNG
Table 8.1. Genetics o f T1D. Modified from
HLA-DRB1 and HLA-DQB1 are the major components of IDDM1 336-343. 
Approximately 95% of white patients with T1D have either alleles DR3 or DR4, and 
55% -60% have both alleles 344, though different susceptibility HLA alleles may be 
involved in other ethnic groups than white populations 345. The DR2 allele has been 
observed to have a protective effect 344. In the case of HLA-DQB1, the substitution of 
Asp57 for Ala, Val or Ser in the molecule has been strongly associated with T1D 336, 
338. This change on its own is not enough to fully explain the HLA effect in the disease.
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However, if an allele DQB1 *0302 is associated with a DR4 allele, thus makes a 
strongly predisposing haplotype 346.
The second most significant susceptibility locus (IDDM2) is the 5' flanking 
polymorphism of the insulin gene (VNTR-INS), located on chromosomal region 1 lpl5 
347. IDDM2 consists of a VNTR (variable number of tandem repeats) located 596 bp 
upstream of the start site of transcription of the INS gene 348_35°. The VNTR-INS 
presents three alleles (S, M, L) that have been associated with different levels of the 
insulin mRNA in both thymus 351,352 and the pancreatic islets 353,354. Alleles at a SNP 
located 23 bases upstream from the INS gene have been associated with specific alleles 
in the VNTR 355.
Other loci have been identified by a positional cloning approach based on scanning the 
genome and identifying chromosomal regions, rather than particular genes. Uniformly- 
spaced previously mapped microsatellite marker loci are used to identify regions 
linked to the disease. This method is applied in both families and in population based 
studies. However, in polygenic traits such as T1D is difficult to identify large families 
with multiple affected members. Therefore, the affected sib-pairs (ASPs) method is an 
alternative and it has been proven to be especially valuable in identifying most of the 
susceptibility loci shown in Table 8.1. This method requires determination of the 
genotypes of pairs of siblings affected with the disease to compare the average 
. proportion of alleles shared at each marker locus . By these means, locus IDDM12 
on 2q33 357 1999, where the CTLA4 gene lies, was identified. This gene has been 
implicated in T1D 357'360 as well as in Grave’s disease 361 and Hashimoto tryroiditis 362. 
This gene is expressed only in activated T-lymphocytes and functions by down 
regulating T-cell function 363 and so seems to be a likely candidate for involvement in
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disorders with autoimmune pathogenesis, such is T1D.
Even though the majority of T1D patients present a pathogenic process related to 
autoimmunity, there is a group (-10%) that does not present autoimmune pathogenesis 
(T1BD). By studying families and ASPs with T1BD (Non-autoimmune) locus 
IDDM11 was identified on chromosome 14 364. Most support for linkage in this locus 
came from the subset of families where there was not increased sharing of HLA 
alleles.
1.3 Polygenic versus Oligogenic inheritance in T1D.
A completely different approach used to map susceptibility genes in polygenic 
diseases is animal models. Studies in animal models have provided indications that 
human T1D may have both polygenic and oligogenic inheritance. Studies on the non- 
obese diabetic mouse strain (NOD) have suggested approximately 15 loci contributing 
to disease ’ . In this mouse strain a chromosomal region was identified on
chromosome 1 that was associated with the susceptibility for T1D, which has syntheny 
with human chromosome 2 367. Evaluation of this region in humans led to the 
identification of a 23 cM region on chromosome 2, which contains three susceptibility 
T1D loci including 1DDM12 (IDDM7, IDDM12 and IDDM13) m 'm . Despite the fact 
it is not possible to assess the mode of inheritance, several genes conferring 
susceptibility to T1D have been identified in this chromosomal region, such as 
(CTLA4, HOXD8, IGF2, IGFBP2 andlGFBPS) 357>368.371-373.
An important challenge of studying the genetics of T1D, where there is accumulation 
of weak effects at many different loci, is to identify the loci themselves and determine
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to which a particular locus influences disease susceptibility. Evidence for oligogenic 
inheritance of T1D has been provided in BB rats 374'376 and LETR rats 377 with one or 
two non-MHC (equivalent to HLA) genes interacting with MHC susceptibility. In 
humans, there are two reported examples of a single gene that increases the risk for 
diabetes independently of HLA. The first was the autoimmune regulator gene (AIRE) 
on chromosome 21. AIRE mutations cause autoimmune polyendocrine syndrome type 
1 (APS-1), which includes insulin-dependent diabetes 378. The second example was 
found in a large family of Bedouin with multiple affected individuals with T1D. this 
study led to the identification of locus IDDM17 on chromosomal region 10q25, 
Interestingly, no evidence of linkage to HLA was found in this family, possibly due to 
a markedly increase of high-risk alleles.
1.4 Preliminary results.
In Colombia, DM occurs at a frequency of 7% in both sexes, and the prevalence of the 
intolerance to the oral test glucose has been found to be 5% in men and 7% in women 
38°. In 1996, Montoya et al. studied HLA alleles in T1D patients from Antioquia- 
Colombia, and identified two susceptibility haplotypes: DRB10301-DQA10501 - 
DQB\020\ with a frequency of 50% in cases versus 12.5% in controls; and DRB104- 
DQA103-DQB10302 with a frequency as high as 53.8% in cases and 28.6 in controls
381
More recently, Uribe and colleagues (2004) analyzed a large Colombian family 
presenting with T1D, where 11 affected individuals were identified in two generations 
(Figure 8.1). An affected father transmitted the disease to 8 daughters. Two sons were
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unaffected. Two other affected individuals were also identified in another branch of 
the family. There was evidence of dominant inheritance which was consistent with 
both an autosomal gene and x-linkage 382 (see Figure 8.1).
In the first study, we evaluated linkage to several candidate loci, including IDDM1, 
IDDM2, IDDM4, IDDM7, IDDM11, IDDM12 and IDDM13. In addition DXS1068 
was also analyzed. Furthermore, we also evaluated markers every 10 cM (Linkage 
panel set v.2, Applied Biosystems) on chromosomes 2 and 11, as part of the beginning 
of a genome scan. AntiGAD (Anti Glutamic Acid Decarboxilase) antibodies were 
evaluated in serum from patients where this was available. Linkage analsyis showed 
lod scores of either zero or exclusion (<-2) in all the candidate loci tested and 
interestingly also showed a peak of lod score of 2.31 for telomeric marker D2S319 at 
0=0, at chromosomal region 2p25. AntiGAD antibodies were positive in two late onset 
patients, confirming an autoimmune process (T1AD) in this family and ruling out 
other possible diagnoses such as MODY
asm 44(M)38(18)
Figure 8.1. Colombian family with T1D. Below each individual is shown current age/age at dead (age at 
diagnoses) when available. Sample code is shown for available individuals. Individuals 111:11 and 
111:12 were positive for antiGAD antibodies.
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1.5 Aims
The aim of this chapter was to further persue to linkage to marker D2S319 on 
chromosome 2. Also, to evaluate whether a haplotype was segregating with the 
disease in this Colombian family or if, on the contrary, random allele segregation was 
observed between the disease and markers at 2p25. Identification of a haplotype 
segregating with the disease would add evidence supporting the original hypothesis of 
the presence of a novel susceptibility T1D locus on chromosomal region 2p25 382. 
Identification of the actual mutant gene might allow the identification of the molecular 
processes that lead death of cells p islet in this family, adding knowledge to the 
complex set of cellular events that are presumed to participate in triggering this 
disease.
2. Patients and Methods
2.1 Patients
Patients were diagnosed as T1D according to international criteria . The parents and 
13 children compose the main branch of this pedigree (8 alive and 5 dead). The father 
was diagnosed at age 43. He was never obese and got progressively thin until six 
months after diagnosis. He only responded to treatment with insulin. He died due to 
an insulinic comma (double insulin dose) at age 64. Of 13 children, 8 were diabetic (all 
women), 7 required insulin from the stage of the initial diagnosis and one (111:11,
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Figure 8.1) started treatment with diet for the first two years. For the following three 
years she required oral hypoglyceamiants, and finally has required treatment with 
insulin.
Four affected children (111:5, 111:6,111:8 and 111:10) died due to complications directly 
related to Diabetes. Three of them (111:5, III:8 and 111:10, Figure 8.1) died because of 
chronic renal insufficiency, on average 22.6 years after diagnosis. Individual 111:6 died 
due to a coronary disease of early onset. A living patient (III: 13) developed chronic 
renal insufficiency and required transplantation 382.
2.2 Power simulation
In order to estimate the power to detect linkage, a simulation was carried out including 
the following assumptions: Autosomal dominant inheritance with a penetrance of 
98.5% 382 and 92%; an allele frequency of the mutated gene of 0.0001, and a marker 
locus with four alleles of equal frequency. 100 replicas were run using the SLINK 
program .
2.3 Microsatellite marker typing
Ten polymorphic DNA markers were tested in the vicinity of D2S319. These markers 
were D2S2980, D2S323, D2S2393, D2S2245, D2S304, D2S205, D2S2166, D2S2891, 
G62096 and D2S2133 (Figure 2). They all were amplified using 30 cycles of 94° C 30 
sec, 52-60° C 15 sec, 72° C 30 sec, and a final elongation step of 72° C during 10 min. 
Markers were labelled with different fluorescent tags in the F-oligo to allow pooling 
before loading them onto an ABI-377 (Table 8.2).
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Marker Annealing To Label ASR
D2S2980 55° C HEX 232-284
D2S323 55° C FAM 177-193
D2S2393 55° C FAM 244-270
D2S319 55° C FAM 116-138
D2S304 52° C FAM 177-189
D2S205 55° C HEX 143-171
D2S2166 55° C HEX 208-250
D2S2891 57° C FAM 141
G62096 55° C HEX 145
D2S2133 60° C FAM 98-102
Table 8.2. Marker loci typed around marker locus D2S319 at 2p25 in a Colombian family with 
T1D. ASR=Average size range. These markers were evaluated at different times, so that they 
were pooled at least in pairs.
2.4 Linkage and Haplotype analysis
Linkage analysis was carried out using same assumptions as for the power simulation. 
Allele frequencies were assumed as 1/n (n=number of alleles) and a phenocopy rate of 
zero. Two-point lod scores were calculated with MLINK 44. Haplotypes were 
reconstructed using simwalk2 49.
3. Results
3.1 Power simulations
Table 8.3 shows the results of the power simulation. At both penetrances an average 
lod score of about 2 is expected. The simulation also indicated that approximately 29% 
chance of finding a Z>3 in this family was possible, when penetrance 0.985 was used. 
Using penetrance of 0.92 a 25% chances of finding a Z>3 was obtained.
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Expected Lod score (Z) at 0= 0 Probability o f reaching Z> to:
Penetrance Average Zmax 1 2 3
0.985 2.39 3.57 74 57 29
0.92 1.98 3.14 76 60 25
Table 8.3. Power simulation for family with T1D.
3.2 Two-point analysis
Table 8.4 shows the two-point lod scores for markers according to genetic map shown 
in Figure 8.2. It can be noticed that marker D2S319 presented the highest lod score 
(Z= 2.53) at 0= 0. The second highest lod score (Z= 2.0) was found for marker 
D2S2393 at 0= 0.072. Markers D2S323 and D2S2245 presented maximum lod scores 
close to zero (Z=0.4 and Z = 0.37, respectively) because they were uninformative for 
linkage. The remaining markers were informative for linkage and their Z max was 
over 0.85 at different recombination fractions. These results support the notion of a 
locus in T1D at 2p25.
The locus by locus analysis was focused on the main branch of the pedigree (Figure
8.3).
For marker D2S2980 all affected individuals received an allele 1 from 11:4, with 
exception of the affected individual 11:12 who is a recombinant and received allele 2. 
Consistently, Z<-2 (0= 0) was obtained, which indicates exclusion (Table 8.4).
For marker D2S323 lack of informativity of individual 11:4 explains the low lod score. 
As both affected and unaffected children of IT.4 received an allele 3, it was possible to 
infer that 11:4 was homozygous 3/3 for this marker (Figure 8.3). A recombination 
seems to have occurred in individual 111:12 in the interval D2S323-D2S2393. 
However, since marker locus D2S323 appeared as homozygous, it is not possible to
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determine whether this is between D2S323-D2S2393 or D2S323-D2S2980 (see Figure
8.3). This indicates that the telomeric border of the candidate region is marker 
D2S2980.
Locus
Recombination fraction, 0
0 max Z max0 0.1 0.2 0.3 0.4 0.5
D2S2980 -5.23 0.8 0.86 0.62 0.25 0 0.16 0.89
D2S323 0.4 0.28 0.18 0.08 0.02 0 0.001 0.4
D2S2393 -1.52 1.98 1.63 1.09 0.44 0 0.072 2
D2S2245 0.37 0.27 0.17 0.09 0.02 0 0.001 0.37
D2S319 2.53 2.17 1.68 1.1 0.44 0 0.001 2.53
D2S304 -7.52 0.78 0.83 0.58 0.21 0 0.159 0.86
D2S205 -6.97 1.03 1.03 0.72 0.28 0 0.144 1.1
D2S2166 -3.19 1.48 1.23 0.8 0.3 0 0.086 1.48
Table 8.4. Two-point lod scores for markers flanking D2S319 locus. Analysis included penetrance=
0.985
Marker locus D2S2393 showed a Zmax= 2.0 at 0= 0.072 (Table 8.4). Every affected 
child in the large nuclear family received an allele 3 at this marker locus from 11:4. In 
contrast, the unaffected individuals received an allele 1 from him. In contrast to the 
observation in the large branch where allele 3 was segregating with the disease, 
affected individual 111:3 received an allele 1 from his mother. The lack of allele sharing 
caused the Z maximum to be at 0 ^  0 (Table 8.4). If we excluded individuals 111:1, 
111:2 and 111:3 from the analysis, the highest lod score is then obtained at 0= 0 (Z= 
1.76, Table 8.5). For marker D2S2245 there was no linkage information since this 
marker was monomorphic. Everybody in the pedigree was homozygous 2/2 with 
exception of 11:3, who was 1/2.
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□
11:3
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*
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D2S2980 3.76 1 3 0 2 3 2 1 2 2
D2S323 5.04 3 3 0 1 4 3 3 3 2
D2S2393 7.05 3 1 2 2 5 1 3 1 4
D2S2245 7.05 2 2 2 2 1 2 2 2 2
D2S319 7.60 2 1 2 2 1 1 2 1 2
D2S304 10.04 3 4 0 2 2 4 3 4 1
D2S205 10.42 2 1 4 4 3 1 2 1 2
D2S2166 10.86 2 5 0 2 4 5 2 5 3
H o i  b  j i f  6  j i f  4
111:1 Hl:2 111:3 Ml:4 111:5 Kl:6 111:7 111:8 111:9 111:10 111:11
(8)
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N:5
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21 33(8) 44(18) 35 36(18) 48
4
111:12
4
111:13
6
111:14 111:15
45(28) 44(34) 43(13) 41 40
IH:16
39(14)
D2S2980 3.76 01 3 2 3 1 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 1 1
D2S323 5.04 o | 3 1 3 3 3 3 2 3 2 3 3 3 3 3 2 3 2 3 2 3 1
D2S2393 7.05 2 1 2 1 3 1 1 4 1 4 3 1 1 3 4 1 4 1 1 3 1
D2S2245 7.05 2 | 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 1
D2S319 7.60 2 I 1 2 1 2 3 1 2 1 2 2 3 2 I 3 2 2 1 2 1 3 2 1
D2S304 10.04 0 | 4 2 4 3 3 4 1 4 1 3 3 3 1 3 3 1 4 1 4 3 4
D2S205 10.42 4 1 4 1 2 2 1 2 1 2 2 2 2 1 2 2 2 1 2 1 2 1
D2S2166 10.86 ° l 5 2 5 2 1 5 3 5 3 2 1 2 1 1 2 3 5 3 5 1 5
Figure 8.3. Pedigree ofColombian femily with T1D. Haplotypes were inferred for individuals 1:1, 1:2, 0:2 and 11:4 since no sample was available from them. 
Below each symbol is shown current age/age at dead (age at diagnosis) when available. Haplotypes for markers according to genetic map in Figure 1 are shown. 
Two key recombinant events were observed in 111:12 and 111:16 allowing establish a candidate region between marker loci D2S2980 and D2S304. 111:11 and 111:12 
were positive for antiGAD antibodies.
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For marker D2S319, a lod score of 2.53 was obtained, at 0= 0, representing the highest 
lod score for this set of markers. Every affected individual in the large branch of the 
family received an allele 2 from individual 11:4, and unaffected individuals 
alternatively received an allele 1. Individual 111:3 was genotype 2/1, and considering 
the lack of a sample from his father (11:2), it is not possible to determine where allele 2 
comes from. Therefore there is no evidence of recombination and the maximum lod 
score results at 0= 0 (Table 8.4).
If individuals 111:1,111:2 and 111:3 were excluded from the analysis, the Z max still is 
obtained at 0= 0 (Table 8.5).
Locus
Recombination fraction, 0
6 max Z max0 0.1 0.2 0.3 0.4 0.5
D2S2980 -3.67 0.98 0.86 0.58 0.22 0 0.107 0.98
D2S323 -0.33 -0.17 -0.09 -0.04 -0.01 0 0.5 0
D2S2393 1.76 1.61 1.29 0.87 0.36 0 0.001 1.76
D2S2245 -0.25 -0.14 -0.07 -0.03 -0.01 0 0.5 0
D2S319 2.12 1.78 1.37 0.9 0.37 0 0.001 2.12
D2S304 -4.24 0.65 0.69 0.51 0.2 0 0.157 0.71
D2S205 -4.28 0.65 0.69 0.51 0.2 0 0.157 0.71
D2S2166 -4.24 0.65 0.69 0.51 0.2 0 0.157 0.71
Table 8.4. Two-point lod scores for markers flanking D2S319 locus excluding individual 11:1 ’s family.
Marker D2S304 showed evidence of a recombinant in the large nuclear family. Every 
affected individual received an allele 3 from individual 11:4, with the exception of 
individual 111:16, who received an allele 4 from him. Allele 4 is the allele that all four 
available unaffected individuals in this branch of the family received from 11:1.
• Affected individual 111:3 also received an allele 4 from his mother. These observations 
allow identification of two recombinant individuals for this marker locus in the 
pedigree, establishing that the centromeric limit in the candidate region is D2S304 
(Figure 8.3), and its associated lod score is -7.52 at 0= 0 (Table 8.4).
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When analyses were done only for the main nuclear family and using a penetrance= 
0.92, the lod scores were slightly higher than when using penetrance= 0.985.
However, more important than the lod score itself is the recombination fraction at 
which those lod scores were obtained. So, maximum lod scores at q= 0 were obtained 
for marker D2S2393 and D2S319 (Table 8.5). Thus, exclusion of linkage was 
obtained for markers D2S2980, D2S304, D2S205 and D2S2166 (Table 8.5). The 
remaining four markers formed a consistent disease-associated haplotype.
3.3 Haplotvpe and Multipoint analysis
In the main nuclear family, all affected individuals carry a disease-associated 
haplotype characterized by alleles 3-3-2-2 at markers D2S323-D2S2393-D2S2245- 
D2S319. Among the unaffected individuals, 11:1 is the only carrier of this haplotype. 
11:1 has two affected children, one of them (111:3) seems to correspond to a phenocopy 
since he does not carry the disease-associated haplotype (Figure 8.3).
Figure 8.4 shows the multipoint analysis for the complete pedigree. Lod scores were 
positive for the interval D2S323-D2S319 (Zmax= 0.148 in the interval D2S323- 
D2S2393), providing little evidence in favour of linkage.
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Figure 8.4. Multipoint analysis for markers according to the genetic map shown in Figure 2.
However, further analysis excluding II: 1 ’s family resulted in a raise of the multipoint 
lod scores in the interval that corresponds to the candidate region (i.e. for the interval 
D2S2980-D2S304, Figure 8.5). Its maximum lod score is 1.146 At the interval 
D2S2393-D2S319.
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Figure 8.5. Multipoint analysis excluding individual II: 1 ’s family. Penetrance= 0.92.
4. Discussion
The purpose of this chapter was to evaluate whether a haplotype was segregating with 
T1D in 2p25 in order to confirm the findings reported by Uribe and colleagues 382.
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Although this family presents with a high penentrance, resembling MODY, autosomal 
dominant disease with presence of antiGAD antibodies in addition to severity and 
disease related complications points to autoimmune T1D rather than other diagnoses. 
Evidence of autommunity was found in individuals 111:11 and 111:12, who presented 
high titers of antiGAD antibodies.
Analysis of seven additional polymorphic markers linked to D2S319 led to the 
demonstration of a maximum two-point lod score of 2 for marker loci D2S2393 (Table 
8.4), suggesting that true linkage of 2p25 to T1D is present in this family. A higher 
lod score than 2.31 for D2S319 was obtained in our analyses because we assigned a 
lower value for the suggested population allele frequency of the mutation, since all 
indications are that this is an extremely rare allele. It was decreased to 0.0001, from
0.003 in the model used by Uribe and colleagues 382.
Moreover, a disease-associated haplotype characterized by alleles 3-3-2-2 at markers 
D2S323-D2S2393-D2S2245-D2S319 (Figure 8.3) was identified. Marker D2S2980 
corresponds to the telomeric limit identified in this study. Similarly, centromeric 
marker to D2S319 (i.e. D2S304) corresponds to the centromeric limit of the candidate 
region identified here (Figures 8.3). The candidate region is 3.24 Mb long and spans 
6.28 cM. Typing extra markers (e.g. STRs or SNPs) in between D2S319-D2S304 will 
result in a narrower centromeric limit of the candidate region. Narrowing the 
telomeric limit could also be possible. Considering that marker D2S323 was not 
informative for linkage, the recombination delimiting the telomeric limit can still be 
more precisely identified. Thus, by typing extra markers in the intervals D2S2980- 
D2S323 and D2S323-D2S22393, further refining of the region could be achieved. 
Three already typed markers that have not got a reported genetic position are shown in
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Table 8.6. Even so, two of these are non informative for linkage, since they were 
monomorphic, are presented here mainly to prevent that somebody else type them 
again.
Individual D2S2891 G62096 D2S2133
11:1 1 1 1 1 2 2
11:3 1 1 1 1 0 0
11:5 1 1 1 1 1 2
111:2 1 1 1 1 1 2
111:3 1 1 1 1 1 2
111:6 1 1 1 1 1 2
111:7 1 1 1 1 2 2
111:9 1 1 1 1 2 2
111:11 1 1 1 1 1 2
111:12 1 1 1 1 1 2
111:13 1 1 1 1 2 2
111:14 1 1 1 1 2 2
111:15 1 1 1 1 1 2
111:16 1 1 1 1 1 2
Table 8.6. Genotypes for three extra markers with genetic positions not available. These markers were 
not used in multipoint analysis because o f the inability to distinguish between centromeric and 
telomeric flanking markers to D 2S319 in the genetic map.
The age at onset shows a large range in this family, 8-43 years. Considering that the 
oldest person diagnosed was 11:4 (onset at 43 years old) and that the other affected 
individuals presented age at onset much younger than him (8-34), there is the 
possibility that anticipation is involved. Thus, expansion (of a trinucleotide repeat 
array) is a possibility, since when the array increases over certain size, the disease will 
appear earlier. For example, in Huntington disease it has been documented that the 
larger the expansion, the younger the age at onset149.
Oligogenic inheritance has previously been reported for two autoimmune disorders 
that usually are thought of as polygenic . In one of these studies a single
locus on chromosome 10 (.IDDM17) provided most of the genetic component in the
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family studied. No evidence of linkage to HLA was found 379. The present results are 
similar to those of Verge and colleagues (1998) 379, since only linkage to 2p25 has 
been identified and no linkage to any of four STRs in HLA-class II was observed
Looking at candidate genes in this region, it appears that at least one is a very good 
candidate. This is TPO, which encodes the enzyme thyroid peroxidase. Antibodies 
against TPO in T1D patients have been reported 384. TPO gene has 17 exons and 
expands 129.16 kb and locates just centromeric to D2S2980. Mutations in TPO have 
been reported in families with total iodine organification defect (TIOD), which leads to 
congenital hypothyroidism 385. CTLA4 (.IDDM12), which has been associated with 
T1D 357*360 and has also been associated with thyroid disorders (Graves disease 361 and 
Hashimoto thyroiditis 362). So, in a similar way to CTLA4, it will not be surprising if 
TPO mutations were associated to T1D in the family presented here.
ACPI (Erythrocyte acid phosphatase) is located just telomeric of D2S2980 (outside the 
candidate region). Genotypes for low activity of this enzyme have been associated 
with higher glyceamic levels in T1D
In conclusion, a haplotype segregating with T1 AD has been identified in an extended 
Colombian family. This haplotype spans 3.4 Mb on chromosomal region 2p25.
Further fine mapping needs to be done before engaging in evaluating candidate genes 
in the region. However, TPO gene seems strikingly good candidate. This family is the 
third evidence of oligogenic inheritance of T1D.
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CHAPTER NINE
GENERAL DISCUSSION
This thesis aimed to make progress on the genetic characterization of several 
Mendelian forms of complex disorders, including Parkinson’s disease, Generalized 
Epilepsy with Febrile Seizures Plus [GEFS+], Batten’s disease, Type 1 Diabetes 
[T1D], Multiform Movement Disorder [MMD] and Abdominal Epilepsy [AE]. All 
individuals studied here are from Antioquia -  Colombia.
In Parkinson disease (PD) -Chapter 3-, progress was made in three aspects. First, three 
affected individuals (V ;l, V:12 and VI:2, Figure 3.4), who originally were identified 
as sporadic cases and only carriers of mutation c.736 G>A in PARK2, were found to be 
members of the same extended pedigree from the same town (Peque). In addition, 
family PJF3, in which this mutation was originally reported 36 was also found to be a 
branch of the same extended pedigree in Peque. Haplotype analysis of the extended 
pedigree at the PARK2 locus indicated that the three affected individuals shared a 
second haplotype (Table 3.5) that eventually could be associated with a second 
mutation segregating in the family. An exon 3 duplication was found in individuals 
V:1 and VI:2. Individual V:12 was not tested and based on the haplotype shared I 
assumed him to be also carrier of such a duplication. This observation provides 
evidence against those reports claiming that being carrier (heterozygous) of PARK2 
mutations is a genetic risk factor for being affected by PD 65,83,110,113,118,128,129. An 
important factor for those studies not to have found second mutations (e.g. deletions of 
duplications) is that they have mainly used SSCP and sequence, in addition to lacking 
large pedigrees where haplotype analysis could provide sights of a second mutation in 
those affected individuals with only one mutation identified.
A second aspect is, when analysing four intragenic STRs in a group of 23 sporadic 
cases, it was found that association to PARK2 was detected for alleles at marker loci 
D6S1550 and D6S980 (Table 3.8). Furthermore, when the analysis included the
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haplotype made of the four marker loci, an increase in the statistical significance was 
observed. None of these 23 cases carries the c.736 G>A mutation; only one of them is 
a carrier of 321-322insGT mutation (previously reported in Antioquia) and judging 
from the haplotype analysis none of these carry the exon 3 duplication. However, 
these results suggest that mutations that went undetected by SSCP and sequencing will 
eventually be found in this set of sporadic cases in PARK2 gene.
The third aspect was the fact that the Spanish family where c.736 G>A was reported, 
showed a completely different chromosome from the one in the Colombian families. 
This observation suggests that recurrent mutation could be a good explanation; 
however, since nobody knows how old is the Spanish chromosome carrying the c.736 
G>A mutation, and considering that recombination could have taken away the shared 
regions with the Colombian chromosomes, it is necessary to evaluate markers more 
closely linked to the mutation (SNPs) and if still no haplotype is shared, then the 
hypothesis of recurrent mutation would be favoured.
In Multiform Movement Disorder (MMD) -Chapter 4- study of one family with the 
disorder and based on the most appropriate differential diagnoses, several candidate 
genes were excluded, including PARK1, PARK2, PARK8, PANK2, and PARK8. Brain 
pathology in one of the deceased patients (individual 111:6 ) revealed massive iron 
accumulation in various parts of her brain. This observation was similar to the reports 
by Curtis and colleagues 159 and evaluation of linkage to the gene FTL, reported by 
them provided no evidence in favour of linkage. Thus, considering the power 
limitations of the pedigree studied, a genome wide scan was performed in this family 
hoping to find linkage to a region where a clear candidate gene involved in iron 
metabolism lies. Results indicated that there are two candidate genes to be evaluated 
since both of them are associated with iron metabolism. These are the Neuroglogin
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gene (NGB) on chromosome 14 and the Ferritin Heavy Chain gene (FTH1) on 
chromosome 11. For the case of NGB, one unaffected individual (111:3, Figure 4.4) 
carrying the disease associated haplotype was identified. This observation could be 
explained by incomplete penetrance or also by random segregation (i.e. no linkage to 
the disorder).
FTH1 seems a very plausible candidate, since a previous report linked the light chain 
(FTL) of the ferritin to a disorder presenting with pathological features very alike to 
those presented by the family studied by us 159. However, two-point analysis showed 
that the maximum lod score (Marker D11S4151, Zmax= 0.97) is obtained at 0= 0.1. 
Typing markers more tightly linked to FTH1 would evaluate whether this gene is the 
one implicated in the disorder in this family.
In GEFS+ -Chapter 5- a set of six families were analyzed for candidate genes/loci 
involved in GEFS+ and Febrile Seizures (FS). From this set, three families (Families 
1, 6 and 7) showed linkage to markers at 2q23-24, where FEB3/SCN1A/SCN2A genes 
lie. In Family 1, a combination of SSCP and base sequence of SCN1A gene revealed a 
c.5213 A>G mutation, which lead to the D1742G substitution. This mutations lies in 
the pore forming loop of domain IV of the protein and its conservation through related 
genes might explain the severity of its phenotype, which contrasts with the mild 
severity and penetrance reported for GEFS+ ’ . Families 6 and 7 do not carry this
mutation and are being further evaluated in SCN1A gene.
Family 5 showed linkage to GABR cluster. This cluster involves GABRG2, GABRA1, 
GABRA6 and GABRB2 genes. Of these, only GABRG2 has been associated to GEFS+ 
243 2002, 246 Sequencing of the coding region of this gene failed to identify disease 
causing mutations. In addition, an affected individual appeared as recombinant for
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marker SHGC-132760, confirming exclusion of GABRG2 in this family (Figures 5.2 & 
5.6). Evaluation of GABRA1, GABRA6 and GABRB2 genes is currently underway. 
Families 3 and 4 seemed not to be linked to any of the genes/loci evaluated. However, 
Family 3 requires more evaluation in locus FEB2 since exclusion has not been 
obtained; but at the same time very low lod scores have been obtained in this family 
since all affected individuals carry a haplotype (Figure 5.7), which is also carried by 
unaffected individuals as well as by both parents in the family.
In Batten disease -  Chapter 6- an extended family was studied. Three affected 
individuals in two consanguineous nuclear families from the same pedigree presented 
with clinical Batten disease (i.e. Juvenile onset). However, pathological analysis of 
skin biopsy revealed inclusions consisting of fingerprint profiles, often condensed, and 
occasionally associated with lipid droplets, suggestive of a variant NCL. Genetic 
analysis excluded CLN3, since both affected children appeared heterozygous for STRs 
linked to this gene (Figure 6.3). SSCP and sequencing confirmed exclusion. Similarly, 
typing markers linked to CLN1, CLN2, CLN6 and CLN8 genes resulted in exclusion 
(Figure 3, Table 4). Evaluation of markers linked to CLN5 showed that only affected 
individuals were homozygous for a haplotype characterized by alleles 1-1-1 at markers 
D13S156-D13S162-D13S1306. These markers flank the CLN5 gene. Sequence 
analysis of CLN5 revealed a transition of G to A at position 1627 in exon 2 (c.1627 
G>A; Figure 5A) and was not found in any of 29 controls. This mutation leads to the 
substitution Argll2Hys and was found to be highly conserved among vertebrates 
(Figure 6.5B). c.1627 G>A is the first CLN5 mutation reported outside Europe and 
associated with a Juvenile phenotype rather than late infantile. Previous reports have 
documented four CLN5 mutations in patients from Finland, Sweden and Holland 269’ 
, all of them presenting a late infantile pheotype. Evaluation of the molecular effect
195
of this mutation should facilitate an understanding of disease mechanisms, including 
the formation of lysosomal deposits.
In Abdominal Epilepsy (AE) -Chapter 7- a large family presenting with a disorder 
that, although clinical characterization is underway, the most appropriate diagnosis is 
Abdominal epilepsy (AE). AE has never been reported as a familial form; however 
here we are reporting a multigenerational pedigree including 15 affected individuals. 
Both sexes are affected about equally (53% females) and clear autosomal dominant 
inheritance was observed. Having no clear candidate genes to evaluate a genome scan 
was conducted. Two-point analysis revealed a Zmax= 4.18 at marker locus D8S512. 
Fine mapping of the region resulted in a maximum multipoint lod score of 4.63 in the 
interval D8S1767-D8S1192. This region extends 1.3 Mb, which corresponds to 1.85 
cM. Interestingly, this locus (i.e. AE) is overlapped by FEB1 locus 215. It could be the 
case that both disorders are due to mutations in the same gene, located in our candidate 
region. Despite the disorders are types of epilepsy they are also very different 
phenotypes. For example, none of the patients in our family presented febrile seizures, 
which is the phenotype linked to FEB1. In our candidate region there are three genes 
identified, DEPDC2, VEST1 and the hypothetical protein DKFZp547E186. 
Uncovering the mutant gene in this family could involve evluation of functional 
domains of other proteins implicated in epilepsy to see whether they have some degree 
of homology with DEPDC2, VEST1 or DKFZp547E186. If a level of homology is 
identified, then sequence of the gene implicated would reveal the mutation responsible 
for the disorder in this family. If no homology was identified, sequencing of all the 
three genes would be the next step. This is the first locus reported for AE so far.
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Finally, in Type 1 Diabetes [T1D] -Chapter 8- an extended pedigree with the disease 
was studied. Here, I have further evaluated a novel locus that was identified by Uribe
' l O ' J
and colleagues . This family was analyzed for several candidate loci, including 
IDDM1, IDDM2, IDDM4, IDDM7, IDDM12, IDDM12 and DXS1068. Additonally, 
markers across chromosomes 2 and 11 were typed at an average density of 10 cM 
(Linkage panel set v.2, Applied Biosystems) as part of the beginning of a genome 
scan. We obtained lod scores of either zero or exclusion in all candidate regions 
evaluated. However, one peak of Z= 2.31 at 0= 0 for telomeric marker D2S319 was 
obtained. AntiGAD antibodies were positive in two individuals (111:11 and 111:12), 
which are a marker of autoimmunity in T1D. Here I have examined seven additional 
markers around D2S319. A maximum two-point lod score of 2 for marker loci 
D2S2393 was obtained (Table 8.4), suggesting that true linkage of 2p25 to T1D is 
present in this family. A haplotype characterized by alleles 3-3-2-2 at markers 
D2S323-D2S2393-D2S2245-D2S319 was identified (Figure 3). This candidate region 
is 3.24 Mb long and spans 6.28 cM. Based on the observation that CTLA4 is 
associated with both T1D 357'360 and thyroid disorders (Graves disease 361 and 
Hashimoto thyroiditis 362), the TPO gene which has been associated with thyroid 
disorders ’ is a potential candidate gene since it lies in our candidate gene. 
Nevertheless, the candidate region can still be further narrowed down in the telomeric 
region. The identification of this locus represents the second evidence of oligogenic 
. inheritance in T1D.
In conclusion, various different findings have been achieved in this thesis work.
Despite having ascertained my population sample from a homogeneous population,
evidence of locus and allelic heterogeneity was evident. Locus heterogeneity was clear
in GEFS+, since the set of families were linked to different loci. Allelic heterogeneity
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was evident in Parkinson disease, where different mutations explain the disease in 
some individuals and the great majority of sporadic cases, although linked to PARK2 
are presenting mutations that went undetected.
Considering that the families and individuals studied here are affected by high 
penetrant mutations and that they originate in a homogeneous population in addition to 
the rarity of the disorders (i.e. Early-onset Parkinson disease), a high level of 
heterogeneity was found. Therefore, if studying low penetrant mutations and quite 
prevalent disorders (complex traits) much more heterogeneity can be expected. This 
emphasises the importance of ascertaining population samples from homogeneous 
populations, specially when studying complex disorders, even for Mendelian forms 
when one single family lacks of the power to detect significant linkage on its own.
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Appendix 1. Markers typed by deCODE.
Locus Marker 3hr
Genetic position (cM)
Marshfield deCODE
deCODE
Distance
Cytogen 
etic band
Hetero­
zygosity
D1S468 AFM280we5 1 4.22 5.44 0 p36.32 72.7
D1S2870 AFMa052wg1 1 14.04 11.68 6.23 p36.31 80
D1S450 AFM247te9 1 20.61 16.99 5.32 p36.22 78.67
D1S2667 AFMa224wg9 1 24.68 20.36 3.37 p36.22 83.82
D1S434 AFM217yh8 1 29.93 21.8 1.44 p36.22 62.55
D1S2697 AFMa298yc5 1 29.07 7.27 69.22
D1S2620 AFMal 14yd5 1 52.7 43.94 14.86 p36.12 41.51
D1S241 AFM211xa1 1 61.1 54.23 10.29 p35.1 56.61
D1S255 AFM260zg5 1 65.47 59.98 5.75 p34.3 73.69
D1S2861 AFM092xd11 1 72.59 68.18 8.21 p34.2 66.07
D1S2713 AFMa349yb5 1 73.81 69.43 1.25 p34.1 75.84
D1S2797 AFMb359wd1 1 75.66 70.48 1.06 p33 75.11
D1S197 AFM073xe9 1 76.27 73.67 3.19 p32.3 80.25
D1S2652 AFMal 84xe1 1 80.77 78.87 5.2 p32.3 59.93
D1S476 AFM289yc1 1 85.68 80.34 1.47 p32.2 67.42
D1S2846 AFM345xb5 1 91.89 87.95 7.61 p31.3 51.87
D1S2788 AFMb351xc9 1 93.86 89.08 1.13 p31.3 81.69
D1S219 AFM161xb2 1 101.48 98.97 9.9 p31.1 79.75
D1S2841 AFM333zh9 1 106.45 105.86 6.88 p31.1 76.38
D1S500 AFM343vf9 1 107.56 106.4 0.54 p31.1 61.45
D1S430 AFM210vc9 1 109.04 107.37 0.97 p31.1 70.69
D1S2766 AFMb320yf1 1 118.14 112.11 4.74 p22.3 78.47
D1S2865 AFMa050ta5 1 120.28 114.17 2.06 p22.3 60.63
D1S435 AFM217zb2 1 125.51 117.67 3.5 p22.2 71.65
D1S206 AFM113xf6 1 134.2 124.95 7.28 p21.2 71.93
D1S495 AFM323ya5 1 136.88 126.35 1.4 p21.1 87.16
D1S2688 AFM186xg7 1 139.02 129.08 2.73 p21.1 60.8
219
D1S189 AFM036xc5 1 149.2 140.46 11.38 p13.1 79.82
D1S498 AFM336xb1 1 155.89 147.7 7.24 q21.3 80.49
D1S1653
CHLC.GATA43A0
4
1 164.09 154.54 6.83 q23.1 66.22
D1S484 AFM297wb9 1 169.68 160.45 5.91 q23.3 70.72
D1S2628 AFMal 25ze5 1 177.86 168.68 8.23 q23.3 64.97
D1S452 AFM248wg5 1 188.85 176.39 7.7 q24.2 73.46
D1S2818 AFMc025xh9 1 198.3 187.03 10.64 q25.3 71.3
D1S413 AFM165xc9 1 212.44 198.52 11.49 q31.3 72.64
D1S2717 AFMb002zg5 1 218.46 208.15 9.62 q32.1 69.93
D1S249 AFM234wt6 1 220.65 210.82 2.67 q32.1 85.96
D1S2685 AFMa274wa5 1 222.84 213.64 2.82 q32.2 76.84
D1S245 AFM224xc1 1 227.81 216.77 3.14 q32.2 84.33
D1S205 AFM108ya3 1 229.13 217.22 0.44 q32.2 80.4
D1S237 AFM205xd8 1 232.81 222.18 4.96 q41 77.6
D1S2641 AFMA151YH5 1 238.52 230.38 8.2 q41 68.9
D1S2833 AFM321xe5 1 245.05 238.23 7.85 q42.2 84.82
D1S2709 AFMa342ye5 1 247.23 239.64 1.41 q42.2 67.72
D1S2850 AFM088xe5 1 256.26 251.42 11.78 q43 68.79
D1S2785 AFMb349xb9 1 266.27 262.68 11.26 q43 82.86
D2S323 AFM263WB5 2 5.4 4.61 0 p25.3 59.88
D2S319 AFM108XH8 2 7.6 7.81 3.2 p25.2 74.27
D2S2211 AFMA272YC5 2 15.61 18.24 10.42 p25.1 76.32
D2S398 AFMA127XB9 2 23.57 28.03 9.79 p25.1 69.57
D2S168 AFM240VF6 2 27.06 29.73 1.7 p25.1 83.1
D2S305 AFM073YA5 2 38.87 42.8 13.07 p24.1 75.72
D2S146 AFM198WC5 2 49.04 52.91 10.12 p23.2 50.93
D2S2328 AFMC014YC1 2 61 66.77 13.85 p22.1 89.12
D2S2156 AFMA119YE5 2 73.61 78.42 11.65 p16.3 74.39
D2S1364 GATA23H01 2 77.97 82.83 4.41 p16.1 61.32
D2S337 AFM275ZA9 2 80.69 86.05 3.22 p15 87.96
D2S2152 AFMA111YA9 2 87.62 94.62 8.57 p13.3 53.63
D2S2110 AFMA116ZH9 2 90.82 99.58 4.96 p13.2 78.05
220
D2S2116 AFMB313XD5 2 95.67 103.5 3.93 p12 71.66
D2S388 AFM333VH5 2 107.46 112.75 9.25 p11.2 74.38
D2S293 AFM205XA1 2 118.16 122.55 9.8 q12.2 83.49
D2S363 AFM303WC5 2 125.18 130.95 8.4 q14.1 67.79
D2S347 AFM289XB1 2 131.51 138.31 7.36 q14.3 77.04
D2S2271 AFMB285YH5 2 133.65 143.62 5.31 q14.3 80.92
D2S2256 AFM205xd4 2 141.62 149.54 5.92 q21.2 69.18
D2S2324 AFMC010ZA5 2 153.66 164.37 14.83 q23.3 68.83
D2S1353 ATA27H09 2 164.51 171.63 7.25 q24.1 82.78
D2S2330 AFMC015YD9 2 169.41 174.85 3.22 q24.3 83.89
D2S2188 AFMA203YE5 2 180.79 186.25 11.4 q31.1 73.75
D2S118 AFM066XC1 2 190 195.34 9.09 q32.2 78.74
D2S2321 AFMC009WH1 2 205.06 209.45 14.11 q33.3 74.21
D2S317 AFM094XF11 2 208.58 213.81 4.36 q34 58.97
D2S2361 AFMA052TC1 2 210.43 216.94 3.13 q35 73.85
D2S2382 AFMA082XC5 2 213.49 218.52 1.59 q35 80.79
D2S163 AFM234WA9 2 218.45 226.25 7.72 q35 80.73
D2S133 AFM165ZH8 2 224.33 232.12 5.88 q36.1 62.59
D2S427 GATA12H10 2 236.7 243.39 11.27 q37.1 72.98
D2S2202 AFMA239YC5 2 249.22 253.23 9.84 q37.2 68.46
D2S338 AFM276ZF5 2 250.54 253.84 0.61 q37.2 81.75
D2S395 AFM356TE5 2 261.34 262.12 8.28 q37.3 80.57
D2S140 AFM182YA5 2 263.56 265.28 3.16 q37.3 75.3
D3S4559 3PTEL25 3 1.32 1.08 0 p26.3 61.65
D3S1270 AFM122XB6 3 6.96 3.28 2.2 p26.3 72.24
D3S3630 AFMB296ZF5 3 10.7 6.22 2.95 p26.3 76.55
D3S3050 GATA88H04 3 14.46 10.68 4.46 p26.2 83.51
D3S2397
CHLC.GATA51A0
5
3 16.21 5.53 p26.1 66.67
D3S1515 UT440 3 18.38 19.89 3.68 p26.1 49.67
D3S3591 AFMA303YB1 3 24.89 23.9 4.02 p26.1 59.58
D3S1263 AFM079YG5 3 36.1 30.71 6.81 p25.3 87.76
D3S2385 GAAT3E04 3 38.54 33.55 2.84 p25.1 62.08
221
D3S1567 AFM234YA11 3 49.18 48.03 14.47 p24.2 49.17
D3S2335 AFM312YF5 3 50.94 50.4 2.37 p24.2 65.64
D3S1266 AFM095XC1 3 52.6 52.22 1.82 p24.1 75.89
D3S3547 AFMA108YC1 3 55.11 56.45 4.23 p24.1 71.79
D3S3521 AFM345YG5 3 63.12 66.4 9.95 p22.2 82.84
D3S3672 AFMB352XE1 3 72.21 76.71 10.31 p14.3 62.97
D3S1600 AFM308XC9 3 85.97 89.02 12.31 p14.2 75.84
D3S3551 AFMA116XA9 3 99.38 99.23 10.21 p13 87.58
D3S3653 AFMB326XB5 3 107.19 106.92 7.7 p12.3 66.72
D3S1271 AFM126ZC5 3 117.76 115.24 8.32 q12.2 67.37
D3S3045 GATA84B12 3 124.16 120.29 5.05 q13.12 81.72
D3S1558 AFM057XA5 3 133.93 129.21 8.92 q13.31 73.84
D3S1589 AFM290ZF1 3 141.79 136.43 7.22 q21.3 68.36
D3S3637 AFMB309XA9 3 149.8 146.26 9.83 q22.2 90.02
D3S1569 AFM240XB2 3 158.38 154.11 7.85 q24 77.64
D3S1308 AFM240VE1 3 165.85 160.67 6.56 q25.1 71.7
D3S1607 AFM319YB1 3 172.27 168.31 7.65 q25.31 79.88
D3S1564 AFM224YA3 3 180.8 175.21 6.89 q26.2 47.97
D3S3725 AFMA082ZD9 3 181.87 178.27 3.06 q26.31 85.51
D3S3041
CHLC.GATA81H0
5
3 188.29 185.92 7.65 q26.32 77.63
D3S3592 AFMA306XG9 3 198.68 195.05 9.13 q27.1 79.92
D3S1580 AFM270ZG9 3 207.73 206.43 11.38 q28 84.57
D3S3663 AFMB343ZF5 3 214.45 213.15 6.72 q28 0
D3S240 MFD30 3 218.66 219.97 6.82 q29 22.48
D3S1265 AFM087YB7 3 222.83 222.34 2.37 q29 85.98
D3S1311 AFM254VE1 3 224.88 225.05 2.71 q29 79.78
D4S412 AFM196XB6 4 4.74 4.57 0 p16.3 79.85
D4S2935 AFMA247XB5 4 13.96 14.07 9.51 p16.1 61.69
D4S394 AFM037YG1 4 16.01 15.28 1.21 p16.1 80.15
D4S2928 AFMA223WG1 4 23.17 23.84 8.56 p16.1 56.85
D4S3341 GGAT18G02 4 29.68 32.25 8.41 p15.32 66.3
D4S404 AFM158XC7 4 37.16 41 8.75 p15.2 74.06
222
D4S3022 AFMA045ZD5 4 39.3 43.89 2.9 p15.2 88.28
D4S391 AFM016XF3 4 43.59 48.95 5.06 p15.2 86.2
D4S2912 AFMA126XA9 4 47.58 48.97 0.01 p15.1 69.64
D4S1587 AFM288YB5 4 50.53 55.94 6.98 p15.1 73.26
D4S405 AFM161YF6 4 56.95 62.1 6.16 p14 84.28
D4S428 AFM255ZF1 4 64.24 71.03 8.93 qi2 67.07
D4S2389 ATA22B11 4 79.69 84.72 13.69 q13.3 65.12
D4S1553 AFM210WH8 4 90.28 92.45 7.73 q21.22 52.84
D4S423 AFM224XD6 4 100.75 102.7 10.25 q22.1 80.97
D4S1572 AFM265VA9 4 107.95 110.14 7.44 q24 84.82
D4S406 AFM164TF6 4 117.06 117.48 7.35 q25 88.46
D4S1615 AFM336XH5 4 128.31 129.75 12.27 q28.1 75.8
D4S1575 AFM268YB1 4 132.05 134.67 4.92 q28.3 59.61
D4S424 AFM225XB10 4 144.56 142.05 7.38 q31.21 78.37
D4S1586 AFM288VB9 4 147.06 144.42 2.37 q31.21 76.22
D4S2962 AFMB292XB5 4 152.98 148.06 3.64 q31.23 76.76
D4S3046 AFMA071WG5 4 162.47 159.33 11.27 q32.2 75.41
D4S1539 AFM185XE1 4 176.19 173.75 14.42 q34.1 66.59
D4S1607 AFM310WF5 4 183.63 184.14 10.39 q34.3 81.32
D4S3041 AFMA062TC9 4 187.64 189.52 5.38 q35.1 68.29
D4S408 AFM165XC11 4 195.06 193.5 3.97 q35.1 76.91
D4S1540 AFM185XF8 4 199.93 195.66 2.16 q35.1 55.77
D4S2930 AFMA224XH1 4 208.07 209.27 13.61 q35.2 77.3
D5S1981 AFMA217ZH1 5 1.72 1.21 0 p15.33 74.25
D5S2088 AFMA050ZD9 5 9.41 12.05 10.84 p15.33 71.34
D5S2054 AFMB355WB1 5 14.3 16.64 4.59 p15.32 65.24
D5S635 AFM276YB9 5 14.91 18.11 1.46 p15.32 71.41
D5S1486
CHLC.GATA21F0
8
5 21.1 27.25 9.14 p15.2 66.23
D5S2081 AFM347TA5 5 24.48 31.94 4.69 p15.2 63.54
D5S2031 AFMB312XH5 5 36.25 42.23 10.29 p14.3 79.09
D5S674 AFM331ZE9 5 47.09 56.71 14.48 p13.3 79.93
D5S2021 AFMB285XC9 5 54.79 61.33 4.62 p13.2 63.96
223
D5S628 AFM254wf1 5 60.92 71.14 9.81 q11.2 46.78
D5S2072 AFM312ZH5 5 73.35 80.82 9.68 q12.3 73.84
D5S424 AFM214ZG9 5 81.95 93.23 12.41 q13.3 75.63
D5S1397 UT6142 5 85.25 98.14 4.91 q14.1 83.75
D5S1725 GATA89G08 5 97.82 106.88 8.74 q14.3 75.44
D5S409 AFM184YB6 5 109.63 114.89 8.01 q21.1 59.52
D5S2027 AFMB304XB5 5 119.5 120.95 6.06 q22.1 77.42
D5S2065 AFMC031XB5 5 122.01 122.49 1.54 q22.3 68.6
D5S490 AFM214YG1 5 133.65 134.52 12.03 q23.2 52.76
D5S2017 AFMB074XG1 5 145.21 145.35 10.83 q31.3 82.26
D5S2090 AFMA052TH5 5 150.34 153.72 8.37 q32 81.19
D5S410 AFM191xd8 5 156.47 162.45 8.73 q33.2 77.54
D5S2066 AFMC033XH1 5 165.13 171.45 9 q34 64.12
D5S400 AFM112YB6 5 174.8 181.34 9.89 q34 82.99
D5S1973 AFMA196XG1 5 175.34 184.16 2.83 q35.1 42.49
D5S2069 AFM302WC9 5 182.35 194.4 10.23 q35.2 73.29
D5S469 AFM137XF6 5 203.46 9.06 q35.3 48.87
D5S2006 AFMB005WF9 5 197.54 211.06 7.61 q35.3 71.8
D6S244 91232/91316 6 5.66 0 p25.3 51.97
D6S1617 AFM205xh4 6 7.02 12.18 6.52 p25.1 84.5
D6S309 AFM265ZH9 6 14.07 21.6 9.43 p24.3 84.9
D6S1279
CHLC.GATA82E0
4
6 30.35 8.75 p24.1 74.65
D6S422 AFM234XA3 6 35.66 44.68 14.33 p22.3 77.6
D6S1660 AFMb355wg5 6 40.14 48.37 3.69 p22.3 77.37
D6S273 AFM142XH6 6 44.96 53.25 4.87 p21.33 73.72
D6S1575 AFM172XB6 6 60.44 63.69 10.45 p21.1 82.89
D6S459 AFM312XC5 6 69.66 72.59 8.9 p21.1 58.17
D6S452 AFM301WB9 6 73.13 74.58 1.99 p12.3 82.52
D6S1557 AFMA191ZH5 6 82.59 87.06 12.48 q13 71.09
D6S460 AFM312YB9 6 89.83 93.4 6.34 q14.1 80.72
D6S458 AFM311WA5 6 100.91 102.77 9.38 q16.1 56.39
D6S268 AFM115XH2 6 114.93 115.03 12.25 q2i 76.37
224
D6S1712 AFMA074WF5 6 122.51 123.79 8.77 q22.31 72.83
D6S1656 AFMB338ZF9 6 131.07 134.76 10.97 q23.2 78.54
D6S270 AFM127XB2 6 135.47 138.78 4.02 q23.2 73.96
D6S1009 GATA32B03 6 137.74 142.71 3.93 q23.3 78.06
D6S1637 AFMB314YD5 6 147.13 154.79 12.07 q24.3 76.97
D6S441 AFM269ZE1 6 154.1 164.5 9.71 q25.2 86.08
D6S419 AFM218XB6 6 159.98 170.85 6.35 q25.3 76.11
D6S1581 AFMA247ZD9 6 164.78 174.43 3.58 q26 68.13
D6S305 AFM242ZG5 6 166.39 176.93 2.5 q26 84.65
D6S1599 AFMA342VB5 6 169.95 179.13 2.2 q26 72.78
D6S1277 GATA81B01 6 173.31 180.81 1.68 q27 77.08
D6S297 AFM212YF6 6 182.11 187.65 6.84 q27 60.94
D6S503 GGAA8D08 6 184.51 190.17 2.53 q27 69.85
D6S446 AFM290XF5 6 189 194.22 4.05 q27 70.01
D7S2474 AFMB017YH1 7 3.13 3.71 0 p22.3 78
D7S2201 GATA61G06 7 10.68 12.21 8.5 p22.1 60.24
D7S513 AFM217YC5 7 17.74 23.24 11.03 p21.3 85.38
D7S664 AFM281VC9 7 20.84 26.72 3.49 p21.3 72.05
D7S1795 GATA21B01 7 36.03 38.61 11.88 p15.3 62.58
D7S2463 AFM044XB8 7 38.48 40.51 1.9 p15.3 72.5
D7S516 AFM224XG5 7 41.69 45.36 4.85 p15.1 72.18
D7S2250 AFM098xc1 7 54.11 55.9 10.54 p14.2 80.87
D7S2541 AFMA043XB5 7 61.53 63.45 7.55 p14.1 77.19
D7S691 AFM350VA9 7 63.67 64.93 1.49 p14.1 76.61
D7S519 AFM238VB12 7 69.03 70.24 5.31 p13 82.09
D7S2429 AFMA153TF5 7 76.71 80.22 9.98 q11.21 71.78
D7S502 AFM199VH8 7 78.65 80.93 0.7 q11.22 85.87
D7S2500 AFMB335WD9 7 80.42 83.71 2.78 q11.22 66.82
D7S672 AFM289VE9 7 84.52 86.43 2.72 q11.22 86.02
D7S2443 AFMA222WA5 7 93.1 94.47 8.04 q21.11 76.77
D7S2485 AFM051xb12 7 100.34 5.88 q21.11 61.57
D7S657 AFM263YD9 7 104.86 105.59 5.24 q21.3 78.58
D7S554 AFM248TE5 7 109.66 109.67 4.08 q21.3 72.82
225
D7S2509 AFM273VG5 7 112.85 114.48 4.81 q22.1 62.98
D7S2459 AFMA305YE9 7 119.81 120.05 5.57 q22.3 76.49
D7S2418 AFMA124XB9 7 122.48 122.15 2.1 q31.1 73.43
D7S530 AFM249XF9 7 134.55 133.2 11.05 q32.2 75.57
D7S2533 AFM087ZF11 7 138.42 141.74 8.54 q33 51.65
D7S684 AFM312WB5 7 147.22 149.78 8.04 q34 82.72
D7S1824 GATA32C12 7 149.9 152.03 2.25 q34 85.46
D7S661 AFM277ZF5 7 155.1 155.04 3.01 q35 73.53
D7S1805 GATA4H10 7 161.21 165.55 10.51 q36.1 78.28
D7S2447 AFM175YG1 7 175.77 179.62 14.07 q36.2 66.62
D7S2423 AFMA133ZC9 7 181.97 192.24 12.62 q36.3 68.87
D8S264 AFM143XD8 8 0.73 3.54 0 p23.3 83.21
D8S1819 AFMA050ZD5 8 9.96 16.91 13.37 p23.1 79.82
D8S520 AFM234YE5 8 20.61 21.48 4.58 p23.1 78.69
D8S516 AFM214ZB4 8 17 22.5 1.02 p23.1 61.41
D8S258 AFM107XB6 8 41.55 36.13 13.63 p21.3 70.92
D8S1734 AFMA337ZH5 8 46.26 42.1 5.97 p21.2 67.95
D8S1820 AFMA051ZB1 8 56.04 49.17 7.07 p21.1 75.01
D8S505 AFM198TB2 8 60.87 55.98 6.81 P12 78.85
D8S1737 AFMA344WA5 8 67.27 69.34 13.36 q11.23 51.39
D8S1763 AFMB307XB9 8 78.78 73.88 4.54 q12.1 65.08
D8S512 AFM206XH4 8 81.68 78.06 4.17 q12.3 59.32
D8S279 AFM203WC1 8 91.46 86.52 8.46 q13.3 86.62
D8S1707 AFM147YB6 8 101.69 97.46 10.95 q21.3 67.04
D8S1778 AFMB327YH1 8 110.2 106.89 9.43 q22.2 84.49
D8S1762 AFMB307XB5 8 112.42 108.03 1.14 q22.2 75.83
D8S1470 GATA68H01 8 118.7 10.67 q23.3 67.43
D8S1799 AFM283XB5 8 133.64 131.69 12.99 q24.13 85.03
D8S1793 AFMC014XF5 8 137.92 135.13 3.43 q24.21 81.64
D8S263 AFM141XA5 8 141.68 141.47 6.35 q24.21 65.45
D8S1746 AFMB018WF5 8 149.46 150.11 8.64 q24.22 64.19
D8S1783 AFMB340XD5 8 154.02 152.34 2.23 q24.23 75.13
D8S274 AFM182XA3 8 154.02 153.61 1.27 q24.23 75.32
226
D8S1743 AFMB011XG1 8 162.94 160.11 6.5 q24.3 82.64
D9S1779 AFM026TG9 9 0 0 0 p24.3 57.69
D9S1686 AFM238ZC1 9 14.78 11.93 11.93 p24.1 58.54
D9S286 AFM344YC9 9 18.06 18.53 6.6 p24.1 87.91
D9S168 AFM158XF12 9 21.88 24.28 5.75 p23 79.28
D9S1808 AFMA297WE9 9 26.24 28.24 3.96 p23 59.84
D9S235 UT727 9 27.32 32.65 4.41 p22.3 59.21
D9S171 AFM186XC3 9 42.73 47.16 14.52 p21.3 78.13
D9S2149 GATA137A02 9 54.5 55.3 8.14 p21.1 77.37
D9S1777 AFMA119VG9 9 64.72 67.34 12.04 q21.11 49.89
D9S1876 AFMA054ZE1 9 67.93 70.42 3.08 q21.12 82.29
D9S175 AFM224ZH10 9 70.33 72.8 2.38 q21.13 82.23
D9S1843 AFMB321YF9 9 80.31 79.87 7.07 q21.31 77.62
D9S307 MFD308 9 89.23 9.36 q21.33 71.26
D9S283 AFM318XC9 9 95 5.77 78.68
D9S287 AFM347ZF5 9 103.42 101.54 6.54 q22.32 69.02
D9S261 AFM210ZE7 9 117.37 114.65 13.11 q31.2 59.92
D9S1675 AFM303TA9 9 120.04 117.44 2.8 q31.3 81.61
D9S1828 AFM205TG6 9 120.04 117.67 0.23 q31.3 79.88
D9S1824 AFMB025YE1 9 122.23 123.56 5.88 q32 79.47
D9S934 GATA64G07 9 127.98 127.72 4.16 q33.1 75.65
D9S1682 AFMA061XD9 9 132.09 132.09 4.37 q33.2 68.1
D9S1825 AFMB029XG1 9 136.47 136.35 4.26 q33.3 78.75
D9S1830 AFMB036XF5 9 145.21 149.36 13.01 q34.13 71.65
D9S1793 AFMA191YB5 9 150.42 1.07 82.09
D9S1838 AFMB303ZG9 9 163.84 164.1 13.68 q34.3 85.81
D10S249 AFM207WD12 10 2.13 1.19 0 p15.3 78.35
D10S602 AFM343VD9 10 4.32 5.71 4.52 p15.3 68.88
D10S1218 CHLC.ATA10G07 10 5.21 11.3 5.59 p15.2 11.62
D10S189 AFM063XF4 10 19 20.56 9.26 p14 69.37
D10S1649 AFM155ZG1 10 27.19 26.55 5.99 p14 85.62
D10S1430 GATA84C01 10 33.18 32.11 5.56 p13 73.78
D10S570 AFM268ZH1 10 33.48 32.73 0.62 p13 81.85
I
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D10S191 AFM066XA1 10 37.9 37.42 4.69 p13 81.12
D10S1653 AFMA175YD1 10 40.36 38.92 1.5 p13 81.38
D10S1661 AFMA204XG9 10 42.5 41.4 2.47 p13 79.79
D10S600 AFM338TA5 10 54.23 54.33 12.93 p12.1 80.18
D10S1746 AFMC012XC5 10 65.97 65.42 11.1 q11.21 60.47
D10S196 AFM115XF2 10 70.23 71.95 6.53 q11.23 71.96
D10S609 CHLC.GATA2G08 10 80.19 82.33 10.38 q21.2 69.95
D10S537 AFM203XC5 10 91.13 91.46 9.12 q22.1 86.09
D10S580 AFM284VF5 10 96.72 97.94 6.48 q22.3 72.77
D10S1677 AFMA233WG5 10 100.08 100.72 2.78 q22.3 71.76
D10S1753 AFM287ZE1 10 112.58 113.42 12.7 q23.31 74.46
D10S185 AFM019TH6 10 116.34 116.07 2.65 q23.33 80.95
D10S1267 AFMA301XE1 10 125.41 125.15 9.08 q24.32 87.36
D10S597 AFM331XA9 10 128.73 129.57 4.42 q25.1 61.21
D10S1693 AFMA344XC1 10 137.39 141.5 11.94 q26.11 79.3
D10S1656 AFMA184XD9 10 149.25 154.8 13.3 q26.13 75.95
D10S575 AFM270XB1 10 153.78 160.19 5.39 q26.2 71.41
D10S1676 AFMA232YH9 10 160.04 164.6 4.41 q26.2 68.41
D10S1651 AFMA162XG1 10 168.77 176.24 11.64 q26.3 84.34
D10S212 AFM198ZB4 10 170.94 181.66 5.41 q26.3 65.13
D11S4046 AFMB042YF5 11 2.79 0 0 p15.5 85.5
D11S1760 AFM114YC9 11 11.67 8.79 8.79 p15.4 74.38
D11S1331 AFM277WG1 11 12.92 12.38 3.59 p15.4 72.31
D11S4170 AFMB341YE5 11 20.93 23.4 11.02 p15.2 78.51
D11S902 AFM072YD3 11 21.47 26.23 2.82 p15.1 82.46
D11S928 AFM234WH12 11 26.34 34.9 8.68 p15.1 65.69
D11S4080 AFMA109ZG9 11 33.02 43.29 8.38 p14.3 80.91
D11S1776 AFMA041ZE5 11 40.12 49.46 6.17 p13 84.56
D11S1360 AFM362TB9 11 50.88 58.18 8.72 p12 65.96
D11S4191 AFM338WC1 11 60.09 66.18 8 q12.1 84.63
D11S4087 AFMA152YH1 11 68.55 73.81 7.63 q13.2 46.13
D11S937 AFM256ZB5 11 79.98 85.42 11.61 q14.1 90.73
D11S1780 AFMA082WB9 11 90.29 94.12 8.7 q14.2 73.5
228
D11S1886 AFM347TE5 11 100.62 107.71 13.59 q22.3 51.77
D11S4206 AFMA102XF9 11 105.17 110.81 3.1 q22.3 71.16
D11S908 AFM120XE9 11 108.59 118.66 7.86 q23.3 72.37
D11S4089 AFMA162WF5 11 119.07 126.83 8.17 q23.3 75.93
D11S4151 AFMB290YH1 11 127.33 135.73 8.9 q24.2 80.56
D11S2367 GATA72A01 11 148.23 12.5 45.05
D11S969 AFM205VF10 11 154.38 6.15 q25 69.32
D12S352 AFM303XD9 12 0 0.68 0 P13.33 65.05
D12S1656 AFMB292WE5 12 2.79 4.23 3.55 p13.33 70.02
D12S372 GATA4H03 12 6.42 8.63 4.4 p13.32 74.88
D12S374 GATA7F09 12 14.23 16.84 8.21 p13.31 72.54
D12S336 AFM273ZC9 12 19.68 24.76 7.91 P13.31 66.1
D12S364 AFM345WE1 12 30.6 31.97 7.21 p13.1 86.98
D12S1591 AFMA119XE5 12 43.38 44.81 12.85 p12.1 80.68
D12S1337 UT7594 12 51.8 6.99 p11.22 57.54
D12S1704 AFMA047WF1 12 50.9 52.93 1.13 p11.22 65.23
D12S85 AFM122XF6 12 61.34 61.77 8.84 q13.11 62.93
D12S368 AFMA128YD5 12 66.03 67.92 6.15 q13.13 83.28
D12S83 AFM112YF4 12 75.17 75.48 7.56 q14.1 71.88
D12S1294 GATA73H09 12 83.69 8.21 q15 81.43
D12S326 AFM238WA1 12 86.4 92.97 9.28 q21.2 78.93
D12S351 AFM302WD9 12 95.56 103.1 10.13 q21.33 77.02
D12S95 AFM207VE1 12 96.09 104.42 1.32 q22 78.68
D12S1346 AFM211XF2 12 97.16 106.03 1.6 q22 56.02
D12S2081 GATA7A02 12 101.98 110.59 4.56 q23.1 65.46
D12S1636 AFMA336XC1 12 114.28 120.17 9.57 q23.3 74.71
D12S1613 AFMA205YG9 12 116.08 124.08 3.91 q23.3 53.89
D12S1583 AFMA106WH5 12 119.55 127.22 3.14 q24.11 84.82
D12S354 AFM304WH5 12 123.77 133.66 6.44 q24.21 75.19
D12S369 AFMA142ZC5 12 125.31 134.33 0.67 q24.21 75.22
D12S366 AFM351TB9 12 133.33 140.32 5.99 q24.23 81.03
D12S2073 GATA10C07 12 139.61 144.14 3.81 q24.31 70.13
D12S2078 CHLC.GATA32F0 12 155.99 11.85 q24.32 76.5
229
5D12S1609 AFMA197ZD9 12 153.33 160.72 4.73 q24.32 63.01
D12S1723 AFMA082ZE9 12 164.63 173.29 12.57 q24.33 66.84
D13S175 AFM249XB1 13 6.03 3.24 0 q12.11 70.85
D13S232 MFD299 13 6.99 8.98 5.74 q12.12 75.45
D13S1243 AFMA217YB5 13 9.79 11.57 2.59 q12.12 75.4
D13S221 AFM248WC1 13 12.91 16.88 5.31 q12.13 82.06
D13S217 AFM205XH12 13 17.21 22.89 6.01 q12.3 74.81
D13S289 AFM321XB1 13 21.51 28.14 5.26 q12.3 72.69
D13S171 AFM255ZE9 13 25.08 31.99 3.84 q13.1 68.07
D13S219 AFM225XE5 13 28.87 36.49 4.51 q13.3 58.18
D13S218 AFM210ZB2 13 32.9 40.44 3.95 q13.3 63.56
D13S272 AFM120XA3 13 45.55 54.31 13.87 q14.2 69.83
D13S279 AFM284ZA9 13 53.17 65.83 11.52 q21.33 77.14
D13S271 AFM115XA11 13 64.97 80.33 14.5 q31.1 79.32
D13S1241 AFMA204YH9 13 76.26 91.34 11.01 q32.1 80.43
D13S1256 AFMB291WF1 13 84.87 100.66 9.32 q33.1 69.06
D13S1809 GATA135E01 13 90.27 107.62 6.96 q33.2 63.48
D13S1315 AFMA058XD5 13 102.73 119 11.38 q34 76.47
D13S293 AFMA127XH5 13 114.98 131.92 12.92 q34 52.7
D14S261 AFM238YD6 14 6.46 9.53 0 q11.2 69.27
D14S1043 AFM324TC9 14 9.36 9.83 0.29 q11.2 49.45
D14S1280 GATA31B09 14 25.87 23.04 13.21 qi2 68.03
D14S262 AFM240VC5 14 28.01 25.73 2.7 qi2 63.23
D14S1071 AFMA102ZD9 14 31.75 29.19 3.46 qi2 71.84
D14S741 GATA74A05 14 36.76 35 5.81 q13.1 68.97
D14S70 AFM191VE1 14 40.11 37.63 2.63 q13.1 76.88
D14S75 AFM214YG5 14 44.06 43.2 5.56 q13.3 76.45
D14S976 AFMA116ZB5 14 50.5 46.8 3.61 q21.3 82.31
D14S978 AFMA122YA5 14 53.19 51.44 4.63 q22.1 84.3
D14S276 AFM292WE1 14 56.36 57.33 5.89 q22.3 74.37
D14S1011 AFMB027YC9 14 74.96 70.01 12.68 q24.1 76.96
D14S258 AFM224ZF12 14 76.28 70.4 0.39 q24.2 76.67
230
D14S1433 GATA169E06 14 84.69 74.94 4.54 q24.3 56.52
D14S616 GATA70B06 14 92.69 85.45 10.5 q31.3 67.65
D14S67 AFM137XH12 14 95.89 88.68 3.24 q31.3 89.54
D14S1044 AFM324VG5 14 99.88 92.86 4.17 q32.11 63.11
D14S81 AFM260XB1 14 108.22 99.25 6.4 q32.12 79.1
D14S1054 AFM361TA9 14 113.17 102.52 3.27 q32.13 75.93
D14S987 AFM161YD12 14 114.81 106.22 3.7 q32.2 74.44
D14S1019 AFMB323YE9 14 118.68 109.31 3.09 q32.2 41.91
D14S1426 GATA136B01 14 125.88 117.81 8.5 q32.2 77.37
D14S542
TF66(GT)/TF67(C
A)
14 126.06 8.26 q32.33 76.92
D15S128 AFM273YF9 15 6.11 6.06 0 q11.2 80.48
D15S975 AFMA216ZC9 15 13.06 13.46 7.4 q12 62.78
D15S1019 AFMB336YF1 15 19.12 21.44 7.98 q13.1 58.38
D15S165 AFM248VC5 15 20.24 23.51 2.07 q13.3 70.77
D15S231 GTAT1B2 15 24.06 27.43 3.92 q13.3 48.9
D15S118 AFM112XA1 15 32.58 35.23 7.8 q14 73.96
D15S1012 AFMB298WH9 15 35.95 39.39 4.16 q15.1 72.74
D15S146 AFM070XD7 15 39.72 43.14 3.75 q15.1 69.07
D15S1016 AFMB324YH9 15 47.29 52.71 9.57 q21.2 90.73
D15S117 AFM098YG1 15 51.21 58.09 5.38 q21.3 79.64
D15S988 AFMA301ZE9 15 66.9 70.39 12.3 q22.33 53.9
D15S114 AFM019TC9 15 72.94 82.51 12.13 q24.3 64.6
D15S1005 AFMB080ZH9 15 75.27 86.82 4.31 q25.1 80.6
D15S158 AFM234VF12 15 86.81 100.89 14.07 q26.1 69.46
D15S1004 AFMB077YD5 15 98.44 110.96 10.07 q26.2 69.96
D15S130 AFM072YB11 15 100.59 111.55 0.59 q26.2 73.77
D15S816 GATA73F01 15 100.59 114.36 2.81 q26.2 68.74
D15S157 AFM217ZG1 15 102.21 116.14 1.78 q26.2 41.86
D15S212 AFM331VB5 15 109.29 124.08 7.94 q26.2 74.81
D15S120 AFM164ZC9 15 112.58 130.4 6.32 q26.3 61.39
D16S521 AFMA139WG1 16 1.08 1.15 0 p13.3 70.21
D16S3065 AFMA323YF5 16 8.16 10.64 9.49 p13.3 76.48
231
D16S423 AFM249YC5 16 10.36 14.97 4.33 p13.3 76.76
D16S418 AFM225XD2 16 14.77 20.61 5.64 p13.2 85.25
D16S3062 AFMA305XB1 16 27.05 32.07 11.46 p13.12 75.61
D16S500 AFM112XG5 16 28.3 33.31 1.25 p13.12 81.48
D16S410 AFM165YB6 16 35.44 41.83 8.52 p12.3 58.97
D16S3068 AFMA349ZH9 16 48.53 51.27 9.43 p12.1 79.43
D16S3080 AFMB068ZB9 16 59.68 61.1 9.83 q12.1 76.89
D16S3034 AFMA184XG1 16 69.05 68.27 7.17 q12.2 65.16
D16S3057 AFMA299YF1 16 77.13 76.36 8.08 q13 71.67
D16S514 AFM330VD9 16 81.15 83.1 6.74 q21 81.28
D16S503 AFM274YA5 16 83.55 84.26 1.16 q21 81.5
D16S515 AFM340YE5 16 92.1 94.69 10.43 q23.1 84.86
D16S516 AFM350VD1 16 100.39 101.24 6.55 q23.1 74.81
D16S505 AFM296TB1 16 108.96 108.07 6.83 q23.2 74.54
D16S763 GATA2F07 16 120.63 12.56 q24.1 69.79
D16S2621 GATA71F09 16 130.41 131.46 10.83 q24.2 80.66
D17S849 AFM234WG3 17 0.63 0.63 0 p13.3 70.77
D17S831 AFM058xf4 17 6.6 7.47 6.84 p13.3 84.63
D17S1832 AFMB022WF9 17 13.07 16.79 9.32 p13.2 71.88
D17S804 AFM225ZC1 17 21.01 28.96 12.17 p13.1 61.78
D17S799 AFM192YH2 17 31.96 37.94 8.98 P12 77.07
D17S922 AFM197XH6 17 35.55 41.55 3.61 P12 62.36
D175839 AFM200YB12 17 37.8 43.77 2.21 P12 58.81
D17S1824 AFMB002YC1 17 49.67 53.22 9.46 q11.2 82.15
D17S2194 GATA169F02 17 54.17 58.94 5.72 q11.2 71.27
D17S1867 AFM296TB5 17 59.32 66.96 8.02 q12 70.63
D17S1299 GATA25A04 17 62.01 71.13 4.17 q21.2 74.53
D17S1868 AFM301YE5 17 64.16 76.3 5.17 q21.32 77.36
D17S1795 AFMA154ZA9 17 68.44 77.3 1 q21.33 74.83
D17S957 AFM323WD9 17 80.38 89.64 12.33 q23.2 53.83
D17S794 AFM168XD12 17 83.4 94.36 4.73 q23.3 57.69
D17S944 AFM277VG9 17 82.56 95.11 0.75 q23.3 76.77
D17S940 AFM268YD5 17 89.89 102.6 7.49 q24.2 54.83
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D17S1351 AFMA346XG5 17 95.99 108.83 6.23 q24.3 76.5
D17S1603 AFMA135XD5 17 102.99 117.82 8.99 q25.1 67.8
D17S1847 AFMB310YF5 17 111.22 126.71 8.89 q25.3 59.73
D17S836 AFM163YG1 17 112.92 128.03 1.32 q25.3 60.66
D17S784 AFM044XG3 17 116.86 132.74 4.71 q25.3 76.83
D18S1105 AFM182XG5 18 2.84 3.97 0 p11.32 69.85
D18S63 AFM205TD6 18 8.3 9.84 5.87 p11.31 77.5
D18S967 GATA116D12 18 19.64 21.74 11.91 p11.31 54.01
D18S464 AFM259VH9 18 31.17 33.37 11.63 p11.22 50.22
D18S1107 AFMA289WE1 18 51.21 47.29 13.92 q11.2 76.38
D18S877 GATA64H04 18 54.4 54.03 6.75 q12.1 71
D18S1102 AFMA224WB1 18 62.84 59.89 5.86 q12.2 78.34
D18S474 AFM295XH1 18 71.32 68.99 9.1 q21.1 80.68
D18S450 AFM191VC7 18 68.91 70.78 1.79 q21.1 77.65
D18S64 AFM212XG5 18 84.8 77.54 6.76 q21.32 72.18
D18S1134 AFMB330ZC5 18 88.62 87.2 9.65 q21.32 72.15
D18S1147 AFMA049ZE5 18 90.6 88.5 1.31 q21.33 85.35
D18S465 AFM260YH1 18 100.11 92.91 4.4 q22.1 76.77
D18S469 AFM116YG11 18 109.18 106.38 13.47 q22.3 64.95
D18S554 AFM296WD5 18 119.44 117.94 11.57 q23 84.59
D19S886 AFMA310WD9 19 0 0.9 0 p13.3 67.84
D195591 GATA44F10 19 9.84 10.59 9.69 p13.3 74.16
D19S427 MFD319 19 20.75 10.17 p13.3 76.64
D19S584 ATA19D12 19 34.25 33.17 12.41 p13.2 41.37
D19S226 AFM256YC9 19 42.28 37.98 4.81 p13.12 85.86
D19S593 GATA64E12 19 45.48 43.02 5.04 p13.11 64.62
D19S414 AFM295XG9 19 54.01 55.81 12.78 q12 74.2
D19S208 AFM116XC7 19 59.36 63.1 7.3 q13.12 70.2
D19S903 AFMB039YE9 19 69.5 73.21 10.11 q13.31 77.09
D19S867 AFMa115wg5 19 77.54 84.6 11.39 q13.33 80.9
DG19S186
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19 92.14 7.54 q13.41 43.2
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D19S572 AFMA083WB5 19 88.85 99.88 7.74 q 13.42 84.61
D19S418 AFM319VB5 19 92.56 107.71 7.83 q13.42 61.29
D19S605 AFMB005WH1 19 95.26 108.45 0.74 q13.42 58.69
D19S573 AFMA054YF1 19 100.38 113.23 4.78 q13.43 42.69
D20S113 AFM205TH8 20 8.97 7.68 0 p13 45.5
D20S882 AFMB290WH5 20 15.05 18.3 10.62 p12.3 71.12
D20S115 AFM218YG3 20 21.15 25.35 7.05 p12.3 67.43
D20S189 AFM292XB5 20 30.56 34.88 9.53 p12.2 71.96
D20S904 AFM291WE5 20 37.65 42.54 7.66 p12.1 78.72
D20S912 AFMA070XG5 20 46.71 52.19 9.64 p11.23 80.72
D20S859 AFM189XB6 20 51.36 60.73 8.55 q11.23 74.15
D20S107 AFM142XH4 20 55.74 63.19 2.46 q12 78.4
D20S108 AFM163YH8 20 57.38 65.64 2.45 q12 73.75
D20S481 GATA47F05 20 62.32 70.97 5.33 q13.12 84.13
D20S838 AFMA139WF5 20 64.88 71.23 0.27 q13.12 64.54
D20S178 AFM240vd6 20 66.16 75.47 4.23 q13.13 80.15
D20S1083 GAAT1F1 20 77.75 83.33 7.86 q13.2 60.46
D20S100 AFM057XA3 20 84.78 90.85 7.52 q13.31 74.49
D20S171 AFM046XF6 20 95.7 100.84 9.99 q13.32 80.1
D21S1904 AFMB356WG1 21 2.13 7.23 0 q21.1 53.02
D21S1432 GATA11C12 21 2.99 8.75 1.53 q21.1 69.89
D21S1899 AFMB321WF5 21 9.72 16.2 7.45 q21.1 85.08
D21S1905 AFMB361YE9 21 11.3 17.29 1.09 q21.1 77.67
D21S1902 AFM268XG1 21 13.05 19.54 2.25 q21.1 62.08
D21S272 AFM206XG5 21 19.39 23.96 4.42 q21.2 77.96
D21S1442 GATA24H09 21 24.73 29.5 5.53 q21.3 83.89
D21S1909 AFM288YG5 21 28.48 33.81 4.31 q22.11 79.96
D21S1898 AFMB308XE5 21 31.26 38.62 4.81 q22.11 78.64
D21S1895 AFMB280XD9 21 33.84 41.37 2.75 q22.12 84.97
D21S1252 AFM261zg1 21 35.45 44.04 2.67 q22.13 84
D21S1919 AFMA085ZA5 21 38.65 45.79 1.75 q22.13 83.87
D21S270 AFM031XC5 21 38.08 46.25 0.46 q22.13 86.61
D21S1255 AFM283XH9 21 39.22 48.28 2.04 q22.2 82.92
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D21S266 AFM234XG9 21 45.87 57.33 9.05 q22.3 55.56
D22S420 AFM217XF4 22 4.06 5.72 0 q11.1 72.79
D22S427 AFM288we5 22 8.32 6 0.28 q11.21 64.29
D22S539 AFMA037ZD1 22 14.44 15.82 9.82 q11.22 53.4
D22S1174 AFM309WD5 22 19.32 20.03 4.21 q11.23 69.95
D22S315 AFM183xe9 22 21.47 23.91 3.89 q12.1 77.8
D22S1154 AFMA298YB5 22 23.37 25.73 1.81 q12.1 69.71
D22S531 UT5900 22 27.48 36.2 10.47 q12.2 58.41
D22S1265 ACT2A09 22 32.93 40.84 4.64 q12.3 68.22
D22S276 AFM165ZA5 22 47.31 51.21 10.38 q13.2 67.27
D22S928 AFMA048WA5 22 52.08 59.39 8.18 q13.31 74.66
D22S1170 AFM268yg1 22 55.26 68.42 9.02 q13.31 61.56
DXS9903 GATA164D10 X 13.5 9.65 0 P22.33 30.69
DXS1223 AFM309YC1 X 16.75 16.52 6.87 P22.31 46.92
DXS7108 AFMA184WF1 X 18.37 19.97 3.45 P22.22 42.25
DXS1224 AFM311VF5 X 21.23 26.38 6.41 P22.22 28.01
DXS1229 AFM337WD5 X 27.59 35.8 9.42 P22.12 21.11
DXS7593 AFMA346ZC1 X 25.97 38.41 2.61 p22.11 43.48
DXS1048 AFM151XG11 X 29.76 43.89 5.48 p21.3 39.41
DXS1061 AFM205YD2 X 30.3 44.23 0.33 p21.3 44.02
DXS1214 AFM283WG9 X 33.54 47.36 3.14 p21.2 43.36
DXS1049 AFM155ZE1 X 36.79 56.63 9.27 p21.1 29.95
DXS1069 AFM240WA9 X 37.33 62.13 5.5 p11.4 38.84
DXS8083 AFMC024XC5 X 46.54 71.55 9.42 p11.3 41.4
DXS1216 AFM287ZG1 X 53.58 85.3 13.76 q13.1 36.86
DXS1217 AFM288YE9 X 59.72 91.84 6.54 q21.31 35.59
DXS6799 GATA29G07 X 64.41 101.75 9.91 q21.33 33.94
DXS8020 AFMA162TC1 X 65.5 104.17 2.41 q22.1 43.62
DXS8110 AFMA086WG5 X 70.91 110.32 6.15 q23 9.61
DXS8055 AFMB291YE5 X 70.91 118.09 7.77 q23 34.19
DXS1001 AFM248WE5 X 75.79 123.76 5.67 q24 45.64
DXS8059 AFMB303XD1 X 78.5 127.15 3.39 q25 37.15
DXS8074 AFMB355XC9 X 82.84 141.05 13.9 q26.3 35.28
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DXS984 AFM105XC5 X 85.55 149.84 8.79 q27.1 36.8
DXS8106 AFMA074TF9 X 91.64 158.66 8.82 q27.3 40.84
DXS8073 AFMB354WA9 X 94.22 164.42 5.76 q27.3 38.21
DXS1193 AFM199WC7 X 97.89 174.06 9.64 q28 45.54
DXS8103 AFMA065WD9 X 100.73 183.79 9.74 q28 46.12
DXS1073 AFM276XH9 X 102.35 193.73 9.94 q28 37.66
236
Appendix 2.
Two point lod score results for Multiform Movement Disorder (MMD) family in 
chapter four.
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Recombination fraction
Locus geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Z max
D1S468 5.44 -5.89 -1.35 -0.55 -0.19 -0.04 0.5 0
D1S2870 11.68 -7.79 -0.82 -0.29 -0.1 -0.02 0.5 0
D1S450 16.99 -7.49 -1 -0.4 -0.14 -0.03 0.5 0
D1S2667 20.36 -8.84 -1.63 -0.72 -0.28 -0.07 0.5 0
D1S434 21.8 -8.04 -1.36 -0.61 -0.24 -0.06 0.5 0
D1S2697 29.07 -2.6 -0.89 -0.41 -0.16 -0.04 0.5 0
D1S2620 43.94 -0.07 -0.04 -0.02 -0.01 0 0.5 0
D1S241 54.23 -7.56 -0.86 -0.3 -0.1 -0.02 0.5 0
D1S255 59.98 -6.91 -0.23 0.05 0.07 0.03 0.5 0.08
D1S2861 68.18 -7.09 -0.83 -0.26 -0.06 0 0.5 0
D1S2713 69.43 -0.34 -0.19 -0.09 -0.04 -0.01 0.5 0
D1S2797 70.48 0.29 0.21 0.13 0.06 0.02 0 0.29
D1S197 73.67 0.29 0.21 0.13 0.06 0.02 0 0.29
D1S2652 78.87 -10.44 -0.79 -0.24 -0.05 0 0.5 0
D1S476 80.34 -9.48 -0.14 0.13 0.14 0.06 0.5 0.16
D1S2846 87.95 -0.05 -0.03 -0.02 -0.01 0 0.5 0
D1S2788 89.08 -10.44 -0.79 -0.24 -0.05 0 0.5 0
D1S219 98.97
D1S2841 105.86 -7.1 -0.79 -0.24 -0.05 0 0.5 0
D1S500 106.4 -0.4 -0.21 -0.11 -0.04 -0.01 0.5 0
D1S430 107.37 -0.42 -0.22 -0.11 -0.05 -0.01 0.5 0
D1S2766 112.11 -7.68 -0.79 -0.24 -0.05 0 0.5 0
D1S2865 114.17 -8.91 -0.79 -0.24 -0.05 0 0.5 0
D1S435 117.67 -0.39 -0.21 -0.1 -0.04 -0.01 0.5 0
D1S206 124.95 -1.27 0.17 0.36 0.29 0.11 0.213 0.36
D1S495 126.35 -1.27 0.17 0.36 0.29 0.11 0.213 0.36
D1S2688 129.08 0.26 0.78 0.67 0.42 0.14 0.101 0.78
D1S189 140.46 0.25 0.17 0.11 0.05 0.01 0 0.25
D1S498 147.7 -1.27 0.17 0.36 0.29 0.11 0.213 0.36
D1S1653 154.54 0.26 0.82 0.73 0.5 0.19 0.112 0.82
D1S484 160.45 0.46 0.38 0.27 0.15 0.04 0 0.46
D1S2628 168.68 -0.35 -0.19 -0.1 -0.04 -0.01 0.5 0
D1S452 176.39 1.69 1.34 0.96 0.55 0.18 0 l iZ
D1S2818 187.03 -3.1 -0.73 -0.22 -0.04 0 0.5 0
D1S413 198.52 -3.1 -0.73 -0.22 -0.04 0 0.5 0
D1S2717 208.15 -2.02 -0.42 -0.09 0.01 0.01 0.5 0.01
D1S249 210.82 -2.16 -0.5 -0.12 -0.01 0.01 0.5 0
D1S2685 213.64 -1.23 -0.4 -0.18 -0.07 -0.02 0.5 0
D1S245 216.77 -7.83 -1.36 -0.63 -0.25 -0.06 0.5 0
D1S205 217.22 -1.23 -0.4 -0.18 -0.07 -0.02 0.5 0
D1S237 222.18 -8.62 -1.65 -0.73 -0.29 -0.07 0.5 0
D1S2641 230.38 -8.91 -1.65 -0.73 -0.29 -0.07 0.5 0
D1S2833 238.23 -0.42 -0.23 -0.12 -0.05 -0.01 0.5 0
D1S2709 239.64 -8.88 -1.55 -0.7 -0.27 -0.06 0.5 0
D1S2850 251.42 -7.77 -1.36 -0.61 -0.24 -0.06 0.5 0
D1S2785 262.68 -6.67 -1.62 -0.72 -0.28 -0.07 0.5 0
Table 4.6. Two-point lod scores for chromosome 1 in MMD family.
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Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max
Z
max
D2S323 4.61 -6.78 -1.33 -0.59 -0.23 -0.06 0.5 0
D2S319 7.81 -9.35 -1.66 -0.73 -0.28 -0.07 0.5 0
D2S2211 18.24 -8.56 -1.41 -0.63 -0.25 -0.06 0.5 0
D2S398 28.03 -5.39 -0.83 -0.34 -0.13 -0.03 0.5 0
D2S168 29.73 -8.46 -1.46 -0.65 -0.26 -0.06 0.5 0
D2S305 42.8 -6.19 -1.5 -0.66 -0.26 -0.06 0.5 0
D2S146 52.91 -0.33 -0.18 -0.09 -0.04 -0.01 0.5 0
D2S2328 66.77 -5.79 -1.33 -0.54 -0.19 -0.04 0.5 0
D2S2156 78.42 -7.88 -1.32 -0.53 -0.19 -0.04 0.5 0
D2S1364 82.83 -5.79 -1.33 -0.54 -0.19 -0.04 0.5 0
D2S337 86.05 -7.88 -0.56 -0.14 0 0.02 0.5 0.22
D2S2152 94.62 -7.6 0.39 0.45 0.33 0.13 0.173 0.45
D2S2110 99.58 -7.59 0.16 0.26 0.2 0.08 0.192 0.26
D2S2116 103.5 -8.13 -0.34 -0.12 -0.04 -0.01 0.5 0
D2S388 112.75 -6.4 0.3 0.33 0.23 0.08 0.165 0.34
D2S293 122.55 -7.77 -0.39 -0.05 0.04 0.03 0.5 0.48
D2S363 130.95 -7.65 -0.14 0.14 0.16 0.07 0.5 0.072
D2S347 138.31 -6.74 -1.02 -0.46 -0.18 -0.04 0.5 0
D2S2271 143.62 -7.66 -0.79 -0.24 -0.05 0 0.5 0
D2S2256 149.54 -5.85 -1.08 -0.43 -0.15 -0.03 0.5 0
D2S2324 164.37 -0.36 -0.19 -0.1 -0.04 -0.01 0.5 0
D2S1353 171.63 -9.26 -1.45 -0.66 -0.27 -0.06 0.5 0
D2S2330 174.85 -0.47 -0.24 -0.12 -0.05 -0.01 0.5 0
D2S2188 186.25 -10.44 -1.73 -0.76 -0.3 -0.07 0.5 0
D2S118 195.34 -7.09 0.46 0.42 0.25 0.08 0.128 0.47
D2S2321 209.45 -4.02 -1.22 -0.49 -0.17 -0.03 0.5 0
D2S317 213.81 -4.13 -1.41 -0.63 -0.25 -0.06 0.5 0
D2S2361 216.94 -1.23 -0.4 -0.18 -0.07 -0.02 0.5 0
D2S2382 218.52 -5.27 -1.73 -0.76 -0.3 -0.07 0.5 0
D2S163 226.25 -6.06 -1.34 -0.61 -0.24 -0.06 0.5 0
D2S133 232.12 -5.95 -1.36 -0.62 -0.25 -0.06 0.5 0
D2S427 243.39 -7.22 -1.03 -0.41 -0.15 -0.03 0.5 0
D2S2202 253.23 -8.24 -1.65 -0.73 -0.29 -0.07 0.5 0
D2S338 253.84 -1.23 -0.4 -0.18 -0.07 -0.02 0.5 0
D2S395 262.12 -6.19 -1.59 -0.7 -0.27 -0.06 0.5 0
D2S140 265.28 -1.72 -0.55 -0.26 -0.1 -0.02 0.5 0
Table 4.7. Two-point lod scores for chromosome 2 in MMD family.
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Recom bination fraction
Order Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D3S4559 1.08 -1.23 -0.4 -0.18 -0.07 -0.02 0.5 0
D3S1270 3.28 -7.67 -1.69 -0.75 -0.29 -0.07 0.5 0
D3S3630 6.22 -0.47 -0.24 -0.12 -0.05 -0.01 0.5 0
D3S3050 10.68 -7.1 -1.69 -0.75 -0.29 -0.07 0.5 0
D3S2397 16.21 -7.1 -1.69 -0.75 -0.29 -0.07 0.5 0
D3S1515 19.89 -7.04 -1.45 -0.64 -0.25 -0.06 0.5 0
D3S3591 23.9 -0.35 -0.19 i o i—1 -0.04 -0.01 0.5 0
D3S1263 30.71 -8.78 -1.67 -0.73 -0.29 -0.07 0.5 0
D3S2385 33.55 -0.19 -0.13 -0.08 -0.04 -0.01 0.5 0
D3S1567 48.03 -0.05 -0.03 -0.02 -0.01 0 0.5 0
D3S2335 50.4 -7.64 -1.42 -0.63 -0.25 -0.06 0.5 0
D3S1266 52.22 -7.93 -1.69 -0.75 -0.29 -0.07 0.5 0
D3S3547 56.45 -0.95 -0.2 -0.05 -0.01 0 0.5 0
D3S3521 66.4 -7.28 -1.55 -0.69 -0.27 -0.06 0.5 0
D3S3672 76.71 -8.28 -1.68 -0.74 -0.29 -0.07 0.5 0
D3S1600 89.02 -6.95 -1.43 -0.65 -0.26 -0.06 0.5 0
D3S3551 99.23 -8.58 -1.08 -0.44 -0.16 -0.03 0.5 0
D3S3653 106.92 0.29 0.21 0.13 0.06 0.02 0 0.29
D3S1271 115.24 -7.84 -1.44 -0.64 -0.25 -0.06 0.5 0
D3S3045 120.29 -7.5 -1.46 -0.59 -0.21 -0.04 0.5 0
D3S1558 129.21 0.29 0.21 0.13 0.06 0.02 0 0.29
D3S1589 136.43 -0.36 -0.19 -0.1 -0.04 -0.01 0.5 0
D3S3637 146.26 -6.16 -0.88 -0.32 -0.12 -0.03 0.5 0
D3S1569 154.11 -3.1 -0.73 -0.2 -0.02 0.02 0.5 0.27
D3S1308 160.67 -3.1 -0.73 -0.2 -0.02 0.02 0.5 0.27
D3S1607 168.31 0.29 0.21 0.13 0.06 0.02 0 0.29
D3S1564 175.21 -0.32 -0.18 -0.09 -0.04 -0.01 0.5 0
D3S3725 178.27 -1.57 -0.09 0.16 0.16 0.07 0.5 0.77
D3S3041 185.92 -1.57 -0.09 0.15 0.15 0.06 0.5 0.17
D3S3592 195.05 -1.27 0.17 0.36 0.29 0.11 0.213 0.36
D3S1580 206.43 -1.27 0.17 0.36 0.29 0.11 0.213 0.36
D3S3663 213.15 -9.23 -0.49 -0.11 0 0.01 0.5 0
D3S240 219.97 -0.02 -0.01 -0.01 0 0 0.5 0
D3S1265 222.34 -8.91 -1.69 -0.75 -0.29 -0.07 0.5 0
D3S1311 225.05 -0.52 -0.26 -0.13 -0.05 -0.01 0.5 0
Table 4.8. Two-point lod scores for chromosome 3 in MMD family.
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Recombination fraction
Order Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D4S412 4.57 -9.21 -1.45 -0.65 -0.26 -0.06 0.5 0
D4S2935 14.07 -0.21 -0.12 -0.07 -0.03 -0.01 0.5 0
D4S394 15.28 -7.88 -1.66 -0.73 -0.28 -0.07 0.5 0
D4S2928 23.84 -0.41 -0.21 -0.11 -0.04 -0.01 0.5 0
D4S3341 32.25 -2.21 -0.52 -0.13 -0.01 0.01 0.5 0.02
D4S404 41 -0.68 -0.31 -0.15 -0.06 -0.01 0.5 0
D4S3022 43.89 -0.66 -0.3 -0.14 -0.06 -0.01 0.5 0
D4S391 48.95 -2.19 -0.51 -0.13 -0.01 0.01 0.5 0
D4S2912 48.97 -2 -0.42 -0.08 0.01 0.01 0.5 0
D4S1587 55.94 -2.02 -0.43 -0.09 0.01 0.01 0.5 0
D4S405 62.1 -2.12 -0.48 -0.12 0 0.01 0.5 0
D4S428 71.03 -0.34 -0.18 -0.09 -0.04 -0.01 0.5 0
D4S2389 84.72 -1.3 -0.47 -0.23 -0.1 -0.02 0.5 0
D4S1553 92.45 -7.08 -1.28 -0.57 -0.23 -0.05 0.5 0
D4S423 102.7 -8.24 -1.65 -0.73 -0.29 -0.07 0.5 0
D4S1572 110.14 -1.23 -0.4 -0.18 -0.07 -0.02 0.5 0
D4S406 117.48 -8.62 -1.69 -0.75 -0.29 -0.07 0.5 0
D4S1615 129.75 -7.93 -1.69 -0.75 -0.29 -0.07 0.5 0
D4S1575 134.67 -7.85 -1.65 -0.72 -0.28 -0.06 0.5 0
D4S424 142.05 -8.95 -1.42 -0.62 -0.24 -0.05 0.5 0
D4S1586 144.42 -0.45 -0.23 -0.11 -0.05 -0.01 0.5 0
D4S2962 148.06 -10.44 -1.69 -0.75 -0.29 -0.07 0.5 0
D4S3046 159.33 -9.07 -1.54 -0.69 -0.27 -0.06 0.5 0
D4S1539 173.75 -6.63 -0.38 -0.06 0.02 0.02 0.5 0.07
D4S1607 184.14 -7.96 -1.47 -0.66 -0.26 -0.06 0.5 0
D4S3041 189.52 -7.88 -1.61 -0.71 -0.28 -0.06 0.5 0
D4S408 193.5 -7.89 -1.49 -0.67 -0.26 -0.06 0.5 0
D4S1540 195.66 -8.24 -1.65 -0.73 -0.29 -0.07 0.5 0
D4S2930 209.27 -0.65 -0.3 -0.14 -0.06 -0.01 0.5 0
Table 4.9. Two-point lod scores for chromosome 4 in MMD family.
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Recombination fraction
Locus GeneticMap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D5S1981 1.21 -0.51 -0.25 -0.12 -0.05 -0.01 0.5 0
D5S2088 12.05 -8.16 -1.65 -0.73 -0.29 -0.07 0.5 0
D5S2054 16.64 -7.22 -0.59 -0.28 -0.12 -0.03 0.5 0
D5S635 18.11 -8.24 -1.65 -0.73 -0.29 -0.07 0.5 0
D5S1486 27.25 -0.4 -0.21 -0.11 -0.04 -0.01 0.5 0
D5S2081 31.94 -6.65 -0.75 -0.31 -0.12 -0.03 0.5 0
D5S2031 42.23 -6.59 -0.48 -0.11 0 0.01 0.5 0.01
D5S674 56.71 -6.18 -0.2 0.05 0.07 0.03 0.5 0.04
D5S2021 61.33 0.46 0.38 0.28 0.16 0.06 0 0.46
D5S628 71.14 -6.74 -0.74 -0.22 -0.04 0 0.5 0.014
D5S2072 80.82 -6.65 -0.99 -0.44 -0.18 -0.04 0.5 0
D5S424 93.23 -8.53 -0.49 -0.12 0 0.01 0.5 0
D5S1397 98.14 -6.71 -0.53 -0.14 -0.01 0 0.5 0
D5S1725 106.88 0.29 0.21 0.13 0.06 0.02 0 0.29
D5S409 114.89 0.26 0.78 0.67 0.42 0.14 0.1 0.78
D5S2027 120.95 0.55 1.02 0.84 0.52 0.17 0.088 1.03
D5S2065 122.49 0.55 1.02 0.84 0.52 0.17 0.088 1.03
D5S490 134.52 -0.33 -0.18 -0.09 -0.04 -0.01 0.5 0
D5S2017 145.35 -7.91 -0.53 -0.14 -0.01 0 0.5 0
D5S2090 153.72 -7.58 0.4 0.45 0.33 0.13 0.17 0.46
D5S410 162.45 -5.27 0.97 0.82 0.51 0.17 0.101 0.97
D5S2066 171.45 -6.3 -0.15 0 0.03 0.02 0.5 0.25
D5S400 181.34 -8.62 0.11 0.33 0.28 0.12 0.223 0.34
D5S1973 184.16 -8.62 0.11 0.33 0.28 0.12 0.223 0.34
D5S2069 194.4 0.36 0.26 0.16 0.08 0.02 0 0.36
D5S469 203.46 -6.48 -0.41 -0.07 0.01 0.01 0.5 0.01
D5S2006 211.06 -0.11 -0.06 -0.04 -0.02 0 0.5 o
Table 4.10. Two-point lod scores for chromosome 5 in MMD family.
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Recombination fraction
Locus GeneticMap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D6S244 5.66 -6.57 -0.47 -0.1 0 0.01 0.5 0.02
D6S1617 12.18 -8.84 -0.79 -0.24 -0.05 0 0.5 0
D6S309 21.6 -7.38 -1.62 -0.72 -0.28 -0.06 0.5 0
D6S1279 30.35 -6.19 -1.64 -0.73 -0.29 -0.07 0.5 0
D6S422 44.68 -9.4 -1.56 -0.7 -0.28 -0.07 0.5 0
D6S1660 48.37 -0.41 -0.21 -0.11 -0.04 -0.01 0.5 0
D6S273 53.25 0.29 0.21 0.13 0.06 0.02 0 0.29
D6S1575 63.69 -8.2 -1.41 -0.6 -0.23 -0.05 0.5 0
D6S459 72.59 -5.69 -1.46 -0.66 -0.26 -0.06 0.5 0
D6S452 74.58 -0.27 0.06 0.13 0.1 0.03 0.207 0.13
D6S1557 87.06 -5.54 -0.82 -0.36 -0.14 -0.03 0.5 0
D6S460 93.4 -2.17 -0.58 -0.22 -0.07 -0.01 0.5 0
D6S458 102.77 -0.04 -0.02 -0.01 -0.01 0 0.5 0
D6S268 115.03 0.32 0.23 0.14 0.07 0.02 0 0.32
D6S1712 123.79 -6.15 -1.32 -0.54 -0.19 -0.04 0.5 0
D6S1656 134.76 -5.9 -0.99 -0.39 -0.14 -0.03 0.5 0
D6S270 138.78 -8.21 -0.82 -0.3 -0.11 -0.03 0.5 0
D6S1009 142.71 -7.52 -1.31 -0.6 -0.24 -0.06 0.5 0
D6S1637 154.79 -7.03 0.07 0.24 0.17 0.05 0.204 0.25
D6S441 164.5 -7.66 -0.79 -0.24 -0.05 0 0.5 0
D6S419 170.85 -7.41 -0.4 -0.06 0.03 0.02 0.5 0.25
D6S1581 174.43 -5.22 -0.23 -0.06 -0.01 0 0.5 0
D6S305 176.93 -7.95 -0.74 -0.29 -0.09 -0.02 0.5 0
D6S1599 179.13 -6.68 -0.52 -0.13 -0.01 0 0.5 0
D6S1277 180.81 -1.23 -0.4 -0.18 -0.07 -0.02 0.5 0
D6S297 187.65 -8.62 -0.79 -0.24 -0.05 0 0.5 0
D6S503 190.17 -8.77 -0.79 -0.24 -0.05 0 0.5 0
D6S446 194.22 -6.7 -0.83 -0.34 -0.12 -0.03 0.5 0
Table 4.11. Two-point lod scores for chromosome 6 in MMD family.
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Recombination fraction
Locus GeneticMap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D7S2474 3.71 -2.13 -0.48 -0.12 0 0.01 0.5 0.02
D7S2201 12.21 -0.99 -0.22 -0.07 -0.02 0 0.5 0
D7S513 23.24 -9.32 -1.55 -0.7 -0.27 -0.06 0.5 0
D7S664 26.72 -9.25 -0.92 -0.37 -0.13 -0.03 0.5 0
D7S1795 38.61 -7.76 -0.43 -0.12 -0.03 -0.01 0.5 0
D7S2463 40.51 -8.82 -1.4 -0.63 -0.25 -0.06 0.5 0
D7S516 45.36 -0.14 -0.08 -0.04 -0.02 0 0.5 0
D7S2250 55.9 -8.08 -1.35 -0.62 -0.25 -0.06 0.5 0
D7S2541 63.45 -9.63 -1.64 -0.73 -0.28 -0.07 0.5 0
D7S691 64.93 -9.45 -1.58 -0.71 -0.28 -0.07 0.5 0
D7S519 70.24 -9.29 -1.62 -0.71 -0.28 -0.06 0.5 0
D7S2429 80.22 -8.36 -1.47 -0.66 -0.26 -0.06 0.5 0
D7S502 80.93 -7.56 -1.63 -0.72 -0.28 -0.07 0.5 0
D7S2500 83.71 -9.07 -1.03 -0.41 -0.15 -0.03 0.5 0
D7S672 86.43 -9.13 -1.58 -0.7 -0.28 -0.07 0.5 0
D7S2443 94.47 0.29 0.21 0.13 0.06 0.02 0 0.29
D7S2485 100.34 -5.74 -0.75 -0.28 -0.09 -0.01 0.5 0
D7S657 105.59 -4.93 -0.87 -0.27 -0.06 -0.01 0.5 0
D7S554 109.67 -5.95 -1.39 -0.61 -0.24 -0.06 0.5 0
D7S2509 114.48 -7.58 -0.91 -0.32 -0.1 -0.02 0.5 0
D7S2459 120.05 -4.46 0.71 0.62 0.37 0.11 0.113 0.72
D7S2418 122.15 -5.27 0.97 0.82 0.51 0.17 0.101 0.97
D7S530 133.2 -6.08 0.39 0.44 0.32 0.12 0.173 0.45
D7S2533 141.74 -0.31 -0.17 -0.09 -0.04 -0.01 0.5 0
D7S684 149.78 -6.15 0.11 0.33 0.28 0.11 0.222 0.34
D7S1824 152.03 -4.92 0.51 0.51 0.35 0.13 0.143 0.54
D7S661 155.04 -7.75 0.38 0.44 0.32 0.12 0.176 0.45
D7S1805 165.55 -5.3 0.31 0.41 0.31 0.12 0.187 0.41
D7S2447 179.62 -0.37 -0.2 -0.1 -0.04 -0.01 0.5 0
D7S2423 192.24 -9.24 -0.79 -0.24 -0.05 0 0.5 0
Table 4.12. Two-point lod scores for chromosome 7 in MMD family.
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Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D8S264 3.54 -9.45 -1.63 -0.72 -0.28 -0.07 0.5 0
D8S1819 16.91 -8.91 -1.46 -0.59 -0.21 -0.04 0.5 0
D8S520 21.48 -7.07 -1.12 -0.49 -0.19 -0.05 0.5 0
D8S516 22.5 -6.23 -0.21 -0.04 0 0.01 0.5 0.09
D8S258 36.13 0.29 0.21 0.13 0.06 0.02 0 0.29
D8S1734 42.1 -5.27 -0.86 -0.3 -0.1 -0.02 0.5 0
D8S1820 49.17 -6.77 -1.26 -0.51 -0.18 -0.03 0.5 0
D8S505 55.98 -7.28 -0.32 -0.02 0.05 0.03 0.5 0.25
D8S1737 69.34 -6.55 -0.47 -0.1 0.02 0.02 0.5 0.25
D8S1763 73.88 -3.57 -0.45 -0.09 0.02 0.02 0.5 0.23
D8S512 78.06 0.59 0.45 0.31 0.16 0.05 0 0.59
D8S279 86.52 0.34 0.24 0.15 0.07 0.02 0 0.34
D8S1707 97.46 0.24 0.17 0.1 0.05 0.01 0 0.24
D8S1778 106.89 0.26 0.18 0.11 0.05 0.01 0 0.26
D8S1762 108.03 -10.5 -1.67 -0.74 -0.29 -0.07 0.5 0
D8S1470 118.7 -8.26 -1.29 -0.57 -0.22 -0.05 0.5 0
D8S1799 131.69 -9.3 -1.46 -0.66 -0.27 -0.06 0.5 0
D8S1793 135.13 -8.81 -1.52 -0.69 -0.27 -0.07 0.5 0
D8S263 141.47 -6.93 -1.41 -0.63 -0.25 -0.06 0.5 0
D8S1746 150.11 -0.56 -0.27 -0.13 -0.05 -0.01 0.5 0
D8S1783 152.34 -5.43 -0.56 -0.15 -0.02 0 0.5 0
D8S274 153.61 -0.13 -0.08 -0.04 -0.02 0 0.5 0
D8S1743 160.11 -4.25 -0.56 -0.15 -0.02 0 0.5 0
Table 4.13 Two-point lod scores for chromosome 8 in MMD family.
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Recombination fraction
Locus GeneticMap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D9S1779 0 -0.2 0.04 0.08 0.04 0.01 0.178 0.08
D9S1686 11.93 0.05 0.29 0.31 0.21 0.07 0.159 0.32
D9S286 18.53 -0.19 0.08 0.15 0.11 0.04 0.201 0.15
D9S168 24.28 0.07 0.04 0.02 0.01 0 0 0.07
D9S1808 28.24 -1.14 -0.65 -0.33 -0.14 -0.03 0.5 0
D9S235 32.65 -0.71 -0.39 -0.2 -0.08 -0.02 0.5 0
D9S171 47.16 -0.17 -0.02 0.01 0.02 0.01 0.5 0.02
D9S2149 55.3 -0.14 -0.09 -0.05 -0.02 -0.01 0.5 0
D9S1777 67.34 -0.64 -0.34 -0.17 -0.07 -0.02 0.5 0
D9S1876 70.42 0.05 0.02 0.01 0 0 0 0.05
D9S175 72.8 -0.59 -0.21 -0.04 0.02 0.01 0.5 0.24
D9S1843 79.87 0.5 0.53 0.43 0.26 0.09 0.064 0.54
D9S307 89.23 -0.16 0.1 0.15 0.11 0.04 0.202 0.15
D9S283 95 0.44 0.38 0.28 0.16 0.05 0 0.44
D9S287 101.54 -0.12 -0.07 -0.03 -0.01 0 0.5 0
D9S261 114.65 0.37 0.45 0.38 0.24 0.08 0.5 0.45
D9S1675 117.44 0.22 0.2 0.15 0.08 0.02 0.022 0.22
D9S1828 117.67 -0.07 0.25 0.29 0.21 0.07 0.173 0.3
D9S1824 123.56 -0.61 -0.24 -0.07 -0.01 0 0.5 0
D9S934 127.72 -0.67 -0.26 -0.08 -0.01 0 0.5 0
D9S1682 132.09 -0.54 -0.2 -0.05 0 0 0.5 0
D9S1825 136.35 -0.83 -0.34 -0.12 -0.03 0 0.5 0
D9S1830 149.36 -0.44 -0.15 -0.05 -0.02 -0.01 0.5 0
D9S1793 150.42 0.23 0.16 0.1 0.04 0.01 0 0.23
D9S1838 164.1 -0.4 -0.1 0.02 0.04 0.02 0.5 0.52
Table 4.14. Two-point lod scores for chromosome 9 in MMD family.
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Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D10S249 1.19 -5.85 -0.73 -0.27 -0.08 -0.01 0.5 0
D10S602 5.71 -4.93 -0.91 -0.32 -0.11 -0.02 0.5 0
D10S1218 11.3 -3.15 -0.95 -0.43 -0.17 -0.04 0.5 0
D10S189 20.56 -5.55 -0.62 -0.17 -0.03 0 0.5 0
D10S1649 26.55 -8.91 0.01 0.22 0.16 0.04 0.21 0.22
D10S1430 32.11 -7.43 -0.87 -0.31 -0.1 -0.02 0.5 0
D10S570 32.73 0.32 0.23 0.14 0.07 0.02 0 0.32
D10S191 37.42 0.35 0.25 0.16 0.08 0.02 0 0.35
D10S1653 38.92 -6.95 -1.25 -0.5 -0.17 -0.03 0.5 0
D10S1661 41.4 -7.41 -1.48 -0.67 -0.26 -0.06 0.5 0
D10S600 54.33 -7.39 -1.47 -0.67 -0.26 -0.06 0.5 0
D10S1746 65.42 -6.96 -1.41 -0.63 -0.25 -0.06 0.5 0
D10S196 71.95 -7.19 -1.52 -0.68 -0.27 -0.06 0.5 0
D10S609 82.33 -0.06 -0.04 -0.02 -0.01 0 0.5 0
D10S537 91.46 -6.69 -0.38 -0.14 -0.05 -0.01 0.5 0
D10S580 97.94 -0.19 -0.11 -0.06 -0.03 -0.01 0.5 0
D10S1677 100.72 -0.25 -0.14 -0.07 -0.03 -0.01 0.5 0
D10S1753 113.42 -6.14 -0.86 -0.3 -0.1 -0.02 0.5 0
D10S185 116.07 -4.92 -0.23 0.03 0.05 0.01 0.5 0
D10S1267 125.15 -6.98 -0.87 -0.31 -0.11 -0.03 0.5 0
D10S597 129.57 -0.18 -0.11 -0.06 -0.02 -0.01 0.5 0
D10S1693 141.5 -6.15 -0.87 -0.31 -0.11 -0.03 0.5 0
D10S1656 154.8 -7.58 -1.15 -0.45 -0.15 -0.03 0.5 0
D10S575 160.19 -8.87 -1.57 -0.69 -0.27 -0.06 0.5 0
D10S1676 164.6 0.29 0.21 0.13 0.06 0.02 0 0.29
D10S1651 176.24 -8.62 -0.83 -0.3 -0.11 -0.03 0.5 0
D10S212 181.66 -8.62 -1.46 -0.59 -0.21 -0.04 0.5 0
Table 4.15. Two-point lod scores for chromosome 10 in MMD family
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Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D11S4046 0 -0.48 -0.24 -0.12 -0.05 -0.01 0.5 0
D11S1760 8.79 -7.76 -1.03 -0.42 -0.15 -0.03 0.5 0
D11S1331 12.38 -6.09 -0.62 -0.22 -0.07 -0.01 0.5 0
D11S4170 23.4 -7.5 -1.46 -0.59 -0.21 -0.04 0.5 0
D11S902 26.23 -8.68 -1.6 -0.72 -0.28 -0.07 0.5 0
D11S928 34.9 -7.09 -1.46 -0.59 -0.21 -0.04 0.5 0
D11S4080 43.29 -6.38 -0.6 -0.2 -0.05 0 0.5 0
D11S1776 49.46 -5.27 0.07 0.25 0.19 0.06 0.207 0.25
D11S1360 58.18 0.32 0.23 0.14 0.07 0.02 0 0.32
D11S4191 66.18 -7.09 0.07 0.24 0.17 0.05 0.203 0.24
D11S4087 73.81 -4.12 0.06 0.23 0.16 0.05 0.204 0.23
D11S937 85.42 -5.27 0.97 0.82 0.51 0.17 0.101 0.97
D11S1780 94.12 -5.56 -0.3 -0.1 -0.03 -0.01 0.5 0
D11S1886 107.71 -7.01 0.97 0.82 0.51 0.17 0.101 0.97
D11S4206 110.81 0.34 0.25 0.15 0.08 0.02 0 0.34
D11S908 118.66 -0.13 -0.08 -0.04 -0.02 0 0.5 0
D11S4089 126.83 -6 0.43 0.47 0.33 0.12 0.164 0.48
D11S4151 135.73 -4.33 0.97 0.82 0.51 0.17 0.101 0.97
D11S2367 148.23 -4.17 0.43 0.47 0.33 0.12 0.163 0.48
D11S969 154.38 -5.74 -0.05 0.16 0.15 0.06 0.5 0.16
Table 4.16. Two-point lod scores for chromosome 11 in MMD family.
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Recombination fraction
Locus Geneticmap 0.0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D12S352 0.68 -0.35 -0.19 -0.1 -0.04 -0.01 0.5 0
D12S1656 4.23 0.29 0.21 0.13 0.06 0.02 0 0.29
D12S372 8.63 -6.29 -1.08 -0.44 -0.16 -0.04 0.5 0
D12S374 16.84 -9.17 -1.43 -0.64 -0.25 -0.06 0.5 0
D12S336 24.76 -7.85 -1.39 -0.63 -0.25 -0.06 0.5 0
D12S364 31.97 -0.49 -0.25 -0.12 -0.05 -0.01 0.5 0
D12S1591 44.81 -7.44 -1.39 -0.63 -0.25 -0.06 0.5 0
D12S1337 51.8 -0.06 -0.04 -0.02 -0.01 0 0.5 0
D12S1704 52.93 -0.11 -0.07 -0.04 -0.02 0 0.5 0
D12S85 61.77 -1.98 -0.41 -0.08 0.01 0.01 0.5 0
D12S368 67.92 -1.27 0.12 0.27 0.18 0.05 0.193 0.27
D12S83 75.48 -1.27 0.12 0.27 0.18 0.05 0.195 0.27
D12S1294 83.69 0.12 0.06 0.03 0.01 0 0 0.12
D12S326 92.97 -0.19 0.48 0.49 0.34 0.12 0.149 0.51
D12S351 103.1 -6.14 0.47 0.44 0.28 0.09 0.13 0.49
D12S95 104.42 -8 -0.61 -0.17 -0.02 0 0.5 0
D12S1346 106.03 -7.62 -0.14 0.13 0.15 0.06 0.5 0.22
D12S2081 110.59 -7.65 -0.42 -0.08 0.01 0.01 0.5 0
D12S1636 120.17 -7.35 -0.48 -0.11 0 0.01 0.5 0.04
D12S1613 124.08 -0.23 -0.13 -0.07 -0.03 -0.01 0.5 0
D12S1583 127.22 -8.08 -0.61 -0.17 -0.03 0 0.5 0
D12S354 133.66 -0.15 -0.09 -0.05 -0.02 0 0.5 0
D12S369 134.33 -9.42 -0.95 -0.39 -0.14 -0.03 0.5 0
D12S366 140.32 -1.57 -0.09 0.15 0.15 0.06 0.5 0.24
D12S2073 144.14 -7.89 0.35 0.43 0.31 0.12 0.177 0.43
D12S2078 155.99 -0.16 0.49 0.49 0.34 0.13 0.146 0.52
D12S1609 160.72 -1.27 0.17 0.36 0.29 0.11 0.213 0.36
D12S1723 173.29 -8.78 -1.62 -0.71 -0.28 -0.06 0.5 0
Table 4.17. Two-point lod scores for chromosome 12 in MMD family.
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Recombination fraction
Locus GeneticMap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D13S175 3.24 -7.62 -1.63 -0.72 -0.28 -0.07 0.5 0
D13S232 8.98 -6.26 -1.6 -0.71 -0.28 -0.07 0.5 0
D13S1243 11.57 -1.57 -0.09 0.15 0.15 0.06 0.5 0.17
D13S221 16.88 -8.91 -0.79 -0.24 -0.05 0 0.5 0
D13S217 22.89 -8.14 -1.21 -0.52 -0.2 -0.05 0.5 0
D13S289 28.14 -9.29 -1.56 -0.69 -0.27 -0.06 0.5 0
D13S171 31.99 -9.32 -1.46 -0.65 -0.26 -0.06 0.5 0
D13S219 36.49 -8.64 -0.96 -0.43 -0.17 -0.04 0.5 0
D13S218 40.44 -1.48 -0.54 -0.25 -0.1 -0.02 0.5 0
D13S272 54.31 -8.78 -1.62 -0.71 -0.28 -0.06 0.5 0
D13S279 65.83 -7.26 -1.38 -0.63 -0.25 -0.06 0.5 0
D13S271 80.33 -9.31 -1.47 -0.67 -0.27 -0.06 0.5 0
D13S1241 91.34 -0.45 -0.23 -0.12 -0.05 -0.01 0.5 0
D13S1256 100.66 -8.77 -1.46 -0.67 -0.27 -0.06 0.5 0
D13S1809 107.62 -4.86 -0.64 -0.24 -0.08 -0.02 0.5 0
D13S1315 119 -1.26 -0.41 -0.18 -0.07 -0.02 0.5 0
D13S293 131.92 -2.47 -0.39 -0.12 -0.02 0 0.5 0.06
Table 4.18. Two-point lod scores for chromosome 13 in MMD family.
Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max
z
max
D14S261 9.53 -0.15 -0.09 -0.05 -0.02 -0.01 0.5 0
D14S1043 9.83 -0.04 -0.03 -0.01 -0.01 0 0.5 0
D14S1280 23.04 -9.16 -1.4 -0.64 -0.26 -0.06 0.5 0
D14S262 25.73 -1.23 -0.4 -0.18 -0.07 -0.02 0.5 0
D14S1071 29.19 -8.91 -1.69 -0.75 -0.29 -0.07 0.5 0
D14S741 35 -9.21 -0.78 -0.32 -0.12 -0.03 0.5 0
D14S70 37.63 -9.25 -0.8 -0.33 -0.12 -0.03 0.5 0
D14S75 43.2 -9.19 -1.42 -0.65 -0.26 -0.06 0.5 0
D14S976 46.8 -1.57 -0.08 0.16 0.16 0.06 0.5 0.18
D14S978 51.44 -1.24 -0.36 -0.13 -0.04 -0.01 0.5 0
D14S276 57.33 -3.1 -0.73 -0.22 -0.04 0 0.5 0
D14S1011 70.01 -0.47 -0.24 -0.12 -0.05 -0.01 0.5 0
D14S258 70.4 -1.59 -0.14 0.08 0.08 0.03 0.5 0.03
D14S1433 74.94 -0.01 0.59 0.55 0.37 0.13 0.126 0.6
D14S616 85.45 -3.45 0.97 0.82 0.51 0.17 0.101 0.97
D14S67 88.68 0.29 0.21 0.13 0.06 0.02 0 0.29
D14S1044 92.86 -0.12 -0.07 -0.04 -0.02 0 0.5 0
D14S81 99.25 -7.09 0.07 0.24 0.17 0.05 0.203 0.24
D14S1054 102.52 1.18 0.91 0.62 0.33 0.1 0.001 1.18
D14S987 106.22 -7.49 -0.78 -0.23 -0.03 0.01 0.5 0.24
D14S1019 109.31 0.33 0.24 0.15 0.07 0.02 0.001 0.33
D14S1426 117.81 -8.41 -0.72 -0.21 -0.04 0 0.5 0
D14S542 126.06 0.29 0.21 0.13 0.06 0.02 0.001 0.29
Table 4.19. Two-point lod scores for chromosome 14 in MMD family.
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Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D15S128 6.06 -6.46 -1.46 -0.59 -0.2 -0.04 0.5 0
D15S975 13.46 0.34 0.25 0.15 0.08 0.02 0 0.34
D15S1019 21.44 -0.09 -0.06 -0.03 -0.01 0 0.5 0
D15S165 23.51 -5.27 0.07 0.24 0.17 0.05 0.203 0.24
D15S231 27.43 0.29 0.21 0.13 0.06 0.02 0 0.29
D15S118 35.23 0.34 0.25 0.16 0.08 0.02 0 0.34
D15S1012 39.39 -7.02 -1.26 -0.56 -0.22 -0.05 0.5 0
D15S146 43.14 -0.42 -0.22 -0.11 -0.05 -0.01 0.5 0
D15S1016 52.71 0.3 0.21 0.13 0.06 0.02 0 0.29
D15S117 58.09 -7.39 -0.87 -0.31 -0.1 -0.02 0.5 0
D15S988 70.39 -7.85 -1.25 -0.51 -0.18 -0.03 0.5 0
D15S114 82.51 -0.33 -0.18 -0.09 -0.04 -0.01 0.5 0
D15S1005 86.82 -8.51 -1.48 -0.66 -0.26 -0.06 0.5 0
D15S158 100.89 0.59 0.45 0.31 0.16 0.05 0 0.59
D15S1004 110.96 0.33 0.24 0.15 0.07 0.02 0 0.33
D15S130 111.55 0.59 0.45 0.31 0.16 0.05 0 0.59
D15S816 114.36 -3.45 0.01 0.22 0.17 0.05 0.212 0.22
D15S157 116.14 -4.63 0.01 0.22 0.17 0.05 0.212 0.22
D15S212 124.08 0.59 0.45 0.31 0.16 0.05 0 0.59
D15S120 130.4 -0.15 -0.09 -0.05 -0.02 -0.01 0.5 0
Table 4.20. Two-point lod scores for chromosome 15 in MMD family.
Recom bination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D16S521 1.15 -6.94 -1.41 -0.63 -0.25 -0.06 0.5 0
D16S3065 10.64 -1.57 -0.6 -0.29 -0.12 -0.03 0.5 0
D16S423 14.97 -8.91 -0.79 -0.24 -0.05 0 0.5 0
D16S418 20.61 -7.65 -0.14 0.13 0.14 0.06 0.5 0.16
D16S3062 32.07 -7.85 -0.49 -0.12 -0.01 0.01 0.5 0
D16S500 33.31 -1.23 -0.4 -0.18 -0.07 -0.02 0.5 0
D16S410 41.83 0.35 0.25 0.16 0.08 0.02 0 0.34
D16S3068 51.27 -7.09 0.07 0.25 0.19 0.06 0.207 0.25
D16S3080 61.1 -8.04 -0.58 -0.15 0 0.02 0.5 0.24
D16S3034 68.27 -7.83 -0.43 -0.12 -0.03 -0.01 0.5 0
D16S3057 76.36 -0.11 -0.06 -0.04 -0.02 0 0.5 0
D16S514 83.1 -7.82 0.07 0.25 0.17 0.05 0.204 0.25
D16S503 84.26 0.28 0.2 0.12 0.06 0.02 0 0.28
D16S515 94.69 -1.47 -0.13 0.07 0.06 0.01 0.5 0
D16S516 101.24 -1.27 0.17 0.36 0.29 0.11 0.213 0.36
D16S505 108.07 0.55 1.07 0.93 0.64 0.26 0.098 1.07
D16S763 120.63 1.23 1.07 0.84 0.54 0.2 0 1.23
D16S2621 131.46 -6.16 0.11 0.33 0.28 0.11 0.222 0.34
Table 4.21. Two-point lod scores for chromosome 16 in MMD family.
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Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D17S849 0.63 -8.78 -1.26 -0.54 -0.21 -0.05 0.5 0
D17S831 7.47 -7.52 -1.19 -0.52 -0.2 -0.05 0.5 0
D17S1832 16.79 0.29 0.21 0.13 0.06 0.02 0 0.29
D17S804 28.96 -6.15 0.11 0.33 0.28 0.12 0.223 0.34
D17S799 37.94 -8.44 0.11 0.33 0.28 0.12 0.223 0.34
D17S922 41.55 -8.82 -0.84 -0.26 -0.06 0 0.5 0
D17S839 43.77 -6.74 -1.04 -0.39 -0.11 -0.01 0.5 0.05
D17S1824 53.22 -7.3 -0.65 -0.22 -0.05 0 0.5 0.06
D17S2194 58.94 0.59 0.45 0.31 0.16 0.05 0 0.59
D17S1867 66.96 -7.67 -0.72 -0.26 -0.07 -0.01 0.5 0.06
D17S1299 71.13 -7.09 -0.83 -0.25 -0.04 0.01 0.5 0.22
D17S1868 76.3 -5.56 -0.62 -0.16 -0.01 0.02 0.5 0.22
D17S1795 77.3 -7.09 -0.83 -0.25 -0.04 0.01 0.5 0.22
D17S957 89.64 0.37 0.27 0.17 0.08 0.02 0 0.37
D17S794 94.36 -5.47 -0.58 -0.15 0 0.02 0.5 0.22
D17S944 95.11 0.27 0.19 0.12 0.06 0.02 0 0.27
D17S940 102.6 -0.04 -0.03 -0.02 -0.01 0 0.5 0
D17S1351 108.83 0.3 0.22 0.13 0.06 0.02 0 0.3
D17S1603 117.82 0.35 0.25 0.16 0.08 0.02 0 0.35
D17S1847 126.71 -3.8 -1.27 -0.58 -0.23 -0.05 0.5 0
D17S836 128.03 -3.1 -0.77 -0.27 -0.09 -0.02 0.5 0
D17S784 132.74 -4.16 -0.67 -0.23 -0.06 0 0.5 0.05
Table 4.22. Two-point lod scores for chromosome 17 in MMD family.
Recom bination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D18S1105 3.97 -0.37 -0.2 -0.1 -0.04 -0.01 0.5 0
D18S63 9.84 -0.46 -0.23 -0.12 -0.05 -0.01 0.5 0
D18S967 21.74 -6.7 -1.18 -0.5 -0.19 -0.04 0.5 0
D18S464 33.37 -8.24 -1.65 -0.73 -0.29 -0.07 0.5 0
D18S1107 47.29 -6.29 -1.53 -0.69 -0.28 -0.07 0.5 0
D18S877 54.03 -0.5 -0.25 -0.12 -0.05 -0.01 0.5 0
D18S1102 59.89 -9.35 -1.66 -0.73 -0.28 -0.07 0.5 0
D18S474 68.99 -7.84 -0.49 -0.11 0 0.01 0.5 0
D18S450 70.78 -6.76 0.08 0.22 0.18 0.07 0.218 0.22
D18S64 77.54 -7.68 -0.79 -0.24 -0.05 0 0.5 0
D18S1134 87.2 -8.91 -0.79 -0.24 -0.05 0 0.5 0
D18S1147 88.5 -8.91 -0.79 -0.24 -0.05 0 0.5 0
D18S465 92.91 -6.69 -0.71 -0.27 -0.09 -0.01 0.5 0
D18S469 106.38 -8.74 -0.79 -0.24 -0.05 0 0.5 0
D18S554 117.94 -7.01 -1.45 -0.65 -0.26 -0.06 0.5 0
Table 4.23. Two-point lod scores for chromosome 18 in MMD family.
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Recombination raction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D19S886 0.9 -7.08 -1.46 -0.59 -0.21 -0.04 0.5 0
D19S591 10.59 0.74 0.62 0.46 0.27 0.09 0 0.74
D19S427 20.75 -9.38 -0.84 -0.26 -0.06 0 0.5 0
D19S584 33.17 -7.91 0.01 0.22 0.16 0.05 0.21 0.22
D19S226 37.98 -9.26 -1.08 -0.44 -0.16 -0.03 0.5 0
D19S593 43.02 -5.86 -0.73 -0.22 -0.04 0 0.5 0
D19S414 55.81 -7.66 -0.24 0.03 0.05 0.01 0.5 0
D19S208 63.1 -4.63 0.01 0.22 0.16 0.05 0.211 0.22
D19S903 73.21 -9.37 -0.84 -0.26 -0.06 0 0.5 0
D19S867 84.6 -5.68 -0.68 -0.2 -0.04 0 0.5 0
DG19S186 92.14 -0.06 -0.04 -0.02 -0.01 0 0.5 0
D19S572 99.88 -5.27 0.11 0.33 0.28 0.11 0.222 0.34
D19S418 107.71 -6.16 0.11 0.33 0.28 0.11 0.222 0.34
D19S605 108.45 -5.27 0.32 0.42 0.31 0.12 0.185 0.42
D19S573 113.23 -0.07 -0.05 -0.02 -0.01 0 0.5 0
Table 4.24. Two-point lod scores for chromosome 19 in MMD family.
Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D20S113 7.68 -7.44 -0.2 0.01 0.05 0.02 0.5 0.04
D20S882 18.3 -6.21 -0.58 -0.16 -0.02 0 0.5 0
D20S115 25.35 -6.61 -0.73 -0.29 -0.11 -0.02 0.5 0
D20S189 34.88 -8.55 -1.41 -0.64 -0.25 -0.06 0.5 0
D20S904 42.54 -7.76 -1.03 -0.42 -0.15 -0.03 0.5 0
D20S912 52.19 -0.44 -0.23 -0.11 -0.05 -0.01 0.5 0
D20S859 60.73 0.29 0.21 0.13 0.06 0.02 0 0.29
D20S107 63.19 -7.74 -0.87 -0.31 -0.1 -0.02 0.5 0
D20S108 65.64 -6.16 -0.88 -0.32 -0.12 -0.03 0.5 0
D20S481 70.97 -7.78 -0.87 -0.31 -0.11 -0.02 0.5 0
D20S838 71.23 -8.82 -1.08 -0.44 -0.16 -0.04 0.5 0
D20S178 75.47 -7.03 -1.47 -0.67 -0.27 -0.06 0.5 0
D20S1083 83.33 -7.94 -0.3 -0.1 -0.03 -0.01 0.5 0
D20S100 90.85 -8.62 -1.46 -0.59 -0.2 -0.04 0.5 0
D20S171 100.84 -3.4 -0.98 -0.4 -0.14 -0.03 0.5 0
Table 4.25. Two-point lod scores for chromosome 20 in MMD family.
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Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D21S1904 7.23 -6.85 -0.25 -0.08 -0.02 0 0.5 0
D21S1432 8.75 -7 -1.22 -0.49 -0.17 -0.03 0.5 0
D21S1899 16.2 -6.66 -1.21 -0.48 -0.17 -0.03 0.5 0
D21S1905 17.29 -7.66 -1.2 -0.48 -0.16 -0.03 0.5 0
D21S1902 19.54 0.23 0.18 0.14 0.09 0.03 0 0.23
D21S272 23.96 -7.29 -1.16 -0.46 -0.16 -0.03 0.5 0
D21S1442 29.5 -8.62 -1.69 -0.75 -0.29 -0.07 0.5 0
D21S1909 33.81 -0.94 -0.19 -0.04 0 0 0.5 0.06
D21S1898 38.62 -0.18 -0.11 -0.06 -0.02 -0.01 0.5 0
D21S1895 41.37 -0.41 -0.22 -0.11 -0.04 -0.01 0.5 0
D21S1252 44.04 -8.79 -1.66 -0.73 -0.28 -0.07 0.5 0
D21S1919 45.79 -7.92 -0.53 -0.14 -0.01 0.01 0.5 0
D21S270 46.25 -0.52 -0.26 -0.13 -0.05 -0.01 0.5 0
D21S1255 48.28 -7.92 -0.55 -0.14 -0.02 0 0.5 0
D21S266 57.33 -8.09 -0.61 -0.17 -0.02 0 0.5 0.01
Table 4.26. Two-point lod scores for chromosome 21 in MMD family.
Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max
Zm
ax
D22S420 5.72 -8.36 -0.5 -0.12 -0.01 0.01 0.5 0
D22S427 6 -0.09 -0.06 -0.03 -0.01 0 0.5 0
D22S539 15.82 -3.7 -0.75 -0.28 -0.08 -0.01 0.5 0
D22S1174 20.03 -5.33 -0.5 -0.12 -0.01 0.01 0.5 0
D22S315 23.91 0.32 0.23 0.14 0.07 0.02 0
0.3
2
D22S1154 25.73 -9.63 -0.76 -0.24 -0.05 0 0.5 0
D22S531 36.2 -0.33 -0.18 -0.09 -0.04 -0.01 0.5 0
D22S1265 40.84 -5.32 -0.5 -0.12 -0.01 0 0.5 0
D22S276 51.21 -6.11 -0.58 -0.16 -0.02 0 0.5 0
D22S928 59.39 -6.09 -1.1 -0.49 -0.19 -0.04 0.5 0
D22S1170 68.42 -8.17 -1.15 -0.49 -0.19 -0.05 0.5 0
Table 4.27. Two-point lod scores for chromosome 22 in MMD family.
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Appendix 3.
Two point lod score results for Abdominal Epilepsy (AE) family in chapter seven.
255
Recombination fraction
Locus genetic map 0 0.1 0.2 0.3 0.4 Thetamax Z max
D1S468 5.44 -13.54 -3.78 -1.85 -0.89 -0.34 0.5 0.19
D1S2870 11.68 -4.48 -0.06 0.12 0.15 0.11 0.289 0.15
D1S450 16.99 -18.98 -4.42 -2.14 -0.99 -0.34 0.5 0.11
D1S2667 20.36 -12.92 -6.38 -3.53 -1.78 -0.69 0.5 0.45
D1S434 21.8 -7.55 -2.97 -1.44 -0.65 -0.21 0.5 0.03
D1S2697 29.07 -18.36 -5.13 -2.7 -1.38 -0.55 0.5 0.49
D1S2620 43.94 -5.36 -1.74 -0.82 -0.38 -0.13 0.5 0.04
D1S241 54.23 -8.24 -0.42 -0.17 -0.09 -0.03 0.5
D1S255 59.98 -5.05 -0.7 -0.4 -0.22 -0.1 0.5 0.3
D1S2861 68.18 -8.25 -2.73 -1.1 -0.36 -0.03 0.463 0.02
D1S2713 69.43 0.12 0.1 0.07 0.05 0.03 0 0.12
D1S2797 70.48 0.12 0.1 0.07 0.05 0.03 0 0.12
D1S197 73.67 -18.99 -4.25 -1.99 -0.86 -0.26 0.5 0.02
D1S2652 78.87 -14 -2.44 -0.91 -0.26 0 0.449 0.03
D1S476 80.34 -8.09 -1.03 -0.34 -0.06 0.04 0.418 0.04
D1S2846 87.95 -13.05 -1.8 -0.79 -0.31 -0.08 0.5 0
D1S2788 89.08 -4.94 -0.61 -0.33 -0.18 -0.07 0.5 0.1
D1S219 98.97
D1S2841 105.86 -19.51 -2.63 -1.07 -0.39 -0.09 0.5 0
D1S500 106.4 -13.13 -0.63 0.06 0.21 0.14 0.303 0.21
D1S430 107.37 -23.06 -2.36 -0.84 -0.24 -0.03 0.5 0
D1S2766 112.11 -18.15 -1.32 -0.33 0.01 0.06 0.384 0.07
D1S2865 114.17 -5.42 -0.67 0.03 0.2 0.14 0.312 0.2
D1S435 117.67 -22.99 -1.77 -0.55 -0.11 -0.01 0.5 0.02
D1S206 124.95 -12.39 -1.41 -0.24 0.13 0.14 0.353 0.17
D1S495 126.35 -17.84 -0.27 0.34 0.4 0.23 0.268 0.42
D1S2688 129.08 -10.64 -1.36 -0.37 -0.02 0.05 0.385 0.04
D1S189 140.46 -4.81 -0.35 -0.13 -0.03 0.01 0.432 0.43
D1S498 147.7 -17.45 0.21 0.57 0.5 0.23 0.225 0.58
D1S1653 154.54 -5.05 -0.7 -0.4 -0.22 -0.1 0.5 0.3
D1S484 160.45 -19.2 -0.76 0.13 0.33 0.19 0.5 0.03
D1S2628 168.68 -18.26 -3.3 -1.41 -0.58 -0.19 0.5 0.11
D1S452 176.39 -8.13 -0.73 -0.16 0.01 0.03 0.5 0.67
D1S2818 187.03 -13.65 -1.95 -0.65 -0.17 -0.05 0.5 0.53
D1S413 198.52 -14.16 -2.49 -1.18 -0.53 -0.17 0.5 0.02
D1S2717 208.15 -5.25 1.04 0.94 0.66 0.29 0.114 1.05
D1S249 210.82 -19.38 -3.11 -1.26 -0.48 -0.16 0.5 0.28
D1S2685 213.64 -19.2 -3.37 -1.47 -0.63 -0.24 0.5 0.5
D1S245 216.77 0 0 0 0 0 0.1 0
D1S205 217.22 -19.08 -4.07 -1.86 -0.85 -0.34 0.5 0.66
D1S237 222.18 -18.46 -3.45 -1.71 -0.88 -0.4 0.5 1.21
D1S2641 230.38 -19.36 -4.6 -2.28 -1.11 -0.42 0.5 0.23
D1S2833 238.23 -12.2 -1.43 -0.7 -0.34 -0.13 0.5 0.09
D1S2709 239.64 -14.46 -2.23 -0.83 -0.23 0.01 0.444 0.03
D1S2850 251.42 -11.66 -0.57 0.13 0.29 0.21 0.307 0.29
D1S2785 262.68 -18.15 -1.02 -0.06 0.22 0.19 0.338 0.23
Table 7.5. Two-point lod scores for chromosome 1 in AE family
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Recomb ination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Z max
D2S323 4.61 -5.14 0.96 0.74 0.42 0.11 0.082 0.97
D2S319 7.81 -9.91 -1.35 -0.19 0.2 0.23 0.356 0.25
D2S2211 18.24 -11.64 -0.61 0.28 0.5 0.39 0.31 0.5
D2S398 28.03 -12.33 -1.05 0.08 0.43 0.37 0.333 0.45
D2S168 29.73 -12.93 -1.94 -0.75 -0.21 0.01 0.444 0.03
D2S305 42.8 -13.03 -2 -0.52 0.06 0.19 0.388 0.19
D2S146 52.91 -7.25 -1.51 -0.43 0 0.12 0.399 0.12
D2S2328 66.77 -13.55 -0.45 0.36 0.5 0.32 0.284 0.5
D2S2156 78.42 -4.4 -0.58 0.02 0.2 0.18 0.337 0.22
D2S1364 82.83 -3.96 0.57 0.62 0.5 0.3 0.167 0.62
D2S337 86.05 -12.22 0.7 1.15 0.99 0.54 0.212 1.15
D2S2152 94.62 -12.19 2.24 2.04 1.5 0.75 0.115 2.24
D2S2110 99.58 -8.8 -0.09 0.15 0.14 0.04 0.5 0.12
D2S2116 103.5 -5.71 -0.9 -0.39 -0.15 -0.03 0.5 0
D2S388 112.75 -12.26 -1.74 -0.47 0.02 0.13 0.391 0.13
D2S293 122.55 -17.56 -1.41 -0.23 0.15 0.18 0.361 0.2
D2S363 130.95 -8.83 -0.43 0.21 0.34 0.24 0.298 0.34
D2S347 138.31 -17.55 -3.95 -1.74 -0.68 -0.16 0.5 0
D2S2271 143.62 -13.86 -4.2 -1.94 -0.82 -0.24 0.5 0.01
D2S2256 149.54 -6.18 -1.7 -1.09 -0.65 -0.27 0.5 0.21
D2S2324 164.37 -7.36 -2.02 -0.98 -0.44 -0.13 0.5 0.01
D2S1353 171.63 -13.86 -3.31 -1.44 -0.59 -0.17 0.5 0.02
D2S2330 174.85 -6.18 -1.09 -0.39 -0.09 0.02 0.431 0.03
D2S2188 186.25 -13.56 -2 -0.52 0.06 0.19 0.388 0.19
D2S118 195.34 -13.42 -1.6 -0.39 0.05 0.15 0.384 0.15
D2S2321 209.45 -11.85 -1.3 -0.12 0.28 0.29 0.352 0.33
D2S317 213.81 -6.83 -0.78 -0.31 -0.09 -0.01 0.458 0
D2S2361 216.94 -6.25 -1.3 -0.42 -0.06 0.06 0.414 0.06
D2S2382 218.52 -12.33 -1.58 -0.33 0.14 0.21 0.375 0.22
D2S163 226.25 -13.66 -2.41 -0.81 -0.14 0.09 0.42 0.09
D2S133 232.12 -5.73 -1.73 -0.9 -0.46 -0.18 0.5 0.15
D2S427 243.39 -9.75 -2.47 -1.04 -0.38 -0.07 0.48 0
D2S2202 253.23 -18.93 -3.59 -1.59 -0.63 -0.15 0.5 0
D2S338 253.84 -19.08 -3.06 -1.23 -0.44 -0.1 0.5 0
D2S395 262.12 -19.01 -3.6 -1.64 -0.72 -0.25 0.5 0.1
D2S140 265.28 -9.23 -2.43 -1.16 -0.52 -0.17 0.5 0.02
Table 7.6. Two-point lod scores for chromosome 2 in AE family
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Recomb ination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D3S4559 1.08 -5.72 -1.59 -0.51 -0.08 0.06 0.413 0.06
D3S1270 3.28 -12.77 -4.24 -2.16 -0.99 -0.34 0.5 0
D3S3630 6.22 -12.63 -3.13 -1.44 -0.63 -0.19 0.5 0
D3S3050 10.68 -9.22 -0.13 0.22 0.28 0.2 0.29 0.29
D3S2397 16.21 -12.93 -1.49 -0.47 -0.09 0.03 0.431 0.03
D3S1515 19.89 0.3 0.25 0.2 0.14 0.08 0 0.29
D3S3591 23.9 -7.85 -3.58 -1.8 -0.86 -0.31 0.5 0.01
D3S1263 30.71 -14.95 -2.57 -1.17 -0.53 -0.18 0.5 0.04
D3S2385 33.55 -6.23 -1.24 -0.59 -0.3 -0.13 0.5 0.2
D3S1567 48.03 -10.17 -2.53 -1.4 -0.76 -0.32 0.5 0.53
D3S2335 50.4 -5.58 -1.7 -0.81 -0.39 -0.15 0.5 0.09
D3S1266 52.22 -6.17 -2.55 -0.99 -0.31 -0.02 0.46 0.02
D3S3547 56.45 -3.87 0.3 0.4 0.35 0.21 0.205 0.4
D3S3521 66.4 -17.37 -0.73 0.12 0.34 0.26 0.317 0.34
D3S3672 76.71 -5.15 -2.45 -0.88 -0.21 0.03 0.434 0.05
D3S1600 89.02 -4.06 0.78 0.75 0.45 0.1 0.138 0.82
D3S3551 99.23 -13.34 -0.05 0.54 0.56 0.31 0.251 0.6
D3S3653 106.92 2.73 2.28 1.77 1.18 0.52 0 2.73
D3S1271 115.24 -8.26 1.53 1.32 0.93 0.41 0.091 1.53
D3S3045 120.29 -8.01 1.79 1.53 1.07 0.49 0.085 1.79
D3S1558 129.21 -12.83 1.55 1.66 1.29 0.65 0.162 1.7
D3S1589 136.43 -7.69 0.58 0.88 0.74 0.35 0.205 0.9
D3S3637 146.26 -10.88 -0.74 -0.04 0.12 0.06 0.5 0.9
D3S1569 154.11 -11.54 -1.29 -0.38 -0.02 0.08 0.403 0.08
D3S1308 160.67 -5.05 -0.7 -0.4 -0.22 -0.1 0.5 0.3
D3S1607 168.31 -4.88 -0.79 -0.23 -0.04 0.01 0.5 0.02
D3S1564 175.21 -5.05 -0.7 -0.4 -0.22 -0.1 0.5 0.3
D3S3725 178.27 -12.63 -4.14 -2.18 -1.12 -0.44 0.5 0.4
D3S3041 185.92 0 0 0 0 0 0.1 0
D3S3592 195.05 -16.92 -3.06 -1.23 -0.44 -0.1 0.5 0
D3S1580 206.43 -11.05 -0.36 0.28 0.38 0.22 0.275 0.4
D3S3663 213.15 -5.05 -0.7 -0.4 -0.22 -0.1 0.5 0.3
D3S240 219.97 0.12 0.1 0.08 0.05 0.03 0 0.12
D3S1265 222.34 -12.63 -3.13 -1.56 -0.74 -0.26 0.5 0
D3S1311 225.05 -17.54 -3.96 -1.81 -0.8 -0.27 0.5 0
Table 7.7. Two-point lod scores for chromosome 3 in AE family
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Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D4S412 4.57 -12.94 -1.99 -0.66 -0.12 0.06 0.418 0.06
D4S2935 14.07 -5.05 -0.71 -0.4 -0.23 -0.1 0.5 0.3
D4S394 15.28 -12.46 -1.37 -0.33 0.07 0.15 0.383 0.15
D4S2928 23.84 -5.05 -0.7 -0.4 -0.22 -0.1 0.5 0.3
D4S3341 32.25 -11.79 -0.62 0.19 0.37 0.27 0.308 0.37
D4S404 41 -11.73 -0.73 0.13 0.32 0.21 0.304 0.32
D4S3022 43.89 -13.69 -0.57 0.24 0.38 0.23 0.286 0.38
D4S391 48.95 -13.67 -1.61 -0.42 0 0.07 0.382 0.07
D4S2912 48.97 -10.11 -1.41 -0.58 -0.22 -0.05 0.495 0
D4S1587 55.94 -11.48 -1.8 -0.73 -0.29 -0.12 0.5 0.5
D4S405 62.1 -14.31 -1.95 -0.72 -0.22 -0.03 0.472 0
D4S428 71.03 -7.49 -2.27 -0.92 -0.32 -0.06 0.48 0
D4S2389 84.72 -9.24 -1.38 -0.43 -0.07 0.03 0.424 0.03
D4S1553 92.45 -4.98 -1.22 -0.52 -0.19 -0.03 0.481 0
D4S423 102.7 -12.64 -1.9 -0.68 -0.19 -0.01 0.459 0.01
D4S1572 110.14 -17.36 -2.96 -1.15 -0.34 0 0.451 0.04
D4S406 117.48 -12.93 -2.02 -0.71 -0.15 0.06 0.427 0.06
D4S1615 129.75 -6.97 -1.2 -0.49 -0.17 -0.02 0.469 0
D4S1575 134.67 -4.09 0.06 0.17 0.16 0.1 0.23 0.2
D4S424 142.05 -5.08 -0.33 -0.1 -0.01 0.02 0.404 0.02
D4S1586 144.42 -17.64 -2.46 -0.89 -0.19 0.06 0.428 0.08
D4S2962 148.06 -7.65 -0.11 0 0.01 0 0.5 0.01
D4S3046 159.33 -14.3 -1.64 -0.39 0.09 0.18 0.381 0.2
D4S1539 173.75 1.17 0.91 0.63 0.35 0.1 0 1.17
D4S1607 184.14 -13.49 -1.78 -0.68 -0.22 -0.03 0.47 0
D4S3041 189.52 0.11 0.07 0.03 0.01 0 0 0.11
D4S408 193.5 -5.09 -0.72 -0.4 -0.22 -0.1 0.5 0.24
D4S1540 195.66 0.12 0.1 0.08 0.05 0.03 0 0.12
D4S2930 209.27 -6.59 -3.13 -1.56 -0.74 -0.26 0.5 0.09
Table 7.8. Two-point lod scores for chromosome 4 in AE family
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Recombination fraction
Locus GeneticMap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D5S1981 1.21 -13.71 -3.34 -1.51 -0.67 -0.26 0.5 0.43
D5S2088 12.05 -7.37 -2.7 -1.37 -0.67 -0.25 0.5 0.1
D5S2054 16.64 -5.94 -2.19 -0.96 -0.38 -0.09 0.5 0
D5S635 18.11 -5.92 -2.17 -0.95 -0.37 -0.09 0.5 0
D5S1486 27.25 -13.56 -3.24 -1.33 -0.45 -0.06 0.47 0.01
D5S2081 31.94 -6.19 -1.31 -0.6 -0.27 -0.09 0.5 0.03
D5S2031 42.23 -5.54 -0.7 -0.3 -0.12 -0.03 0.5 0
D5S674 56.71 -6.26 -1.28 -0.38 -0.02 0.08 0.402 0.08
D5S2021 61.33 -6.23 -0.81 -0.17 0.07 0.11 0.373 0.11
D5S628 71.14 0 0 0 0 0 0.1 0
D5S2072 80.82 0.42 0.35 0.28 0.2 0.11 0 0.42
D5S424 93.23 -0.01 -0.01 0 0 0 0.1 0
D5S1397 98.14 -5.47 -0.45 0.12 0.27 0.22 0.321 0.28
D5S1725 106.88 0.23 0.2 0.16 0.11 0.05 0 0.23
D5S409 114.89 -6.95 -1.34 -0.31 0.07 0.14 0.377 0.14
D5S2027 120.95 -8.51 0.05 0.29 0.26 0.12 0.227 0.3
D5S2065 122.49 -17.84 -2.41 -0.87 -0.2 0.05 0.432 0.06
D5S490 134.52 0.3 0.25 0.2 0.15 0.08 0 0.3
D5S2017 145.35 -13.23 -0.48 0.15 0.28 0.2 0.305 0.28
D5S2090 153.72 -9.21 -1.14 -0.35 -0.03 0.06 0.408 0.07
D5S410 162.45 -14.16 -2.58 -1.05 -0.38 -0.09 0.5 0
D5S2066 171.45 -6.6 -3.42 -1.67 -0.8 -0.3 0.5 0.21
D5S400 181.34 -18.48 -4.36 -2.23 -1.09 -0.41 0.5 0.19
D5S1973 184.16 0.4 0.34 0.27 0.19 0.1 0 0.4
D5S2069 194.4 -7.25 -2.01 -0.83 -0.29 -0.04 0.469 0
D5S469 203.46 -5.72 -1.59 -0.51 -0.08 0.06 0.413 0.06
D5S2006 211.06 -19.13 -2 -0.74 -0.22 -0.03 0.472 0
Table 7.9. Two-point lod scores for chromosome 5 in AE family
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Recomb nation fraction
Locus GeneticMap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D6S244 5.66 -7.22 -1.53 -0.58 -0.16 0.01 0.446 0.02
D6S1617 12.18 -9.36 -0.96 -0.21 0.05 0.08 0.365 0.08
D6S309 21.6 -13.56 -3.51 -1.62 -0.75 -0.31 0.5 0.79
D6S1279 30.35 -4.94 0.33 0.45 0.32 0.13 0.184 0.45
D6S422 44.68 -11.2 -2.23 -0.76 -0.2 -0.05 0.5 0.41
D6S1660 48.37 -8.7 -1.27 -0.15 0.18 0.13 0.5 0.06
D6S273 53.25 -12.04 -1.62 -0.75 -0.32 -0.09 0.5 0
D6S1575 63.69 -13.85 -3.44 -1.57 -0.7 -0.25 0.5 0.24
D6S459 72.59 -6.64 -1.64 -0.86 -0.44 -0.17 0.5 0.14
D6S452 74.58 -6.62 -0.89 -0.42 -0.19 -0.06 0.5 0.02
D6S1557 87.06 -13.86 -3.15 -1.37 -0.55 -0.16 0.5 0.02
D6S460 93.4 -13.76 -3.85 -1.76 -0.78 -0.26 0.5 0.09
D6S458 102.77 -9.07 -4.3 -2.14 -1.04 -0.4 0.5 0.26
D6S268 115.03 -19.38 -2.92 -1.3 -0.54 -0.16 0.5 0.03
D6S1712 123.79 -6.23 -2.66 -1.34 -0.65 -0.24 0.5 0.09
D6S1656 134.76 -14.63 -1.57 -0.5 -0.11 -0.03 0.5 0.44
D6S270 138.78 0.42 0.35 0.28 0.2 0.11 0 0.42
D6S1009 142.71 -15.87 -1.27 -0.12 0.21 0.16 0.328 0.23
D6S1637 154.79 -18.96 -2.02 -0.85 -0.32 -0.07 0.5 0
D6S441 164.5 -19.37 -2.16 -0.66 -0.11 0.02 0.5 0.02
D6S419 170.85 -15.34 -2.19 -0.85 -0.3 -0.09 0.5 0.1
D6S1581 174.43 -11.62 -1.24 -0.46 -0.17 -0.07 0.5 0.25
D6S305 176.93 -19.2 -3.31 -1.44 -0.59 -0.17 0.5 0.02
D6S1599 179.13 -19.28 -4.95 -2.39 -1.09 -0.37 0.5 0.08
D6S1277 180.81 -19.38 -4.96 -2.44 -1.18 -0.45 0.5 0.32
D6S297 187.65 -5.36 -0.6 -0.32 -0.17 -0.07 0.5 0.11
D6S503 190.17 -13.95 -5.25 -2.65 -1.28 -0.47 0.5 0.19
D6S446 194.22 -10.71 -2.36 -1.09 -0.51 -0.2 0.5 0.1
Table 7.10. Two-point lod scores for chromosome 6 in AE family
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Recombination fraction
Locus GeneticMap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D7S2474 3.71 -11.82 -1.91 -0.62 -0.1 0.07 0.418 0.07
D7S2201 12.21 -5.26 -0.34 -0.11 -0.02 0.01 0.416 0.01
D7S513 23.24 -14.22 -0.85 -0.2 0.05 0.1 0.381 0.1
D7S664 26.72 -4.54 0.38 0.46 0.38 0.22 0.184 0.46
D7S1795 38.61 -7.06 -0.06 0.21 0.21 0.11 0.247 0.23
D7S2463 40.51 -8.58 -1.17 -0.36 -0.04 0.06 0.41 0.06
D7S516 45.36 -17.55 -2 -0.52 0.06 0.19 0.388 0.19
D7S2250 55.9 -14.09 -0.32 0.23 0.35 0.26 0.3 0.35
D7S2541 63.45 -13.86 -2.65 -1.02 -0.3 0 0.448 0.04
D7S691 64.93 -7.03 -0.92 -0.13 0.15 0.17 0.361 0.18
D7S519 70.24 -5.93 -1.27 -0.38 -0.02 0.08 0.401 0.08
D7S2429 80.22 -8.18 -3.6 -1.62 -0.66 -0.17 0.5 0
D7S502 80.93 -11.21 -1.65 -0.68 -0.24 -0.04 0.474 0
D7S2500 83.71 -8.56 -1.26 -0.43 -0.09 0.03 0.427 0.03
D7S672 86.43 -17.46 -2.96 -1.12 -0.31 0.02 0.444 0.05
D7S2443 94.47 -17.44 -5.24 -2.69 -1.32 -0.49 0.5 0.27
D7S2485 100.34 -13.37 -0.67 0.02 0.2 0.16 0.323 0.2
D7S657 105.59 -23.06 -3 -1.21 -0.43 -0.09 0.5 0
D7S554 109.67 -7.47 -0.74 -0.44 -0.26 -0.1 0.5 0.02
D7S2509 114.48 -14.07 -2.94 -1.33 -0.56 -0.16 0.5 0
D7S2459 120.05 -12.63 -1.21 -0.24 0.05 0.06 0.5 0.08
D7S2418 122.15 -11 -1.54 -0.5 -0.08 0.06 0.416 0.06
D7S530 133.2 0 0 0 0 0 0.1 0
D7S2533 141.74 -18.81 -1.86 -0.62 -0.15 -0.01 0.463 0
D7S684 149.78 -19.04 -1.18 -0.26 0.03 0.04 0.5 0.04
D7S1824 152.03 -14.47 -2.19 -0.96 -0.37 -0.08 0.5 0
D7S661 155.04 -11.37 -2.44 -1.17 -0.52 -0.17 0.5 0.02
D7S1805 165.55 -13.83 -0.56 0.08 0.22 0.13 0.298 0.22
D7S2447 179.62 -6.11 -1.17 -0.68 -0.41 -0.2 0.5 0.82
D7S2423 192.24 -14.16 -2.89 -1.27 -0.54 -0.17 0.5 0.25
Table 7.11. Two-point lod scores for chromosome 7 in AE family
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Recombination :raction
Locus
Genetic
map 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D8S264 3.54 -10.46 -3.11 -1.25 -0.45 -0.1 0.5 0
D8S1819 16.91 -12.58 -2.81 -1.14 -0.38 -0.04 0.466 0.01
D8S520 21.48 -8.16 -1.6 -0.34 0.13 0.21 0.374 0.22
D8S516 22.5 -12.01 -1.81 -0.53 -0.04 0.1 0.404 0.1
D8S258 36.13 0.12 0.1 0.08 0.05 0.03 0 0.12
D8S1734 42.1 -2.83 1.17 1.1 0.85 0.48 0.118 1.18
D8S1820 49.17 -2.56 2.41 2.17 1.59 0.79 0.106 2.41
D8S505 55.98 -2.82 2.17 1.96 1.42 0.71 0.109 2.17
D8S1737 69.34 0.38 0.9 0.78 0.52 0.19 0.101 0.9
D8S1763 73.88 -2.23 2.05 1.74 1.22 0.56 0.078 2.06
D8S512 78.06 4.18 3.48 2.7 1.83 0.86 0 4.18
D8S279 86.52 -5.91 1.57 1.69 1.35 0.77 0.164 1.72
D8S1707 97.46 2.11 1.79 1.43 1.02 0.55 0 2.11
D8S1778 106.89 2.7 2.28 1.83 1.31 0.71 0 2.7
D8S1762 108.03 2.76 2.92 2.39 1.68 0.82 0.045 3.04
D8S1470 118.7 -3.01 1.36 1.23 0.93 0.52 0.104 1.36
D8S1799 131.69 -13.51 -0.23 0.44 0.54 0.36 0.278 0.54
D8S1793 135.13 -4.8 -1.4 -0.21 0.19 0.23 0.359 0.25
D8S263 141.47 -4.4 -0.87 -0.21 0.04 0.09 0.384 0.09
D8S1746 150.11 -10.46 -2.56 -0.96 -0.26 0.01 0.444 0.04
D8S1783 152.34 -10.17 -2.48 -0.9 -0.23 0.02 0.439 0.04
D8S274 153.61 -11.07 -1.28 -0.1 0.28 0.28 0.347 0.32
D8S1743 160.11 -6.81 -0.61 -0.11 0.02 0.02 0.5 0.37
Table 7.12. Two-point lod scores for chromosome 8 in AE family
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Recom bination fraction
Locus GeneticMap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D9S1779 0 -17.54 -5.83 -3.02 -1.54 -0.63 0.5 0.97
D9S1686 11.93 0 0 0 0 0 0.1 0
D9S286 18.53 -14.18 -2.8 -1.22 -0.51 -0.17 0.5 0.05
D9S168 24.28 -13.86 -1.41 -0.24 0.12 0.09 0.5 0.5
D9S1808 28.24 -14.17 -0.6 -0.09 0.02 -0.02 0.5 0.63
D9S235 32.65 -5.05 -0.7 -0.4 -0.22 -0.1 0.5 0.29
D9S171 47.16 -7.68 -0.67 -0.08 0.13 0.13 0.354 0.15
D9S2149 55.3 -13.55 0.09 0.62 0.6 0.29 0.238 0.66
D9S1777 67.34 2.14 1.78 1.37 0.9 0.37 0 2.14
D9S1876 70.42 -12.83 0.9 1.14 0.92 0.45 0.189 1.14
D9S175 72.8 -6.66 -0.68 -0.09 0.12 0.13 0.357 0.15
D9S1843 79.87 -5.75 -1.73 -0.89 -0.45 -0.18 0.5 0.14
D9S307 89.23 -13.42 -0.28 0.47 0.54 0.29 0.5 0.04
D9S283 95 -5.79 -0.17 0.12 0.14 0.06 0.5 0.16
D9S287 101.54 -14.1 -2.43 -1.16 -0.52 -0.16 0.5 0.02
D9S261 114.65 -6.35 -2.79 -1.38 -0.67 -0.26 0.5 0.16
D9S1675 117.44 -17.35 -2 -0.87 -0.35 -0.1 0.5 0
D9S1828 117.67 -7.7 -0.85 0.01 0.25 0.2 0.328 0.26
D9S1824 123.56 -13.86 -2.76 -1.2 -0.49 -0.15 0.5 0.03
D9S934 127.72 -9.36 -2.2 -0.85 -0.25 0 0.45 0.03
D9S1682 132.09 -17.85 -3.16 -1.3 -0.44 -0.06 0.47 0.01
D9S1825 136.35 - 11.11 -1.86 -0.58 -0.06 0.1 0.408 0.1
D9S1830 149.36 -5.74 -0.29 0.04 0.13 0.11 0.321 0.13
D9S1793 150.42 -13.62 -1.17 -0.18 0.17 0.2 0.36 0.21
D9S1838 164.1 -9.41 -1.78 -0.56 -0.09 0.06 0.42 0.06
Table 7.13. Two-point lod scores for chromosome 9 in AE family
264
Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D10S249 1.19 -5.4 -0.05 0.18 0.16 0.05 0.5 0.25
D10S602 5.71 -18.71 0.13 0.66 0.64 0.33 0.242 0.69
D10S1218 11.3 0 0 0 0 0 0.1 0
D10S189 20.56 -11.99 -1.86 -0.6 -0.09 0.07 0.415 0.07
D10S1649 26.55 -12.5 -3.37 -1.47 -0.57 -0.14 0.5 0
D10S1430 32.11 -14.06 -2.89 -1.24 -0.47 -0.11 0.5 0
D10S570 32.73 -17.56 -2.56 -1.01 -0.35 -0.07 0.5 0
D10S191 37.42 -17.66 -4.31 -2.09 -0.98 -0.35 0.5 0.16
D10S1653 38.92 -12.39 -4.38 -2.12 -0.99 -0.34 0.5 0.11
D10S1661 41.4 -14.06 -4.45 -2.2 -1.05 -0.38 0.5 0.15
D10S600 54.33 -13.56 -5.35 -2.72 -1.33 -0.49 0.5 0.21
D10S1746 65.42 -13.45 -5.07 -2.57 -1.26 -0.47 0.5 0.25
D10S196 71.95 -13.38 -3.93 -1.98 -0.98 -0.38 0.5 0.24
D10S609 82.33 0 0 0 0 0 0.1 0
D10S537 91.46 -7.6 -5.49 -3.02 -1.6 -0.66 0.5 0.78
D10S580 97.94 -13.56 -6.03 -3.18 -1.63 -0.65 0.5 0.57
D10S1677 100.72 -6.16 -4.42 -2.22 -1.11 -0.48 0.5 1.38
D10S1753 113.42 -3.7 0.32 0.5 0.39 0.17 0.199 0.5
D10S185 116.07 -13.95 -3.2 -1.38 -0.58 -0.23 0.5 0.9
D10S1267 125.15 -5.78 -1.16 -0.23 0.06 0.04 0.5 0.43
D10S597 129.57 0.89 0.76 0.61 0.44 0.24 0 0.89
D10S1693 141.5 -13.73 -0.86 0.04 0.26 0.19 0.316 0.26
D10S1656 154.8 -13.81 -2.09 -0.88 -0.33 -0.08 0.5 0
D10S575 160.19 -6.11 -0.19 0.11 0.14 0.05 0.5 0.14
D10S1676 164.6 -6.66 -1 -0.49 -0.23 -0.08 0.5 0.02
D10S1651 176.24 -19.25 -4.01 -1.82 -0.76 -0.21 0.5 0
D10S212 181.66 -8.75 -2.45 -0.95 -0.29 -0.02 0.459 0.02
Table 7.14. Two-point lod scores for chromosome 10 in AE family
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Recom bination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D11S4046 0 -6.47 -1.61 -0.41 0.02 0.1 0.389 0.11
D11S1760 8.79 -4.45 -0.99 -0.36 -0.13 -0.04 0.5 0.06
D11S1331 12.38 -6.68 -1.19 -0.48 -0.16 -0.02 0.468 0
D11S4170 23.4 -11.85 -2.39 -1.13 -0.5 -0.15 0.5 0.02
D11S902 26.23 -6.17 -1.35 -0.22 0.13 0.12 0.341 0.16
D11S928 34.9 -4.34 -0.11 0.07 0.11 0.08 0.303 0.11
D11S4080 43.29 -18.89 -1.84 -0.62 -0.16 -0.03 0.5 0.03
D11S1776 49.46 -5.49 -0.61 -0.3 -0.14 -0.06 0.5 0.07
D11S1360 58.18 -6.93 -1.56 -0.79 -0.41 -0.16 0.5 0.07
D11S4191 66.18 -10.19 -1.53 -0.66 -0.3 -0.14 0.5 0.54
D11S4087 73.81 -4.87 -0.1 0.12 0.1 0.03 0.5 0.03
D11S937 85.42 -18.67 -2.23 -1.06 -0.52 -0.23 0.5 0.75
D11S1780 94.12 -9.74 -0.66 -0.19 0 0.05 0.395 0.05
D11S1886 107.71 -6.77 -0.44 -0.09 0 0.01 0.5 0.1
D11S4206 110.81 0.07 0.07 0.07 0.06 0.04 0.06 0.07
D11S908 118.66 -7.84 0.07 0.45 0.42 0.22 0.236 0.47
D11S4089 126.83 -6.17 -1.41 -0.24 0.13 0.14 0.353 0.17
D11S4151 135.73 -12.01 -1.04 -0.29 -0.05 -0.02 0.5 0.27
D11S2367 148.23 -10.13 -1.47 -0.57 -0.19 -0.04 0.5 0
D11S969 154.38 -13.73 -3.38 -1.43 -0.52 -0.09 0.481 0
Table 7.15. Two-point lod scores for chromosome 11 in AE family
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Recombination raction
Locus Geneticmap 0.0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D12S352 0.68 -13.33 -0.8 -0.17 0.03 0.05 0.359 0.06
D12S1656 4.23 0 0 0 0 0 0.1 0
D12S372 8.63 -12.74 -1.66 -0.64 -0.22 -0.06 0.5 0.01
D12S374 16.84 -14.38 -1.07 -0.2 0.07 0.08 0.355 0.1
D12S336 24.76 -4.14 0.23 0.34 0.3 0.18 0.211 0.34
D12S364 31.97 -14.06 -1.1 -0.18 0.14 0.17 0.36 0.18
D12S1591 44.81 -12.93 -0.48 0.15 0.29 0.21 0.305 0.28
D12S1337 51.8 -6.96 -0.74 -0.25 -0.13 -0.08 0.5 0.11
D12S1704 52.93 -7.33 -0.24 0.2 0.28 0.2 0.29 0.28
D12S85 61.77 -8.44 -0.58 -0.04 0.14 0.13 0.343 0.15
D12S368 67.92 -23.07 -2.3 -0.79 -0.17 0.05 0.428 0.06
D12S83 75.48 -18.88 -2.3 -0.79 -0.17 0.05 0.428 0.06
D12S1294 83.69 -12.64 -3.32 -1.61 -0.75 -0.27 0.5 0.09
D12S326 92.97 -13.23 -5.8 -2.92 -1.41 -0.51 0.5 0.2
D12S351 103.1 -0.01 -0.01 -0.01 0 0 0.5 0
D12S95 104.42 -11.05 -3.58 -1.89 -0.96 -0.38 0.5 0.28
D12S1346 106.03 -10.65 -1.48 -0.6 -0.26 -0.1 0.5 0.05
D12S2081 110.59 -5.77 -3.18 -1.58 -0.75 -0.27 0.5 0.09
D12S1636 120.17 -19.02 -4.4 -2.28 -1.13 -0.42 0.5 0.21
D12S1613 124.08 -4.26 -0.06 0.09 0.11 0.08 0.282 0.11
D12S1583 127.22 -18.43 -3.92 -1.89 -0.88 -0.3 0.5 0.1
D12S354 133.66 -3.72 -0.89 -0.39 -0.15 -0.04 0.5 0
D12S369 134.33 -17.21 -3.93 -1.73 -0.68 -0.16 0.5 0
D12S366 140.32 -10.67 -2.6 -1.3 -0.62 -0.22 0.5 0.08
D12S2073 144.14 -6.81 -2.1 -0.92 -0.37 -0.1 0.5 0
D12S2078 155.99 -6.6 -1.18 -0.34 0 0.09 0.397 0.09
D12S1609 160.72 -7.49 -0.98 -0.34 -0.07 0.03 0.422 0.03
D12S1723 173.29 -12.62 -2.95 -1.19 -0.42 -0.09 0.5 0
Table 7.16. Two-point lod scores for chromosome 12 in AE family
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Recom Dination fraction
Locus GeneticMap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D13S175 3.24 -14.25 -3.85 -1.91 -0.92 -0.33 0.5 0.1
D13S232 8.98 -9.67 -2.88 -1.38 -0.66 -0.25 0.5 0.25
D13S1243 11.57 0.12 0.1 0.07 0.05 0.03 0 0.12
D13S221 16.88 -12.31 -2.11 -1.21 -0.71 -0.31 0.5 0.3
D13S217 22.89 -14.19 -1.28 -0.46 -0.15 -0.06 0.5 0.21
D13S289 28.14 -7.26 -2.33 -1.26 -0.67 -0.27 0.5 0.32
D13S171 31.99 -14.45 -5.32 -2.83 -1.42 -0.55 0.5 0.34
D13S219 36.49 -8.89 -4.07 -1.92 -0.86 -0.28 0.5 0.05
D13S218 40.44 -11.1 -4.5 -2.36 -1.14 -0.42 0.5 0.17
D13S272 54.31 -7.07 -4.16 -2.15 -1.12 -0.48 0.5 1.26
D13S279 65.83 -13.78 -3.51 -1.62 -0.74 -0.28 0.5 0.35
D13S271 80.33 -11.49 -5.86 -3.11 -1.61 -0.68 0.5 1.35
D13S1241 91.34 -11.36 -4.14 -2.18 -1.12 -0.44 0.5 0.36
D13S1256 100.66 -17.75 -3.72 -1.73 -0.75 -0.22 0.5 0.02
D13S1809 107.62 -18.73 -2.17 -0.97 -0.39 -0.1 0.5 0
D13S1315 119 -13.51 -3.05 -1.36 -0.55 -0.14 0.5 0
D13S293 131.92 1A 2.04 1.63 1.16 0.63 0 2.4
Table 7.17. Two-point lod scores for chromosome 13 in AE family
Recom bination Taction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Z max
D14S261 9.53 -11.3 -3.41 -1.5 -0.59 -0.14 0.5 0
D14S1043 9.83 -9.71 -0.97 -0.28 -0.05 0 0.5 0
D14S1280 23.04 -7.41 -0.41 0.27 0.44 0.33 0.301 0.44
D14S262 25.73 -7.68 -0.52 0.05 0.22 0.19 0.333 0.23
D14S1071 29.19 -13.06 -1.95 -0.49 0.07 0.2 0.386 0.2
D14S741 35 -13.56 -1.95 -0.49 0.07 0.2 0.383 0.2
D14S70 37.63 -11.31 -1.89 -0.89 -0.39 -0.12 0.5 0.01
D14S75 43.2 -12.75 -1.37 -0.33 0.07 0.15 0.385 0.15
D14S976 46.8 -7.54 0.22 0.55 0.51 0.3 0.228 0.56
D14S978 51.44 -17.59 -1.41 -0.28 0.07 0.09 0.355 0.11
D14S276 57.33 -13.45 -2.25 -0.79 -0.2 0.01 0.443 0.03
D14S1011 70.01 -13.26 -4.15 -1.97 -0.89 -0.3 0.5 0.06
D14S258 70.4 -13.38 -4.15 -1.97 -0.89 -0.3 0.5 0.06
D14S1433 74.94 -7.87 -1.64 -0.84 -0.46 -0.2 0.5 0.13
D14S616 85.45 -11.32 -1.94 -0.99 -0.49 -0.19 0.5 0.1
D14S67 88.68 -6.37 -2.76 -1.48 -0.78 -0.32 0.5 0.25
D14S1044 92.86 -16.95 -4.11 -2.18 -1.12 -0.44 0.5 0.33
D14S81 99.25 -17.07 -2.25 -0.99 -0.39 -0.09 0.5 0
D14S1054 102.52 -17.21 -2.26 -0.99 -0.39 -0.09 0.5 0
D14S987 106.22 -12.01 -1.54 -0.59 -0.17 0.01 0.446 0.02
D14S1019 109.31 -17.26 -2.26 -1 -0.39 -0.09 0.5 0
D14S1426 117.81 -5.05 -0.71 -0.4 -0.23 -0.1 0.5 0.3
D14S542 126.06 -19.38 -3.31 -1.41 -0.54 -0.13 0.5 0
Table 7.18. Two-point lod scores for chromosome 14 in AE family
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Recomb nation fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D15S128 6.06 -11.7 -4.25 -2.04 -0.95 -0.35 0.5 0.2
D15S975 13.46 -13.73 -1.6 -0.69 -0.3 -0.11 0.5 0.14
D15S1019 21.44 -19.08 -3.11 -1.26 -0.48 -0.16 0.5 0.28
D15S165 23.51 -14.45 -1.53 -0.58 -0.16 0.01 0.5 0.02
D15S231 27.43 -7.29 -0.32 0 0.09 0.08 0.333 0.09
D15S118 35.23 -13.81 -2.18 -1 -0.47 -0.19 0.5 0.56
D15S1012 39.39 -9.31 -0.97 -0.02 0.26 0.23 0.338 0.28
D15S146 43.14 -12.23 0.07 0.6 0.6 0.37 0.247 0.64
D15S1016 52.71 -4.88 -0.77 -0.24 -0.02 0.04 0.408 0.04
D15S117 58.09 -11.94 -1.65 -0.41 0.05 0.15 0.386 0.15
D15S988 70.39 0.42 0.35 0.28 0.2 0.11 0.001 0.42
D15S114 82.51 -9.83 -1.31 -0.5 -0.17 -0.04 0.5 0
D15S1005 86.82 -9.25 -0.55 0.13 0.29 0.22 0.313 0.29
D15S158 100.89 -7.35 -0.79 -0.31 -0.1 -0.01 0.46 0
D15S1004 110.96 -13.56 -4.07 -1.85 -0.78 -0.22 0.5 0.01
D15S130 111.55 -14.46 -2.42 -1.03 -0.39 -0.09 0.5 0
D15S816 114.36 -7.35 -3.3 -1.69 -0.85 -0.33 0.5 0.32
D15S157 116.14 -9.08 -2.46 -1.03 -0.36 -0.06 0.5 0
D15S212 124.08 -12.84 -4.52 -2.35 -1.19 -0.46 0.5 0.3
D15S120 130.4 -13.98 -2.72 -1.13 -0.44 -0.13 0.5 0.07
Table 7.19. Two-point lod scores for chromosome 15 in AE family
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D16S521 1.15 -13.68 -3 -1.37 -0.61 -0.21 0.5 0.4
D16S3065 10.64 -8.31 -0.27 0.17 0.24 0.16 0.282 0.25
D16S423 14.97 -9.17 -3.44 -1.7 -0.8 -0.28 0.5 0.08
D16S418 20.61 -13.83 -3.94 -1.77 -0.72 -0.19 0.5 0
D16S3062 32.07 -8.83 -3.38 -1.45 -0.54 -0.1 0.5 0
D16S500 33.31 -5.93 -2.43 -1.16 -0.52 -0.17 0.5 0.02
D16S410 41.83 -13.81 -4.53 -2.25 -1.08 -0.39 0.5 0.19
D16S3068 51.27 -8.16 -3.31 -1.47 -0.61 -0.18 0.5 0.02
D16S3080 61.1 -5.79 -0.88 -0.42 -0.2 -0.08 0.5 0.08
D16S3034 68.27 -14.16 -4.37 -2.11 -0.96 -0.31 0.5 0.08
D16S3057 76.36 -17.55 -4.81 -2.3 -1.03 -0.33 0.5 0.05
D16S514 83.1 -14.16 -4.49 -2.22 -1.05 -0.38 0.5 0.16
D16S503 84.26 -13.96 -3.8 -1.86 -0.89 -0.32 0.5 0.12
D16S515 94.69 -10.31 -3.51 -1.73 -0.81 -0.28 0.5 0.08
D16S516 101.24 -7.35 -0.96 -0.32 -0.05 0.03 0.416 0.04
D16S505 108.07 -13.77 -2.7 -1.14 -0.42 -0.09 0.5 0
D16S763 120.63 -13.45 -0.93 -0.35 -0.12 -0.03 0.5 0
D16S2621 131.46 -13.45 -1.37 -0.55 -0.21 -0.05 0.5 0
Table 7.20. Two-point lod scores for chromosome 16 in AE family
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Recomb nation fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
Max Zmax
D17S849 0.63 -6.49 -0.84 -0.19 0.05 0.1 0.379 0.1
D17S831 7.47 -13.86 -2.38 -0.84 -0.18 0.05 0.429 0.06
D17S1832 16.79 -5.86 -0.68 -0.07 0.14 0.14 0.355 0.16
D17S804 28.96 -4.78 1.41 1.29 0.98 0.56 0.107 1.41
D17S799 37.94 -4.65 0.69 0.85 0.73 0.44 0.195 0.85
D17S922 41.55 -5.11 0.27 0.5 0.46 0.28 0.228 0.5
D17S839 43.77 -0.59 0.1 0.19 0.16 0.09 0.214 0.19
D17S1824 53.22 -4.68 0.01 0.17 0.18 0.12 0.267 0.2
D17S2194 58.94 0.83 0.7 0.51 0.3 0.12 0 0.83
D17S1867 66.96 -11.79 -3.1 -1.3 -0.51 -0.14 0.5 0.02
D17S1299 71.13 0 0 0 0 0 0.1 0
D17S1868 76.3 -13.85 -3.13 -1.56 -0.74 -0.26 0.5 0.08
D17S1795 77.3 -5.8 -3.12 -1.55 -0.74 -0.26 0.5 0.08
D17S957 89.64 -8.1 -1.18 -0.48 -0.16 -0.02 0.468 0
D17S794 94.36 -6.14 -2.18 -1.12 -0.55 -0.21 0.5 0.11
D17S944 95.11 -5.26 -2.25 -1.17 -0.59 -0.23 0.5 0.14
D17S940 102.6 -7.97 -2.15 -0.95 -0.37 -0.09 0.5 0
D17S1351 108.83 -5.93 -1.22 -0.35 -0.01 0.09 0.399 0.09
D17S1603 117.82 -14.77 -2.52 -0.95 -0.26 0.01 0.444 0.04
D17S1847 126.71 -9.67 -1.69 -0.61 -0.14 0.04 0.431 0.04
D17S836 128.03 0.12 0.1 0.08 0.05 0.03 0 0.12
D17S784 132.74 -8.08 -1 -0.21 0.08 0.13 0.37 0.13
Table 7.21. Two-point lod scores for chromosome 17 in AE family
Recombinaton fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D18S1105 3.97 -4.65 0.64 0.83 0.72 0.44 0.202 0.83
D18S63 9.84 -10.16 -0.73 0.13 0.34 0.26 0.314 0.35
D18S967 21.74 -13.91 -0.85 -0.02 0.21 0.18 0.334 0.22
D18S464 33.37 -6.12 -1.39 -0.58 -0.23 -0.07 0.5 0
D18S1107 47.29 -12.6 -3 -1.21 -0.43 -0.09 0.5 0
D18S877 54.03 -3.65 0.81 0.66 0.36 0.09 0.098 0.81
D18S1102 59.89 -14.39 -4.85 -2.44 -1.2 -0.46 0.5 0.36
D18S474 68.99 -12.12 -3.49 -1.85 -0.95 -0.38 0.5 0.32
D18S450 70.78 -17.38 -4.15 -1.99 -0.93 -0.34 0.5 0.2
D18S64 77.54 -12.33 -3.84 -1.96 -0.95 -0.34 0.5 0.13
D18S1134 87.2 -7.4 -3.46 -1.59 -0.71 -0.25 0.5 0.1
D18S1147 88.5 -13.68 -4.62 -2.31 -1.1 -0.39 0.5 0.13
D18S465 92.91 -13.86 -4.43 -2.23 -1.11 -0.43 0.5 0.32
D18S469 106.38 -8.7 -2.02 -0.86 -0.32 -0.06 0.485 0
D18S554 117.94 -12.03 -3.2 -1.39 -0.56 -0.17 0.5 0.02
Table 7.22. Two-point lod scores for chromosome 18 in AE family
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Recomb nation fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D19S886 0.9 -17.55 -1.81 -0.53 -0.01 0.13 0.399 0.13
D19S591 10.59 -14.39 -2 -0.52 0.06 0.19 0.388 0.19
D19S427 20.75 -17.55 -2.52 -0.98 -0.32 -0.04 0.473 0
D19S584 33.17 -12.95 -0.77 -0.04 0.19 0.18 0.344 0.2
D19S226 37.98 -19.03 -2.47 -1.05 -0.43 -0.14 0.5 0.04
D19S593 43.02 -7.15 -2.81 -1.38 -0.68 -0.27 0.5 0.22
D19S414 55.81 -7.59 0.05 0.46 0.48 0.31 0.254 0.49
D19S208 63.1 -14.58 -1.58 -0.61 -0.24 -0.09 0.5 0.26
D19S903 73.21 -22.89 -3 -1.21 -0.43 -0.09 0.5 0
D19S867 84.6 -13.56 -3.12 -1.28 -0.44 -0.06 0.469 0.013
DG19S186 92.14 -11.42 -1.79 -0.83 -0.36 -0.11 0.5 0.015
D19S572 99.88 -11.39 -2.39 -1.28 -0.67 -0.27 0.5 0.31
D19S418 107.71 -14.4 -2.95 -1.12 -0.31 0.02 0.444 0.05
D19S605 108.45 -5.05 -0.7 -0.4 -0.22 -0.1 0.5 0.3
D19S573 113.23 0.06 0.05 0.04 0.03 0.01 0.001 0.06
Table 7.23. Two-point lod scores for chromosome 19 in AE family
Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D20S113 7.68 -5.11 -0.79 -0.31 -0.1 -0.01 0.463 0
D20S882 18.3 -12.03 -1.69 -0.66 -0.23 -0.05 0.5 0
D20S115 25.35 -12.99 -1.3 -0.3 0.07 0.14 0.376 0.14
D20S189 34.88 -0.01 -0.01 -0.01 0 0 0.471 0
D20S904 42.54 -13.18 -1.03 -0.22 0.06 0.11 0.375 0.11
D20S912 52.19 -14.16 -3.3 -1.41 -0.54 -0.13 0.5 0
D20S859 60.73 0.77 0.65 0.53 0.38 0.21 0 0.77
D20S107 63.19 -14.04 -2.92 -1.29 -0.53 -0.15 0.5 0
D20S108 65.64 -17.55 -2.96 -1.12 -0.31 0.02 0.44 0.05
D20S481 70.97 -13.86 -2.96 -1.12 -0.31 0.02 0.44 0.05
D20S838 71.23 -8.77 -1.88 -0.76 -0.26 -0.03 0.469 0
D20S178 75.47 -8.01 -0.58 0.02 0.2 0.18 0.337 0.21
D20S1083 83.33 -6.86 -0.27 0.06 0.14 0.1 0.311 0.14
D20S100 90.85 -12.59 -0.65 0.21 0.42 0.32 0.312 0.42
D20S171 100.84 -8.66 -1.36 -0.51 -0.17 -0.03 0.484 0
Table 7.24. Two-point lod scores for chromosome 20 in AE family
271
Recombination fraction
Locus
Genetic
map 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D21S1904 7.23 0 0 0 0 0 0.1 0
D21S1432 8.75 -5.06 1.15 1.27 0.99 0.52 0.168 1.29
D21S1899 16.2 -12.75 -2.56 -1.02 -0.37 -0.11 0.5 0.08
D21S1905 17.29 -7.55 -1.15 -0.25 0.03 0.05 0.358 0.06
D21S1902 19.54 -5.05 -0.7 -0.4 -0.22 -0.1 0.5 0.03
D21S272 23.96 0 0 0 0 0 0.1 0
D21S1442 29.5 -17.85 -3.26 -1.41 -0.58 -0.17 0.5 0.03
D21S1909 33.81 -13.69 -3.43 -1.78 -0.89 -0.34 0.5 0.22
D21S1898 38.62 -13.79 -3.26 -1.64 -0.8 -0.29 0.5 0.12
D21S1895 41.37 -13.6 -2.48 -1.18 -0.53 -0.17 0.5 0.02
D21S1252 44.04 -13.85 -3.19 -1.59 -0.76 -0.27 0.5 0.09
D21S1919 45.79 -13.85 -3.18 -1.58 -0.75 -0.27 0.5 0.09
D21S270 46.25 -13.17 -3.18 -1.58 -0.75 -0.27 0.5 0.09
D21S1255 48.28 0.3 0.25 0.2 0.14 0.08 0 0.31
D21S266 57.33 -8.16 -1.26 -0.53 -0.19 -0.03 0.477 0
Table 7.25. Two-point lod scores for chromosome 21 in AE family
Recombination fraction
Locus Geneticmap 0 0.1 0.2 0.3 0.4
Theta
max Zmax
D22S420 5.72 -14.35 -0.45 0.18 0.28 0.16 0.282 0.28
D22S427 6 0.29 0.25 0.2 0.14 0.08 0 0.29
D22S539 15.82 -10.46 -2.61 -1.01 -0.32 -0.03 0.461 0.02
D22S1174 20.03 -9.23 -2.3 -0.91 -0.31 -0.06 0.5 0
D22S315 23.91 -8.44 -3.61 -1.63 -0.66 -0.17 0.5 0
D22S1154 25.73 -13.68 -4.11 -1.9 -0.81 -0.23 0.5 0.01
D22S531 36.2 -6.68 -1.01 -0.5 -0.24 -0.09 0.5 0.04
D22S1265 40.84 -10.01 -2.83 -1.34 -0.59 -0.18 0.5 0.02
D22S276 51.21 -12.99 -2.18 -0.96 -0.37 -0.09 0.497 0
D22S928 59.39 -17.8 -1.48 -0.31 0.09 0.15 0.372 0.16
D22S1170 68.42 -4.68 0.02 0.18 0.18 0.12 0.251 0.19
Table 7.26. Two-point lod scores for chromosome 22 in AE family
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Appendix 4.
Papers published
Here I am annexin three published papers in addition to a manuscript submitted to Am 
J Med Genet.
The paper “A Novel Cys212Tyr founder in parkin and allelic heterogeneity of juvenile 
parkinsonism in a population from North West Colombia” was not part of my PhD but 
it is included as it was basic to the chapter on PARK2 and early onset Parkinson 
disease.
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ABSTRACT
Background A parkin Cys212Tyr substitution due to a G736A mutation has been 
observed in two early onset PD families from the province of Antioquia in North West 
Colombia and (independently) in one family from Spain. Microsatellite haplotype 
analysis indicates that point mutations of parkin represent unique events, suggesting that 
sharing of these mutations across populations is due to migration or common ancestry.
Objective To assess the extent of the founder effect for the G736A mutation in Antioquia 
and the possible introduction of this mutation through migration from Spain.
Methods We ascertained 7 additional Antioquian early onset PD cases (from 5 nuclear 
families) and screened for parkin mutations with a restriction assay recognizing the 
G736A substitution, SSCP and exon dosage. We carried out a haplotype analysis using 
11 microsatellites in the parkin region and estimated the time since introduction of the 
G736A mutation in Antioquia based on the frequency of recombinant haplotypes.
Results Genealogical investigations allowed the identification of recent connections 
between 6 of the 7 Colombian families examined. The 7 new juvenile PD cases identified 
carry the G736A mutation, 4 in homozygous form. The three heterozygous patients also 
carry a duplication of exon 3. All Colombian patients with the parkin G736A mutation 
share a core haplotype for markers <lcM away from the mutation. The estimated age for 
' the G736A substitution in Antioquia is 15 generations. In the Spanish family, this 
mutation is present in a different microsatellite haplotype.
Conclusions An extensive founder effect for the G736A mutation has been documented 
in Antioquia. So far 13 carriers of the mutation (10 homozygotes) from 7 nuclear families 
have been confirmed. A second parkin mutation (a duplication of exon 3), is present in 
the three G736A heterozygote carriers. Haplotype analysis excludes a recent relationship 
between the Colombian and Spanish patients studied and is consistent with the 
introduction of this mutation in early colonial times.
Introduction
We previously reported the finding of a parkin Cys212Tyr substitution in JPD 
patients from Antioquia in North-West Colombia (Pineda-Trujillo et al. 2001). This 
aminoacid substitution is caused by a G to A transition at position 736 (G736A) of the 
parkin cDNA. Patients homozygous for this mutation were observed in two unrelated 
Antioquian families, pointing to the occurrence of a founder effect in this region. This 
same G736A mutation was subsequently reported in one Spanish family (Hoenicka et al. 
2002). Since the population of Antioquia is mostly of Spanish ancestry (Carvajal- 
Carmona et al. 2003) and as previous surveys suggest that point mutations of parkin are 
unique events (Periquet et al. 2001), the identification of the G736A mutation in Spain 
suggests that this mutation could have been taken to Antioquia by Spanish migrants. This 
could have resulted in a founder effect due to the genetic isolation of Antioquia.
Here we report the molecular characterization of 7 additional Antioquian early 
onset PD cases (from 5 nuclear families) and of the single Spanish family available with 
the parkin G736A mutation. An extensive founder effect in Antioquia has been 
evidenced with a total of 14 carriers of the C736A mutation identified so far. The analysis 
of all available cases with the G736A substitution is consistent with the introduction of 
this mutation early in colonial times. A nuclear family with an apparent dominant 
transmission of early onset PD was identified but this was explained by the segregation of 
a second mutation (a duplication of exon 3) in this isolated population.
Methods
Patients
Patients presented with parkin sonism (bradikynesia, rigidity and resting tremor) before 
45 years of age and had a good response to levodopa. In cases not available for 
examination, affection status was inferred from a review of clinical records or family 
interview. Diagnosis was confirmed by neuropathological analysis of one case (a detailed 
description of clinical and pathological findings of the patients studied is given in 
Moreno et al submitted).
Mutation screening
The G736A mutation was tested using a mismatched primer introducing a site for 
restriction enzyme Ndel 5TCTTTCAGGAATTTTTCTTTACAT3’ (Pineda-Trujillo et 
al, 2001). The reverse primer was Exon 6R as described (Kitada et al. 1998). PCRs were 
performed in a final volume of 25 microlitters with 30-100 ng/pL of genomic DNA, 0.33 
pM of each primer, IX of Qiagen HotStarTaq Master Mix Kit. PCR conditions included 
94o 15’ of initial denaturing followed by 10 cycles of 94ol5”, 48ol5” and 72o30”; then 
20 cycles of 89ol5”, 48ol5” and 72o30”, followed by a final elongation step of 72ol0\ 
Restriction digestion was performed overnight using 5-10 units per sample according to 
manufacturer specifications (New England Biolabs). Restriction fragments were run in a 
3.5% agarose ethidium-bromide gel. For single strand conformational polymorphism 
(SSCP) screening all exons were amplified as reported by Kitada et al. 1998 and PCR 
products run in 10% non-denaturing polyacrylamide gels followed by standard silver 
Staining. Exon dosage was carried out as described in(West et al. 2002).
Microsatellite marker typing
Eleven microsatellite markers (D6S255, D6S437, D6S1581, D6S1579, D6S1550, 
D6S253, D6S305, D6S980, D6S1599, D6S1277, D6S386) were typed in the parkin gene 
region (Figure 1). These were amplified in a final volume of 10 pL using 30-100 ng/DL 
of genomic DNA, 0.33pM of each primer and lx of Qiagen HotStarTaq Master Mix Kit. 
PCR conditions were as follows: 94ol5’ followed by 5 cycles of94o30” 58o30” and 
72o30”; then 26 cycles of 89ol5”56ol5”72o30” and a final extension at 72o for 10 min. 
Allelic sizes were determined using Genescan 2.1 and Genotyper 3.5 software (Applied 
Biosystems).
Data analysis
Haplotypes were reconstructed using the Simwalk2 program (Sobel and Lange 1996).
The age since the introduction of the mutation was estimated based on the frequency of 
recombinants (Reich and Goldstein 1999). According to this method, G = -ln(P)/M where 
G is time in generations since the introduction of the mutation, P the proportion of non­
recombinant chromosomes (taking the most frequent haplotype as the ancestral) and M 
the genetic distance between marker and mutation. The recombination rate on both sides 
of the G736A mutation varies greatly (Figure 1). In the region 3’ from the mutation (in 
the sense of transcription) current genetic maps do not show evidence of recombination 
between markers D6S1579 and D6S305, covering an interval of about 1.2Mb. Further 
downstream, recombination rate is about average for the genome (-IMb/cM). The 
interval between markers D6S305 and D6S980, which overlaps the mutation, has an 
estimated genetic distance of -1.4 cM for a physical distance o f-461,336 bp
(~329,526bp/cM). The rate of recombination increases sharply between markers D6S980 
and D6S1599 (upstream of the mutation), which are 182,972bp apart but separated by a 
distance of 6.7cM on the genetic map (~27,309bp/cM).
Results
Genealogical investigations identified some common ancestors between 6 of the 7 
Antioquian early onset PD families (Figure 2). In one of the nuclear families there 
appears to be vertical transmission of PD as individual VI:2 is affected and her mother 
(V:9) and two sibs of the mother (V:7 and V:8) are also affected (Figure 2).
Mutation screening identified the G736A mutation in all available affected 
individuals (Figure 2). In all but three patients (V:l, V:12 and VI:2), the mutation is 
present in homozygous form. One of these patients (VI:2) is a member of the family 
showing vertical transmission of early onset PD. Carrier status for the G736A mutation 
was confirmed in unaffected members of several families.
Microsatellite analysis identified a core haplotype consisting of alleles 3, 3, 1 at 
markers D6S1550, D6S253 and D6S305 respectively (Figures 1 and 3). This core 
haplotype is shared by all Antioquian PD patients, including individuals from the single 
family with no documented connection to the other pedigrees (Figures 3 and 4). The 
G736A mutation in the Spanish PD family is present in a microsatelllite haplotype that 
differs from that observed in Antioquia at all the markers examined (Figure 4).
The three patients heterozygous for the G736A mutation (V:l V:12 and VI:2) 
share the microsatellite haplotype associated with this mutation and a second haplotype 
characterized by alleles 5,2, 3, 2,4 at markers D6S253, D6S305, D6S980, D6S1599 and
D6S1277 (Figure 2). An unaffected individual (VI:4), currently aged 20, also carries 
these two haplotypes. SSCP and sequencing of parkin exons did not identify other point 
mutations but exon dosage detected an exon 3 duplication in these individuals.
The two microsatellite flanking markers nearest to the G736A mutation that show 
evidence of recombination with the mutation are D6S1579 and D6S980 (Figures 1 and 
3). Across the most recent generation of all the families examined, 7 recombinant 
chromosomes are observed for marker D6S980 and 5 for D6S1579 (Figure 3). To 
account for the large variation in rates of recombination of the parkin region (see 
methods), we assumed a recombination rate of 1,000,000bp/cM (the genome average) 
between the G736A mutation and marker D6S1579 and of 178,418bp/cM (the average 
for the region D6S305 to D6S1599) between the mutation and marker D6S980 (figure 1). 
The resulting estimates for the time since introduction of the mutation in Antioquia are 15 
and 17 generations based on the data for markers D6S1579 and D6S980, respectively.
Comment
Our findings document the occurrence of an extensive founder effect for the 
parkin G736A mutation in Antioquia. Fourteen individuals from seven nuclear families 
carrying this mutation have now been identified in the region. Previous studies have 
indicated the presence of PD-related symptomatology in some heterozygous carriers of 
parkin mutations (Foroud et al. 2003; Khan et al. 2005). Interestingly, the father of the 
Spanish family shown in figure 4 is heterozygous for the G736A mutation and presented 
progressive supranuclear palsy (Morales et al. 2002). Three of the patients identified in 
Antioquia are heterozygous for the G736A mutation, including one case in a family
showing vertical transmission of early onset PD. However, the analyses carried out here 
confirmed the presence of a second mutant haplotype of parkin (carrying an exon 3 
duplication) in all heterozygous cases, thus excluding the possibility that heterozygosity 
of the G736A mutation is responsible for PD in these cases.
Although genealogical connections between six of the seven nuclear families have 
been documented, including ancestors common to several families 4-5 generations ago 
(Figure 2), no couple ancestral to all living affecteds (thus including the founder carrier 
of the mutation) was identified. These observations imply that the founding individual 
(the initial carrier of the G736A mutation) lived further back in time. Consistent with this 
scenario, the age estimate obtained for the mutation from the frequency of recombinant 
haplotypes suggests that it was introduced in Antioquia about 16 generations ago. 
Assuming a generation time of 25 years, this would place the appearance of the mutation 
in Antioquia some 400 years ago, or early in colonial times. This mutation could have 
been introduced because of migration from Spain or recurrent mutation in Antioquia.
The observation that the Spanish family with the G736A substitution carries a 
mutant microsatellite haplotype different from the one found in Antioquia, demonstrates 
that there is no recent connection between the families examined in both countries. This 
could indicate that the G736A substitution in Antioquia represents a recurrent mutation. 
However, only one Spanish chromosome was available for study and consequently it is 
not possible to evaluate the degree of association in Spain of the G736A mutation with 
alleles at the markers typed (as done for Antioquia). It is possible that the G736A 
mutation is of considerable age in Europe and is present in Spain on various haplotypic 
backgrounds, one of which is the one observed in Antioquia.
A previous survey using mostly the same microsatellite markers examined here 
demonstrated high disequilibrium for several point mutations in parkin but also 
documented their occurrence on various haplotypic backgrounds (Periquet et al. 2001). 
This observation points to a single origin for these mutations and also suggests that some 
of them are of considerable age. It therefore appears more likely that the G736A mutation 
was introduced to Antioquia by migration from Spain early in colonial times. The age 
estimate obtained for the mutation in Antioquia is also consistent with historical 
information documenting that the period of highest migration from Spain to the Americas 
was during the 16th century (Burkholder and Johnson 2003).
The early onset PD cases identified here represent the largest set of patients 
identified so far carrying an identical parkin mutation. The relative homogeneity of this 
patient group (particularly since they come from the same population) should facilitate 
the investigation of modifying factors influencing disease course and severity. Such 
studies should contribute to further our understanding of the pathogenesis of PD.
References
1. Burkholder MA, Johnson LL. 2003. Colonial Latin America.Oxioxd University 
Press.
2. Carvajal-Carmona LG, Ophoff R, Service S, Hartiala J, Molina J, Leon P, Ospina 
J, Bedoya G, Freimer N, and Ruiz-Linares A (2003) Genetic demography of 
Antioquia (Colombia) and the Central Valley of Costa Rica. Hum. Genet.
3. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C,
Marder K, Conneally PM, and Nichols WC (2003) Heterozygosity for a mutation 
in the parkin gene leads to later onset Parkinson disease. Neurology 60 (5):796- 
801.
4. Hoenicka J, Vidal L, Morales B, Ampuero I, Jimenez-Jimenez FJ, Berciano J, del 
Ser T, Jimenez A, Ruiz PG, and de Yebenes JG (2002) Molecular findings in 
familial Parkinson disease in Spain. Arch.Neurol. 59 (6):966-970.
5. Khan NL, Horta W, Eunson L, Graham E, Johnson JO, Chang S, Davis M, 
Singleton A, Wood NW, and Lees AJ (2005) Parkin disease in a Brazilian 
kindred: Manifesting heterozygotes and clinical follow-up over 10 years. Mov 
Disord. 20 (4):479-484.
6. Morales B, Martinez A, Gonzalo I, Vidal L, Ros R, Gomez-Tortosa E, Rabano A, 
Ampuero I, Sanchez M, Hoenicka J, and Garcia DY (2002) Steele-Richardson- 
Olszewski syndrome in a patient with a single C212Y mutation in the parkin 
protein
1. Mov Disord. 17 (6):1374-1380.
7. Periquet M, Lucking C, Vaughan J, Bonifati V, Durr A, De Michele G, Horstink 
M, Farrer M, Illarioshkin SN, Poliak P, Borg M, Brefel-Courbon C, Denefle P, 
Meco G, Gasser T, Breteler MM, Wood N, Agid Y, and Brice A (2001) Origin of 
the mutations in the parkin gene in Europe: exon rearrangements are independent 
recurrent events, whereas point mutations may result from Founder effects. 
Am.J.Hum.Genet. 68 (3):617-626.
8. Pineda-Trujillo N, Carvajal-Carmona LG, Buritica O, Moreno S, Uribe C, Pineda 
D, Toro M, Garcia F, Arias W, Bedoya G, Lopera F, and Ruiz-Linares A (2001)
A novel Cys212Tyr founder mutation in parkin and allelic heterogeneity of 
juvenile Parkinsonism in a population from North West Colombia. Neurosci.Lett. 
298 (2):87-90.
9. Sobel E and Lange K (1996) Descent graphs in pedigree analysis: applications to 
haplotyping, location scores, and marker-sharing statistics. Am.J.Hum.Genet. 58 
(6): 1323-1337.
West A, Periquet M, Lincoln S, Lucking CB, Nicholl D, Bonifati V, Rawal N, 
Gasser T, Lohmann E, Deleuze JF, Maraganore D, Levey A, Wood N, Durr A, 
Hardy J, Brice A, and Farrer M (2002) Complex relationship between Parkin 
mutations and Parkinson disease. Am.J.Med.Genet. 114 (5):584-591.
Legends to Figures
Figure 1. Map of the parkin gene region showing the location of the G736A mutation 
and the microsatellite markers examined. Nucleotide positions (top) were obtained 
from build 35 of the human genome sequence. Genetic distances between markers 
are shown at the bottom.
Figure 2. Documented genealogical connections between Antioquian families carrying 
the G736A mutation of parkin.
Figure 3. Microsatellite haplotypes in the parkin gene region for Antioquian individuals 
carrying the G736A mutation. The core haplotype shared by all carriers of the 
mutation is shaded. Individual labels are as in Figures 2 and 4. PJF1 refers to the 
pedigree shown in Figure 4 (A). All other individuals correspond to members of the 
pedigree shown in Figure 2.
Figure 4. Microsatellite haplotypes of the parkin gene region in (A) a family from
Antioquia (PJF1) with no known relationship with those shown in Figure 2. (B) The 
only Spanish family identified so far with the G736A mutation. This family also 
segregates a mutation. Haplotype segments shared between family members have 
been color-coded. Allele numbers are as in Figure 3.
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